



COVALENT DRUG BINDING:  
A MECHANISTIC EXPLORATION TO ENHANCE 
SAFETY AND EFFICACY 
 
 
CHAN CHUN YIP 
(B.Sc. Pharm (Hons.), NUS) 
 
 
A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF 
PHILOSOPHY 
DEPARTMENT OF PHARMACY 










I hereby declare that this thesis is my original work and it has been 
written by me in its entirety. I have duly acknowledged all the sources of 
information which have been used in the thesis. 
 






Chan Chun Yip 




This thesis represents the collective contributions of numerous individuals to 
whom I would like to express my deepest gratitude. First and foremost, my 
heartfelt thanks to Prof Eric Chan, my doctoral advisor who has been a wonderful 
mentor since I was an Honors Year student. Thank you for taking a chance on 
someone rough around the edges, and investing time and effort in shaping and 
moulding me to be a better person both professionally and personally. You are a 
person who truly leads by example and clearly walks the talk. I am grateful that 
you are always challenging and inspiring me, and in the process, you have taught 
me that I have, in myself, the capacity to achieve greater heights. Thank you for 
trusting me, giving me the freedom and encouraging me to explore new ideas and 
research interests, and for providing all the necessary support to ensure the 
success of these endeavours. You are always ready to lend a listening ear despite 
your busy schedule, and I deeply appreciate all your advice and counsel. I 
continue to learn from you in so many ways, and I thank God for blessing me 
with you as my mentor and role model. 
I am deeply appreciative of my collaborators at the Singapore Eye Research 
Institute: Dr Zhou Lei and Ms Koh Siew Kwan, who believed in the potential of 
this project, and has tirelessly and generously provided invaluable support and 
technical expertise, without which our investigation on drug-induced protein 
glutathionylation would not have commenced and now come to fruition. I am 
very grateful for your strong commitment to this work and belief in its potential 
that helped sustain it through difficult times. My sincere gratitude to Dr Ong Pei 
Shi for partnering us in investigating the pharmacodynamic interaction between 
lapatinib and endoxifen. Thank you for personally teaching me the cell culture 
iii 
 
and molecular biology techniques needed for this study, and for tirelessly co-
supervising 2 Honors Year students with us. I have learnt a great deal from your 
guidance in and out of the lab. To my collaborators at GlaxoSmithKline R&D 
Singapore: Dr Edward Browne, Dr Kishore Pasikanti and Ms Su Zhiting, my 
deepest gratitude for their unwavering support with investigating the 
pharmacokinetic interaction between lapatinib and endoxifen using the MDCKII-
MDR1 model. A big thank you to Prof Christina Chai for hosting me in your lab 
to perform organic synthesis, for kindly treating me as part of your research group 
and for all the advice, support and encouragement. I am thankful to Dr Ngai Mun 
Hong, Yan Ting, Yanbo and Kuan Chieh for help with the synthetic work, and 
more memorably the camaraderie in and out of the Chai lab. My warmest 
gratitude also to Dr Vinita Uttamsingh and Dr Sophia Nguyen from Concert 
Pharmaceuticals for providing deuterated lapatinib analogues for our evaluation. 
My sincere thanks to past and present members of the Metabolic Profiling 
Research Group: Lee Sun for her guidance and friendship from my days as an 
Honours student; Alex, Davis, Devester, Kwok Foong, Preben, Peirong and 
Wanjing for their invaluable contributions as undergraduate students to the 
different parts of this work, making it greater than the sum of its individual parts; 
Hui Ting, Lee Cheng, Lian Yee, Yanjun, Gopal, Yee Min and Dorinda for 
providing me with their kind assistance for parts of my project; Liyan, Aneesh, 
Aparna, Yun Shan, Thiru, Kai Lun, Ronald, Gopal and Theebarina for making 
MPRG a wonderful and fun group, as well as Hai Ning for being a great friend 
and generously sharing resources; you are all part of precious memories and have 
left an indelible mark in my journey. A special thanks to Lian Yee for all the 
encouragement you have provided to me; your treasured friendship, cherished 
iv 
 
care and unflagging support through thick and thin made it possible to complete 
this journey, and I would not exchange it for anything in this world. 
I would like to convey my gratefulness to the Department of Pharmacy, NUS, for 
my education and I would like to thank in particular Dr Chew Eng Hui and Dr Ho 
Han Kiat for their sharp comments and suggestions which kept this project on the 
right track; Ms Ng Sek Eng, Ms Tan Bee Jen and Mr Sukaman for their excellent 
technical support and administrative efficiency. I would also like to acknowledge 
the financial support from NUS Pharmacy, GlaxoSmithKline, the President’s 
Graduate Fellowship and funding from the FYP research grants for making this 
project a reality. I would also like to remember the late Prof Sidney Nelson, who 
carried out pionerring investigations on acetaminophen toxicity and inspired us to 
investigate acetaminophen-induced protein glutathionylation.  
To my dad and mum: no words can adequately express my thanks and gratitude 
for all your love, care, concern and patience; supporting me through difficult 
times, and celebrating my achievements and successes; for your unwavering 
belief and unceasing encouragement; and being ever ready with a listening ear 
and a comforting shoulder. As difficult as it sometimes was for me during these 
eight years that I was away from home, it must have been harder for you; I am 
grateful for your trust and support which enabled me to pursue my dreams. Thank 
you for making countless trips between home and Singapore to visit me and keep 
me well-stocked with necessities, and never once griping or complaining. To the 
rest of my family and loved ones: I could not have completed this journey without 
you. Each of you gave of yourself in some way that made this possible. I thank 
God every day that I have you in my life.  
v 
 
And finally, to my Lord and Saviour Jesus Christ: thank you for leading me 
through all these years, and for placing me at the right time and right place, with 
the right people, doing the right thing. Looking back, I can see Your hand in 
action guiding me and providing me with all that I need. Thank you for giving me 
a new perspective of Your creation as a scientist. Having glimpsed the marvelous 
intricacies of Your work in this thesis, I am utterly convinced that “… in Him all 
things were created: things in heaven and on earth, visible and invisible, whether 
thrones or powers or rulers or authorities; all things have been created through 
Him and for Him. He is before all things, and in Him all things hold together.” 




Table of Contents 
DECLARATION ................................................................................................... I 
ACKNOWLEDGMENTS ................................................................................... II 
TABLE OF CONTENTS ................................................................................... VI 
SUMMARY ........................................................................................................... X 
PUBLICATIONS AND CONFERENCE ABSTRACTS ................................ XI 
LIST OF TABLES ........................................................................................... XIII 
LIST OF FIGURES ........................................................................................... XV 
LIST OF SUPPLEMENTARY TABLES ...................................................... XXI 
LIST OF SUPPLEMENTARY FIGURES ................................................... XXII 
LIST OF ABBREVIATIONS ...................................................................... XXIII 
CHAPTER 1 INTRODUCTION ....................................................................1 
1.1 The Burden of Adverse Drug Reactions .....................................................1 
1.2 Classification of ADRs ..................................................................................2 
1.3 Xenobiotic Metabolism and Reactive Metabolite Formation ...................4 
1.4 Covalent Drug Binding and Protein Adduct Formation ...........................5 
1.5 Toxicological Significance of Covalent Binding .........................................6 
1.5.1 Overt Consequences of Covalent Binding ........................................................... 6 
1.5.1.1 Mechanism-based Inactivation ................................................................... 6 
1.5.1.2 Type B idiosyncratic drug reactions ........................................................... 9 
1.5.1.3 Type C dose-dependent toxicity ............................................................... 11 
1.5.2 Covert Effects of Covalent Binding ................................................................... 12 
1.5.3 Limitations of the Covalent Binding Hypothesis................................................ 15 
1.6 Pharmacological Significance of Covalent Binding .................................16 
1.7 Research Objectives and Significance .......................................................19 
1.7.1 Research Question and Objectives .................................................................... 19 
1.7.2 Thesis Outline .................................................................................................. 20 
1.7.3 Significance of Project ...................................................................................... 21 
CHAPTER 2 DRUG-INDUCED PROTEIN GLUTATHIONYLATION 22 
2.1 Chapter Summary .......................................................................................22 
2.2 Chapter Introduction ..................................................................................24 
2.2.1 Protein Post-translational Modifications ............................................................ 24 
2.2.2 Mechanisms of Cysteine Glutathionylation ....................................................... 24 
2.2.3 Biological Consequences of Cysteine Glutathionylation .................................... 27 
2.2.4 Covalent Binding in APAP Hepatotoxicity ........................................................ 30 
2.2.5 APAP-induced Protein Glutathionylation .......................................................... 32 
2.2.6 Approaches to Detect Protein Glutathionylation ................................................ 35 
2.3 Materials and Methods ...............................................................................37 
2.3.1 Materials .......................................................................................................... 37 
vii 
 
2.3.2 Development of the GluICAT Methodology to Profile Protein Glutathionylation38 
2.3.2.1 Indirect Monitoring of GAPDH Glutathionylation and Deglutathionylation
 38 
2.3.2.2 Direct Monitoring of GADPH Deglutathionylation .................................. 38 
2.3.2.3 GluICAT Processing of Glutathionylated GAPDH ................................... 39 
2.3.2.4 LC/MS/MS Detection of GluICAT-treated Glutathionylated GAPDH. ..... 40 
2.3.3 GluICAT Profiling of APAP-induced Protein Glutathionylation in HepaRG Cells . 
  ........................................................................................................................ 41 
2.3.3.1 Cell Culture ............................................................................................. 41 
2.3.3.2 Biochemical Analyses ............................................................................. 42 
2.3.3.3 Drug Treatment of HepaRG Cells ............................................................ 42 
2.3.3.4 Harvesting of Drug-treated Cell Lysate .................................................... 43 
2.3.3.5 GluICAT Processing of Drug-treated Cell Lysate ..................................... 43 
2.3.3.6 Data Analysis .......................................................................................... 44 
2.3.3.7 Pathway Analysis and Proteo-metabonomic Mapping .............................. 45 
2.3.3.8 Heat Map Representation of Glutathionylation Patterns ............................ 46 
2.4 Results ..........................................................................................................47 
2.4.1 Development of GluICAT Methodology to Profile Protein Glutathionylation .... 47 
2.4.1.1 Indirect Monitoring of GAPDH Glutathionylation and Deglutathionylation
 47 
2.4.1.2 Direct Monitoring of GAPDH-SG Deglutathionylation ............................ 48 
2.4.1.3 GluICAT profiling of glutathionylated GAPDH ....................................... 49 
2.4.2 Time-course of APAP Toxicity in HepaRG Cells .............................................. 52 
2.4.3 GluICAT Profiling of APAP-induced Protein Glutathionylation in HepaRG Cells . 
  ........................................................................................................................ 53 
2.4.3.1 Pathway Analysis of APAP-induced Glutathionylation ............................ 53 
2.4.3.2 Proteo-metabonomic Mapping of APAP-induced Glutathionylation ......... 71 
2.4.3.3 Longitudinal Progression of APAP-induced Protein Glutathionylation ..... 78 
2.4.3.4 Effect of Dose and Bioactivation on APAP-induced Protein 
Glutathionylation ..................................................................................... 81 
2.4.3.5 Comparative Analysis of AMAP- and APAP-induced Protein 
Glutathionylation ..................................................................................... 84 
2.5 Discussion .....................................................................................................87 
2.5.1 Development of the GluICAT Methodology to Profile Protein Glutathionylation87 
2.5.2 Analysis of APAP-induced Protein Glutathionylation ........................................ 95 
2.5.2.1 HepaRG as a Model for Investigating APAP-induced Protein 
Glutathionylation ..................................................................................... 95 
2.5.2.2 Longitudinal Biochemical Analyses of APAP Toxicity ............................ 95 
2.5.2.3 Overview of APAP-induced Protein Glutathionylation ............................. 96 
2.5.2.4 Proteo-metabonomic Mapping of Reactome-derived Pathways ................. 97 
2.5.2.5 Additional Glutathionylated Proteins Related to APAP-induced 
Hepatotoxicity ....................................................................................... 109 
2.5.2.6 Longitudinal Progression of APAP-induced Protein Glutathionylation ... 118 
2.5.2.7 Dose- and Bioactivation-dependent Protein Glutathionylation by APAP . 120 
2.5.2.8 Comparative Analysis of AMAP- and APAP-induced Protein 
Glutathionylation ................................................................................... 123 
2.6 Chapter Conclusion ..................................................................................126 
CHAPTER 3 STRATEGIES TO MITIGATE THE DELETERIOUS 
EFFECTS OF COVALENT BINDING ..........................................................128 
3.1 Chapter Summary .....................................................................................128 
3.2 Chapter Introduction ................................................................................130 
3.2.1 Generation of Reactive Metabolites from Lapatinib ......................................... 130 
3.2.2 Adverse Drug Reactions Associated with Lapatinib......................................... 133 
3.2.3 Variables Affecting Lapatinib-induced DDIs and ADRs .................................. 134 
3.2.3.1 Reducing Generation of Reactive Metabolites from Lapatinib ................ 134 
3.2.3.2 Assessing the Capacity of Lapatinib in Generation of Reactive Metabolites .. 
  ............................................................................................................. 140 
viii 
 
3.2.4 Mitigating Lapatinib-induced DDIs and ADRs through Deuteration and CYP3A5 
Genotyping ..................................................................................................... 142 
3.3 Materials and Methods .............................................................................143 
3.3.1 Materials ........................................................................................................ 143 
3.3.2 Kinetic Studies of Lapatinib Metabolite and GSH Adduct Formation from 
Lapatinib and Deuterated Lapatinib Analogues in Pooled HLM, rCYP3A4 and 
rCYP3A5 ....................................................................................................... 145 
3.3.3 Time- and Concentration-dependent Inactivation of CYP3A4/5 by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM ............................................. 146 
3.3.3.1 Assessment of the Suitability of Midazolam as a Probe Substrate ........... 146 
3.3.3.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM using Testosterone as 
Probe Substrate ..................................................................................... 147 
3.3.4 Cytotoxicity of Lapatinib and O-d2 Lapatinib in BT474 Breast Cancer Cells .... 147 
3.3.5 Time- and Concentration-dependent Inhibition of CYP3A4/5 by Lapatinib in 
CYP3A5 Genotyped HLM .............................................................................. 148 
3.3.6 Phenotyping of CYP3A4/5 Activity in CYP3A5 Genotyped HLM via 
Testosterone 6β-Hydroxylation ....................................................................... 148 
3.3.7 Quantitation of Lapatinib, Midazolam and Testosterone Metabolites, and 
Detection of GSH Adduct Formation by LC/MS/MS ....................................... 149 
3.3.8 Data Analysis ................................................................................................. 151 
3.3.8.1 Enzyme Kinetics Analysis ..................................................................... 151 
3.3.8.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib or 
Deuterated Lapatinib Analogues ............................................................ 152 
3.4 Results ........................................................................................................153 
3.4.1 Optimization of Chromatographic Separation for OD Lapatinib and ND Lapatinib
 153 
3.4.2 Kinetic Studies of Lapatinib Metabolite Formation from Lapatinib and Deuterated 
Lapatinib Analogues in Pooled HLM, rCYP3A4 and rCYP3A5 ....................... 154 
3.4.3 Kinetic Studies of GSH Adduct Formation from Lapatinib and Deuterated 
Lapatinib Analogues in Pooled HLM .............................................................. 158 
3.4.4 Time- and Concentration-dependent Inactivation of CYP3A4/5 by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM ............................................. 159 
3.4.4.1 Assessment of the Suitability of Midazolam as a Probe Substrate ........... 159 
3.4.4.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM using Testosterone as a 
Probe Substrate ..................................................................................... 161 
3.4.5 Cytotoxicity of Lapatinib and O-d2 Lapatinib in BT474 Breast Cancer Cells .... 164 
3.4.6 Time- and Concentration-dependent Inhibition of CYP3A4/5 by Lapatinib in 
CYP3A5-Genotyped HLM ............................................................................. 164 
3.4.7 GSH Adduct Formation as a Function of CYP3A5 Genotype .......................... 170 
  ...................................................................................................172 3.5 Discussion
3.5.1 Influence of Selective Deuteration on the Metabolic and Bioactivation 
Susceptibilities of Lapatinib ............................................................................ 172 
 3.5.2 Impact of CYP3A5 Genetic Polymorphism on CYP3A4/5 Inactivation by 
 ........................................................................................................ 177 Lapatinib
3.6 Chapter Conclusion ..................................................................................182 
CHAPTER 4 CIRCUMVENTING COVALENT BINDING VIA 
COMBINATORIAL LAPATINIB AND ENDOXIFEN THERAPY ...........183 
4.1 Chapter Summary .....................................................................................183 
4.2 Chapter Introduction ................................................................................185 
4.2.1 Tamoxifen in the Treatment of Breast Cancer ................................................. 185 
4.2.2 Challenges in Tamoxifen Therapy ................................................................... 187 
4.2.2.1 Inter-individual Variability .................................................................... 187 
4.2.2.2 Development of Tamoxifen Resistance .................................................. 187 
4.2.3 Overcoming Tamoxifen Resistance due to ERα/HER2 Crosstalk ..................... 190 
4.2.4 Lapatinib and Endoxifen: a Superior Combination? ......................................... 191 
4.3 Materials and Methods .............................................................................195 
ix 
 
4.3.1 Materials ........................................................................................................ 195 
4.3.2 Effect of Lapatinib on Tamoxifen Bioactivation .............................................. 196 
4.3.2.1 Effect of Lapatinib on Intrinsic Clearances of Tamoxifen and 4-OHT in 
Pooled HLM ......................................................................................... 196 
4.3.2.2 Quantification of Tamoxifen Metabolites by LC/MS/MS ....................... 197 
4.3.2.3 Data Analysis ........................................................................................ 198 
4.3.3 Investigation of Pharmacodynamic Interaction between Lapatinib and Tamoxifen 
or its Active Metabolites ................................................................................. 199 
4.3.3.1 Cell Culture ........................................................................................... 199 
4.3.3.2 In Vitro Monotherapy Cytotoxicity Assay .............................................. 200 
4.3.3.3 In Vitro Combination Therapy Cytotoxicity Assay ................................. 201 
4.3.3.4 Western Blot ......................................................................................... 202 
4.3.4 Determination of Pharmacokinetic Interaction between Lapatinib and Endoxifen ... 
  ...................................................................................................................... 204 
4.3.4.1 Cell Culture ........................................................................................... 204 
4.3.4.2 Transport Assay .................................................................................... 205 
4.3.4.3 Quantification of Substrates using LC/MS/MS ....................................... 207 
4.3.4.4 Determination of Efflux Ratio and Monolayer Integrity .......................... 208 
4.4 Results ........................................................................................................209 
4.4.1 Effect of Lapatinib on Tamoxifen Bioactivation .............................................. 209 
4.4.2 Pharmacodynamic Interaction between Lapatinib and Tamoxifen or its Active 
Metabolites in the De Novo Tamoxifen-Resistant Luminal B Subtype ............. 210 
4.4.2.1 Monotherapy in MCF-7 and BT474 Cells .............................................. 210 
4.4.2.2 Combination Therapy in MCF-7 and BT474 Cells ................................. 211 
4.4.3 Pharmacodynamic Interaction between Lapatinib and Tamoxifen or Endoxifen in 
the Luminal A Subtype with Acquired Tamoxifen Resistance .......................... 215 
4.4.3.1 Monotherapy in MCF-7, TAM-R and MCF-7/HER2 Cells ..................... 215 
4.4.3.2 Combination Therapy in MCF-7, TAM-R and MCF-7/HER2 Cells ........ 216 
4.4.3.3 Western Blot Analysis of Combination Therapy in MCF-7 and TAM-R 
Cells...................................................................................................... 219 
4.4.4 Pharmacokinetic Interaction between Lapatinib and Endoxifen in MDCKII-MDR1 
Cells ............................................................................................................... 221 
4.4.4.1 Substrate Assay ..................................................................................... 221 
4.4.4.2 Inhibitor Assay ...................................................................................... 222 
4.4.4.3 Pairwise Combinatorial Treatment ......................................................... 223 
4.5 Discussion ...................................................................................................225 
4.5.1 Lapatinib Impairs CYP3A4/5-Dependent Bioactivation of Tamoxifen ............. 225 
4.5.2 Lapatinib Exhibits Pharmacodynamic Synergism with Endoxifen in De Novo 
Tamoxifen Resistant Luminal B BT474 Cells .................................................. 227 
4.5.3 Lapatinib Exhibits Pharmacodynamic Synergism with Endoxifen in Luminal A 
Subtypes with Acquired Tamoxifen Resistance ............................................... 228 
4.5.3.1 Monotherapy and Combination Therapy ................................................ 228 
4.5.3.2 Acquired Tamoxifen Resistance Alters ERα and HER2 Expression Patterns . 
  ............................................................................................................. 230 
4.5.3.3 Tamoxifen and Endoxifen Show Differential Effects on ERα Expression and 
Phosphorylation in MCF-7 and TAM-R Cells ........................................ 231 
4.5.3.4 Lapatinib Reverses Tamoxifen Resistance by Overcoming ERα/HER2 
Crosstalk ............................................................................................... 232 
4.5.4 Lapatinib and Endoxifen Exhibit Mutual Pharmacokinetic Synergism via P-gp 
Inhibition ........................................................................................................ 233 
4.5.5 Lapatinib and Endoxifen: the Superior Combination ....................................... 237 
4.6 Chapter Conclusion ..................................................................................241 






Covalent drug binding to proteins results in deleterious effects. Adverse drug 
reactions (ADRs) occur when overt covalent binding alters protein structure and 
function directly, or indirectly, by covertly inducing aberrant protein post-
translational modifications such as protein glutathionylation. Collectively, these 
drug-induced protein modifications disrupt protein function and cellular 
homeostasis. However, the identity of many targets and the biological 
consequences of their modifications remain unknown. Using acetaminophen 
(APAP) as a model toxicant, we uncovered a suite of proteins glutathionylated by 
APAP, and correlated them to signatures of APAP hepatotoxicity using proteo-
metabonomic mapping. Based on the mapping, we further elucidated the 
mechanisms of action of prophylactics and antidotes against APAP 
hepatotoxicity. Overt covalent binding can lead to inactivation of CYP450 
enzymes and cause drug-drug interactions (DDIs). We explored drug deuteration 
to reduce reactive metabolite formation and patient genotyping to stratify 
susceptibility to DDIs caused by lapatinib. We negated the apparent liability of 
covalent binding by investigating the interaction between lapatinib and endoxifen, 
revealing potent pharmacodynamic and pharmacokinetic synergism that 
overcomes tamoxifen resistance and enhances breast cancer pharmacotherapy. 
This work offers a fresh perspective on covalent drug binding by first elucidating 
its mechanisms and consequences, which informs innovative strategies to 
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 Chapter 1 Introduction 
1.1 The Burden of Adverse Drug Reactions 
Despite decades of drug development efforts and clinical experience, adverse 
drug reactions (ADRs) remain a critical issue in pharmacotherapy. The World 
Health Organization (WHO) defines ADRs as ‘a response to a drug that is 
noxious, unintended and occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease or for modification of the 
physiological function’ (1). ADRs contribute to increased clinical morbidity and 
mortality (2), up to half of which are preventable (3). ADRs account for up to 
30% of hospital admissions in North America, accompanied by prolonged 
hospital stays and elevated risks of iatrogenic complications such as hospital 
acquired infections (4). This is further exacerbated in vulnerable pediatric and 
geriatric populations, where up to 30% of ADRs in children are life-threatening or 
fatal (5).  
The economic burden of ADRs on healthcare systems is significant, as ADRs are 
estimated to cost USD 30.1 billion annually due to increased hospitalization, 
prolongation of hospital stays and additional clinical investigations (4). Further 
indirect costs are also incurred by patients and their caregivers due to reduced 
worker productivity (4). From an industry perspective, 30% of compound attrition 
during the development process is attributed to toxicity (6), which increases 
research and development expenditure and further magnifies the costs of 
medicines. 
Unsurprisingly, considerable effort has been devoted to understanding the 
mechanistic basis of drug toxicities in order to design safer medications. For 
example, pharmaceutical companies develop comprehensive preclinical toxicity 
2 
 
screening programs, ranging from cell-based models to animal studies, using a 
variety of molecular biology tools such as gene knockouts and knockdowns, 
systems biology platforms and in silico algorithms to detect potential toxicities of 
new chemical entities (6). However, the reliability and predictivity of these 
approaches remain unsatisfactory, as attrition rates due to toxicity remain high 
(7). This situation is clearly illustrated in a review by Lasser et al. which found 
that of a total of 548 drugs approved between 1975-1999, 45 drugs (8.2%) 
acquired one or more black box warnings, and 16 (2.9%) were withdrawn from 
the market owing to ADRs that were not predicted from animal testing and/or 
clinical trials (8). 
1.2 Classification of ADRs 
A number of approaches have been developed to classify ADRs, each with 
varying considerations of clinical presentation, pharmacology, mechanisms of 
toxicity and patient factors. The following classification is adapted from the 
framework proposed by Smith and Obach (9) which places greater emphasis on 
pharmacology and mechanistic features, and facilitates subsequent discussion in 
section 1.5. ADRs can be broadly categorized into type A, type B and type C 
reactions. Type A (augmented) reactions are associated with an exaggerated 
therapeutic response related to the primary pharmacology of the drug (e.g. 
hypotension with antihypertensives), occurring either at the target site (e.g. 
hypoglycaemia with sulphonylureas) or at a distant region (e.g. headache with 
nitroglycerin) (10). Type A reactions are usually common, dose dependent, 
predictable, associated with a low mortality risk and managed through dose 
adjustment or discontinuation of treatment (10).  
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Conversely, type B (bizarre or idiosyncratic) reactions are uncommon (between 1 
in 10 000 to 1 in 100 000) (11), unpredictable with a high risk of mortality (10) 
and not associated with the pharmacological action. Type B reactions are also 
described as idiosyncratic drug reactions (IDRs) and the two terminologies will be 
used interchangeably. Because the frequency of type B reactions is relatively low, 
they are often not detected until the drug has gained broad exposure in the patient 
population. Additional features of type B reactions also include repeat 
administration for onset, delayed onset, rapid onset upon rechallenge, lack of an 
apparent dose dependence, adaptation and tolerance, cross-sensitivity with other 
drugs, and pharmacogenetic association (9). Collectively, these features suggest 
an underlying immunological pathogenesis. For example, the delay in onset may 
be attributed to activation of the adaptive immune system, which requires a longer 
duration to initiate an immune response. In contrast, once the initial response is 
established, immunological memory primes the immune system for a much faster 
response, accounting for the rapid onset of toxicity upon repeat exposure to the 
implicated drug. Examples of type B reactions include carbamazepine-induced 
Stevens-Johnson syndrome and flucloxacillin-induced hepatotoxicity.  
Similar to type B reactions, type C (chemical) reactions is unrelated to the 
pharmacology of the drug. However, distinct from type B reactions, it is 
characterized by a rapid onset, typically occurring after a single high dose, and 
predictable. A crucial feature of type C reactions is the toxicity being a 
consequence of covalent complex formed between the drug or its reactive 
metabolite with cellular macromolecules, and the fraction of the complexes 
formed is proportional to the extent of toxicity (9). In other words, the toxicity 
spectrum generally reflects an apparent dose-response relationship, which 
accounts for its predictability. The classical example of a type C reaction is 
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hepatotoxicity elicited by acetaminophen (APAP) overdose. Although distinctive 
features of type B and C reactions have been presented, some drugs exhibit 
overlaps between the two classes and the distinction is not always clear in 
practice. 
1.3 Xenobiotic Metabolism and Reactive Metabolite Formation 
Xenobiotics are broadly defined as chemical compounds which are foreign to a 
living organism (12), and include substances such as drugs, pesticides and dyes. 
Xenobiotics are typically metabolized via phase I (functionalization) reactions, 
which include oxidative, reductive and hydrolytic pathways, where a functional 
group such as OH, NH2 or COOH is added or exposed, and aqueous solubility of 
the resulting metabolite is increased modestly (11). Phase II (conjugation) 
reactions involve attaching bulky groups such as glucuronides, sulfates and other 
moieties to an existing or newly introduced phase I functionality, resulting in a 
marked increase in hydrophilicity relative to the unconjugated counterpart (11). 
An exception is with methylation and acetylation which cause a moderate 
increase in hydrophobicity. Xenobiotics can undergo phase I followed by phase II 
reactions, or directly proceed to phase II conjugations. The increase in aqueous 
solubility facilitates the excretion of metabolites via the urine or bile.  
The liver is the main organ of biotransformation, where phase I reactions are 
primarily mediated by cytochrome P450 (CYP450) enzymes, a superfamily of 
heme-containing enzymes that catalyze the oxidative metabolism of structurally 
diverse endogeneous and exogeneous compounds, including drug molecules. 
CYP450 enzymes are categorized into several subfamilies, members of which 
include CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, which 
participate in the metabolism of more than 80% of drugs (13). Of these enzymes, 
the CYP3A4/5 family comprising primarily CYP3A4 and CYP3A5 is involved in 
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the biotransformation of more than 50% of currently marketed drugs (13). Several 
non-CYP450 enzymes such as monoamine oxidases, peroxidases, aldehyde 
oxidase, and alcohol dehydrogenases are also capable of phase I 
biotransformations (11). Separately, phase II reactions are catalysed by their 
respective transferases such as UDP-glucuronosyltransferases (UGT), 
sulfotransferases (SULT) and others. Apart from the liver, extra-hepatic sites of 
metabolism such as the gut, lung, kidney, skin and heart also contribute to overall 
biotransformation. 
Drug metabolism is generally considered a detoxification mechanism to terminate 
the action of drugs, preventing their accumulation to toxic levels.  In the case of 
prodrugs, metabolism exposes the pharmacophore to permit target engagement 
and elicit pharmacological activity. However, for certain drugs the same 
biotransformation processes can generate electrophilic, reactive metabolites, a 
phenomenon termed ‘bioactivation’. This process can involve phase I and/or II 
reactions, either through a single enzymatic reaction or via sequential 
biotransformations to yield the reactive intermediate.  
Due to the electrophilic nature of these reactive metabolites, they react readily 
with nucleophilic cellular macromolecules such as proteins and DNA. The 
resulting covalent complex is termed as an adduct. This work focuses the 
consequences of adduct formation with proteins. 
1.4 Covalent Drug Binding and Protein Adduct Formation  
Covalent binding of xenobiotics to proteins was first observed by Elizabeth and 
James Miller nearly 70 years ago, who found that rat liver proteins were coloured 
yellow by a carcinogenic dye, methylaminoazobenzene (14). The concept that 
covalent binding was responsible for the toxicity of drugs and other xenobiotics 
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was developed from the seminal work of Mitchell, Gillette and colleagues (15) in 
the 1970s on APAP toxicity, which established that APAP was metabolized in the 
liver by CYP2E1 to form an electrophilic reactive metabolite, N-acetyl-p-
benzoquinone imine (NAPQI) that in turn formed adducts with liver proteins. The 
extent of covalent binding by NAPQI correlated with the degree of hepatotoxicity 
induced by APAP. Both covalent binding and toxicity could be attenuated by 
reaction with hepatic glutathione (GSH), a nucleophilic scavenger later found to 
be critical in the detoxification of reactive xenobiotics, thus substantiating the 
causal relationship of covalent binding with APAP hepatotoxicity (16).  
From these studies, the covalent binding hypothesis was developed, positing that 
electrophilic functionalities arising from xenobiotic metabolism result in 
increased reactivity, thus promoting random and indiscriminate binding to cellular 
macromolecules such as proteins and DNA. Such off-target and promiscuous 
binding may interfere with or modify normal biological protein function, 
ultimately culminating in drug-induced toxicity.  
1.5 Toxicological Significance of Covalent Binding 
1.5.1 Overt Consequences of Covalent Binding 
In this thesis, the term “overt” consequences of covalent binding is used to refer 
to the formation of a drug-protein adduct and the resulting effect of the adduction 
on the function of the victim protein. This is in contrast to the “covert” 
consequences referred to in section 1.5.2. 
1.5.1.1 Mechanism-based Inactivation 
As opposed to detoxification, biotransformation of drugs or xenobiotics by 
CYP450 enzymes may result in bioactivation and the generation of reactive 
metabolites that bind covalently and irreversibly to the enzyme prior to their 
release from the active site. This phenomenon is known as ‘mechanism-based 
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inactivation’ (MBI), a unique form of enzyme inhibition where the reactive 
metabolite inactivates the enzyme responsible for its generation. Hence, MBI is 
also described as ‘suicide inactivation’. The reactive metabolite can form an 
adduct with either the CYP450 apoprotein or the porphyrin ring of the heme 
prosthetic group, each resulting in unique toxicological consequences (13).  
From a functional perspective, MBI of CYP450 enzymes cause permanent 
inactivation of the enzyme which persists until fresh enzymes are synthesized 
(13). The magnitude of inactivation is proportional to the fraction of reactive 
metabolites that successfully form the protein adduct, thus is dose-dependent and 
is a type C reaction. Given the prominent role of CYP450 enzymes in drug 
metabolism, their inactivation can give rise to serious DDIs which arise when 
‘victim’ drugs accumulate in the patient, leading to supratherapeutic effects, or 
subtherapeutic effects if the victim drug is a prodrug. Accordingly, the clinical 
sequelae can range from unexpected toxicity to inefficacious therapy, requiring 
dose adjustment or complete avoidance of the particular drug combination. For 
example, mibefradil, a calcium channel blocker approved for the treatment of 
hypertension in 1997, was withdrawn within a year of approval due to life-
threatening DDIs with CYP3A4 substrates, including nifedipine, simvastatin, 
tacrolimus, cyclosporine and digoxin (17). In one instance, after consuming a 
single dose of the antihypertensive nifedipine 24 h after the last dose of 
mibefradil, the patient suffered from refractory hypotension and bradycardia, and 
died within 24 h of ingestion (18).   
From a structural standpoint, if the reactive metabolite binds to the apoprotein, 
MBI can lead to the haptenization of CYP450 enzymes. A hapten is defined as a 
low molecular weight chemical that binds irreversibly to a protein through the 
formation of a covalent bond (19). Although a foreign substance, drugs do not 
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normally activate the immune system due to their small size; however when 
covalently bound to proteins, these haptens appear foreign to the immune system 
and trigger an immunological response, either against only the haptenized protein 
or both haptenized and native unhaptenized proteins. For the former, toxicity 
persists for as long as the drug is administered and until the hapten is cleared; 
while for the latter, it can result in autoimmune toxicity that continues even after 
therapy discontinuation. A classical example of this outcome is tienilic acid, 
which is a mechanism-based inactivator of CYP2C9. Tienilic acid was developed 
for the treatment of arterial hypertension and launched in 1979, but was 
withdrawn after a few months due to unexpected hepatotoxicity. Subsequent 
investigations revealed that the thiophene ring of tienilic acid was bioactivated by 
CYP2C9 to an electrophilic S-oxide, that in turn alkylated the OH group of serine 
365 in the active site of CYP2C9 (20). Auto-antibodies directed against the 
CYP2C9-expressing liver and kidney (anti-LKM2 antibodies) were found in 60% 
of patients experiencing tienilic acid-induced hepatitis (21), which were reactive 
against both native and adducted CYP2C9 (22), suggesting that the haptenization 
of CYP2C9 by tienilic acid triggered immune-mediated hepatitis. Other examples 
of MBI leading to the generation of auto-antibodies include dihydralazine-
induced hepatitis (CYP1A2) and halothane-induced hepatitis (CYP2E1) (22). 
A different outcome is observed when the reactive metabolite binds to the 
porphyrin ring. This occurs as a result of alkylation of one of the four pyrrole 
nitrogens of the porphyrin ring, triggering a dissociation of the heme group from 
the CYP450 enzyme where the iron is released, while the protoporphyrin ring 
accumulates (23). In genetically predisposed individuals, this can cause acute 
porphyria, which presents as a neuropsychiatric syndrome characterized by 
autonomic involvement in the form of tachycardia and hypertension, as well as 
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motor disturbances that can progress to respiratory paralysis and fluctuating 
psychiatric manifestations ranging from depression to violent agitation or frank 
psychosis (24). For over a hundred years certain drugs have been known to 
precipitate attacks of acute porphyria and are contraindicated in susceptible 
individuals. Drugs which have been identified mechanistically to trigger this 
condition via MBI include nifedipine, griseofulvin and carbamazepine (22, 24). 
Both CYP450 apoprotein haptenization and porphyrin alkylation can be 
considered type B reactions. 
Although MBI has been described extensively in literature with reference to 
CYP450 enzymes, it is not restricted solely to the CYP450 family. Theoretically, 
any enzyme that metabolically generates a reactive metabolite that in turn adducts 
the active site is susceptible to MBI. These include non-CYP450 enzymes such as 
nitric oxide synthase (25) and angiotensin-converting enzyme (ACE) (26). 
Interestingly, MBI is not necessarily always a detrimental event. For example, 
MBI of ACE has been exploited as a therapeutic strategy to develop potent and 
long-lasting anti-hypertensives (26).  
1.5.1.2 Type B idiosyncratic drug reactions 
In the last decade, significant advances were made in resolving the underlying 
mechanisms of type B IDRs. Certain IDRs have been found to be precipitated by 
the formation of a hapten with drugs. In this regard, it is similar to haptens formed 
as a result of MBI; however the protein targets are not restricted to metabolic 
proteins such as CYP450 enzymes, and bioactivation of the drug to a reactive 
metabolite may not be a pre-requisite. In other words, the toxicities caused by 
MBI are a subset of IDRs, but for ease of discussion, they have been reviewed 
earlier in section 1.5.1.1.  
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Flucloxacillin-induced hepatotoxicity exhibits all the features of type B reactions, 
including a strong pharmacogenetic association with the HLA-B*57:01 allele, 
where individuals carrying this allele exhibit a significantly greater risk for 
flucloxacillin-induced hepatotoxicity (odds ratio of 80.6) (27). The human 
leukocyte antigen (HLA) locus of genes codes for the major histocompatibility 
complex (MHC) cell surface proteins, which present self and non-self (foreign) 
antigens to circulating T cells, the latter of which triggers the adaptive immune 
system to mount an immune response. Haptens act as foreign antigens which are 
endocytosed by antigen-presenting cells such as dendritic cells. They then 
undergo antigen processing to form peptide fragments which are then loaded unto 
the peptide-binding cleft of an MHC complex and presented on the cell surface. 
The immunogenic hapten-derived peptide can be recognized by circulating T cells 
bearing complementary T cell receptors, which then initiates the adaptive immune 
cascade of events (28). Flucloxacillin possesses a β-lactam ring which is 
inherently reactive and has been shown to bind to nucleophilic lysine residues of 
serum albumin without requiring prior bioactivation. However, despite the 
ubiquitous presence of flucloxacillin-albumin adducts in flucloxacillin-treated 
patients, only patients bearing the HLA-B*57:01 allele exhibit flucloxacillin-
induced hepatotoxicity, presumably because the MHC class I molecule coded by 
this allele possesses a binding cleft with the appropriate topology to accommodate 
the immunogenic flucloxacillin-bound peptide (29). While the HLA allele defines 
the successful presentation of the immunogenic peptide, the effector T cells which 
recognize the MHC-peptide complex defines the liver-specific toxicity of 
flucloxacillin. All T cell clones responsive to flucloxacillin express the chemokine 
receptors CCR2 and CCR9, which direct the migration and accumulation of 
immune cells in the liver (29). 
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Apart from flucloxacillin, other drugs such as sulfamethoxazole and nevirapine 
exhibit IDRs with strong evidence that covalent binding is the key trigger (19); 
however the exact mechanisms are still under investigation. Unlike flucloxacillin, 
bioactivation of sulfamethoxazole and nevirapine to reactive metabolites precedes 
the toxicological event. Interestingly, the skin-specific toxicities for both drugs is 
attributed to local bioactivation by metabolic enzymes within the skin 
(sulfamethoxazole – phase I flavin-containing monooxygenase 3; nevirapine – 
phase II sulfotransferase) (19), as opposed to a systemic pathway via a particular 
effector T cell population as observed with flucloxacillin.  
1.5.1.3 Type C dose-dependent toxicity 
Pioneering work on what are now recognized as type C toxicants including 
APAP, bromobenzene, phenacetin, and 4-ipomeanol helped define the covalent 
binding hypothesis and establish the foundations of mechanistic toxicology. 
Common to all type C toxicants is bioactivation to a reactive metabolite, followed 
by covalent binding, crucially, in a dose-dependent manner. This feature permits 
demarcation of a reproducible dose threshold for toxicity, and can be reliably 
extrapolated based on body weight for dosing special patient populations such as 
pediatrics. Importantly, the dose-toxicity relationship forms the basis of managing 
overdoses through the use of nomograms. For example, healthy adults with 
normal liver function can tolerate a daily dose not exceeding 4 g of APAP, while 
pediatric dosing is recommended at 10-15 mg/kg/dose (30). For APAP overdose, 
the Rumack-Matthew nomogram guides treatment using N-acetylcysteine with 
considerations of APAP plasma concentration and time post-ingestion. 
Available evidence suggests that metabolism-dependent covalent binding is the 
inciting event in type C reactions. 4-ipomeanol is a natural cytotoxin isolated 
from sweet potatoes infected with the mold Fusarium solani, responsible for 
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pulmonary toxicities in animals including cattle and rodents. Subsequent 
investigations revealed that the furan ring of 4-ipomeanol is bioactivated by 
CYP450 enzymes (e.g. CYP4B1 in rodent lungs) to electrophilic epoxides and 
α,β-unsaturated di-aldehyde reactive metabolites capable of covalent binding (31). 
Pre-treatment of rats with CYP450 inhibitors such as pyrazole markedly reduced 
in vivo covalent binding and lethal toxicity of 4-ipomeanol (32). Conversely, pre-
treatment of rats with diethylmaleate, which depletes endogeneous GSH, a 
nucleophilic scavenger, markedly increased 4-ipomeanol covalent binding and 
toxicity (32). Separately, modulations of CYP450 activity by inducers and 
inhibitors, as well as GSH levels in rodent studies of APAP toxicity (33, 34) have 
reproduced similar trends as those of 4-ipomeanol. Furthermore, peak levels of 
APAP covalent binding consistently preceded hepatic necrosis by 1-2 h (15), 
indicating a temporal, cause-and-effect relationship. Collectively, these evidences 
underscore the key role of covalent binding as a critical driver in initiating type C 
toxicity.  
1.5.2 Covert Effects of Covalent Binding 
The formation of protein adducts with drugs or their reactive metabolites 
described in the previous section can be regarded as a form of exogeneous post-
translational modification (PTM) of proteins. Since protein function is determined 
by its 3-dimensional structure, it is immediately obvious that overt protein 
modification through covalent binding can modulate the functional properties of 
proteins. Less well-recognized, however, is that covalent binding by drugs can 
exert a covert, secondary change in protein structure by inducing endogeneous 
PTMs such as acetylation and glutathionylation. 
Endogeneous PTMs play crucial roles in regulating many complex biological 
networks, maintaining homeostasis and responding to perturbations such as 
13 
 
cellular stress. For example, epigenetic control of gene expression is regulated via 
reversible acetylation of histones by histone acetyl transferases (HATs) and 
histone deacetylases (HDACs), where histone acetylation results in chromatin 
decondensation, allowing access to transcription factors and co-activators (35). 
Cellular metabolism levels can dynamically modulate protein acetylation based 
on the relative cellular concentrations of nicotinamide adenine dinucleotide 
(NAD+) and acetyl-coenzyme A (acetyl-CoA). In a fasting state, increasing levels 
of NAD+ activate sirtuins possessing HDAC-like activities. Sirtuins mediate 
protein deacetylation by cleaving NAD+ to nicotinamide and ADP–ribose, and 
transfering the acetyl group from acetyl-CoA to ADP–ribose (35). Conversely, 
when nutrient abundance increases, acetyl-CoA levels rise, leading to an increase 
in acetyltransferase activities and protein acetylation (35). Thus protein 
acetylation is thought to behave as a metabolic sensor and transduces signals 
depending on the cellular metabolic status. Congruent with this theory, many 
mitochondrial proteins can be acetylated which culminates in altered activity (36), 
suggesting that acetylation can modulate mitochondrial metabolism.  
When constitutive protein PTM patterns are altered, perturbations in cellular 
homeostasis occur that may in turn lead to pathological outcomes. For example, 
abnormal acetylation has been documented in cancer (37), as it dysregulates gene 
expression and cellular metabolism as observed in malignancy. This analogy can 
be extended to covert protein modifications induced by drugs, and it becomes 
obvious that drugs that trigger aberrant PTMs and may yield unintended 
beneficial or adverse effects.  
Aspirin (acetylsalicylate) is widely used for its antipyretic, analgesic, anti-
inflammatory and anti-thrombotic effects. Aspirin binds covalently to, 
transacetylates and inhibits the cyclooxygenases (COX)-1 and -2. Inhibition of 
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COX-2 produces the analgesic and anti-inflammatory effects, while inhibition of 
COX-1 results in ulceration and stomach bleeds, well-known adverse effects of 
aspirin (38). The covalent inhibition of platelet COX-1 blocks the conversion of 
arachidonic acid to thromboxane A2 which has pro-thrombotic activity (39). 
Beyond acetylation of COX enzymes, aspirin can induce aberrant acetylation of 
over 500 proteins involved in tumour suppression (e.g. EIF2, eIF4/p70S6K and 
mTOR), bioenergetics (e.g. glycolysis, gluconeogenesis) and other pathways (40). 
However, the functional consequence of this neo-acetylation pattern is still 
unclear, and needs to be established to elucidate the biological implications of 
aspirin-induced acetylation. 
Another endogeneous PTM induced by covalent binding is protein 
glutathionylation, which is perpetrated by APAP. APAP-induced protein 
glutathionylation will be discussed in greater detail in Chapter 2. The ability of 
drug covalent binding to modulate basal physiological PTM patterns is a critical 





1.5.3 Limitations of the Covalent Binding Hypothesis  
Despite the numerous examples provided in this chapter on ADRs elicited by 
drug covalent binding, there are limits to the applicability of the covalent binding 
hypothesis. A crucial argument is that not all instances of covalent binding 
translate to appreciable toxicity; and vice versa not all toxicities (with reference to 
type B and type C reactions) arise as a result of covalent binding. 
For instance, while the association between covalent binding and APAP toxicity 
is clear, the regioisomer of APAP, 3'-hydroxyacetanilide (AMAP) causes 
equivalent levels of covalent binding as APAP, yet is non-hepatotoxic in mice 
(41). Further investigations revealed that APAP and AMAP bind differentially to 
liver proteins, where AMAP displays greater selectivity for proteins in the 
endoplasmic reticulum (42), while APAP preferentially forms adducts with 
mitochondrial proteins (43). These observations led to the refinement of the 
covalent binding hypothesis to include the paradigm that only a subset of protein 
adducts are critical to mediate toxicity, also known as the critical target 
hypothesis. In other words, the total binding to cellular proteins may be less 
relevant than selective modifications of specific critical targets (44). However, the 
identities of these critical targets have proven elusive, due to methodological and 
analytical limitations. For example, although over 30 liver proteins including 
enzymes have been found to be adducted to APAP, the activity of most modified 
enzymes were only modestly affected (44), and are not thought to be critical 
drivers of hepatotoxicity.  
The poor predictivity of covalent binding for toxicity, particularly IDRs is the 
subject of much scholarship, and has been extensively reviewed in literature (11, 
16, 44-47). As alluded to earlier, one key reason lies in the inability to 
comprehensively profile and identify the protein targets of covalent binding, due 
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to current methodological and analytical limitations. It is impossible to determine 
the consequences of covalent binding without inferring potentially perturbed 
pathways from adducted proteins. Even for well-investigated drugs like APAP, 
about 30 adducted proteins have been identified, which are likely only a fraction 
of the total adducted species. This incomplete picture hampers toxicological 
interpretations. 
Secondly, the drug-protein adduct can induce secondary PTMs such as acetylation 
and glutathionylation. Current knowledge on the ability of drugs to induce such 
PTMs is limited. Furthermore, it can be difficult to distinguish between drug-
induced, aberrant PTMs and basal, homeostatic PTMs. 
Thirdly, the biological effects of a PTM, whether exogenously or endogenously 
derived are often unknown, and can range from unchanged, amplified or 
attenuated protein function. This adds additional complexity to the interpretation 
of the effects of covalent binding. Although biochemical assays can be performed 
to elucidate the biology of a PTM, they often are performed in a simplified, 
reconstituted cell-free system which lacks the dynamic in vivo interactions of a 
biological network and may not reveal the complete biological function of the 
PTM. Greater efforts are required to address these gaps in order to advance our 
understanding of covalent binding in toxicity. 
1.6 Pharmacological Significance of Covalent Binding 
Because of the possibility that covalent binding may elicit toxicity, traditionally, 
overt covalent binding as a mechanism of action is considered unfavorable in 
drug development due to the potential for off-target reactivity and toxicological 
sequelae. Nevertheless, covalent drugs (i.e. drugs that bind covalently to the target 
protein to elicit pharmacological effects) feature prominently in terms of revenue 
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and prescription rates (48). For example, 26 covalent drugs collectively account 
for USD 33 billion in worldwide annual sales, while in 2008, clopidogrel and 
esomeprazole accounted for 60 million prescriptions in America (48). Covalent 
drugs are utilized for a wide range of indications, including cardiovascular 
(aspirin, clopidogrel), infectious disease (β-lactam antibiotics), gastrointestinal 
(esomeprazole), central nervous system (rasagiline), oncology (5-fluorouracil) 
and many others. In almost all cases, their covalent nature was not by rational 
design, but discovered through serendipity as the mechanism of action surfaced 
during the late optimization stage, or even post-marketing (49). 
Despite concerns of toxicity, there has been a resurgence of interest in covalent 
drugs in recent years due to the recognition of several unique advantages. 
Mechanistically, the binding of a covalent inhibitor begins by non-covalent 
interactions with the target protein, positioning the electrophile in close proximity 
to the target nucleophilic residue. The resulting complex undergoes covalent bond 
formation, giving rise to the desired irreversible inhibition (48). Covalent drugs 
permit the possibility of achieving increased potency and isoform selectivity by 
targeting a poorly conserved amino acid residue. Uniquely, a sustained duration 
of action can be achieved as inhibition persists until further target protein 
synthesis, essentially uncoupling pharmacodynamic effects from 
pharmacokinetics of drug exposure, allowing less frequent dosing and lower 
doses, possibly minimizing dose-dependent off-target covalent binding. 
Additionally, covalent binding overcomes situations of high concentration levels 
of endogenous substrate (e.g. ATP) competing with reversible inhibitors (e.g. 
kinase inhibitors). Studies also demonstrate that irreversible inhibitors may be 
more effective against drug resistance, as covalent EGFR inhibitors remained 
active against mutant EGFR forms, while reversible inhibitors displayed no 
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activity (50). It is hypothesized that mutant forms of EGFR reduce the non-
covalent affinity between the inhibitor and its target, resulting in diminished or 
abolished activity for reversible inhibitors. However, given sufficient exposure to 
the covalent inhibitor, even mutants that react slower due to the poorer affinity 
eventually become fully inhibited, hence the covalent inhibitor retains activity. 
With these considerations, medicinal chemistry strategies are focused on 
balancing reactivity with selectivity. Functionalities that have moderate 
electrophilicity, such as acrylamides have become the moiety of choice, which 
target nucleophiles such as thiols of cysteine residues, particularly those that are 
poorly conserved or rare among members of a protein family to achieve 
selectivity (48, 49). These efforts led to the development of a number of 
candidates currently in clinical development or have been approved by the U.S. 
Food and Drug Administration (US FDA), such as allitinib, neratinib, ibrutinib, 
afatinib, abiraterone, telapravir and others (49). Despite these advances from an 
efficacy viewpoint, concerns regarding off-target covalent binding and the 
toxicity aspects remain. While tempered electrophiles such as acrylamides may in 
general react slower with cysteines, around 10% of solvent-exposed cysteines are 
hyper-reactive, and off-target binding with this subset of cysteines is 
unpredictable even with careful tuning of binding characteristics (51). 
Additionally, the role of bioactivation of these electrophilic functionalities require 
due consideration, as these processes can modulate the reactivity of the 
electrophiles and thus the propensity for off-target covalent binding. For example, 
apart from directly reacting with the endogenous nucleophile GSH to form a 
conjugate, the acrylamide moiety of allitinib is also epoxidated by CYP450 
enzymes followed by dihydrodiol formation by epoxide hydrolase, or GSH 
conjugation, the latter of which is suggestive of the formation of a reactive 
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metabolite (52). With the increasing interest in covalent drugs juxtaposed against 
the background of covalent binding and toxicity, it is clear that additional efforts 
are required to meet the challenge of interrogating the complete covalent binding 
repertoire of covalent drugs, including on- and off-target binding.  
1.7 Research Objectives and Significance 
1.7.1 Research Question and Objectives 
Although covalent drug binding and protein adduct formation have long been 
implicated in ADRs, there remains a significant disconnect between the initial 
adduction event and subsequent toxicological outcomes due to a number of 
reasons which have been discussed in section 1.5.3, that in turn impedes efforts to 
develop approaches which can reduce or prevent ADRs. This knowledge gap is 
made more apparent when taking into account that covalent binding as a 
pharmacological strategy is becoming increasingly prominent in drug 
development. The overarching aims of this thesis are therefore to (1) explore 
covalent drug binding from a mechanistic perspective and (2) leverage insights 
gained from these findings to enhance safety and efficacy of pharmacological 
therapy. The specific objectives of this thesis are as follows: 
1. Elucidate the consequences of covert protein modification in the form of 
drug-induced protein glutathionylation using APAP as a model toxicant. 
2. Determine the influence of structural modification via selective 
deuteration and CYP3A5 genotype on CYP3A inactivation and reactive 
metabolite formation using lapatinib as a model toxicant. 
3. Develop an effective combinatorial drug treatment to overcome tamoxifen 
resistance in breast cancer by circumventing the irreversible inactivation 
of CYP3A by lapatinib.  
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1.7.2 Thesis Outline 
As presented in the preceding sections, both the causes and consequences of 
covalent drug binding are multi-faceted. In order to address the objectives stated 
previously, APAP and lapatinib are used as probe toxicants to investigate 
different aspects of covalent binding which are further elaborated below. 
In Chapter 2, we performed a mechanistic investigation of covert drug-induced 
protein glutathionylation in human HepaRG hepatocytes using APAP as a 
toxicant. We present literature evidence supporting aberrant glutathionylation by 
APAP as a process secondary to covalent binding, and proceed to elucidate the 
influence of glutathionylation on the toxicological manifestations of APAP 
toxicity. Our findings also provide mechanistic insights which illuminate the 
mode of action for known prophylactics and antidotes which protect against or 
reverse APAP hepatotoxicity. We further demonstrate that aberrant APAP-
induced glutathionylation is a time-, dose- and bioactivation-dependent process, 
and suggest that covert protein glutathionylation is a previously unknown 
mechanism of ADRs. Chapter 3 details two strategies to mitigate the deleterious 
effects of covalent binding using lapatinib as a model toxicant. Previously, our 
research group has determined the mechanisms by which lapatinib undergoes 
bioactivation to result in CYP3A inactivation. Building upon these investigations, 
we explore selective drug deuteration as an approach to reduce the bioactivation 
of lapatinib to reactive metabolites and the associated inactivation of CYP3A. We 
also elucidate the potential of using CYP3A5 genotype to prospectively stratify 
individuals who might be at increased risk of CYP3A inactivation and reactive 
metabolite formation by lapatinib. In Error! Reference source not found., we 
attempt to turn the apparent liability resulting from lapatinib-induced CYP3A 
inactivation into a pharmacological opportunity, by developing a combinatorial 
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drug treatment using lapatinib and endoxifen to overcome tamoxifen-resistance in 
breast cancer.  
1.7.3 Significance of Project 
Understanding the mechanisms of drug-induced toxicity is crucial in developing 
efficacious and safe pharmaceuticals. Even though much work has been done on 
the effects of covalent binding in toxicity, several mechanistic aspects such as 
covert protein modification secondary to covalent binding remain unaddressed. 
With a clear understanding of such covert protein modifications, judicious 
interventions at biological pathways affected by these modifications serve as 
opportunities for therapeutic interventions. This work also illustrates how 
mechanistic information regarding the overt effects of covalent binding can be 
translated into viable strategies to mitigate the deleterious effects of protein 
adduction. Finally, this project encourages a different perspective on covalent 
binding by demonstrating that it is not necessarily a detrimental event, and the 
knowledge can be applied to optimize pharmacotherapy. Collectively, this thesis 
offers a fresh outlook on covalent drug binding and innovative strategies to 




 Chapter 2 Drug-induced Protein Glutathionylation 
2.1 Chapter Summary 
Background: Protein glutathionylation of cysteine thiols is an important 
regulatory post-translational modification governing cellular homeostasis. APAP 
can covertly induce aberrant protein glutathionylation, as a secondary outcome of 
covalent binding between its reactive metabolite and proteins. Perturbation of 
basal glutathionylation could explain the hepatotoxicity of APAP. However, due 
to a lack of suitable analytical approaches, this phenomenon has not yet been 
investigated. 
Objective: In this chapter, we aimed to develop an LC/MS-based proteomics 
method to comprehensively profile cellular protein glutathionylation. 
Subsequently, we applied this methodology to characterize and understand the 
biological consequences of aberrant glutathionylation induced by APAP. 
Methodology: The GluICAT technique was modified from the OxICAT 
approach by incorporating the filter-aided sample preparation (FASP) protocol, 
which provides an efficient solution to overcome the technical difficulties in 
profiling protein glutathionylation. GluICAT was then used to examine APAP-
induced glutathionylation in HepaRG cells in a time-, dose- and bioactivation 
dependent manner. 3’-Hydroxyacetanilide (AMAP), a reportedly non-toxic 
regioisomer of APAP, was used as a comparator. 
Results and discussion: Using GluICAT, APAP was found to cause aberrant 
glutathionylation of critical proteins involved in energy metabolism, protein 
turnover, defense against cellular stress, calcium dynamics and mitochondrial 
permeability transition pore (MPTP) opening. Proteo-metabonomic mapping 
revealed a remarkable coherence between the functional impairments induced by 
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glutathionylation and metabolic derangements caused by APAP, particularly in 
energy metabolism and GSH synthesis. Glutathionylation also provided an 
explanation for altered calcium dynamics and could be involved in MPTP 
opening. Importantly, aberrant glutathionylation accounted for many of the key 
hallmarks of APAP toxicity. Longitudinal analysis suggested that protein 
glutathionylation of key proteins occurred in the early stages (3-6 h) of APAP 
toxicity, characterized by impairment of mitochondrial respiration, loss of ATP 
synthesis, GSH depletion and abnormal calcium dynamics. Furthermore, temporal 
glutathionylation patterns suggested that a key group of glutathionylated proteins 
was responsible for toxicity, which appeared to be distinct from other proteins 
glutathionylated, possibly as a consequence of toxicity. The former was likely a 
result of overt covalent binding, while the latter correlated with temporal 
increases in oxidative stress. APAP-induced glutathionylation was also dose- and 
bioactivation-dependent, further underscoring the relationship between covert 
glutathionylation and overt covalent binding. Finally, AMAP and APAP 
unexpectedly exhibited broad overlaps in glutathionylated proteins, agreeing with 
recent findings that both agents were toxic in human liver.  
Conclusion: Aberrant protein glutathionylation by APAP is likely to be driven by 
overt covalent binding, and is responsible mechanistically for the early events in 
APAP toxicity. This study highlights a previously unrecognized mechanism of 
drug-induced liver injury which is secondary to covalent binding. Our findings 
will encourage examination of drug-induced protein glutathionylation in 
compounds where covalent binding is implicated in toxicity, particularly those 
sharing the quinone-imine toxicophore with APAP.   
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2.2 Chapter Introduction 
2.2.1 Protein Post-translational Modifications 
Despite consisting of a conserved set of 20 common amino acids that serve as 
fundamental building blocks, the human proteome is one of the most diverse set 
of biological molecules. While the human genome is estimated to consist of about 
25 000 genes (53), the proteome is far larger in size, estimated at over 1 million 
proteins (54). This diversity is driven in part by alternative splicing in mRNA, 
creating sequence variants of proteins that translate into an assortment of 
functional activity. Modifications on the side chains of amino acid residues by the 
covalent attachment of chemical moieties, termed post-translational modifications 
(PTMs) further extend the range of protein functions as these structural changes 
modulate numerous cellular functions, including metabolism, signal transduction, 
protein turnover and cell division (55). Over 200 different PTMs have been 
identified, ranging from glycosylation, ubiquitination, methylation, acetylation, 
amidation, glutathionylation and the most widely studied, phosphorylation (56). 
Nearly all amino acid side chains can undergo some form of PTM, making the 
range of possible modified proteins nearly limitless. 
2.2.2 Mechanisms of Cysteine Glutathionylation 
Although cysteine is one of the least abundant amino acids in eukaryotic proteins 
(estimated at 1.9%) (57), it is frequently observed to concentrate in functionally 
important sites in proteins, playing regulatory, catalytic, cofactor binding and 
other roles (58). The functional significance of cysteine is further substantiated by 
a higher frequency of genetic diseases occurring due to cysteine mutations than is 
expected from its natural abundance (59). The prominence of cysteine is due in 
part to its exceptional PTM versatility. Its thiol side chain can undergo a variety 
of chemical modifications, including disulfide formation, farnesylation, 
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geranylgeranylation, glutathionylation, isoprenylation, nitrosylation, oxidation, 
palmitoylation and sulfhydration (60), with correspondingly varied biological 
effects. Cysteine glutathionylation, occasionally referred to as glutathiolation has 
gained interest in recent years as part of a group of redox-sensitive thiol 
modifications that also include oxidation and nitrosylation.  
Unlike PTMs such as phosphorylation, which are generally enzymatically-driven, 
oxidation, nitrosylation and glutathionylation can be spontaneous events, making 
these modifications sensitive to changes in oxidative stress. Chemically, the thiol 
group possesses an average pKa of around 8.6 which means that most cysteines 
remain protonated in the reducing cytoplasmic milleu, but the pKa can vary 
between 3.5 to 10, depending on the microenvironment surrounding the cysteine 
thiol (61). For example, the pKa can be lowered by positively charged or 
protonated amino acids which stabilize the thiol in the deprotonated, thiolate 
form, and increases its reactivity and nucleophilicity (61). Apart from the intrinsic 
reactivity of a particular thiol group, solvent accessibility also determines if the 
cysteine residue interacts with other chemical moieties capable of thiol 
modification. Cysteine residues buried within the hydrophobic core of a protein 
are less likely to be modified compared with surface, solvent exposed residues 
(61). Finally, the pH of the macroenvironment also influences the likelihood of 
deprotonation, particularly if the pH is higher than the pKa. The pH of cellular 
compartments and organelles can vary from as low as 4.7 (lysosome), to 7.2 
(nucleus and cytosol) and 8 (mitochondria) (62). Thus the reactivity of a 





Cysteines undergo glutathionylation through a variety of mechanisms, as 
illustrated in Figure 2-1. This includes (1) oxidation to a sulfenic acid followed by 
reaction with GSH, (2) thiol-disulfide exchange with oxidized glutathione 
(GSSG), (3) nitrosylation of the cysteine residue followed by reaction with 
reduced GSH, (4) reaction of the reduced cysteine thiol with nitrosoglutathione 
(GSNO), or (5) reaction between two thiyl radicals (63) (Figure 2-1). These 
reactions can be mediated either chemically through reactive oxygen/nitrogen 
species (ROS/RNS), or enzymatically, as documented with glutathione-S-
transferase π (GSTπ) and glutaredoxin 1 (Grx1) (64). Conversely, cellular 
deglutathionylation is exclusively an enzymatic process which is mediated by 
Grx1, glutaredoxin 2 (Grx2), sulfiredoxin (Srx) and protein disulfide isomerase 
(PDI) (63). An important point to note is that while oxidative stress can induce a 
variety of thiol modifications, thiol oxidation and nitrosylation can ultimately lead 
to protein glutathionylation. Therefore, glutathionylation could be considered to 






Figure 2-1 Mechanisms of cysteine glutathionylation via reaction with ROS, 
RNS, GSSG, GSNO or OH
·
. Pr-SH: free protein thiol; Pr-SOH: protein sulfenic 
acid; Pr-SNO: nitrosylated protein thiol; Pr-S-SG: glutathionylated protein; ROS: 
reactive oxygen species; RNS: reactive nitrogen species; GSNO: 
nitrosoglutathione; OH
·
: hydroxyl radical; Pr-S
·





(2) GSSG, (4) GSNO 
 
Grx1, Grx2, Srx, PDI 
27 
 
2.2.3 Biological Consequences of Cysteine Glutathionylation  
Glutathionylation results in a change in size and charge of the cysteine residue, 
where the addition of the tripeptide causes an increase in molecular weight by 305 
Da and a net increase in negative charge contributed by the glycine residue of 
GSH (65). This structural and electronic change can alter the functional properties 
of the protein, particularly if the modified cysteine residue is located in a 
functionally important region. In the case of enzymes, this most often results in an 
inhibition of enzymatic activity when the modified cysteine is present in the 
active site, and is often observed in enzymes involved in energy metabolism (63). 
However, this is not always the case, as an increase in catalytic activity (e.g. 
phosphatase activity of carbonic anhydrase III) (66), alteration in DNA binding of 
transcription factors (67, 68), and modulation of protein stability (69, 70) have 
been documented.  
Given that glutathionylation can modulate protein function, it is plausible that 
beyond individual proteins, glutathionylation can regulate more complex 
pathways and networks. Protein glutathionylation has often been described as 
analogous to phosphorylation, due to the many parallels between these two PTMs. 
Glutathionylation meets several criteria to be ascribed a regulatory role. Firstly, 
like phosphorylation, glutathionylation is reversible; secondary, it can be 
regulated enzymatically, as is phosphorylation via kinases; and finally, there is a 
certain degree of specificity, as only cysteines in a particular microenvironment 
and milleu are sufficiently reactive to undergo glutathionylation (63). However, 
there are unique characteristics of glutathionylation that differ from that of 
phosphorylation. For example, glutathionylation can occur non-enzymatically in 
response to a change in the cellular redox status, while phosphorylation is 
dependent on kinase activity. Also, while clear amino acid consensus sequences 
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that facilitate phosphorylation have been described, no such motifs have been 
found that predicts glutathionylation sites.  
The redox-sensitive nature of glutathionylation renders it suitable as a regulatory 
mechanism to protect the cell against oxidative stress. For example, oxidative 
stress-induced glutathionylation of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and triosephosphate isomerase (TPIS) involved in glycolysis reroutes 
metabolic substrates such as glucose-6-phosphate into the pentose phosphate 
pathway, which is a key pathway responsible for generating nicotinamide adenine 
dinucleotide phosphate (NADPH), an electron donor for the antioxidant enzymes 
glutathione reductase and thioredoxin reductase, and is essential to maintain the 
reducing environment of the cytosol and counteract oxidative stress. Upon 
alleviation of oxidative stress, glutaredoxin reverses GAPDH and TPIS 
glutathionylation, restoring their catalytic activity (71). Apart from regulating 
metabolic fluxes, glutathionylation has also been described to modulate signal 
transduction pathways (kinases and Ras proteins), cell survival and apoptosis 
(caspases and death receptors), calcium homeostasis, protein degradation via 
ubiquitination, cellular migration (cytoskeletal proteins), energy metabolism 
(glycolysis, fatty acid β-oxidation, citric acid cycle and oxidative 
phosphorylation) and other pathways, which have been extensively reviewed (64, 
65, 72, 73).  
In some cases, glutathionylation may not have a discernible impact on protein 
function. It has been speculated that glutathionylation serves as a mechanism to 
protect cysteine thiols from permanent damage in oxidative stress. By forming 
mixed disulfides with redox-sensitive cysteine thiols, they are no longer available 
for further reactions such as irreversible oxidation to sulfonic acids ( 
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Figure 2-2), which are resistant to cellular repair mechanisms and leads to 
proteasomal degradation (73). This allows the preservation of cysteine and protein 
integrity until the oxidative stress is overcome and deglutathionylation 
mechanisms restore the thiol to its basal state (73).  
 
 
Figure 2-2 Cysteine thiol oxidation states. Free thiols can be oxidized to higher 
oxidation states such as sulfenic, sulfinic and sulfonic acids by ROS or RNS. 
Lower oxidation states such as sulfenic and sulfinic acids are reversible, while 
sulfonic acids are considered irreversible (74). 
 
Unsurprisingly, dysregulation of cysteine glutathionylation has been reported in 
various disease conditions, particularly those which develop against a background 
of oxidative stress. These include diabetes, cardiovascular disease (e.g. 
myocardial infarction, cardiac hypertrophy and atherosclerosis), pulmonary 
disease (e.g. chronic obstructive pulmonary disease), malignancies, and 
neurodegenerative disease (e.g. Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease and amyotrophic lateral sclerosis) (64). Importantly, 
aberrant oxidation, nitrosylation and glutathionylation of mitochondrial proteins 
feature prominently in these disease conditions. However, in such situations, it 
can be challenging to separate instances of cysteine glutathionylation that are 
drivers or mediators of pathogenesis from those that are a consequence of 
oxidative stress. Nevertheless, the role of cysteine glutathionylation as a 
functional PTM is undisputed, as glutathionylation has been observed under basal 
conditions to constitutively regulate the function of haemoglobin, γ-crystallin in 




2.2.4 Covalent Binding in APAP Hepatotoxicity 
As described briefly in Chapter 1, early work on elucidating the mechanisms of 
APAP hepatotoxicity centered on covalent binding of the electrophilic reactive 
metabolite, NAPQI, to critical cellular proteins. The essential role of covalent 
binding as the initial trigger of the toxic insult is underscored by the attenuation 
and amplification of hepatotoxicity when covalent binding was diminished and 
magnified by the use of CYP450 inhibitors and inducers respectively, and peak 
levels of covalent binding consistently preceded hepatic necrosis by 1-2 h in 
rodent models (15). Clinical data further supports the association between 
covalent binding and toxicity, where patients experiencing the most severe 
toxicity exhibited the highest levels of APAP adducts in plasma, and adduct levels 
in serum correlate with hepatic transaminase levels in these patients (75).  
Protein adduction by APAP is believed to trigger mitochondrial dysfunction, 
although the mechanism is currently unclear. This dysfunction is characterized by 
inhibition of mitochondrial respiration and enhanced mitochondrial oxidative 
stress (76). The major source of oxidative stress is derived from increased 
generation of superoxide from the electron transport chain, which can react with 
nitric oxide to form peroxynitrite, a potent oxidant and nitrating species. The 
increased mitochondrial oxidative stress, presumably due to APAP covalent 
binding, is thought to result in dissociation of the thioredoxin-apoptosis signal-
regulating kinase 1 (ASK1) complex, leading to the activation of ASK1, which 
phosphorylates and activates c-jun-N-terminal kinase (JNK) (77). It has been 
suggested that oxidative stress or APAP adduction to GSTπ causes the release of 
sequestered JNK from GSTπ, permitting its phosphorylation (77). The activation 
of JNK leads to its translocation to the mitochondria, where it further amplifies 
mitochondrial ROS and peroxynitrite formation through a yet unknown 
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mechanism. The inhibition of JNK activation was reported to cause a profound 
suppression of peroxynitrite formation and mitochondrial ROS formation, and 
was a highly effective intervention against APAP toxicity (76), underscoring the 
importance of activated JNK to the mechanism of toxicity. 
The exacerbated mitochondrial oxidative stress is thought to lead to mitochondrial 
DNA damage, loss of mitochondrial enzymatic activities and trigger the opening 
of the mitochondrial permeability transition pore (MPTP) (78). The latter causes 
the collapse of mitochondrial membrane potential needed to sustain ATP 
synthesis, as well as rupture of the outer mitochondrial membrane, triggering 
release of endonuclease G and apoptosis-inducing factor (AIF) which translocate 
to the nucleus and cause DNA fragmentation, culminating in necrotic cell death 
(77). 
Despite the causal relationship between covalent binding and toxicity, it is clear 
that there remains a significant disconnect between the initial adduction event and 
the subsequent toxic sequelae. Over 30 hepatic proteins were found to form 
adducts with APAP, and diminished activities have been reported for some of 
these proteins, including glutamine synthetase, glutamate dehydrogenase, 
carbamyl phosphate synthetase, aldehyde dehydrogenase, N-10 
formyltetrahydrofolate dehydrogenase and glutamate dehydrogenase (75, 79). 
However the activities of these enzymes were only moderately inhibited 
(approximately 25%), insufficient to account for the toxicity observed with 
APAP. Adduction of glutathione peroxidase (GPx) produced the greatest decrease 
in its activity (60%) (80), however GPx-/- knockout mice did not exhibit an 
increase in liver injury after APAP treatment (81). Similarly, when examining the 
list of APAP protein adducts, no critical targets can be clearly ascribed to the 
toxicity manifestations and hallmarks of APAP-induced hepatotoxicity. The 
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inverse scenario, where hepatotoxic doses of APAP affect hepatic enzymatic 
activities without detectable adduct formation also supports the observation that 
covalent binding alone is an insufficient explanation for APAP toxicity (82). For 
example, calcium-dependent ATPases, plasma membrane Na+-K+-ATPase and 
protein phosphatase activities are decreased after exposure to toxic doses of 
APAP with no evidence of APAP binding to these enzymes (82).  
2.2.5 APAP-induced Protein Glutathionylation 
As described in Chapter 1, the effects of covalent binding are not confined to the 
overt effects of protein adduction, but can also manifest as covert, secondary 
changes to protein structure by inducing aberrant, endogenous PTMs. In the case 
of APAP, literature evidence suggests that in addition to overt protein adduct 
formation, APAP can induce protein glutathionylation as a form of indirect 
protein modification. In the late 1980s, a series of reports by Nelson and 
colleagues indicated that APAP treatment depleted free protein thiols in vitro in 
isolated rat hepatocytes (83, 84) and in vivo in mouse liver (80). Importantly, the 
loss in free protein thiols was much greater than the loss expected from detectable 
covalent binding of protein thiols alone (80). Treatment of liver homogenates 
from these mice with the chemical reductant dithiothreitol (DTT) restored free 
thiol levels, and it was concluded at the time that the loss of free protein thiols 
was due to thiol oxidation (80). Given that mitochondrial oxidative stress is a key 
event in the progression of APAP toxicity, thiol modifications are not unexpected. 
Interestingly, despite causing equivalent levels of covalent binding, the non-toxic 
regioisomer, AMAP did not result in a similar decrease in liver protein thiols in 
mice (80). Further work by Nelson and colleagues provided evidence of the 
formation of an ipso conjugate of NAPQI with GSH that interestingly, could react 
with another free thiol (e.g. of a protein cysteine), resulting in the 
33 
 
glutathionylation of that cysteine and release of APAP. The reverse could also 
happen, where an ipso protein adduct reacts with GSH resulting in protein 
glutathionylation and release of APAP (Figure 2-3). In other words, an ipso 
adduct derived from NAPQI conjugating either with a protein cysteine or GSH, 
can cross react with other free thiols of proteins and GSH, ultimately resulting in 
protein glutathionylation. Using papain as a model protein containing an active 
site cysteine, an ipso adduct of NAPQI with papain was formed that could be 
displaced by GSH to release free APAP from the protein adduct. Crucially, as a 
result of this reaction a mixed disulfide was formed between the thiol group of 
papain and GSH, resulting in its glutathionylation (85). This critical piece of 
evidence proved for the first time that covalent binding by APAP is not 
irreversible, but can in fact induce a secondary, covert protein modification in the 
form of glutathionylation via the formation of an ipso conjugate. More 
importantly, this work illustrates that contrary to current understanding, protein 
glutathionylation is not solely the result of oxidative stress (section 2.2.2), but can 
arise from the direct action of reactive metabolite formation and adduction to 
GSH or cellular proteins. Additionally, protein glutathionylation can occur early 
during the time-course of toxicity as long as an ipso-GSH adduct has been 
formed. Finally, this provides an explanation for the formation of glutathionylated 
proteins at sites (e.g. mitochondria) distant from the smooth endoplasmic 
reticulum where the CYP450 enzymes are localized. While NAPQI is inherently 
unstable and reacts rapidly with surrounding nucleophiles, it is possible that the 
ipso-GSH adduct is sufficiently stable to be transported to the mitochondria where 
it can glutathionylate proteins. Because the ipso-GSH adduct can also decompose 
to yield NAPQI within the physiological pH range, it serves as a latent carrier of 
NAPQI that causes covalent binding in other organelles. This is in contrast to the 
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accepted convention that marked protein adduction occurs only after severe GSH 
depletion. The mechanisms of APAP-induced protein glutathionylation via both 










Figure 2-3 Mechanisms of APAP-induced protein glutathionylation secondary to 
NAPQI formation. Pr-SH: free protein thiol; ROS: reactive oxygen species; RNS: 
reactive nitrogen species; GSNO: nitrosoglutathione; Pr-S-SG: glutathionylated 
protein. 
 
Yang et al. provided further evidence that APAP exposure led to protein 
glutathionylation in mice. Using immunohistochemical staining with anti-APAP 
and anti-GSH antibodies, it was demonstrated that regions of APAP adduct 
formation and protein glutathionylation overlapped (86), indicating a spatial 
correlation between protein adduction and glutathionylation. This substantiates 
the mechanism of APAP-induced protein glutathionylation proposed by Nelson 
and colleagues (85). The magnitude of glutathionylation was also time-dependent, 
and exhibited a zonal distribution by spreading outwards from the centrilobular 
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Despite strong evidence that APAP can induce aberrant protein glutathionylation, 
there are no comprehensive investigations on the suite of glutathionylated 
proteins and the pathways affected by APAP. This represents an important gap in 
our current mechanistic understanding of APAP toxicity.  
2.2.6 Approaches to Detect Protein Glutathionylation 
A variety of techniques have been developed to profile protein glutathionylation, 
and can be broadly divided into gel-based and non-gel-based protein separation 
approaches. The earliest gel-based methods utilize radiolabelled GSH 
incorporated with 3H or 35S, in situ metabolic labeling with 35S-cysteine, anti-
GSH antibodies or biotinylated GSH as handles to detect glutathionylated 
proteins, which are then separated using SDS-PAGE and detected by 
autoradiography, fluorescence, chemiluminescence or liquid 
chromatography/mass spectrometry (LC/MS) via excision of gel spots of interest 
(87). These approaches are constrained by several inherent limitations of gel-
based separation which include (1) inter-gel variability, (2) demand for 
complicated software-based image analysis and normalization, (3) poor separation 
of hydrophobic proteins, (4) under-representation of membrane-bound proteins, 
(5) limited dynamic range, and (6) loss of low-abundance proteins (88). Thus 
such gel-based approaches are unsuitable for an unbiased, proteome-wide 
detection of glutathionylated proteins. These limitations can be overcome through 
the use of in-solution, LC/MS based techniques, which uses LC to separate 
proteins or digested peptides followed by detection using MS with high 
reproducibility, large dynamic range and sensitivity, and unbiased detection of 
hydrophobic or hydrophilic proteins.  In this chapter, we aimed to first develop an 
LC/MS-based proteomic method capable of performing proteome-wide detection 
and identification of glutathionylated proteins. We then applied this novel 
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methodology to comprehensively profile and correlate the global change in 





2.3 Materials and Methods 
2.3.1 Materials 
Acetaminophen (APAP), 3′-hydroxyacetanilide (AMAP), 2-hydroxyethyl 
disulfide (HED), glyceraldehyde-3-phosphate, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), sodium diethyldithiocarbamate trihydrate (DEDC), 
sodium arsenate, β-nicotinamide adenine dinucleotide (NAD+), reduced L-
glutathione (GSH), dithiothreitol (DTT), sodium dodecyl sulfate (SDS), tris(2-
carboyxethyl)phosphine (TCEP) hydrochloride, trichloroacetic acid (TCA) and 
hydrogen peroxide were purchased from Sigma-Aldrich (St Louis, MO, USA). 
NADPH tetrasodium salt was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Glutaredoxin-1 C14S mutant (Grx1) was purchased from 
Cayman Chemicals (Ann Arbor, MA, USA). Tris base was purchased from J. T. 
Baker (Phillipsburg, NJ, USA). Glutathione reductase (GR) was obtained from 
Roche Diagnostics (Basel, Switzerland). Sequencing Grade Modified Trypsin was 
purchased from Promega (Madison, WI, USA). Pierce BCA protein assay kit was 
obtained from Thermo Scientific (Waltham, MA, USA). Phosphate-buffered 
saline was obtained from Vivantis (Selangor, Malaysia). Cleavable ICAT 
(isotope-coded affinity tag) reagents were purchased from ABSciex 
(Framingham, MA, USA). Filter-aided sample preparation (FASP) kits were 
obtained from Expedeon (Cambridgeshire, UK). Water was purified using a 
Milli-Q water purification system (Millipore, Bedford, MA, USA). All other 




2.3.2 Development of the GluICAT Methodology to Profile Protein 
Glutathionylation 
2.3.2.1 Indirect Monitoring of GAPDH Glutathionylation and 
Deglutathionylation 
1 mg/mL GAPDH was incubated with 1.5 mM H2O2 and 5 mM GSH in 270 µL 
100 mM Tris-HCl pH 7.6 buffer for 1 h at room temperature (25°C) to artificially 
induce glutathionylation of its thiol group (89). GAPDH activity was measured 
spectrophotometrically as previously described (90). Briefly, the assay mixture 
contained 0.2 mg/mL GAPDH, 0.1 mM EDTA, 1 mM NAD+, 1 mM sodium 
arsenate and 1 mM glyceraldehyde-3-phosphate in 100 µL of 100 mM Tris-HCl 
pH 7.6. The activity of GAPDH was measured by following the conversion of 
NAD+ to NADH at 340 nm for 15 min at room temperature (25°C). 
Glutathionylated GAPDH (GAPDH-SG) was then deglutathionylated using a 
mixture of 0.4 mM NADPH, 5 mM GSH, 0.9 U/mL GR, 0.1 U Grx1 and 0.1 mM 
EDTA at 37°C for 15 min and GAPDH activity was again assayed as described. 
Untreated native GAPDH activity was also measured as a baseline. Reduction of 
GAPDH-SG was performed using DTT as a positive control. All experiments 
were conducted in triplicates. 
2.3.2.2 Direct Monitoring of GADPH Deglutathionylation 
2.9 mg/mL GAPDH was glutathionylated by incubation with 6 mM H2O2 and 30 
mM GSH in 550 µL 100 mM Tris-HCl pH 7.6 for 30 min. GAPDH-SG 
deglutathionylation was assayed spectrophotometrically as previously described 
(91). Briefly, the assay mixture contained 4.16 mg/mL GAPDH-SG, 10 mM 
NAPDH, 10 mM GSH, 4 U/mL GR, 0.5 U/mL Grx1, and 0.1 mM EDTA in 250 
µL 100 mM Tris-HCl pH 7.6. The deglutathionylation process was monitored by 
following NAPDH consumption for 30 min at room temperature (25°C). Negative 
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control measurements were conducted in the absence of Grx1. A mixed disulfide 
formed between HED and GSH was used as a positive control for the 
deglutathionylation reaction as previously described (92). All experiments were 
conducted in triplicates. 
2.3.2.3 GluICAT Processing of Glutathionylated GAPDH 
GAPDH-SG was generated as described above and subjected to a modified 
OxICAT method (93), termed GluICAT.  Briefly, 200 μL of ice-cold 100% (w/v) 
TCA was added to 100 µg of GAPDH-SG to quench thiol reactivity and 
precipitate GAPDH-SG. The precipitate was centrifuged at 14 000 g for 30 min at 
4°C to obtain a pellet. Denaturing alkylation buffer (DAB) containing 6 M urea, 
200 mM Tris-HCI, pH 8.5, 10 mM EDTA, and 4% (w/v) SDS was freshly 
prepared before use. The protein pellet was rinsed once with 500 µL ice-cold 10% 
(w/v) TCA, followed by a second rinse with 200 µL ice-cold 5% (w/v) TCA. The 
pellet was then redissolved in 80 µL DAB, followed by alkylation with light 
ICAT reagent for 2 h. GAPDH-SG was precipitated using 500 µL of -20°C cold 
acetone and maintained at -20°C overnight. The acetone precipitate was 
centrifuged at 14 000 g for 30 min at 4°C, and the protein pellet was rinsed twice 
with 500 µL -20°C cold acetone to remove excess light ICAT. The protein pellet 
was redissolved in DAB and prepared for the deglutathionylation step using 
FASP. The protein solution was loaded onto a spin column and SDS was removed 
by washing 3 times with 6 M urea, followed by 3 washes with 50 mM ammonium 
bicarbonate to condition the membrane for the subsequent deglutathionylation 
step. To effect deglutathionylation, the following mixture was added: 10 mM 
GSH, 10 mM NADPH, 4 U/mL GR and 0.5 U/mL Grx1 in 100 µL 50 mM 
ammonium bicarbonate and incubated for 1 h at 37°C on the spin column. Excess 
GSH was removed by washing 4 times with 50 mM ammonium bicarbonate. 
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Newly reduced cysteines were labelled with heavy ICAT reagent for 2 h, 
followed by removal of excess heavy ICAT by washing 3 times with 50 mM 
ammonium bicarbonate. Proteins were then digested with trypsin (1:30 
trypsin/protein ratio) for 12-16 h at 37°C. Peptides were eluted with 50 mM 
ammonium bicarbonate and 0.5 M sodium chloride. Peptides were purified using 
avidin affinity chromatography according to manufacturer recommendations. 
Finally the biotin tag was cleaved and samples were desalted using UltraMicro 
Spin Columns (Nest Group, Southborough, MA, USA) before LC/MS/MS 
analysis. In a separate arm, Grx1 was omitted from the deglutathionylation 
mixture as a control. Experiments in each arm (with and without Grx1) were 
performed in triplicates. 
2.3.2.4 LC/MS/MS Detection of GluICAT-treated Glutathionylated GAPDH.  
LC/MS/MS was performed using an Ultimate 3000 nanoLC system (Dionex, 
Thermo Fisher Scientific, MA, USA) coupled to an ABSciex 5600 triple TOF 
(ABSciex, Framingham, MA, USA).  A 50 cm × 75 µm i.d. Acclaim PepMap 
RSLC C18 column was employed (Dionex, Thermo Fisher Scientific, MA, USA). 
This column was connected to a spray tip (New Objectives, Woburn, MA), which 
was directly coupled to the nano-spray interface of the ABSciex 5600 tripleTOF 
mass spectrometer. Samples were loaded onto a trap column (Acclaim PepMap 
100 C18, 2cm × 75µm i.d., Dionex, Thermo Fisher Scientific, MA, USA) at a flow 
rate of 5 µL/min. After a 3 min wash with loading buffer (2/98 v/v of ACN/water 
with 0.1% formic acid), the system was switched into line with the C18 analytical 
capillary column. A step linear gradient of mobile phase B (2/98 v/v of 
water/ACN with 0.1% formic acid) from 5% to 25% over 10 min, 25%-60% for 9 
min, and lastly, 60%-95% over 1 min at flow rate of 300 nL/min was utilized for 
this analysis. Third generation Nanospray Source was installed and other 
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instrumentation settings were as follows: Ionspray Voltage Floating (ISVF) = 
2200 V, curtain gas (CUR) = 30, ion source gas 1 (GS1) = 12, interface heater 
temperature (IHT) = 125°C, declustering potential (DP) = 100 V, nebuliser 
current (NC) = 3 for nitrogen gas. Data was acquired using TOF MS + Hi 
Sensitivity product ion with Analyst TF 1.6 software (ABSciex, Framingham, 
MA, USA).  TOF-MS scan (experiment 1) parameters were set as follows:  0.25 s 
TOF MS accumulation time in the mass range of 350 to 1250 Da was followed by 
MS/MS scan based on the following parameters: mass range was set at 100 to 
1500 Da; switching criteria were set to ions greater than m/z = 350 and smaller 
than m/z = 1250 with charge state of 2 to 5 and an abundance threshold of greater 
than 120 cps. Former target ions were excluded for 4 s and also excluded after 1 
repeat. The maximum number of candidate ions to monitor per cycle was 20 
spectra with an accumulation time of 100 ms. All injections were performed in 
triplicates. The data was processed using ProteinPilot software 4.5 (ABSciex, 
Framingham, MA, USA) with database search using Uniprot Knowledgebase 
(UniProtKB). 
2.3.3 GluICAT Profiling of APAP-induced Protein Glutathionylation in 
HepaRG Cells  
2.3.3.1 Cell Culture 
HepaRG cells at passage 13 were obtained from Biopredic International (Rennes, 
France). The cells were seeded in T-75 flasks at 2 x 106 undifferentiated 
cells/flask and grown to confluence in 710 growth medium (Biopredic, Rennes, 
France). The cells were cultured under a humidified atmosphere of 5% CO2 at 
37⁰C for 14 days before passaging. Medium was renewed every 3 days. Passages 
13 and 14 were neither differentiated nor used as per the vendor’s instructions. 
Differentiation was induced on day 14 by replacing 710 growth medium with 720 
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differentiation medium (Biopredic, Rennes, France) for a further two weeks. The 
cells were maintained up to 4 weeks after differentiation and were used at passage 
15-18 for drug treatment and biochemical analyses. 
2.3.3.2 Biochemical Analyses 
All biochemical analyses were performed in a 96-well plate format. 
Undifferentiated HepaRG cells were seeded in 96-well plates at a density of 9000 
cells/well and then differentiated as described above. After differentiation, 720 
differentiation medium which contains 1.7% DMSO was replaced with HepaRG 
Tox Working Medium (Life Technologies, Carlsbad, CA, USA) which contains 
0.5% DMSO and maintained for an additional week. Cells were treated with 30 
mM APAP for 3, 6, 12 and 24 h for all assays. Cell viability was assessed by the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA). 
Mitochondrial ROS generation was measured using MitoSOX Red Mitochondrial 
Superoxide Indicator (Life Technologies, Carlsbad, CA, USA). Mitochondrial 
superoxide was measured at λex = 396 nm and non-specific oxidation at λex = 510 
nm, while λem = 580 nm was used for both (94). Cellular percentage GSH relative 
to untreated control as an indicator of cell health and oxidative stress was 
quantified using the luminescence-based system of GSH/GSSG-Glo Assay 
(Promega, Madison, WI, USA). All biochemical assays were performed 
according to manufacturer’s instructions.  
2.3.3.3 Drug Treatment of HepaRG Cells 
Undifferentiated HepaRG cells were seeded in 6-well plates at a density of 2 × 
105 cells/well, differentiated, and then maintained in HepaRG Tox Working 
Medium for 1 week in a total volume of 2 mL per well as mentioned above. To 
investigate the time-dependency of APAP glutathionylation, cells were treated 
with 30 mM APAP for 3, 6, 12 and 24 h. To determine dose-dependence of 
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APAP glutathionylation, cells were treated with 0.5 mM or 30 mM APAP for 3 h. 
To assess the influence of CYP2E1 bioactivation on APAP glutathionylation, 
cells were pretreated with DEDC, a CYP2E1 inhibitor for 30 min. The culture 
media was then replaced with DEDC-free media containing 0.5 mM APAP for 3 
h. Cells were also treated with 30 mM AMAP for 6 h to determine the 
glutathionylation profile with the reported non-toxic regioisomer. For vehicle-
treated controls, cells were treated with 1.9% ethanol for 6 h. Every vehicle or 
drug treatment was performed in triplicates across 3 cell passages. 
2.3.3.4 Harvesting of Drug-treated Cell Lysate 
Drug-containing culture media was removed from each well at the appropriate 
time-points and cells were rinsed twice with ice-cold phosphate-buffered saline. 
500 µL of ice-cold 10% (w/v) TCA was added to each well and kept on ice for 10 
min. Cells were then scraped and the suspension was transferred into a 1.5 mL 
microtube. Each well was rinsed with 500 µL of ice-cold 10% (w/v) TCA and 
added to the same microtube. All tubes were kept on ice for 30 min and vortexed 
every 10 min. Samples were stored at -80°C until further processing. 
2.3.3.5 GluICAT Processing of Drug-treated Cell Lysate 
Cell lysates were centrifuged at 14 000 g for 30 min at 4°C. Denaturing alkylation 
buffer (DAB) containing 6 M urea, 200 mM Tris-HCI, pH 8.5, 10 mM EDTA, 
and 4% (w/v) SDS was freshly prepared before use. The protein pellet was rinsed 
once with 500 µL ice-cold 10% (w/v) TCA, followed by a second rinse with 200 
µL ice-cold 5% (w/v) TCA. The pellet was then redissolved in 80 µL DAB and 
quantified using the BCA assay according to manufacturer’s instructions. An 
aliquot containing 100 µg of protein was removed and additional DAB added to a 
final volume of 80 µL. Subsequent sample processing steps were as described in 
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section 2.3.2.3. LC/MS/MS data acquisition of ICAT-tagged peptides was 
performed as described in section 2.3.2.4.  
2.3.3.6 Data Analysis 
Data from the biochemical analyses were expressed as mean ± standard deviation 
(SD). Comparisons between multiple groups were performed with one-way 
analysis of variance (ANOVA) followed by a post-hoc Bonferroni test, where p < 
0.05 was considered significant. 
For GluICAT data, all peptides identified from the database were filtered 
according to the following criteria: at least 95% confidence, and possessing a 
heavy-to-light (H:L) ratio of at least 0.01. Peptides that did not meet the criteria 
were removed from further analysis. Triplicate sets of peptide data from the 
vehicle-treated control arm were consolidated into a single mastersheet using 
Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) and the 
average H:L value across the triplicates was obtained. The average control H:L 
values were then manually curated as follows: For each identified peptide with a 
complete set of 3 H:L values, the H:L values were inspected and where necessary 
the two closest values were retained. This was essential to minimize skew in 
average control H:L values due to outliers. In most cases, two of the three control 
H:L values were close numerically and the outlier was easily identified and 
discarded. In cases where a peptide was represented by less than 3 H:L values 
because it was not detected or identified with at least 95% confidence in one or 
more replicates, no further manual curation was performed. The consolidated list 
of control peptides (each now represented by a single average H:L value) was 
then used for comparison with drug-treated peptides as follows: Peptides were 
cross-matched between the consolidated control list and each drug-treated 
replicate, and the quotient of [H:L treated / H:L control] for each peptide in each 
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drug-treated replicate was obtained. A particular peptide was considered to be 
glutathionylated only if the [H:L treated / H:L control] ratio exceeded 1.5-fold in 
at least 2 of 3 drug-treated replicates. Only peptides satisfying this stringent 
criterion were subjected to further pathway analysis. 
2.3.3.7 Pathway Analysis and Proteo-metabonomic Mapping 
Glutathionylated proteins were submitted for pathway analysis and searched by 
UniProt accession number using the Reactome Pathway Knowledgebase pathway 
analysis tool (version 53) (95). A false discovery rate (FDR) less than 5% was 
applied to returned pathways. Manual inspection of the glutathionylated proteins 
to identify candidates relevant to the known manifestations of APAP toxicity was 
also performed. Enrichment analysis was also performed using the PANTHER 
and GO Ontology database to determine the molecular function and subcellular 
localization of glutathionylated proteins respectively. Proteo-metabonomic 
mapping was applied to pathways meeting the FDR criteria to ascertain the 
relevance of these pathways to APAP toxicology. A comprehensive literature 
search to retrieve references related to metabonomics studies of APAP toxicity 
was performed using the Web of Science portal (Thomson Reuters, Philadelphia, 
PA, USA) with a combination of the keywords ‘acetaminophen’, ‘paracetamol’ 
‘metabolomics’, ‘metabonomics’, ‘metabolic’, ‘phenotyping’, ‘profiling’, 
‘biomarkers’, ‘toxicity’, ‘hepatotoxicity’ or ‘dysfunction’. A list of metabolite 
biomarkers was compiled from reports of APAP-induced metabolic perturbations 
and used to manually annotate glutathionylated protein pathways obtained from 
the Reactome search. Mapped proteomic-metabonomic pathways were then 
examined for their biological relevance and relationship to the known 
manifestations of APAP toxicity. 
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2.3.3.8 Heat Map Representation of Glutathionylation Patterns 
For the temporal study, H:L fold-change values of peptides that were 
glutathionylated in at least 1 time-point were compiled using Microsoft Excel 
2010. The average H:L fold-change across triplicate experiments was calculated 
for each time-point, thus each peptide is described longitudinally during the 
period of 3-24 h post-APAP exposure by 4 H:L fold-change values. The dynamic 
range of H:L fold-change values between different peptides can vary up to 3 
orders of magnitude (as some peptides are more extensively glutathionylated than 
others), which exceeds the dynamic range that can be represented using a colour 
gradient heat map. The average H:L fold-change value across the 4 time-points 
for each peptide was further computed for normalization purposes. In order to 
reduce the dynamic range, the H:L fold-change value of each time-point was 
normalized against the corresponding average H:L fold-change value (across the 
4 time-points) for that particular peptide. To compare among high dose (30 mM) 
APAP, low dose (0.5 mM APAP) and DEDC followed by 0.5 mM APAP, H:L 
fold-change values for each peptide in the different treatment arms were 
normalized against that of 30 mM APAP. Normalized H:L fold-change values 
were then used to construct heat maps illustrating longitudinal, dose-dependent 
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2.4 Results 
2.4.1 Development of GluICAT Methodology to Profile Protein 
Glutathionylation 
2.4.1.1 Indirect Monitoring of GAPDH Glutathionylation and 
Deglutathionylation  
The cycle of GAPDH glutathionylation and deglutathionylation is illustrated in 
Figure 2-4. Native GAPDH was exposed to H2O2 and GSH to induce 
glutathionylation of the redox-sensitive cysteine (Cys149) within its active site, 
while subsequent treatment of glutathionylated GAPDH (GAPDH-SG) with Grx1 
reversed this process. Figure 2-5 illustrates the corresponding GAPDH activity at 
each treatment stage. GAPDH activity as measured by NADH formation was 
highest prior to glutathionylation. The activity declined significantly after 
treatment with H2O2 and GSH, correlating with the glutathionylation of the redox-
sensitive cysteine residue within its active site. The activity was partially restored 
after treatment with Grx1 that reversed the glutathionylation of its active site. This 
provided indirect evidence that GAPDH-SG was generated, and subsequently 
successfully deglutathionylated by Grx1. DTT-mediated reduction of GAPDH-











Figure 2-5 Indirect monitoring of GAPDH glutathionylation and 
deglutathionylation based on GAPDH activity (mean of 3 replicates). 
 
2.4.1.2 Direct Monitoring of GAPDH-SG Deglutathionylation 
During the process of deglutathionylation, GSH is oxidized to GSSG by Grx1, 
while GSSG is in turn reduced by GR using NADPH as a reducing equivalent 
(Figure 2-6). GAPDH-SG deglutathionylation could be directly measured by 
coupling the deglutathionylation activity of Grx1 to GR and tracking the 
consumption of NADPH by GR. Figure 2-7 shows the direct monitoring of 
GAPDH deglutathionylation by Grx1. The decline in absorbance at 340 nm 
relative to native GAPDH indicates that GAPDH-SG which serves as a substrate 
for Grx1 was successfully glutathionylated. Figure S2 shows the same positive 
control reaction using the mixed disulfide formed between HED and GSH as a 
substrate (HED-SG). Both the indirect and direct evidences of GAPDH-SG 
formation and deglutathionylation validated GAPDH-SG as a model 








Figure 2-6 Deglutathionylation of GAPDH-SG mediated by Grx1 coupled to 
GSSG reduction by GR. 
 
 
Figure 2-7 Direct monitoring of GAPDH-SG deglutathionylation based on 
NADPH consumption (mean of 3 replicates). 
2.4.1.3 GluICAT profiling of glutathionylated GAPDH 
In GluICAT, which was adapted from the OxICAT methodology introduced by 
Leichert et al. (93), reduced thiol groups are tagged with light ICAT, while 
glutathionylated thiol groups are selectively reduced by Grx1 and tagged with 
heavy ICAT (Figure 2-8). The ICAT molecule contains a thiol-reactive 
iodoacetamide moiety which binds irreversibly to reduced thiols. Light and heavy 
ICAT are so named because light ICAT contains a 9-carbon linker labelled with 
light 12C isotope, while the linker in heavy ICAT is labelled with heavy 13C 
isotope.  For a singly-charged peptide, both light and heavy ICAT tagged peptides 
co-elute after LC separation but are separated by a mass difference of 9 Da during 








MS detection. Figure 2-9 illustrates MS spectra for a doubly-charged peptide, 
where light and heavy ICAT tagged peptides are separated by 4.5 Da. This 
characteristic signature of co-elution appearing as twin peaks in the MS spectra is 
used to detect and quantitate the H:L ratio. The extent of glutathionylation of a 
particular peptide in a single sample is determined based on the heavy to light 
ICAT ratio, or H:L ratio, where a high H:L ratio indicates a greater degree of 
glutathionylation (93).  
 
Figure 2-8 Schematic illustrating the GluICAT method. Reduced thiols are 
tagged with light ICAT, while glutathionylated thiols are reduced by Grx1 and 
tagged with heavy ICAT, and subsequently detected by LC/MS. 
 
Figure 2-10 shows the overall heavy to light ratio (H:L) of the ICAT tagged 
GAPDH proteins post-GluICAT analysis. GAPDH (untreated), GAPDH-SG (with 
Grx1) and GAPDH-SG (without Grx1) yielded H:L ratios of 0.51, 8.79 and 3.61, 
respectively. GAPDH has a H:L ratio less than 1, indicating that most of the thiol 
groups of GAPDH were in the reduced form, and thus tagged with light ICAT.  
Relative to untreated GAPDH, GAPDH-SG (with Grx1) yielded a higher H:L 
ratio, suggesting that it was glutathionylated. In the OxICAT method, Leichert et 
al. used a threshold of H:L ratio greater than 1.5-fold relative to untreated controls 
to identify peptides that have been oxidized (93). Applying the same criteria for 















GAPDH (untreated), confirming that it was glutathionylated. In the absence of 
Grx1, no deglutathionylation of GAPDH-SG occurred and the glutathionylated 
thiol residues remained inaccessible to heavy ICAT, and the H:L ratio of 
GAPDH-SG (without Grx1) was significantly lower than that of GAPDH-SG 
(with Grx1). At first glance, it appeared peculiar that GAPDH-SG (without Grx1) 
yielded a higher H:L ratio than that of GAPDH (untreated). This was however not 
unexpected as compared to GAPDH (untreated), GAPDH-SG (without Grx1) 
possessed fewer reduced thiols to be tagged with light ICAT, thus the smaller 












Figure 2-9 Representative MS spectrum for the tryptic GAPDH peptide 
VPTPNVSVVDLTCR obtained from GAPDH-SG. Shown here is the light and 
heavy ICAT tagged version of the tryptic peptide, separated by a mass difference 























Figure 2-10 H:L ratios for GAPDH (untreated) and GAPDH-SG (with (+) or 
without (-) Grx1) from the tryptic GAPDH peptide VPTPNVSVVDLTCR (mean 
of 3 replicates).  
 
2.4.2 Time-course of APAP Toxicity in HepaRG Cells 
Measurements of biochemical perturbations known to be caused by APAP were 
performed in conjunction with the time-points monitored for APAP-induced 
glutathionylation (Figure 2-11). Cell viability and GSH levels declined in a time-
dependent manner, significantly from 3 h onwards. Oxidative stress as measured 
by superoxide and non-specific oxidant formation increased in a time-dependent 








Figure 2-11 Time-course of (A) cell viability and GSH levels and (B) superoxide 
and non-specific oxidant formation in HepaRG cells exposed to 30 mM APAP 
over 24 h. An asterisk indicates p < 0.05 compared to the control. 
 
2.4.3 GluICAT Profiling of APAP-induced Protein Glutathionylation in 
HepaRG Cells  
2.4.3.1 Pathway Analysis of APAP-induced Glutathionylation 
Peptides must exhibit a H:L ratio greater than 1.5-fold compared to the control in 
at least 2 of 3 replicates to be considered candidate glutathionylated peptides. 
Instead of merely taking the average H:L fold-change across three replicates, the 
fold-change in each individual replicate was considered. This additional criterion 
(where peptides must exceed the 1.5-fold threshold in at least 2 replicates) was 
important to minimize the effects of skew of the mean due to an abnormally high 



















instances where the average H:L fold-change was skewed above the 1.5-fold 
threshold due to a single outlier, while the other replicates had low H:L values 
below the 1.5-fold threshold, and this might lead to peptides falsely identified as 
glutathionylated. For peptides that satisfied the criteria, average H:L fold-change 
values were manually inspected for each peptide and outliers removed where 
necessary.  
A total of 898 peptides corresponding to 588 proteins were found to be 
glutathionylated in any one of the 4 time-points monitored (3, 6, 12 or 24 h of 
APAP exposure). A complete list of glutathionylated proteins is provided in Table 
S1. Figure 2-12 illustrates the distribution of protein function for the 
glutathionylated proteins. 49% of these proteins exhibit catalytic activity, while 
29% are mitochondrial proteins and 13% reside in the endoplasmic reticulum. 
Pathway analysis of glutathionylated proteins using Reactome revealed three 
groups of biological processes that were aberrantly glutathionylated by APAP: (1) 
energy metabolism, (2) protein turnover, and (3) defense against cellular stress. 
Energy metabolism broadly encompassed proteins involved in glycolysis, import 
of fatty acids across the mitochondrial membrane, mitochondrial fatty acid β-
oxidation, pyruvate metabolism, citric acid cycle, respiratory electron transport 
and ATP synthesis, gluconeogenesis, pentose phosphate pathway and fatty acyl-
CoA biosynthesis. Protein turnover involved proteins participating in amino acid 
metabolism, protein initiation, elongation and termination, protein folding and 
protein degradation. Defense against cellular stress included proteins responsible 
for detoxification of reactive oxygen species, phase I and II metabolism, GSH and 
sulfur amino acid metabolism, and cellular response to heat stress. Further manual 
analysis of the glutathionylated proteins revealed proteins relevant to calcium 
dynamics and formation of the MPTP. Proteins and peptides found to be 
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glutathionylated by APAP temporally in these three groups are summarized in 
Table 2-1, Table 2-2, Table 2-3 and Table 2-4. Collectively, these three groups 
comprise 239 peptides and 179 proteins, approximately 27% and 30% of total 
glutathionylated peptides and proteins respectively. 
 
Figure 2-12 Distribution of protein functions for proteins glutathionylated by 
APAP at any time-point. Numerals indicate number of proteins in each category. 






Table 2-1 Glutathionylation profile of proteins involved in energy metabolism as a function of time. Values in red represent the average H:L fold-
change of peptides normalized to the control that exceed a 1.5-fold threshold across at least 2 replicates. 




H:L fold-change across time (h) 
3 6 12 24 
Glycolysis 
P30153 Serine/threonine-protein phosphatase 2A 65 











Q14738 Serine/threonine-protein phosphatase 2A 56 
kDa regulatory subunit delta isoform  
2A5D CVSSPHFQVAER 1.70 - 1.12 - 
P04075 Fructose-bisphosphate aldolase A  ALDOA ALANSLACQGK 1.96 0.79 0.94 1.08 
P60174 Triosephosphate isomerase  TPIS IAVAAQNCYK 1.76 1.62 0.98 0.84 
P00558 Phosphoglycerate kinase 1  PGK1 ACANPAAGSVILLENLR 1.26 0.89 1.01 36.18 
P06733 Alpha-enolase  ENOA QIGSVTESLQACK 9.70 7.15 5.49 0.07 
P14618 Pyruvate kinase PKM  KPYM AAMADTFLEHMCR 0.90 1.60 1.17 0.50 
GIFPVLCK 0.99 1.74 1.07 0.59 






O43772 Mitochondrial carnitine/acylcarnitine carrier 
protein 
MCAT CLLQIQASSGESK 8.76 0.93 1.13 0.99 
P50416 Carnitine O-palmitoyltransferase 1, liver 
isoform  




P28330 Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
ACADL AFVDNCLQLHEAK 1.35 1.89 1.41 - 
P49748 Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
ACADV CLTEPSSGSDAASIR 3.15 3.44 2.47 1.27 
  GLQVPSELGGVGLCNTQYAR 2.33 1.21 1.43 1.18 
P55084 Trifunctional enzyme subunit beta, 
mitochondrial  
ECHB FNNWGGSLSLGHPFGATGCR 3.07 - 2.97 - 
P30084 Enoyl-CoA hydratase, mitochondrial  ECHM ALNALCDGLIDELNQALK 1.63 0.93 1.06 0.71 
Q16698 2,4-Dienoyl-CoA reductase, mitochondrial DECR VHAIQCDVRDPDMVQNTVSELI
K 










H:L fold-change across time (h) 
3 6 12 24 
 
P05165 Propionyl-CoA carboxylase alpha chain, 
mitochondrial  
PCCA MADEAVCVGPAPTSK 2.72 1.39 1.60 0.98 












Q96PE7 Methylmalonyl-CoA epimerase, mitochondrial MCEE DCGGVLVELEQA 85.5 - 1.00 - 
Pyruvate 
metabolism 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial DLDH ILGPGAGEMVNEAALALEYGAS
CEDIAR 
3.26 2.92 2.64 - 
P08559 Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial  
ODPA VDGMDILCVR 2.74 1.24 1.60 1.05 
P10515 Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial  
ODP2 ASALACLK 2.73 2.58 1.13 0.51 
Citric acid cycle 
O75390 Citrate synthase, mitochondrial  CISY LPCVAAK 5.94 1.28 1.46 1.79 
Q99798 Aconitate hydratase, mitochondrial  ACON CTTDHISAAGPWLK 1.63 1.45 1.38 0.85 
P51553 Isocitrate dehydrogenase [NAD] subunit 
gamma, mitochondrial  
IDH3G HACVPVDFEEVHVSSNADEEDIR 1.11 1.59 0.94 1.03 
  LGDGLFLQCCR 1.94 - - - 
P48735 Isocitrate dehydrogenase [NADP], 
mitochondrial  
IDHP DLAGCIHGLSNVK 1.34 1.87 1.46 1.24 
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial  
IDH3A CSDFTEEICR 1.93 0.03 0.99 2.04 
Q02218 2-Oxoglutarate dehydrogenase, mitochondrial  ODO1 DVVVDLVCYR 1.90 3.06 1.18 1.27 
  CSTPGNFFHVLR 3.62 - - - 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial DLDH ILGPGAGEMVNEAALALEYGAS
CEDIAR 
3.26 2.92 2.64 - 
P53597 Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial  
SUCA IICQGFTGK 1.30 1.00 1.19 2.47 
  LIGPNCPGVINPGECK 1.63 - 1.09 0.29 
P31040 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  
SDHA GLSEAGFNTACVTK 1.86 - 1.73 1.15 










H:L fold-change across time (h) 
3 6 12 24 
 
P21912 Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial 
SDHB CGPMVLDALIK 2.24 3.92 1.85 0.82 
Q99643 Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial  
C560 SLCLGPALIHTAK 1.21 2.46 1.68 1.06 





P28331 NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial  
NDUS1 DCFIIYQGHHGDVGAPIADVILPG
AAYTEK 
1.85 1.14 - 1.26 
O95299 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial  
NDUAA CEVLQYSAR 2.32 - 1.29 - 
P49821 NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
NDUV1 GAGAYICGEETALIESIEGK 1.99 1.94 8.73 - 
P31040 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial  
SDHA GLSEAGFNTACVTK 1.86 - 1.73 1.15 
   GVIALCIEDGSIHR 1.23 1.78 1.00 0.37 
P21912 Succinate dehydrogenase [ubiquinone] iron-
sulfur subunit, mitochondrial 
SDHB CGPMVLDALIK 2.24 3.92 1.85 0.82 
Q99643 Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial  
C560 SLCLGPALIHTAK 1.21 2.46 1.68 1.06 
P31930 Cytochrome b-c1 complex subunit 1, 
mitochondrial  
QCR1 NALVSHLDGTTPVCEDIGR 1.38 1.00 1.22 2.12 
SICYAETGLLGAHFVCDR 5.21 - 1.44 0.93 












P08574 Cytochrome c1, heme protein, mitochondrial  CY1 HLVGVCYTEDEAK 1.16 1.88 0.78 0.43 
P24539 ATP synthase F(0) complex subunit B1, 
mitochondrial  
AT5F1 CIADLK 1.88 1.47 1.39 - 
P13804 Electron transfer flavoprotein subunit alpha, 
mitochondrial  
ETFA LGGEVSCLVAGTK 0.94 1.03 1.45 2.98 
  TIYAGNALCTVK 3.90 1.20 2.59 1.32 
P38117 Electron transfer flavoprotein subunit beta ETFB HSMNPFCEIAVEEAVR 1.26 1.34 1.39 2.09 
 
Q16134 Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial  










H:L fold-change across time (h) 
3 6 12 24 
 
   FCPAGVYEFVPVEQGDGFR 105 131 117 137 
P42704 Leucine-rich PPR motif-containing protein, 
mitochondrial  
LPPRC LEDVALQILLACPVSK 1.05 1.89 1.63 1.38 
LIASYCNVGDIEGASK 1.61 1.10 1.33 1.18 
Gluconeogenesis 
 
P00505 Aspartate aminotransferase, mitochondrial  AATM TCGFDFTGAVEDISK 2.88 1.02 0.95 0.48 
VGAFTMVCK 2.20 1.17 0.66 0.70 
ACANPAAGSVILLENLR 1.26 0.89 1.01 36.18 
Q16822 Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial  
PCKGM YVAAAFPSACGK 0.99 1.17 1.83 3.21 
P40925 Malate dehydrogenase, cytoplasmic MDHC MGVLDGVLMELQDCALPLLK 7.25 - 6.29 - 
   GCDVVVIPAGVPR 2.49 1.33 1.14 1.30 
P04075 Fructose-bisphosphate aldolase A  ALDOA ALANSLACQGK 1.96 0.79 0.94 1.08 
P06733 Alpha-enolase  ENOA QIGSVTESLQACK 9.70 7.15 5.49 0.07 
P00558 Phosphoglycerate kinase 1  PGK1 ACANPAAGSVILLENLR 1.26 0.89 1.01 36.18 
P11498 Pyruvate carboxylase, mitochondrial  PYC GLYAAFDCTATMK 4.96 3.14 3.48 4.84 
P53007 Tricarboxylate transport protein, mitochondrial  TXTP GIGDCVR 1.48 1.59 1.14 0.80 
P40926 Malate dehydrogenase, mitochondrial  MDHM GCDVVVIPAGVPR 2.49 1.33 1.14 1.30 




P11413 Glucose-6-phosphate 1-dehydrogenase  G6PD DNIACVILTFK 3.47 1.96 1.27 0.84 
   DVMQNHLLQMLCL 2.88 1.26 1.01 1.45 
   LILDVFCGSQMHF 2.33 1.09 1.34 0.92 
P52209 6-Phosphogluconate dehydrogenase, 
decarboxylating  
6PGD MVHNGIEYGDMQLICEAYHLMK 6.29 - 9.79 - 
SAVENCQDSWR 1.77 2.05 1.50 0.97 
P29401 Transketolase TKT CSTFAAFFTR 2.24 0.98 1.06 1311 
AIIVDGHSVEELCK 1.92 3.77 1.18 0.68 
P37837 Transaldolase TALDO ALAGCDFLTISPK 1.76 2.10 1.10 0.66 
Fatty acyl-CoA 
biosynthesis 
P49327 Fatty acid synthase  FAS AALQEELQLCK 1.09 1.82 1.14 2.34 
   AAPLDSIHSLAAYYIDCIR 3.06 4.64 2.65 2.78 
   ACLDTAVENMPSLK 15.8 5.37 0.98 1.21 










H:L fold-change across time (h) 
3 6 12 24 
    CTVFHGAQVEDAFR 1.72 1.54 1.16 0.96 
    LSIPTYGLQCTR 2.79 1.30 0.95 1.41 
    MASCLEVLDLFLNQPH 1.53 3.60 1.15 1.18 
    SFYGSTLFLCR 1.06 1.52 0.98 1.31 
 
   TGGAYGEDLGADYNLSQVCDG
K 
2.85 2.07 2.40 0.04 
 P33121 Long-chain-fatty-acid--CoA ligase 1  ACSL1 AAEGEGEVCVK 1.17 1.35 1.14 1.94 
 CGVEVTSMK 1.73 1.02 1.22 1.95 
 GFEGSFEELCR 2.12 2.16 1.39 1.31 
    GIQVSNNGPCLGSR 2.61 1.39 1.33 3.57 
 LIAIVVPDVETLCSWAQK 2.42 3.07 1.59 1.24 
 O95573 Long-chain-fatty-acid--CoA ligase 3  ACSL3 NTPLCDSFVFR 3.30 1.36 1.21 1.48 
 O60488 Long-chain-fatty-acid--CoA ligase 4 ACSL4 TALLDISCVK 1.12 1.63 1.39 1.39 
 Q9ULC5 Long-chain-fatty-acid--CoA ligase 5 ACSL5 GLAVSDNGPCLGYR 1.14 1.09 1.65 2.39 
    IVQAVVYSCGAR 1.40 1.43 1.37 2.38 
 P53396 ATP-citrate synthase  ACLY AVQGMLDFDYVCSR 1.02 1.13 1.26 1.86 
 FICTTSAIQNR 2.11 1.45 1.57 - 
 P53007 Tricarboxylate transport protein, mitochondrial  TXTP GIGDCVR 1.48 1.59 1.14 0.80 
 Q53GQ0 Very-long-chain 3-oxoacyl-CoA reductase  DHB12 MININILSVCK 1.52 2.32 1.80 0.46 








Table 2-2 Glutathionylation profile of proteins involved in protein turnover as a function of time. Values in red represent the average H:L ratio of 
peptides normalized to the control that exceed a 1.5-fold threshold across at least 2 replicates. 




H:L fold-change across time (h) 
3 6 12 24 
Amino acid 
metabolism 
Q9UDR5 Alpha-aminoadipic semialdehyde synthase, 
mitochondrial  
AASS AGGILQEDISEACLILGVK 1.05 1.65 1.13 0.72 
  QLLCDLVGISPSSEHDVLK 1.08 4.00 0.86 1.34 
P35520 Cystathionine beta-synthase  CBS CIIVMPEK 1.69 - - - 
Q14353 Guanidinoacetate N-methyltransferase  GAMT TEVMALVPPADCR 1.29 - 1.21 2.72 
P30038 Delta-1-pyrroline-5-carboxylate dehydrogenase, 
mitochondrial  
AL4A1 CDDSVGYFVEPCIVESK 3.29 - 1.83 2.55 
P31327 Carbamoyl-phosphate synthase [ammonia], 
mitochondrial  
CPSM SAYALGGLGSGICPNR 1.68 0.98 1.17 - 
P23526 Adenosylhomocysteinase  SAHH QAQYLGMSCDGPFKPDHYR 5.12 - - - 
O15382 Branched-chain-amino-acid aminotransferase, 
mitochondrial  
BCAT2 EVFGSGTACQVCPVHR 8.21 - - - 
  LCLPSFDK 13.63 1.06 1.27 1.14 
  LELLECIR 12.00 4.60 2.40 0.90 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate 
reductase  
GRHPR GVAGAHGLLCLLSDHVDK 1.28 2.27 1.39 1.13 
  NCVILPH 1.58 1.08 1.33 1.14 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial  DLDH ILGPGAGEMVNEAALALEYGAS
CEDIAR 
3.26 2.92 2.64 - 
P19623 Spermidine synthase  SPEE QFCQSLFPVVAY 1.81 - - - 
P00505 Aspartate aminotransferase, mitochondrial  AATM TCGFDFTGAVEDISK 2.88 1.02 0.95 0.48 
   VGAFTMVCK 2.20 1.17 0.66 0.70 
P21953 2-oxoisovalerate dehydrogenase subunit beta, 
mitochondrial  
ODBB GLLLSCIEDK 1.92 2.23 1.25 - 
P34896 Serine hydroxymethyltransferase, cytosolic  GLYC YYGGAEVVDEIELLCQR 2.09 1.39 1.71 1.40 










H:L fold-change across time (h) 
3 6 12 24 
    CSTPGNFFHVLR 3.62 - - - 
 P04424 Argininosuccinate lyase  ARLY CAGLLMTLK 3.12 - 1.47 - 
    MAEDLILYCTK 4.71 3.25 1.50 2.96 
 P49189 4-trimethylaminobutyraldehyde dehydrogenase  AL9A1 SPLIIFSDCDMNNAVK 1.58 1.15 1.12 1.20 
 P48506 Glutamate--cysteine ligase catalytic subunit  GSH1 GYVSDIDCR 104 44.4 46.1 1.00 
 
P31937 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial  






P25398 40S ribosomal protein S12 RS12 LVEALCAEHQINLIK 1.37 2.89 1.27 1.00 
   QAHLCVLASNCDEPMYVK 3.41 - 1.30 1.4 
P23396 40S ribosomal protein S3  RS3 ACYGVLR 1.90 1.17 1.26 1.09 
   GCEVVVSGK 1.81 1.93 1.27 1.24 
   GLCAIAQAESLR 2.22 1.19 3.21 3.25 
P61247 40S ribosomal protein S3a  RS3A LFCVGF 2.31 4.25 1.41 - 
P62241 40S ribosomal protein S8 RS8 NCIVLIDSTPYR 1.37 2.46 1.07 0.77 
P05388 60S acidic ribosomal protein P0  RLA0 AGAIAPCEVTVPAQNTGLGPEK 2.22 0.93 1.38 2.13 
   CFIVGADNVGSK 1.8 0.58 0.84 0.50 
   NVASVCLQIGYPTVASVPH 3.03 1.20 1.63 0.94 
P62906 60S ribosomal protein L10a  RL10A VLCLAVAVGH 4.01 - 1.36 - 
   VLCLAVAVGHVK 3.23 - 0.59 - 
P30050 60S ribosomal protein L12 RL12 CTGGEVGATSALAPK 3.43 1.53 1.32 0.55 
P39023 60S ribosomal protein L3  RL3 TVFAEHISDECK 1.39 1.09 1.62 1.28 
    VACIGAWHPAR 1.94 0.97 2.48 - 
    YCQVIR 2.26 0.94 - - 










H:L fold-change across time (h) 
3 6 12 24 
 P36578 60S ribosomal protein L4 RL4 GPCIIYNEDNGIIK 1.37 0.82 1.88 1.01 
    SGQGAFGNMCR 1.73 - 1.56 1.94 
 P46777 60S ribosomal protein L5 RL5 AAAYCTGLLLAR 1.64 0.82 1.11 1.48 
    DIICQIAY 2.33 0.79 1.48 0.85 
    IEGDMIVCAAYAHELPK 2.61 2.32 1.56 0.88 
    VGLTNYAAAYCTGLLLAR 2.09 2.02 - - 
 Q01518 Adenylyl cyclase-associated protein 1  CAP1 CVNTTLQIK 2.07 0.79 1.08 0.35 
    INSITVDNCK 1.49 1.8 1.07 0.41 
 P12814 Alpha-actinin-1  ACTN1 CQLEINFNTLQTK 92.6 6.89 11.6 5.18 
    DGLGFCALIHR 0.99 2.19 0.65 0.03 
    EGLLLWCQR 0.94 1.76 0.89 1.03 
 P23528 Cofilin-1 COF1 HELQANCYEEVKDR 2.15 1.20 1.00 0.92 
 
P68104 Elongation factor 1-alpha 1 EF1A1 DGNASGTTLLEALDCILPPTRPTD
KPLR 
1.49 2.33 1.21 0.77 
 
   SGDAAIVDMVPGKPMCVESFSD
YPPLGR 
0.92 54.0 3.38 1.35 
 P13639 Elongation factor 2  EF2 CLYASVLTAQPR 2.75 1.39 1.1 0.67 
    STLTDSLVCK 1.09 0.44 0.68 1.80 
 
   YVEPIEDVPCGNIVGLVGVDQFL
VK 
0.24 0.08 0.72 2.00 
 
P60842 Eukaryotic initiation factor 4A-I IF4A1 VVMALGDYMGASCHACIGGTN
VR 
2.81 - - - 
 
P62495 Eukaryotic peptide chain release factor subunit 
1  
ERF1 CGTIVTEEGK 2.83 - - - 
 
P47813 Eukaryotic translation initiation factor 1A, X-
chromosomal  










H:L fold-change across time (h) 
3 6 12 24 
 
P41091 Eukaryotic translation initiation factor 2 subunit 
3  
IF2G YNIEVVCEYIVK 1.92 - 0.90 - 
 
P55884 Eukaryotic translation initiation factor 3 subunit 
B  
EIF3B NLFNVVDCK 2.79 2.16 2.09 2.25 
 P60228 Eukaryotic translation initiation factor 3 subunit 
E  
EIF3E IHQCISIN 1.42 1.10 1.15 2.86 
   LFIFETFCR 2.23 - 2.43 - 
 
O75822 Eukaryotic translation initiation factor 3 subunit 
J  
EIF3J ITNSLTVLCSEK 6.16 2.03 1.33 0.82 
 
Q9UBQ5 Eukaryotic translation initiation factor 3 subunit 
K  
EIF3K FICHVVGITYQHIDR 2.08 - 1.35 - 
 P02675 Fibrinogen beta chain  FIBB ECEEIIR 1.63 2.09 - - 
    LESDVSAQMEYCR 0.78 3.33 3.75 3.43 
    TPCTVSCNIPVVSGK 2.91 5.05 3.56 1.08 
 P02679 Fibrinogen gamma chain FIBG CHAGHLNGVYYQGGTYSK 0.80 1.60 2.09 2.13 
 
   VAQLEAQCQEPCKDTVQIHDITG
K 
3.74 5.77 4.55 0.87 
 P21333 Filamin-A  FLNA VHSPSGALEECYVTEIDQDK 2.25 1.42 1.59 0.02 
 P04075 Fructose-bisphosphate aldolase A ALDOA ALANSLACQGK 1.96 0.79 0.94 1.08 
 P62937 Peptidyl-prolyl cis-trans isomerase A  PPIA ANAGPNTNGSQFFICTAK 4.72 3.88 3.80 0.06 
    TNGSQFFICTAK 1.56 0.78 0.84 1.21 
 P07737 Profilin-1  PROF1 CYEMASHLR 1.99 1.60 1.06 - 
    IDNLMADGTCQDAAIVGYK 3.37 - 4.21 - 
 
Q12846 Syntaxin-4  STX4 CNSMQSEYR 1.69 - - - 
O75083 WD repeat-containing protein 1  WDR1 MTVDESGQLISCSMDDTVR 12.4 2.10 0.27 1.18 
Protein folding 
Q9BVA1 Tubulin beta-2B chain TBB2B LTTPTYGDLNHLVSATMSGVTT
CLR 
1.66 - - - 










H:L fold-change across time (h) 
3 6 12 24 
    LADQCTGLQGFLVFHSF 1.34 - 10.9 1.47 
    MVDNEAIYDICR 10.9 10.6 10.7 8.46 
    TTLEHSDCAFMVDNEAIYDICR 1.47 1.77 1.03 - 
 
P68363 Tubulin alpha-1B chain TBA1B AYHEQLSVAEITNACFEPANQM
VK 
1.36 1.25 1.97 1.14 
    LADQCTGLQGF 1.58 - 1.26 0.74 
    TTLEHSDCAFMVDNEAIYDICR 2.03 - 1.22 0.93 
    YMACCLLYR 1.99 - 1.44 3.17 
 P50991 T-complex protein 1 subunit delta TCPD SIHDALCVIR 1.65 2.21 1.24 0.49 
 P50990 T-complex protein 1 subunit theta  TCPQ IGLSVSEVIEGYEIACR 1.63 1.70 0.89 0.43 
 
P68366 Tubulin alpha-4A chain TBA4A AYHEQLSVAEITNACFEPANQM
VK 
1.36 1.13 1.69 1.14 
    MVDNEAIYDICR 12.0 10.6 10.33 8.46 
    SIQFVDWCPTGF 6.53 - 7.97 - 
    TTLEHSDCAFMVDNEAIYDICR 1.47 1.77 1.03 - 
    YMACCLLYR 1.99 - 1.44 3.17 
 P48643 T-complex protein 1 subunit epsilon  TCPE SLHDALCVIR 1.70 2.21 1.24 0.49 
 P17987 T-complex protein 1 subunit alpha  TCPA ALNCVVGSQGMPK 2.11 - 1.34 1.01 
 
   GANDFMCDEMER 3.35 1.95 2.66 2.29 
   IACLDFSLQK 3.11 3.28 1.22 1.05 
   ICDDELILIK 0.98 1.51 1.24 0.93 
P60709 Actin, cytoplasmic 1 ACTB DDDIAALVVDNGSGMCK 25.71 0.76 27.24 1.39 
Protein 
degradation 
Q92890 Ubiquitin fusion degradation protein 1 homolog UFD1 CFSVSMLAGPNDR 99.7 - - - 
P61086 Ubiquitin-conjugating enzyme E2 K   UBE2K ISSVTGAICLDILK 15.1 - - - 










H:L fold-change across time (h) 
3 6 12 24 
 Q14258 E3 ubiquitin/ISG15 ligase TRIM25   TRI25 NTVLCNVVEQFLQADLAR 2.74 - 44.7 - 
 Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1   HUWE1 VLGPAACR 1.66 1.21 1.26 - 
 Q63HN8 E3 ubiquitin-protein ligase RNF213   RN213 STDFLPVDCPVR 1.70 - - - 
 P62333 26S protease regulatory subunit 10B  PRS10 AVASQLDCNFLK 3.05 1.30 13.36 1.21 
 Q99460 26S proteasome non-ATPase regulatory subunit 
1 
PSMD1 QCVENADLPEGEK 1.83 3.58 1.86 0.70 
 PSMD1 MEEADALIESLCR 1.27 1.90 0.74 - 
 
O00232 26S proteasome non-ATPase regulatory subunit 
12 
PSD12 AIYDTPCIQAESEK 
23.3 1.14 2.18 1.80 
 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 
13 
PSD13 FLGCVDIK 
1.30 1.80 1.15 0.81 
 Q16401 26S proteasome non-ATPase regulatory subunit 
5 
PSMD5 FFGNLAVMDSPQQICER 108 - - - 
 PSMD5 TTLCVSILER 1.76 - - - 
 
Q15008 26S proteasome non-ATPase regulatory subunit 
6 
PSMD6 VYQGLYCVAIR 
1.79 0.61 1.03 0.02 






Table 2-3 Glutathionylation profile of proteins involved in defense against cellular stress as a function of time. Values in red represent the average H:L 
ratio of peptides normalized to the control that exceed a 1.5-fold threshold across at least 2 replicates. 




H:L fold-change across time (h) 




P04040 Catalase  CATA LCENIAGHLK 3.04 1.05 1.19 0.34 




5.49 - 4.02 - 
P00441 Superoxide dismutase [Cu-Zn]  SODC HVGDLGNVTADKDGVADVSIED
SVISLSGDHCIIGR 
1.22 1.63 1.81 - 
P04179 Superoxide dismutase [Mn], mitochondrial SODM GHLQIAACPNQDPLQGTTGLIPL
LGID 
83.76 - - - 
Q96HE7 ERO1-like protein alpha  ERO1A YSEEANNLIEECEQAER 0.97 0.94 1.94 1.34 
Q06830 Peroxiredoxin-1  PRDX1 LNCQVIGASVDSHFCH 0.98 - 3.43 - 
Phase I 
functionalization 
P21397 Amine oxidase [flavin-containing] A  AOFA ICELYAK 2.23 2.13 1.33 0.58 
P27338 Amine oxidase [flavin-containing] B  AOFB CIVYYK 3.03 - 1.21 - 
   LCELYAK 2.12 2.13 1.33 0.58 
P07327 Alcohol dehydrogenase 1A  ADH1A NPESNYCLK 300 150 - - 
P00325 Alcohol dehydrogenase 1B  ADH1B MVAVGICR 5.66 2.55 1.81 1.14 
   NPESNYCLK 335 131 115 1.00 
P00326 Alcohol dehydrogenase 1C  ADH1G NPESNYCLK 333 - - - 
P05181 Cytochrome P450 2E1 CP2E1 DLTDCLLVEMEK 2.70 51.58 3.90 - 
P10632 Cytochrome P450 2C8  CP2C8 DFIDCFLIK 3.01 0.96 1.27 1.31 
P00352 Retinal dehydrogenase 1  AL1A1 AYLNDLAGCIK 2.19 1.00 1.00 1.16 
   FPVFNPATEEELCQVEEGDKEDV
DK 
236 164 68.7 - 
   LECGGGPWGNK 4.95 2.69 1.33 - 










H:L fold-change across time (h) 
3 6 12 24 
    YCAGWADK 2.73 1.29 0.91 1.10 
 Q9NR19 Acetyl-coenzyme A synthetase, cytoplasmic  ACSA GATTNICYNVLDR 1.83 72.98 1.22 2.27 
 Q16850 Lanosterol 14-alpha demethylase  CP51A CIGENFAYVQIK 1.07 1.07 1.48 2.41 
 Q9HBI6 Phylloquinone omega-hydroxylase CYP4F11 CP4FB LQCFPQPPK 1.32 1.27 1.10 2.76 
Phase II 
conjugation 
P10620 Microsomal glutathione S-transferase 1  MGST1 VFANPEDCVAFGK 4.95 2.94 2.97 12.16 
P40261 Nicotinamide N-methyltransferase  NNMT IFCLDGVK 2.45 3.18 1.35 0.89 
P48506 Glutamate--cysteine ligase catalytic subunit  GSH1 GYVSDIDCR 104 44.4 46.1 1.00 
P36269 Gamma-glutamyltransferase 5  GGT5 FLNVVQAVSQEGACVYAVSDLR 2.78 39.8 - - 
   HQAPCGPQAF 1.17 0.69 2.38 - 
P48637 Glutathione synthetase  GSHB IEPEPFENCLLR 4.70 - - - 
P23526 Adenosylhomocysteinase   SAHH QAQYLGMSCDGPFKPDHYR 5.12 - - - 
P51580 Thiopurine S-methyltransferase  TPMT SWGIDCLFEK 2.74 - - - 
O60701 UDP-glucose 6-dehydrogenase  UGDH DPYEACDGAH 0.88 1.10 1.59 1.00 
   DVLNLVYLCEALNLPEVAR 4.65 4.50 1.45 1.07 
O60656 UDP-glucuronosyltransferase 1-9  UD19 NHIMHLEEHLLCHR 6.40 - 1.09 0.59 
Q06520 Bile salt sulfotransferase  ST2A1 ICQFLGK 1.00 0.92 1.24 2.13 
GSH and sulfur 
amino acid 
metabolism 
P35520 Cystathionine beta-synthase CBS CIIVMPEK 1.69 - - - 
P23526 Adenosylhomocysteinase   SAHH QAQYLGMSCDGPFKPDHYR 5.12 4.33 - - 
P48506 Glutamate--cysteine ligase catalytic subunit  GSH1 GYVSDIDCR 104 44.4 46.1 1.00 
P48637 Glutathione synthetase  GSHB IEPEPFENCLLR 4.70 - - - 
P19623 Spermidine synthase SPEE QFCQSLFPVVAY 1.81 - - - 
P52788 Spermine synthase SPSY LYCPVEFSK 2.55 - - - 
Cellular 
response to heat  
O95816 BAG family molecular chaperone regulator 2  BAG2 FQSIVIGCALEDQK 2.37 - 0.85 0.84 










H:L fold-change across time (h) 
3 6 12 24 
stress    TVDSPICDFLELQR 1.97 - 1.47 1.61 
 Q15185 Prostaglandin E synthase 3 TEBP LTFSCLGGSDNFK 1.73 1.92 2.69 3.31 
 
P68104 Elongation factor 1-alpha 1 EF1A1 DGNASGTTLLEALDCILPPTRPTD
KPLR 
1.49 2.33 1.21 0.77 
 
   SGDAAIVDMVPGKPMCVESFSD
YPPLGR 
0.92 54.0 3.38 1.35 
 P49792 E3 SUMO-protein ligase RanBP2  RBP2 IAELLCK 2.41 1.17 1.29 - 
 Q8N1F7 Nuclear pore complex protein Nup93 NUP93 CGDLLAASQVVNR 1.61 1.26 1.15 1.41 
 P34932 Heat shock 70 kDa protein 4  HSP74 FLEMCNDLLAR  0.98 2.71 1.01 - 
 O95757 Heat shock 70 kDa protein 4L  HS74L AQFEQLCASLLAR 3.14 3.04 1.23 - 
 P08107 Heat shock 70 kDa protein 1A/1B HSP71 CQEVISWLDANTLAEKDEFEHK 5.07 - - - 
 P11142 Heat shock cognate 71 kDa protein  HSP7C CNEIINWLDK 1.15 3.82 1.00 1.78 
 P07900 Heat shock protein HSP 90-alpha  HS90A CLELFTELAEDK 0.91 1.63 0.33 - 
    FENLCK 3.66 - - - 
 P08238 Heat shock protein HSP 90-beta  HS90B AKFENLCK 1.58 - - - 
    FENLCK 3.60 - - - 
    VFIMDSCDELIPEYLNFIR 67.5 34.3 79.2 50.3 
 P55072 Transitional endoplasmic reticulum ATPase  TERA EAVCIVLSDDTCSDEK 59.4 - 40.2 - 
 
   LADDVDLEQVANETHGHVGADL
AALCSEAALQAIR 
91.9 281 64.0 37.6 







Table 2-4 Glutathionylation profile of proteins involved in calcium dynamics and the mitochondrial permeability transition pore (MPTP) formation as 
a function of time. Values in red represent the average H:L ratio of peptides normalized to the control that exceed a 1.5-fold threshold across at least 2 
replicates. 




H:L fold-change across time (h) 
3 6 12 24 
Calcium 
dynamics 
P16615 Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2  
AT2A2 ANACNSVIK - 1.24 - 1.68 
  GTAVAICR 2.32 1.30 1.18 1.35 
P20020 Plasma membrane calcium-transporting ATPase 
1 





P21796 Voltage-dependent anion-selective channel 
protein 1 
VDAC1 YQIDPDACFSAK 1.67 0.99 1.28 0.88 
P45880 Voltage-dependent anion-selective channel 
protein 2 
VDAC2 SCSGVEFSTSGSSNTDTGK 1.26 0.81 1.32 2.58 
Q9Y277 Voltage-dependent anion-selective channel 
protein 3  
VDAC3 SCSGVEFSTSGHAYTDTGK 0.87 0.83 1.68 1.84 
  VCNYGLTFTQK 0.97 0.96 1.68 2.50 
P12235/ 
P05141 
ADP/ATP translocase 1/2 ADT1/ 
ADT2 
QYKGIIDCVVR 3.42 2.64 1.18 1.15 
P62937 Peptidyl-prolyl cis-trans isomerase A PPIA ANAGPNTNGSQFFICTAK 4.72 3.88 3.80 0.06 
N.B. ‘-’ denotes not detected in at least 2 of 3 replicates  
 71 
 
2.4.3.2 Proteo-metabonomic Mapping of APAP-induced Glutathionylation 
A total of 19 primary research articles investigating APAP-induced metabolic 
perturbations were retrieved from literature and are presented in Table 2-5. These 
investigations utilized both animal models (mice, rat and pig) and human subjects, 
and various biological matrices (serum, plasma, whole blood, urine and liver). A 
total of 81 metabolites were reported to be perturbed by APAP and are involved 
in a variety of biological processes including glycolysis, pyruvate metabolism, 
mitochondrial fatty acid β-oxidation, citric acid cycle, glycogen turnover, GSH 
and sulfur amino acid metabolism, phospholipid turnover, and amino acid and 























Rat Urine NMR Lactate Elevated (97) 
Human Plasma NMR Lactate Elevated (98) 
Human Serum NMR Lactate Elevated  (99) 
Mouse Plasma NMR Pyruvate Elevated (96) 
Rat Plasma NMR Pyruvate Elevated (97) 
Rat Urine NMR, LC/MS Pyruvate Decreased (100) 




Mouse Serum LC/MS Palmitoyl, oleoyl, myristoylcarnitine 
Carnitine 
Acetylcarnitine 
Peak at 4 h followed by decline 
Peak at 8 h followed by decline 
Decreased 
(102) 
Mouse Plasma LC/MS Palmitoyl, oleoyl, myristoyl, palmitoleoyl carnitine Peak at 2 h followed by decline  (103) 
Mouse Serum LC/MS Palmitoyl, linoleoyl, oleoyl carnitine Elevated from 3-12 h (104) 
Mouse Serum LC/MS Palmitoyl, oleoyl, myristoyl, palmitoleoyl carnitine Elevated (105) 
Mouse Serum LC/MS Palmitoyl, oleoyl carnitine Elevated (106) 
Mouse Serum LC/MS Palmitoyl carnitine Elevated (107) 
Human Plasma LC/MS Palmitoyl, linoleoyl, oleoyl carnitine No change from healthy patients (104) 
Human Serum LC/MS Palmitoyl, oleoyl, myristoyl, palmitoleoyl carnitine Elevated (108) 
Rat Serum GC/MS Fatty acids: Oleic acid, vaccenic acid, linoleic acid, 
eicosatrienoic acid, arachidonic acid, eicosapentaenoic acid, 
docosahexaenoic acid, myristic acid, palmitic acid, palmitoleic 
acid, margaric acid, stearic acid, α-linolenic acid, arachidic acid 
Elevated (109) 




NMR Triglycerides, monounsaturated fatty acids 













Metabolites Directionality Ref 
Plasma Triglycerides Elevated 
 Mouse Serum LC/MS Triglycerides, free fatty acids Elevated (103) 
 Mouse Serum LC/MS Triglycerides, free fatty acids Elevated (106) 
Citric acid 
cycle 
Rat Urine NMR 2-oxoglutarate, citrate, succinate Decreased (97) 
Rat Urine NMR, LC/MS 2-oxoglutarate, citrate, succinate Decreased (100) 





Rat Urine LC/MS, 
GC/MS 
Isocitrate, aconitate, oxaloacetate Decreased 
In-house 

















Rat Urine NMR, LC/MS Glucose Decreased (100) 
Rat Liver  Glycogen Decreased  
 Serum  Glucose   
Amino acid  
Mouse Liver NMR Alanine, isoleucine, leucine, lysine, valine, phenylalanine, 
tyrosine 
Elevated (96) 
Rat Plasma NMR Isoleucine Elevated (97) 





Human Plasma NMR 3-hydroxyisovalerate, isoleucine, acetylglycine,  






Mouse Liver CE/TOFMS Spermine, hypotaurine, S-adenosylmethionine, glycine, 
glutamine, spermidine, cysteine, glutamate, taurine 
Decreased (101) 
Rat Urine NMR Taurine Elevated (97) 










Metabolites Directionality Ref 
S-adenosylmethionine 
Taurine 
Rat Urine NMR 5-oxoproline Increased (112) 
Mouse Liver CE/TOFMS Methionine, S-adenosylhomocysteine, ophthalmic acid Elevated (101) 
Rat Liver LC/MS, 
GC/MS 
Taurine, hypotaurine 












Rat Plasma LC/MS, 
GC/MS 
Glycine conjugated bile acids: Glycocholate, 
glycochenodeoxycholate 






Human Serum LC/MS Glycodeoxycholic acid Increased (114) 
Others 
Rat Plasma NMR Trimethylamine, creatinine Elevated (97) 
Rat Urine NMR Allantoin, hippurate, creatinine, trimethylamine N-oxide Decreased (97) 
 
Rat Urine NMR, LC/MS Trimethylamine N-oxide, dimethylamine, hippurate, glycine, 
N,N-dimethylglycine, N-isovalerylglycine, betaine, trans-
aconitate, pipecolinate, ferulic acid 


















Rat Urine LC/MS, 
GC/MS 
Hippurate, pantothenate, phenylacetylglycine, pipecolinate, 
ferulic acid sulfate 







Proteo-metabonomic mapping revealed significant overlaps between the 
biological processes affected by glutathionylation and metabolic perturbations. 
Pathways that were successfully mapped were glycolysis and pyruvate 
metabolism (Figure 2-13), fatty acid β-oxidation (Figure 2-14), citric acid cycle 
(Figure 2-15), respiratory electron transport and ATP synthesis (Figure 2-16), and 
GSH and sulfur amino acid metabolism (Figure 2-17). Glutathionylated proteins 
in each map are marked in red text, and up/down arrows indicate the direction of 
change (increase/decrease) for relevant metabolites. Where divergent changes 
were reported in literature, the corresponding biological matrices used to perform 
the measurements are indicated in italics. 
The proteo-metabonomic maps accounted for majority of the energy metabolism 
pathways. Given that most of the proteins in these pathways possess catalytic 
function, and the substrate repertoire of these proteins are generally narrow, these 
features increased the mapping accuracy and enhanced the confidence in the 
inferred protein-metabolite intersections. On the other hand, despite reports of 
altered amino acid levels, the proteins involved in amino acid metabolism were 
unexpectedly poorly mapped as the number of relevant metabolic derangements 
was low. Additionally, amino acids are involved in multiple pathways, and the 
metabolic perturbations could not be assigned to one particular glutathionylated 
pathway. Mapping was also not possible for protein turnover, detoxification of 
reactive oxygen species and cellular response to heat stress pathways as these did 
not intersect with small molecule metabolite fluxes measured by metabonomics or 
metabolism studies. Proteins involved in phase I and II metabolism have a broad 
range of endogeneous and exogeneous substrates and could not be confidently 
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Figure 2-17 Proteo-metabonomic map of GSH and sulfur amino acid metabolism. 
 
2.4.3.3 Longitudinal Progression of APAP-induced Protein Glutathionylation 
An overview of the temporal H:L fold-change pattern is presented in the heat map 
in  
Figure 2-18. In general, glutathionylated peptides can be grouped into 3 distinct 
clusters based on their peak normalized H:L fold-change values: early (3 h), mid 
(6-12 h) or late (24 h). For visualization purposes, the peak normalized H:L fold-
change values were used to construct the heat map; however, to facilitate analysis 
























































applied to the list of peptides in each cluster to filter them by glutathionylation 
status. Pathway analysis using Reactome applied to glutathionylated proteins 
found in the early cluster returned similar results as those reported in section 
2.4.3.1, indicating that early glutathionylated peptides participate in key pathways 
relevant to APAP toxicity. However, when pathway analysis was applied to 
glutathionylated proteins in the mid and late cluster, the top returned pathways 
were not found to be relevant to APAP toxicity. When the returned results were 
further searched to locate the pathways associated with energy metabolism, 
protein turnover and defense against cellular stress, there was a marked increase 
in the FDR values for these pathways, and they did not fall within the FDR < 0.05 
threshold. 
When examined on the basis of glutathionylation status instead of temporal 
clusters, the highest number of glutathionylated peptides was observed at 3 h, 
followed by a 50% decrease at 6 h, and was stable thereafter until 24 h (Figure 
2-19). Although the total number of glutathionylated peptides remained steady 
from 6-24 h, the number of glutathionylated peptides in the 3 groups of key 
biological processes continued to decrease over time. The temporal decrease in 
the number of glutathionylated peptides that are relevant to APAP toxicity 
appeared to be balanced by an increase in glutathionylation of other peptides. The 
percentages of peptides that did not fall into the three groups of key pathways 















































Figure 2-18 Heat map illustrating clustering of glutathionylated peptides in 3 
distinct groups based on their peak normalized H:L fold-change values: (A) early 
(3 h), (B) mid (6-12 h) and (C) late (24 h). The top 50 peptides (by H:L fold-
change value) in each cluster are presented (mean of triplicate experiments).  
A          B     C 
4.00 
0.01 
3 6 12 24 3 6 12 24 3 6 12 24 





Figure 2-19 Number of glutathionylated peptides as a function of time post-dose, 
plotted by total number and as a subset of biologically relevant processes. 
 
2.4.3.4 Effect of Dose and Bioactivation on APAP-induced Protein 
Glutathionylation 
The glutathionylation patterns associated with 0.5 mM APAP and 0.5 mM APAP 
+ DEDC treatments were compared with that established for 30 mM APAP at the 
3 h time-point. Figure 2-20 represents the H:L fold-change pattern for the 
peptides derived by normalizing the H:L fold-change values for 0.5 mM APAP 
and 0.5 mM APAP + DEDC  against that of 30 mM APAP. As identified in 
section 2.4.3.1, these peptides play critical roles in energy metabolism, protein 
turnover, and defense against cellular stress across the three treatment arms. For 
all three biological processes, 0.5 mM APAP and 0.5 mM APAP + DEDC 
treatments resulted in a decrease in H:L fold-change values compared with that of 
30 mM APAP. Figure 2-21 illustrates the number of peptides glutathionylated (as 
defined by the 1.5-fold change in H:L values) by APAP across all three treatment 
conditions. Comparing 30 mM APAP against 0.5 mM APAP, there was a small 
 82 
 
percentage decrease (7%) in total number of glutathionylated peptides. This 
percentage reduction became more prominent (26%) when the data was compared 
against 0.5 mM APAP + DEDC treatment. When focusing on the peptides 
glutathionylated within the 3 key biological processes, the differences among the 
3 treatments became apparent. For all three sets of biological processes, the 
number of glutathionylated peptides decreased by approximately 50% in the 0.5 
mM APAP and 0.5 mM APAP + DEDC treatment groups when compared against 
30 mM APAP. When comparing the effect of the CYP2E1 inhibitor on APAP-
induced glutathionylation (0.5 mM APAP versus 0.5 mM APAP + DEDC), there 
was no change in the number of glutathionylated peptides involved in energy 
metabolism; however, the number of glutathionylated peptides involved in protein 
synthesis and folding, as well as defense against cellular stress decreased by a 








Figure 2-20 Heat map illustrating H:L fold-change pattern for the peptides 
involved in (A) energy metabolism, (B) protein turnover, and (C) defense against 
cellular stress among three different treatment conditions. H:L fold-change values 


















































Figure 2-21 Number of glutathionylated peptides among different APAP 
treatment conditions, plotted by total number and as a subset of biologically 
relevant processes. 
 
2.4.3.5 Comparative Analysis of AMAP- and APAP-induced Protein 
Glutathionylation 
A total of 265 peptides corresponding to 186 proteins were found to be 
glutathionylated by 30 mM AMAP at 6 h of exposure. Figure 2-22 summarizes 
the comparative analysis of proteins glutathionylated by 30 mM AMAP and 30 
mM APAP. Of these, 74% of total proteins glutathionylated by AMAP were also 
glutathionylated by APAP at any one of 4 time-points monitored. Overlaps 
between proteins glutathionylated by AMAP and APAP were also found for a 
majority of the proteins in energy metabolism (83%), protein turnover (48%), 
defense against cellular stress (73%), and calcium dynamics and MPTP formation 
(100%). Figure 2-23 illustrates the distribution of protein functions associated 
with proteins glutathionylated by AMAP. 62% of proteins glutathionylated by 
AMAP possessed catalytic function, while 42% of these proteins were 
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Figure 2-22 Venn diagrams illustrating the overlaps of glutathionylated proteins 
induced by AMAP and APAP and categorized according to (A) total number, (B) 
energy metabolism, (C) protein turnover, (D) defense against cellular stress and 
(E) calcium dynamics and mitochondrial permeability transition pore formation 
pathways. Numbers within Venn diagram compartments indicate the respective 
number of proteins. Circles coloured in red and blue represent proteins 
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Figure 2-23 Distribution of protein functions associated with proteins 
glutathionylated by AMAP. Numerals indicate number of proteins in each 






2.5.1 Development of the GluICAT Methodology to Profile Protein 
Glutathionylation 
Given the evidence that APAP could induce aberrant protein glutathionylation, 
we sought to investigate the suite of proteins glutathionylated by APAP and 
determine the biological consequences of this perturbation. An examination of 
literature at the start of this study revealed that all current approaches to detect 
glutathionylated proteins involve gel-based methods (87, 115), which are 
constrained by a number of limitations (section 2.2.6). These limitations could be 
overcome through the use of an in-solution, LC/MS-based approach. As there was 
no published methodology that met our requirements, we sought to develop a 
global LC/MS-based proteomic approach to comprehensively profile the 
glutathionylated proteome. 
We chose to build our approach upon the OxICAT method (93) which was 
developed to profile general thiol modifications in oxidatively stressed E. coli. 
The OxICAT method circumvents the limitations of gel-based 2D-gel 
electrophoresis by using an unbiased, in-solution LC/MS approach to interrogate 
the thiol modified proteome. In this method, all reduced cysteine thiols are 
initially labeled with light ICAT. Modified thiols are then reduced in solution 
with the chemical reductant tris(2-carboxyethyl)phosphine (TCEP), before being 
labeled with heavy ICAT and digested by trypsin before separation using LC. In 
other words, thiols that were originally in the reduced form are labeled with light 
ICAT, while those that were modified are labeled with heavy ICAT. Modified 
and reduced peptides co-elute chromatographically but differ by a mass difference 
of 9 Da on the mass spectrum, and this can be detected using MS for 
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quantification and tandem MS/MS for identification. The extent of thiol 
modifications is thus reflected in the H:L ratio, where a high ratio indicates 
extensive thiol modifications. However, the OxICAT method is not able to 
distinguish specific forms of thiol modifications e.g. nitrosylation versus 
glutathionylation, as the thiol reductant TCEP is non-specific. To overcome this 
limitation, we attempted to substitute TCEP with a mutant form of Grx1 which is 
highly specific in catalyzing deglutathionylation (116). We have termed this 
method the GluICAT method, and the main steps are outlined in Figure 2-8. 
The first step in the development of GluICAT was to generate a model 
glutathionylated protein. GAPDH was chosen for this purpose as it contains a 
redox-sensitive cysteine residue (Cys149) at its active site. Glutathionylation of 
this cysteine residue leads to inhibition of its activity, and allowed us to assess the 
generation of GAPDH-SG. Deglutathionylation of GAPDH-SG was demonstrated 
by the restoration of GAPDH activity. GAPDH-SG deglutathionylation was also 
observed directly by monitoring the decrease in NAPDH spectrophotometrically. 
Collectively, our findings confirmed the generation of GAPDH-SG, and the 
ability of Grx1 to deglutathionylate GAPDH-SG, thus GAPDH was subsequently 
used as a model glutathionylated protein for GluICAT. 
The next step involved modifying the OxICAT method by substituting the 
reducing agent TCEP with Grx1 to specifically detect glutathionylated proteins. 
However, it was not possible to directly substitute TCEP with Grx1. TCEP is a 
chemical reductant that can operate under harsh conditions, while Grx1 is an 
enzymatic reductant, and requires gentle, non-denaturing conditions for its 
deglutathionylating activity. In the OxICAT reducing step, the protein pellet is 
dissolved in 6 M urea and 0.5% SDS, followed by the addition of TCEP and 
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heavy ICAT to immediately alkylate newly-reduced thiols. These conditions 
denature Grx1 and alkylate the catalytic cysteine residue in the active site of 
Grx1, rendering it inactive. As modification of the deglutathionylation procedure 
was warranted, we employed FASP to remove denaturing buffers and alkylating 
agents prior to the deglutathionylation step. 
Originally developed to remove SDS from protein samples prior to trypsin 
digestion (117, 118), FASP provides a simple solution to the challenges of 
GluICAT protocol. Central to the FASP procedure is the use of a 30 kDa 
molecular weight cut-off (MWCO) spin filter to retain proteins while allowing 
undesired components of the suspension buffer to be removed, which is illustrated 
in Figure 2-24. It has been demonstrated that despite the large MWCO, proteins 
smaller than the MWCO are retained (118). This is attributed to the unfolded 
nature of detergent-treated proteins which prevents them from passing through the 
membrane.  Additionally, SDS could be easily and nearly completely removed by 
repeated washes with urea. Urea dissociates SDS from proteins and sequesters 
SDS into micelles that in turn pass through the pores of the membrane filter (117). 
As a result, up to 4% w/v of the chaotropic detergent SDS could be used in the 
initial solubilization step, ensuring complete solubilization of hydrophobic 
proteins (e.g. membrane-bound proteins) without the need for sonication that may 
lead to protein shearing. Without FASP, SDS concentration had to be limited to 
0.5%, which would limit protein solubilization and overall proteome coverage. 
Furthermore, following the removal of denaturing urea and SDS, proteins could 
be resuspended in Grx1-friendly ammonium bicarbonate for successful 
deglutathionylation. Apart from that, FASP allowed efficient removal of GSH 
from the deglutathionylation mixture once the process was complete. It has been 
reported that at least 5 mM of GSH is needed for Grx1 deglutathionylation 
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activity (119). However, the presence of GSH is detrimental to the subsequent 
heavy ICAT alkylation step as GSH will compete with newly-deglutathionylated 
thiols for the thiol-reactive iodoacetamide moiety of heavy ICAT. With the use of 
FASP, proteins are retained on the membrane while excess GSH can be removed 
by repeated washes with a buffer. This advantage was also exploited to remove 
excess heavy ICAT which might alkylate trypsin and affect the subsequent 
digestion step. With the prior removal of SDS, efficient trypsin digestion was 
further ensured. Finally, use of FASP allowed us to omit the strong cation 
exchange step (SCX) in the conventional ICAT protocol. Traditionally, after 
trypsin digestion of the ICAT tagged peptides, SCX is used for sample clean-up 
by removing excess ICAT reagents, trypsin, SDS and reductants such as TCEP, as 
trypsin will digest avidin, while SDS interferes with MS detection (120). 
However, because of the extensive number of wash steps we employ throughout 
the protocol and trypsin is retained on the spin column post-digestion, we are able 
to omit SCX from the sample processing step. While the use of FASP increased 






Figure 2-24 GluICAT workflow illustrating the roles of FASP. 
 
An important consideration during sample preparation is to limit artefactual thiol 
modifications of redox-sensitive thiols due to oxidation by atmospheric oxygen. 
We adopted the OxICAT approach, where 10% TCA (w/v) was used to lower the 
pH of protein environment to pH 1-2 during the harvesting step (121). This is 
important because redox-sensitive thiols usually have pKa values between 5-8, 
and thus are easily deprotonated to the reactive thiolate anion. By lowering the pH 
to several units below the pKa, almost all thiols are protonated and less reactive. 
TCA also served as a cell lysis reagent and protein denaturant to inactivate 
endogenous glutaredoxins and thioredoxins which can mediate glutathionylation 
or deglutathionylation reactions. As TCA could not be present throughout the 
entire sample preparation, protein samples were handled and processed on ice to 
reduce the rate of thiol-disulfide exchange (121). All buffers were also degassed 
before use to minimize contact of thiols with dissolved oxygen. However, post-
deglutathionylation, the newly deglutathionylated thiols were not acidified using 
TCA to avoid protein precipitation and ensure subsequent tagging with heavy 
ICAT. Additionally, numerous wash steps were required to ensure depletion of 
GSH prior to tagging with heavy ICAT. During this period, exposure of the redox 
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sensitive thiol to atmospheric oxygen might cause artefactual oxidation, reduce 
tagging by heavy ICAT and lower the H:L ratio. However this did not pose a 
significant problem in our method development, as indicated by the H:L ratio of 
GAPDH-SG (with Grx) which was 23-fold higher than that of GAPDH 
(untreated).  
The suite of glutathionylated proteins identified using GluICAT shows 
remarkable correspondence with proteins that have been detected in other redox 
proteomics studies, which use gel-based and LC/MS-based approaches in a 
variety of tissue matrices including liver (122), heart (123) and macrophages 
(124). Similar findings were also reported in other organisms such as yeast (125) 
and bacteria (93). These suggest that qualitatively, the GluICAT method performs 
comparably with existing approaches. However, most of these methods focus on 
profiling general thiol modifications without distinguishing between 
glutathionylation and oxidation or nitrosylation. This is likely because of the 
technical difficulty in ensuring efficient deglutathionylation while keeping 
proteins in solution. Recently, Su et al. described an alternative LC/MS-based 
approach to identify and quantify glutathionylated proteins (124). In their 
approach, free protein thiols were first blocked with N-ethyl maleimide, which 
irreversibly alkylated all free cysteines. Subsequently, glutathionylated thiols 
were deglutathionylated using a spin column setup where proteins were 
suspended in HEPES buffer. Deglutathionylated proteins were then captured and 
enriched on a thiopropyl resin, followed by on-resin trypsin digestion. Digested 
peptides were then eluted, tagged using the isobaric, multiplex iTRAQ tags and 
analyzed by LC/MS. Thus the extent of glutathionylation is relative to the 
abundance of glutathionylated peptides eluted and quantified using LC/MS in 
each sample. We are heartened that the spin column was also chosen as the 
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approach to effect deglutathionylation by an independent research group. 
However, their methodology is constrained by several limitations. Firstly, during 
sample harvest, 1% Triton X-100, a detergent suspended in HEPES buffer 
containing NEM is used as the cell lysis and protein solubilization agent. This is 
an alternative method of quenching thiol reactivity by rapid alkylation. Using 
NEM has disadvantages because NEM may not be able to access and covalently 
alkylate all free thiols, especially those that are buried within the core of the 
protein. This is exacerbated by the fact that upon cell lysis, intra-organelle 
components such as metal ions and ROS/RNS are released and quickly oxidize 
proteins before NEM can covalently alkylate their free thiols (121). A second 
major limitation is that the glutathionylation signal is assumed to be proportional 
to the abundance of a particular peptide. However, this may not always be the 
case, as an increase in protein expression would also provide the same signal, and 
thus lead to false interpretations. In their study, cells were treated with diamide 
for 30 min before harvest, thus it could be argued that limited changes in protein 
expression would have occurred, and hence their results are unlikely to be 
confounded by this possibility. In the case of APAP and other toxicants, changes 
in protein expression have been well-documented, thus their approach might not 
be able to distinguish between an increase in protein expression versus a true 
increase in protein glutathionylation. Similarly, McGarry et al. recently reported 
the basal glutathionylation of proteins in mouse liver relying on a similar 
approach using resin-assisted enrichment of glutathionylated peptides followed by 
post-deglutathionylation labeling using isobaric iodoTMT tags (126). Since the 
mice were not challenged pharmacologically, protein expression is expected to be 
unchanged, hence the protein abundance signal in this instance can be considered 
equivalent to the glutathionylated protein signal. On the contrary, in the GluICAT 
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approach we label both free and glutathionylated cysteines within a sample using 
light and heavy ICAT respectively. Provided the extent of glutathionylation is 
unchanged, the H:L ratio will remain constant regardless of protein abundance. 
The principle of differential labeling of both free and thiol modified cysteines, 
and not merely appending a reporter signal only to the modified cysteine is crucial 
to avoid this confounding outcome. There are a number of ICAT-based redox 
proteomics approaches which suffer from the same pitfall, where light ICAT and 
heavy ICAT are used to label modified thiols exclusively in 2 different samples 
(123, 127). Although this approach permits greater throughput as both samples 
can be combined and analyzed simultaneously, the approach requires 
quantification of a separate aliquot of each sample to ascertain the protein 
abundance between both samples because the reporter signal (i.e. the ICAT 
reagent) is only appended to the modified cysteine (125). This unnecessarily 
introduces extra steps, reagent costs and analytical time.  
With the advent of newer developments, we anticipate that the GluICAT 
methodology can be further refined and enhanced. For example, the cysteine-
reactive, isobaric iodoTMT tags were recently introduced and have been used to 
profile nitrosylated cysteines (128). Prior to this, ICAT was the only cysteine-
reactive tag matching our requirements that was available in the market. The 
iodoTMT has several advantages over ICAT which makes it attractive as an 
alternative tagging reagent. For example, iodoTMT is 6-plex, while ICAT is 
duplex. This means that 2 iodoTMT reagents can be used to differentially label 
reduced and glutathionylated cysteines per sample, thus 3 samples can be pooled 
together for analysis, reducing analytical time by a factor of 3. Additionally, 
quantitation of peptides labeled with iodoTMT is performed at the MS/MS level, 
which is more sensitive, accurate, higher signal-to-noise ratio and has a larger 
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dynamic range than ICAT (129), which is quantitated at the MS level. This would 
improve reproducibility and sensitivity of the GluICAT method. Incorporation of 
new technologies will be a focus of future investigations using the GluICAT 
method. 
2.5.2 Analysis of APAP-induced Protein Glutathionylation 
2.5.2.1 HepaRG as a Model for Investigating APAP-induced Protein 
Glutathionylation 
Currently, along with primary human hepatocytes, HepaRG cells are the gold 
standard for toxicity and metabolism studies, and these cells express a functional 
suite of disposition-related phase I (including CYP2E1 and CYP3A4) and II 
biotransformation enzymes, as well as transporters at levels that closely resemble 
primary human hepatocytes (130-132). Importantly, unlike primary human 
hepatocytes, expression levels of these proteins are stable for weeks, permitting 
short- to mid-term toxicity studies. Because they are derived from a single donor, 
cell population characteristics and behaviour are homogeneous and reproducible 
across different passages (132). HepaRG cells were also previously established to 
be a suitable model for investigating APAP toxicity, as it recapitulated the 
mechanisms and time-course of APAP toxicity as measured by GSH depletion, 
APAP-protein adduct formation, mitochondrial oxidative stress and peroxynitrite 
formation, mitochondrial dysfunction and LDH release (133).  
2.5.2.2 Longitudinal Biochemical Analyses of APAP Toxicity 
In agreement with literature, a dose of 30 mM APAP resulted in a time-dependent 
decrease in HepaRG cell viability over 24 h. This was corroborated by decreases 
in GSH levels and increases in oxidative stress. Importantly, the extent of cell 
viability closely paralleled GSH depletion. McGill et al. previously reported 
similar findings using 20 mM APAP in HepaRG cells (133). In their study, APAP 
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protein adduct formation (measured using a surrogate indicator of APAP-cysteine 
conjugate formation isolated from cell lysate and media) increased steadily upon 
APAP exposure, and peaked at 6 h followed by a decline during 12-24 h. Levels 
of protein adducts also closely paralleled GSH consumption. Additionally, 
covalent binding did not require extensive GSH depletion or loss of mitochondrial 
membrane potential, indicating that covalent binding can occur well before 
evidence of mitochondrial dysfunction and cell death. While we did not measure 
protein adduct formation in our study, the evidence provided by McGill et al. 
suggested that if protein glutathionylation was dependent on protein adduct 
formation, peak glutathionylation levels should occur within 6 h. Indeed, we 
observed maximal glutathionylation at 3 h followed by a decrease at 6 h which 
remained stable thereafter (Figure 2-19). In order to mimic a situation of toxic 
overdose, we chose to use a concentration of 30 mM APAP in our study as that 
was the upper limit of solubility achieved in our hands.  
2.5.2.3 Overview of APAP-induced Protein Glutathionylation 
From a functional perspective, nearly half of proteins glutathionylated by APAP 
exhibited catalytic activity, which is in agreement with literature. A study by Su et 
al. of oxidative stress-induced protein glutathionylation in mouse macrophages 
determined that 47% of glutathionylated proteins in their study also exhibited 
enzymatic activity (124). Furthermore, nearly 1/3 of glutathionylated proteins in 
our study were localized in the mitochondria, while mitochondrial proteins 
typically comprise about 7% of the total liver proteome (134). The enrichment of 
mitochondrial proteins in our dataset agrees with the central role mitochondrial 
dysfunction plays in APAP-induced hepatotoxicity (77). 
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2.5.2.4 Proteo-metabonomic Mapping of Reactome-derived Pathways 
In the subsequent section, the intersections between APAP-induced 
glutathionylation and the manifestations of APAP toxicity will be discussed. To 
draw meaningful relationships between these two areas, knowledge of the 
biological effects of protein glutathionylation is needed. However, the field of 
protein glutathionylation is still in development, and only a small number of 
glutathionylated proteins have been further interrogated for their functional 
activity. In the absence of direct measurements of the effects of protein 
glutathionylation, we have carefully extrapolated the consequences of 
glutathionylation from similar forms of redox modification such as nitrosylation. 
There is some evidence alluding to parallels between the more well-studied 
nitrosylation, and glutathionylation. For example, glyceraldehyde 3-phosphate 
dehydrogenase (135), aconitate hydratase (136), isocitrate dehydrogenase (137, 
138), mitochondrial complex I (139), ATP synthase (140) and protein disulfide 
isomerase (141) have been reported to undergo both nitrosylation and 
glutathionylation, with both forms of thiol modifications resulting in inhibition of 
protein activity. Similarly, both nitrosylation and glutathionylation decreased the 
affinity for calmodulin binding to ryanodine receptor type 1 (142). Notably, there 
is a large overlap between nitrosylated and glutathionylated proteins, which is not 
unexpected given that nitrosylation can be a precursor to glutathionylation (143, 
144). Although it may be tempting to conclude that nitrosylation and 
glutathionylation yield identical biological effects, this may not always be the 
case. For example, thioredoxin is inhibited by glutathionylation (145), but its 
nitrosylation permits its transnitrosylation of other proteins. Hence, extrapolation 
of data from the biological effects of nitrosylation to that of glutathionylation, 
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where necessary, has been performed with care, and is supported by strong 
supplementary evidence such as complementary metabonomics data. 
Aberrant glutathionylation impairs energy metabolism. The impairment of 
cellular energetics as characterized by depletion of ATP levels is a hallmark of 
APAP toxicity (146). In conjunction with this observation, we found that key 
energy metabolism pathways were glutathionylated by APAP. The glycolytic 
enzymes identified to be glutathionylated in our study (Figure 2-13) were all 
reported to be inhibited by glutathionylation (147, 148), suggesting that glycolysis 
is impaired as a result of APAP-induced glutathionylation. Interestingly, although 
GAPDH has been reported by several groups to be significantly glutathionylated 
by oxidative stress (147), we did not find evidence of glutathionylation in our 
study, as it was only significant in one replicate of the 3 h time-point. Based on 
metabonomics findings of decreased hepatic glucose, elevated plasma pyruvate 
and increased hepatic and plasma lactate levels 6 h post-dose (500 mg/kg APAP 
in mice), Coen et al. hypothesized that glycolysis was increased as a 
compensatory mechanism secondary to mitochondrial impairment (96). Our 
results indicate that the glycolytic proteins were glutathionylated mostly within 
the first 6 h and decreased subsequently, suggesting that glycolytic impairment 
would occur within this period. We also observed that the three proteins forming 
the pyruvate dehydrogenase complex were glutathionylated by APAP, while 
literature evidence indicate that this results in inhibition of pyruvate 
dehydrogenase activity (147). Pyruvate carboxylase (captured under the 
gluconeogenesis pathway (Table 2-1)), which catalyzes carboxylation of pyruvate 
to oxaloacetate was also observed to be glutathionylated, although its significance 
is unknown. It may be premature to conclude that glycolysis was enhanced on the 
basis of the metabonomics findings, as glucose and pyruvate fluxes are multi-
 99 
 
factorial and dynamic. For example, glycolysis, the Cori cycle, citric acid cycle, 
alanine metabolism and gluconeogenesis can modulate the levels of pyruvate 
either through its production or consumption (149). Similarly, glucose fluxes are 
affected by rates of glycolysis, gluconeogenesis, glycogenolysis and glycogenesis. 
Likewise, the increase in lactate levels can be simply interpreted as conversion of 
excess pyruvate to lactate by lactate dehydrogenase, which is unaffected by 
glutathionylation, and thus should not be used as a measure of glycolysis. 
Reflecting the dynamic nature of metabolite fluxes, Coen et al. (96) and Fukuhara 
et al. (97) reported increased plasma pyruvate levels, while decreased levels of 
pyruvate in urine was reported by Sun et al. (100). The conflicting data is likely a 
result of the choice sampling time-points which may give contrasting snapshots of 
the dynamic metabolic fluxes. These divergent findings can be resolved by 
fluxomics investigations which trace metabolite fluxes as a function of time. Our 
findings strongly suggested that glycolysis is impaired during the early stages of 
APAP toxicity and underscored the importance of complementary multi-omics 
investigations to interpret dynamic systems biology data. 
A majority of the proteins involved in long chain fatty acid activation, transport 
across the mitochondrial membrane and β-oxidation were also observed to be 
glutathionylated in our study, while levels of fatty acids and acylcarnitines were 
consistently elevated in metabonomics studies of APAP toxicity (Figure 2-14). 
The mitochondrial carnitine/acylcarnitine carrier protein was reported to be 
reversibly glutathionylated, where glutathionylation inhibits transport of 
acylcarnitines into the mitochondria (150). Separately, Go et al. reported that a 
number of proteins responsible for fatty acid activation, transport across the 
mitochondrial membrane and β-oxidation, including those that we observed to be 
glutathionylated in this present study were redox modified by cadmium, a known 
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hepatotoxicant that induces mitochondrial dysfunction (122). Crucially, a parallel 
metabonomics investigation revealed suppressed levels of acylcarnitines and acyl-
CoA metabolites upon cadmium exposure, suggesting that redox modification of 
these proteins impaired fatty acid β-oxidation. However, the exact nature of the 
redox modification (i.e. oxidation, nitrosylation or glutathionylation) was not 
further elucidated. Further evidence on the effects of redox modifications on fatty 
acid β-oxidation were provided by Moon et al., where oxidation and nitrosylation 
of acyl-CoA dehydrogenases and 3-ketoacyl-CoA thiolase were reported in 
alcoholic fatty liver, and the activity of 3-ketoacyl-CoA thiolase was found to be 
inhibited (151). Although glutathionylation of proteins in this pathway has not 
been explored as extensively as nitrosylation, when taken together, these 
evidences corroborate our hypothesis that APAP induces glutathionylation of 
proteins involved in fatty acid β-oxidation and results in a functional impairment 
of their activity. This manifests from a metabolic perspective as elevated fatty 
acids and acylcarnitines, which are located upstream of these perturbed proteins.  
A series of investigations revealed that pre-treatment of mice with clofibrate, 
whether acute (24 h) or chronic (10 days) prior to APAP exposure conferred 
protection against APAP hepatotoxicity, which was unrelated to the extent of 
covalent binding or GSH depletion (152-154). It was then discovered that PPARα 
activation was the underlying mechanism behind the prophylactic effect of 
clofibrate (155), a PPARα inducer. Nevertheless, the link between PPARα 
activation and APAP toxicity has not been clarified. Interestingly, genes involved 
in fatty acid β-oxidation including carnitine O-palmitoyltransferase, fatty acid 
ligases and acyl-CoA dehydrogenases are reported to be induced by PPARα 
(156). A separate study using the PPARα agonist Wy-14,643 also demonstrated 
protection from APAP toxicity, accompanied by a parallel attenuation of the 
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increase in palmitoylcarnitines observed in untreated mice (107). Collectively, our 
results indicate that glutathionylation is a possible mechanism that links PPARα 
activation, fatty acid β-oxidation and APAP toxicity. We suggest that the 
prophylactic effects of PPARα inducers are accomplished by the upregulation of 
genes involved in fatty acid β-oxidation, thereby dampening the inhibitory effect 
of glutathionylation (and other redox modifications) on these enzymes. 
The citric cycle was also found to be extensively glutathionylated in the present 
study, where 7 of the 8 enzyme systems catalyzing the cycle contained at least 
one glutathionylated subunit (Table 2-1 and Figure 2-15). Independently, multiple 
metabonomics studies indicate a decrease in the levels of citric acid cycle 
substrates, suggesting the APAP-induced glutathionylation resulted in an 
inhibition of citric acid cycle proteins. Indeed, aconitate hydratase (136), 2-
oxoglutarate dehydrogenase E2 subunit (157), isocitrate dehydrogenase (158) and 
succinate dehydrogenase (159) (also known as complex II of the electron 
transport chain) have been reported to undergo glutathionylation, resulting in an 
inhibition in these enzymes. The citric acid cycle has not been directly shown to 
be impaired by APAP, but indirect evidence suggests that APAP causes shortage 
of citric acid cycle substrates, as supplementation of GSH and N-acetylcysteine 
(NAC) post-APAP treatment leads to a partial recovery in ATP levels (160).  This 
is attributed to the amino acid constituents of excess GSH and NAC (i.e. those not 
used to support GSH synthesis) being used as energy substrates in the citric acid 
cycle (160). The aberrant glutathionylation induced by APAP would thus account 
for the decrease in citric acid cycle substrates. Collectively, the preceding 
discussions indicate that the citric acid cycle is indirectly affected by 
perturbations in glycolysis and fatty acid β-oxidation, which deliver the key 
metabolic intermediates pyruvate, acetyl-CoA and succinyl-CoA to the cycle. 
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This impairment is further exacerbated by direct inhibition of the cycle itself via 
glutathionylation. Direct perturbation of the citric acid cycle by APAP thus far 
has not been reported, and is a novel finding of our study. 
APAP has been reported to exert a significant influence on mitochondrial 
respiration. Both complexes I and II in isolated mouse hepatocytes were found to 
be inhibited by NAPQI, the latter of which was more sensitive to NAPQI (146). 
This was accompanied by a decrease in ATP levels, indicative of a functional 
deficit in energy metabolism. These findings were recapitulated in vivo in mice 
(161, 162), and complex III was also reported to be inhibited by APAP (163). 
Covalent binding of APAP to ATP synthase F1 α subunit has been reported (43), 
while APAP was found to inhibit its activity (164). In parallel with these 
observations, complexes I-III and the ATP synthase F0 complex subunit B1 was 
found to be glutathionylated by 30 mM APAP in our study. Separately, 
complexes I, II and ATP synthase F1 subunit α were reported to be inhibited by 
glutathionylation (159, 165, 166). We found that the ATP synthase F1 α subunit 
was glutathionylated at 3 h by 0.5 mM APAP but not with 30 mM APAP; 
however the reason for this discrepency is unclear. The arylation of ATP synthase 
F1 α subunit (43) and its glutathionylation by APAP supports the hypothesis that 
overt covalent binding and covert glutathionylation are inter-related processes. 
The effects of glutathionylation on the electron transfer flavoproteins which pass 
electrons from fatty acid β-oxidation to ubiquinone are currently unknown, but 
they have been reported to undergo nitrosylation (151, 167) with still 
undetermined biological consequences. Collectively, glutathionylation of the 
electron transport chain and ATP synthase accounts for the drastic drop in ATP 
levels and mitochondrial dysfunction observed with APAP. Importantly, after 
APAP treatment in vivo (80, 168), hepatic ATP levels were reported to decline 
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rapidly (maximally within 1-1.5 h) followed by a partial recovery, which is 
consistent with our findings where glutathionylation and impairment of proteins 
involved in energy metabolism is greatest at 3 h and declines thereafter (Figure 
2-19), possibly indicating restoration of ATP synthesis. 
Aberrant glutathionylation triggers oxidative stress. Apart from inhibition of 
oxidative phosphorylation, glutathionylation of the electron transport chain, 
particularly of complex I is known to cause a large increase in superoxide 
formation (165, 169). Increased oxidative stress localized primarily in the 
mitochondria is well-documented in APAP toxicity (168). The primary oxidants 
are superoxide and peroxynitrite (77), which is formed by reaction between 
superoxide and nitric oxide, and is a highly reactive and potent oxidant and 
nitrating species (170). As described in section 2.2.4, the increased oxidative 
stress is believed to trigger JNK activation, which translocates to the 
mitochondria and further amplifies oxidative stress. The increased formation of 
superoxide and peroxynitrite triggers the opening of the MPTP, which leads to the 
collapse of mitochondrial membrane potential and loss of ATP synthesis capacity. 
This also triggers the rupture of the outer mitochondrial membrane and release of 
proteins that translocate to the nucleus and cause DNA fragmentation (77). 
Despite the significant consequences of APAP-triggered oxidative stress, the 
initial triggers of the oxidative stress remains unclear, and is thought to be related 
to covalent binding by NAPQI, although the precise mechanism and protein target 
mediating this event has not yet been elucidated (171). It was suggested that 
covalent inhibition of glutathione peroxidase and depletion of GSH by NAPQI 
contributed to the accumulation of ROS (80), however it is unlikely that inhibition 
of a single member of a family of detoxification enzymes could result in such a 
dramatic outcome. Instead, increased production of oxidants would explain this 
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observation. Of the two primary oxidants, nitric oxide, the precursor of 
peroxynitrite was not significantly increased during the first 6 h following APAP 
administration (172). This suggests that the increase in peroxynitrite is driven by 
an increase in superoxide. The source of the increased superoxide was initially 
proposed to arise from CYP2E1 oxidation of APAP, however it was later 
disproved (77). Furthermore, CYP2E1 is primarily expressed in the endoplasmic 
reticulum, while the oxidative stress is located in the mitochondria. Our results 
suggest that significant glutathionylation of three subunits of complex I, possibly 
secondary to covalent binding is a potential source of increased superoxide 
formation. The timeline of APAP glutathionylation of complex I, which we note 
to occur by 3 h, agrees with reports of an initial increase in mitochondrial 
oxidative stress in the first 2 h of exposure to APAP (82). We also observed an 
increase in mitochondrial oxidative stress at 3 h after exposure to APAP, although 
not statistically significant. 
Aberrant glutathionylation may perturb GSH synthesis. GSH depletion is another 
key hallmark of APAP toxicity, and has been ascribed to conjugation with 
NAPQI to facilitate its excretion and detoxification, and also quenching of 
oxidant species. However, there is evidence that the decrease in GSH levels may 
also be due to compromised GSH synthesis. For example, Harman et al. found no 
evidence of recovery in GSH levels even when hepatocytes were washed free of 
APAP after a 1.5 h exposure (173). Furthermore, by measuring the rate of GSH 
turnover in APAP-treated rats, Lauterberg et al. provided evidence that toxic 
doses of APAP suppressed GSH synthesis (174). Interestingly, we found that a 
number of proteins involved in GSH synthesis and sulfur amino acid metabolism 
were glutathionylated by APAP (Figure 2-17). In a prior pilot study not presented 
here, where HepaRG cells were treated with APAP for 6 h as a single replicate, 
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we found that both isoforms of methionine adenosyltransferase (MAT), which 
catalyzes the rate limiting step of cysteine synthesis (175) were glutathionylated 
by APAP (Table S2). The consequence of MAT glutathionylation is unknown, 
however nitrosylation was reported by Pérez-Mato et al. to inhibit MAT activity 
in rat hepatocytes (176). In spite of this preliminary observation, MAT did not 
meet the glutathionylation criteria at any point of the longitudinal investigation 
(MAT glutathionylation was observed in only 1 replicate of the 3 h time-point, 
Table S2) or with low dose APAP, and the reason for this discrepancy is unclear. 
Nevertheless, MAT remains an intriguing candidate that might undergo 
glutathionylation, as MAT is reported to be covalently bound by APAP (43). In 
support of this, the peptide that was glutathionylated in our pilot study was 
identical to that reported by Pérez-Mato et al. as nitrosylated by GSNO (176). 
Metabonomics studies further corroborate this hypothesis, as levels of S-
adenosylmethionine (SAMe) and S-adenosylhomocysteine (SAH) are decreased 
in APAP toxicity accompanied by an accumulation of methionine. The level of 
trigonelline, which is generated from the methyl acceptor nicotinate during the 
conversion of SAMe to SAH was also decreased. Furthermore, SAMe 
supplementation exerted therapeutic effects similar to NAC in ameliorating liver 
injury in APAP overdose (177). Collectively, these suggest that MAT, if 
glutathionylated, might be inhibited and would explain the inhibition of GSH 
synthesis as well as decrease in associated metabolites. This requires further 
investigation, possibly using alternative analytical methods to determine if MAT 
is glutathionylated by APAP.  
In our study, cystathionine β-synthase (CβS) was found to be glutathionylated by 
APAP. Interestingly, glutathionylation was reported to increase its activity 2-fold 
above basal levels (178). Nevertheless, GSH synthesis remains suppressed, 
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possibly due to MAT inhibition, and the increased CβS activity is futile as it lacks 
the upstream substrates. This is supported by suppressed taurine and hypotaurine 
levels, products of cysteine degradation, indicating a decrease in cysteine levels. 
On the other hand, besides providing energy substrates to maintain the citric acid 
cycle, supplementation with SAMe and NAC would also support increased 
cysteine synthesis rates which is likely to occur in response to CβS 
glutathionylation. Levels of spermidine and spermine, which are metabolites 
upstream of SAMe were decreased, and could be attributed to depletion of SAMe. 
Interestingly, spermidine synthase and spermine synthase, the enzymes 
responsible for their synthesis were glutathionylated, and it is possible that 
glutathionylation resulted in their inhibition. Finally, glutamate cysteine ligase 
(GCL) and glutamate synthetase (GS), the two key enzymes responsible for GSH 
synthesis were also found to be glutathionylated by APAP. While it is tempting to 
infer that glutathionylation might compromise their activity thereby contributing 
to the suppression of GSH synthesis, metabonomics findings suggest otherwise. 
In the absence of cysteine as a substrate, 2-aminobutyrate is conjugated to 
glutamic acid by GCL, and finally to glycine by GS to generate ophthalmate 
(101). This is evidenced by increased levels of γ-glutamyl-2-aminobutyrate and 
ophthalmate, which indicate that GCL and GS retain their catalytic activity. This 
observation illustrates how proteo-metabonomic mapping may be used to guide 
interpretations of the effects of PTMs such as glutathionylation, particularly in 
instances where the biological consequences of the PTM for a particular protein 
are unknown.   
Aberrant glutathionylation may compromise protein turnover. While there is 
good correlation between proteomics and metabonomics data for the pathways 
discussed above, in the case of protein turnover and defense against cellular stress 
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there are limited reports from which deep analysis can be performed. 
Perturbations of protein turnover after APAP exposure have been reported both in 
vitro and in vivo. Interestingly, APAP can inhibit protein synthesis in isolated 
hepatocytes as early as 5 min (179) which remains suppressed at 1 h after 
exposure (180). Similarly, protein synthesis in mice is suppressed at 3 h, but 
recovers to 90% of control levels at 24 h (181). Inhibition of protein degradation 
(179) has also been noted for APAP. In general, in situations of elevated oxidative 
stress, both bacteria and eukaryotic cells exhibit suppressed protein synthesis 
activity, which has been ascribed in part to inactivation of enzymes involved in 
energy metabolism and amino acid synthesis (182), similar to what we have 
described for APAP-induced protein glutathionylation. Research in this area 
appears to be more focused on prokaryotes, however there are similar elements of 
the protein synthesis machinery between prokaryotes and eukaryotes. A number 
of ribosomal proteins (e.g. L5, L14, L7/L12, L27, L31, S2, S4, S17 and S2), 
elongation factors (e.g. ET-Tu, EF-G) and aminoacyl-tRNA synthetases have 
been found to undergo cysteine oxidation in bacteria, but the consequences are 
unclear (182). Oxidation of Cys182 in E. coli threonyl-tRNA synthetase, which is 
responsible for the editing of translated proteins results in protein mistranslation 
and misfolding (183). However, the lack of studies in eukaryotic proteins hampers 
interpretation and extrapolation of the effects of thiol modifications from 
prokaryotic studies. The evidence for glutathionylation in protein degradation is 
better defined. Both the E2 ubiquitin-conjugating enzyme and the 26S proteasome 
also undergo glutathionylation (65, 184), resulting in inhibition of ubiquitination 
and proteasomal degradation, which corroborates our findings and reports of 
inhibition of protein degradation by APAP. It is unlikely that perturbation of 
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protein turnover is the cause of APAP toxicity, but could be a contributing factor 
to exacerbate the original insult.  
Aberrant glutathionylation may affect antioxidant defense. For antioxidant 
defense enzymes, APAP is known to inhibit the activities of mitochondrial 
superoxide dismutase 2 (MnSOD) (185), catalase, glutathione peroxidase and 
glutathione transferase (186). The critical role of MnSOD in APAP toxicity was 
demonstrated in mice heterozygous for MnSOD deficiency, which had increased 
liver injury and peroxynitrite formation (77). On the other hand, overexpression 
and knockout of cytosolic superoxide dismutase 1 (Cu,Zn-SOD) both 
unexpectedly promoted survival in mice after APAP exposure (187). 
Glutathionylation of Cu,Zn-SOD is reported to inhibit its activity in vitro (188); 
however in the light of evidence of APAP resistance in Cu,Zn-SOD knockout 
mice, the relevance of this PTM by APAP is unclear. Separately, 
glutathionylation of MnSOD in rats has been observed with unknown 
consequences (189). Glutathionylation of microsomal glutathione-S-transferase 1 
is associated with a gain in activity and is thought to enhance the detoxification of 
electrophiles (190). Glutathionylation of peroxiredoxin 1 has been shown to 
inhibit its chaperone activity (191). Finally, glutathionylation of heat shock 
protein 70 was demonstrated to increase its chaperone activity and reduce protein 
aggregation (192). On the other hand, glutathionylation of the chaperone heat 
shock protein 90 was found to increase its degradation. Overall, the contribution 
of APAP-induced glutathionylation of proteins involved in defense against 
cellular stress is still unclear, but may impair cellular recovery mechanisms. 
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2.5.2.5 Additional Glutathionylated Proteins Related to APAP-induced 
Hepatotoxicity 
Proteo-metabonomic mapping provides strong evidence that aberrant 
glutathionylation is a precipitating or augmentative mechanism underlying 
impairments in energy metabolism and mitochondrial respiration, the initial 
increase in mitochondrial oxidative stress and suppressed GSH synthesis that 
exacerbates GSH depletion. Nevertheless, there are other aspects of APAP 
toxicity that are not revealed by proteo-metabonomic mapping, as these do not 
directly involve metabolite perturbations. This warrants careful inspection of the 
glutathionylated proteins to extract additional correlations between 
glutathionylation and APAP toxicity. 
Aberrant glutathionylation disrupts calcium dynamics. Maintenance of calcium 
homeostasis in the cell is of vital importance as calcium is an important secondary 
messenger that is involved in regulating numerous cellular processes, including 
muscle contractility, neuronal learning and memory, secretion of hormones, cell 
proliferation, transcription factor activation, mitochondrial citric acid cycle and 
ATP synthesis, apoptosis and others (193). Excessively high cytosolic calcium 
activates cellular proteases, phospholipases and endonucleases, and contributes to 
cell death (193). Given the critical role of calcium, cells normally maintain an 
intracellular calcium level of around 100 nM (194). This is accomplished by 
continuous extrusion of calcium from the cell out to the extracellular space by the 
ATP-dependent plasma membrane Ca2+ ATPase (PMCA), which is referred to by 
different authors as plasma membrane calcium-transporting ATPase, Ca2+-Mg2+ 
ATPase or plasmalemmal Ca2+-ATPase. Additionally, the low intracellular 
calcium is supported by sequestration of calcium into the smooth endoplasmic 
reticulum (sER) and mitochondria, mediated by the smooth endoplasmic reticular 
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Ca2+ ATPase (SERCA) transporter (195) and mitochondrial Ca2+ uniporter 
(MCU) respectively (196). Numerous studies have highlighted APAP-induced 
calcium dysregulation, characterized by a 10-fold increase in cytosolic and 
mitochondrial calcium to micromolar levels (197-199), which occurred as early as 
45 min after APAP exposure (198). This increase strongly paralleled the time-
course of covalent binding (200), and was shown to precede cytotoxicity (199). 
The increase in cytosolic calcium was attributed to inhibition of PMCA and 
diminished extrusion of intracellular calcium, either by arylation or oxidation of 
redox-sensitive thiols on PMCA (83, 198, 201). However, no evidence of a 
protein adduct to PMCA has been found (82), while addition of DTT was shown 
to reverse PMCA inhibition, restore cytosolic calcium to baseline levels and 
prevent APAP-induced cytotoxicity, presumably by reducing the affected PMCA 
thiols (202). Nevertheless, this is only a conjecture, and the exact mechanism of 
PMCA inhibition by APAP remains unknown. Specific chelation of cytosolic 
calcium (203) and co-administration of calcium channel blockers such as 
diltiazem, nifedipine and verapamil (204, 205) were able to reduce APAP toxicity 
by varying degrees, suggesting a causal relationship between the rise in 
intracellular calcium levels and APAP toxicity. The mechanism by which calcium 
channel blockers exert their protective effects has not been fully elucidated. These 
agents typically bind to L-type voltage-gated calcium uptake channels to prevent 
calcium influx in excitable cells, thus eliciting their anti-hypertensive or anti-
arrhythmic effects (205). The liver is known to express one subtype of the L-type 
voltage-gated calcium channel (206), which could be a target of calcium channel 
blockers. Despite strong evidence indicating that dysregulation of calcium 
homeostasis is part of the sequence of events mediating APAP toxicity, little work 
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has been published on this phenomenon after an intense period of investigation 
from the mid-1980s to mid-1990s. 
We found in our study that PMCA1 and SERCA2 were glutathionylated by 
APAP, while MCU was not found to undergo glutathionylation. PMCA has been 
reported to be inhibited by glutathionylation in aortic endothelial cells (207), 
while glutathionylation of SERCA, induced by nitrosylation in cardiac myocytes, 
was found to activate pumping of cytosolic calcium into the sER (208). PMCA 
glutathionylation by APAP provides the missing mechanistic link to explain the 
inhibition of calcium efflux by APAP, and agrees with prior hypotheses that thiol 
oxidation of PMCA is responsible for its inhibition. The effect of APAP on 
SERCA uptake of cytosolic calcium is mixed, with some reports indicating that 
APAP did not increase sER calcium levels (198) within 2.5 h, while others 
observed an increase, albeit not statistically significant, at 4 h with 500 mg/kg 
APAP, and a statistically significant decrease at 4 h with 750 mg/kg APAP (209) 
in mice. We postulate that these contrasting results could possibly be attributed to 
APAP-induced SERCA glutathionylation, which promotes calcium sequestration 
into the sER (208). Calcium release from sER is mediated by the inositol 
triphosphate receptor (IP3R), which is sensitive to intra-reticular calcium levels, 
and spontaneous calcium release occurs when the sER is overloaded with calcium 
following continuous SERCA-mediated calcium uptake (210, 211). Taken 
together, it is possible that SERCA glutathionylation initially results in augmented 
calcium uptake from the cytosol as a mechanism to reduce cytosolic calcium 
levels. However, if the rise in cytosolic calcium levels remains unchecked (e.g. 
due to impaired PMCA calcium extrusion), the enhanced sER calcium 
accumulation past a certain tipping point eventually triggers sER calcium release, 
exacerbating the elevated cytosolic calcium levels. While potentially explaining 
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the variable reports of sER calcium fluxes, this hypothesis remains speculative 
and requires a detailed time-course study of sER calcium dynamics and SERCA 
glutathionylation in parallel. It should be noted that SERCA2, the isoform found 
in cardiac muscle and other non-muscle cells (212) was reported to be 
glutathionylated at Cys674 in rat cardiomyocytes, and is responsible for the 
increased calcium uptake activity. In our study, we found that SERCA2 was 
glutathionylated at Cys635 at 3 h, and at Cys471 at 24 h. We did not detect the 
tryptic peptide containing Cys674 in our study as it was only 4 amino acids long, 
with a size of 495.6 Da. When doubly charged (+2), its m/z of 248.8 is below the 
lower limit of the mass range set for TOF-MS1 scan (section 2.3.2.4). 
Glutathionylation at the other two sites found in our study is novel and has not 
been reported, although unspecified thiol modifications at Cys471, Cys669 and 
Cys998 were reported to be induced by cadmium in mouse liver (122), while 
nitrosylation of Cys560 and Cys998 were reported in untreated mouse liver (213) 
with undetermined effects. Although the effects of glutathionylation at Cys471 and 
Cys635 in our study are presently unknown, it indicates that SERCA is susceptible 
to glutathionylation at multiple sites, and at least one site is reported to exhibit a 
functional consequence. Further studies using alternative proteases for protein 
digestion such as LysC would capture Cys674 in a larger peptide, and permit 
detection of glutathionylation, if present. Separately, we did not find evidence for 
glutathionylation of MCU in our study. To the best of our knowledge, MCU is not 
redox regulated by nitrosylation or glutathionylation. This corroborates existing 
data that mitochondrial calcium uptake is not affected by APAP (209). 
After nearly two decades of little progress in the area of APAP-induced calcium 
dysregulation, Kheradpezhouh et al. recently reported a novel and unexpected 
protein as a key player in the cellular influx of calcium post-APAP exposure. In a 
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series of elegant experiments, the transient receptor potential melastatin 2 
(TRPM2) was demonstrated to mediate the hepatocellular uptake of calcium after 
in vitro exposure to APAP or H2O2 for 1 h. Calcium influx was almost completely 
blocked by TRPM2 inhibitors, while knockdown using siRNA and knockout of 
TRPM2 in rat and mouse hepatocytes respectively achieved a similar effect. 
These results were demonstrated using whole cell patch-clamp techniques, which 
provide a longitudinal trace of ion fluxes. This approach is superior to previous 
studies on calcium dynamics which only yielded snapshots of calcium fluxes. 
Collectively, these demonstrated that TRPM2 is an important ion channel 
mediating hepatocellular calcium influx. Ablation of TRPM2 channels in 
knockout mice decreased AST and ALT levels significantly by up to 7-fold, 
demonstrating a protective effect against APAP toxicity in vivo. The mechanism 
of APAP-induced TRPM2 calcium influx was further demonstrated to be 
dependent on ADP-ribose, which acts as a ligand to activate TRPM2 (214). This 
agrees with independent studies which reported that oxidative stress induced the 
activation of TRPM2, not directly through thiol modifications, but by causing 
mitochondrial dysfunction, which triggers opening of the MPTP. This causes 
hydrolysis of NAD+ to ADP-ribose by NAD+ glycohydrolase (215), which is 
normally sequestered in the mitochondrial intermembrane space and is released 
upon MPTP opening. Another mechanism shown to increase cytosolic ADP-
ribose levels is the activation of poly(ADP-ribose) polymerase (PARP), which 
then results in TRPM2 activation (216). Interestingly, these two events have also 
been reported in APAP toxicity. MPTP opening is a well-known consequence of 
APAP toxicity and is strongly implicated in APAP-induced mitochondrial 
dysfunction (77), while PARP, which is involved in DNA repair, is activated 
upon DNA damage by APAP. Inhibition of MPTP opening and PARP activation 
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have protective effects against APAP toxicity (77, 217). Additionally, more than 
two decades ago, NAPQI was shown to trigger NAD+ hydrolysis, which was 
prevented by incubation with cyclosporin A, an inhibitor of the MPTP (218); 
however the significance of these events were not understood at the time. 
Collectively, these evidences strongly support the findings of Kheradpezhouh et 
al. and corroborate the important role of TRPM2 in the derangement of calcium 
homeostasis by APAP. Kheradpezhouh et al. further noted that in view of their 
results, it is unlikely that PMCA inhibition is responsible for the increase in 
intracellular calcium levels upon APAP exposure; but rather, it appears that 
PMCA inhibition accompanies hepatocellular injury (214). 
We agree with the comprehensive evidence presented by Kheradpezhouh et al. 
that TRPM2 is responsible for APAP-induced calcium entry, and TRPM2 
inhibition is an attractive target for therapeutic intervention in APAP overdose. 
However, we are hesitant to dismiss the role of PMCA inhibition in APAP-
induced calcium dysfunction. As discussed previously, restoration of PMCA 
activity by addition of DTT soon after NAPQI exposure was shown to decrease 
cytosolic calcium to baseline levels and prevent cytotoxicity (202). Hence, similar 
to TRPM2, PMCA modulation can also ameliorate the deleterious effects of 
APAP, indicating that PMCA does contribute towards the abnormal calcium 
dynamics. We believe that these two seemingly incongruous proposals can be 
unified in a single, holistic mechanistic explanation of calcium derangement, by 
considering that the rise in intracellular calcium levels could be a combination of 
both increased calcium influx through TRPM2, and inhibition of calcium efflux 
via PMCA. This hypothesis implies that although activation of TRPM2 alone 
does cause increased calcium influx, constitutive homeostatic mechanisms such 
as PMCA-mediated calcium efflux should reverse or dampen the influx of 
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calcium. We cite two examples to support this theory. Inamura et al. (219) and 
Togashi et al. (220) reported that exposure to ADP-ribose alone caused an 
increase in calcium efflux that was gradually reduced, although not to baseline 
levels. This decline occurred as soon as 1 min after application of ADP-ribose, 
but was attributed to ‘desensitization’, of an unknown mechanism. We propose 
that this decline in calcium levels shortly after ADP-ribose application is, in fact 
the result of competent PMCA-mediated extrusion and/or mitochondria/sER 
sequestration of calcium, as part of normal homeostatic mechanisms. In the case 
of APAP or other oxidants, sustained high intracellular calcium levels are the 
result of a ‘double-whammy’ effect exemplified by amplified influx and 
diminished efflux due to simultaneous TRPM2 activation and PMCA inhibition. 
Indeed, the rise in cytosolic calcium caused by APAP as shown by 
Kheradpezhouh et al. was not dampened, but was instead sustained for 10 min. 
This also accounts for the sustained influx of calcium in other studies which 
examined the effect of oxidants on TRPM2 activation, which are likely to have 
also inactivated PMCA concurrently. In other words, we propose that one without 
the other would not account for the effect of APAP on cellular calcium dynamics, 
and in fact, central to the observed dysregulation is the inhibition of PMCA as a 
result of APAP glutathionylation, creating a perfect storm of events. 
Unfortunately, Kheradpezhouh et al. did not investigate the effects of ADP-ribose 
application alone on calcium dynamics in their experimental system, which would 
confirm or refute our proposal. 
The preceding discussion illustrates the vital, albeit neglected role of calcium 
dynamics in APAP toxicity. In fact, calcium perturbations may also explain some 
yet-unanswered questions in this area, which include the initial trigger for JNK 
activation and also the opening of the MPTP. For example, as discussed in section 
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2.2.4, oxidation of glutathione-S-transferase π (GSTπ) could trigger JNK release 
(77) which is a precursor step for its activation. Alternatively, oxidation of 
thioredoxin can release ASK1, which can phosphorylate and activate JNK (77). 
Both GSTπ and thioredoxin have been reported to undergo glutathionylation 
(147) are promising candidates to explain the activation of JNK which is a crucial 
event; however we did not observe glutathionylation of either protein in this 
present study. Calcium has been reported to activate ASK1 and JNK (221), while 
high calcium levels in the mitochondria are well-known to trigger opening the 
MPTP (222). Interestingly, calcium has been reported to activate nitric oxide 
synthase, increasing nitric oxide production (193), which could have implications 
on peroxynitrite and oxidative stress generation. In light of these recent findings, 
further investigation of calcium dynamics is warranted. 
Aberrant glutathionylation could trigger MPTP opening. While calcium can 
activate MPTP opening, it is possible that protein PTMs may also trigger this 
event. The voltage-dependent anion channel (VDAC) and adenine nucleotide 
translocase (ANT), also known as ADP/ATP translocase have been long thought 
to be the main pore-forming components, however their role has not yet been 
proven conclusively and remain controversial, as the MPTP can still form even 
when either one is absent (222).  Interestingly, we found that VDAC1-3, as well 
as ANT1/2 were glutathionylated by APAP. The consequences of VDAC and 
ANT glutathionylation are still unknown; however there are some potential hints 
as to the effect of glutathionylation. For example, knockdown of cytosolic Grx1 
resulted in increased oxidized VDAC (223) and a loss of mitochondrial 
membrane potential. The oxidation state of the vicinal thiols of VDAC is known 
to critically affect mitochondrial membrane potential and MPTP opening (224), 
and it is possible that VDAC glutathionylation may promote MPTP opening. The 
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effects of thiol modification of ANT remain controversial, with reports of both 
activation and inactivation. Queiroga et al. reported that carbon monoxide 
induced glutathionylation of ANT and also prevented the loss of mitochondrial 
membrane potential (225). Conversely, Halestrap et al. reported that oxidation of 
Cys160 (erroneously reported as Cys159) in ANT rendered the MPTP insensitive to 
ADP-mediated inhibition of calcium-dependent MPTP opening, indirectly 
suggesting that Cys160 oxidation promoted calcium-dependent pore opening (226). 
Interestingly, VDAC and ANT were recently reported to also be nitrosylated. 
Nitrosylation induced by GSNO appeared to potentiate mitochondrial swelling, an 
indication of MPTP opening (140). However, the authors did not demonstrate a 
direct cause-effect relationship between VDAC/ANT nitrosylation with MPTP 
opening. In our study, we found that ANT was glutathionylated at 3-6 h, while 
VDAC was generally glutathionylated at 12-24 h. McGill et al. reported that a 
decrease in mitochondrial membrane potential, an indicator of MPTP opening 
occurred at 12-24 h after exposure to APAP in HepaRG cells (133). The time-
course suggests that VDAC glutathionylation was associated with MPTP opening. 
Cyclophilin D has been reported to modulate pore opening, but we did not 
observe glutathionylation of this protein. Instead, glutathionylation of a related 
protein, cyclophilin A (also known as peptidyl-prolyl cis-trans isomerase A) was 
observed. Although the effects of glutathionylation are not known, cyclophilin A 
has been recently suggested to contribute to the modulatory activity of cyclophilin 
D on MPTP opening (227). 
McGarry et al. recently reported the basal glutathionylation status of mouse liver 
proteins, and disclosed an ongoing study of APAP-induced glutathionylation 
using a resin-assisted enrichment approach to profile protein glutathionylation 
(126). It would be interesting to compare the glutathionylated proteome in our 
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study and that of McGarry et al., given that they have used an in vivo mouse 
model, while we have used an in vitro human model. However, a potential caveat 
is that their methodology would need to account for and distinguish changes in 
protein expression versus changes in protein glutathionylation, as currently their 
reported approach does not take this critical confounder into consideration. 
2.5.2.6 Longitudinal Progression of APAP-induced Protein Glutathionylation 
Overall, APAP-induced protein glutathionylation appeared to peak at 3 h, while 
McGill et al. profiled a temporal increase in APAP-cysteine conjugates (used as a 
surrogate measure of covalent binding) that peaked at 6 h and declined thereafter 
in HepaRG cells (133). This suggested that the majority of the aberrant 
perturbations (which include those found to be relevant to APAP toxicity) 
occurred during the early phase of APAP toxicity as covalent binding is 
developing. Heat map analysis of normalized peak H:L fold-change values 
indicated clustering of peptides in distinct temporal regions, suggesting that 
behind the broad, overall glutathionylation trend, there was a time-dependent 
stratification of glutathionylated peptides. Nonetheless, analysis of 
glutathionylated peptides in the mid and late clusters failed to reveal pathways 
that could be relevant to APAP toxicity.  The markedly weaker associations with 
critical pathways of APAP toxicity during the mid to late time-points suggest that 
the glutathionylation pattern at these periods was diluted with proteins that do not 
have meaningful relationships with APAP toxicity. It is possible that while APAP 
induced temporal glutathionylation of different proteins, only a proportion of 
them are biologically relevant to the development of APAP toxicity. In other 
words, despite an apparent temporal clustering, there could be a large number of 
non-relevant, ‘bystander’ proteins glutathionylated as a result of collateral 
damage. This is likely since the number of glutathionylated peptides in the 3 key 
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biological processes decreased with time, yet the total number of glutathionylated 
peptides remained relatively unchanged. The appearance of temporal clusters is 
unsurprising as a parallel biochemical analysis revealed an increasing trend of 
oxidative stress up to 24 h (Figure 2-11), thus peptides in these clusters could be 
glutathionylated not as a cause, but a consequence of toxicity. Broadly speaking, 
the longitudinal analysis of protein glutathionylation therefore suggests that there 
are two groups of glutathionylated proteins: those that are glutathionylated, likely 
as a result of APAP bioactivation, that initiate or perpetuate the initial stages of 
toxicity; and those that are glutathionylated in the mid to late stages likely by 
oxidative stress, as an outcome of toxicity, and might not contribute to the 
development of toxicity. We are mindful that from a practical standpoint, since 
both processes can occur concurrently it is impossible to definitively assign 
proteins glutathionylated by overt covalent binding and those glutathionylated by 
oxidative stress. Nonetheless, based on the temporal pattern of covalent binding 
reported by McGill et al. in HepaRG cells (maximal at 6 h) (133) versus oxidative 
stress (maximal at 12-24 h) (Figure 2-11), APAP-induced glutathionylation of 
critical proteins (maximal at 3 h) more closely matches the time-course of 
covalent binding than oxidative stress, hence suggesting an association with the 
former. Investigations of the temporal patterns of total covalent binding by APAP 
in HepaRG cells would provide further information on a causal relationship 
between glutathionylation and covalent binding.  
It is important to note that we are not disregarding the biological relevance of 
glutathionylated proteins in the mid and late clusters. It is possible that we are not 
able to make mechanistic connections between glutathionylation and APAP 
toxicity during these time-points because of incomplete information regarding the 
effects of proteins glutathionylated at these time periods. As a notable exception, 
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the opening of the MPTP and loss of mitochondrial membrane potential was 
reported by McGill et al. to occur during the 12-24 h period (133), and VDAC 
was found to be glutathionylated at the same time which allowed a potential 
temporal association to be established. It is expected that as more information on 
the biological consequences of protein glutathionylation is uncovered, the 
importance of glutathionylation during the mid to late stages of APAP toxicity 
will become clearer.    
Altogether, these findings emphasize the importance of proteome-wide, deep 
analysis of glutathionylation. A broad-based overview using non-specific 
approaches like Western blotting would not be able to distinguish these two 
groups of glutathionylated proteins and hamper identification and analysis of the 
critical glutathionylated proteins. In the only other study of APAP-induced 
protein glutathionylation, Yang et al. reported that total protein glutathionylation 
in APAP-treated mice was unexpectedly always lower when compared to control 
mice at 1, 3, 6 and 24 when examined using a Western blot approach. 
Immunohistochemical analyses showed however that there was a spatial 
progression of glutathionylation in livers of APAP-treated mice from the 
centrilobular region outwards over time (86). Their findings corroborate the 
importance of careful interpretations of global patterns which may obscure 
underlying trends. 
2.5.2.7 Dose- and Bioactivation-dependent Protein Glutathionylation by APAP 
To determine whether APAP-induced glutathionylation is dose-dependent, we 
compared the glutathionylation profile of HepaRG cells treated with 30 mM 
APAP and 0.5 mM APAP for 3 h. The 3 h time-point was chosen for comparison 
as it exhibited the highest number of glutathionylated proteins with 30 mM 
APAP, and it was anticipated that any dose-dependent changes in the 
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glutathionylation profile would be most prominent at this time-point. A dose of 
0.5 mM APAP was chosen to investigate the effects of mild APAP exposure on 
protein glutathionylation. This was due in part to dose considerations of the 
CYP2E1 inhibitor diethyldithiocarbamate (DEDC). DEDC, a mechanism-based 
inactivator of CYP2E1 (228) has been shown to markedly reduce lipid 
peroxidation, GSH depletion, malonedialdehyde formation and hepatotoxicity in 
mice when given 30 min before APAP administration, at an approximately 1:1 
molar ratio (229). In vitro, DEDC was found to prevent cytotoxicity only if 
hepatocytes were pre-treated with DEDC, but did not exhibit protective effects 
when added after APAP exposure (230). However, when administered at elevated 
levels, DEDC itself has been shown to cause increase oxidative stress and 
inhibition of antioxidant defense enzymes including superoxide dismutase and 
catalase, decreased GSH levels, increased lipid peroxidation and hepatotoxicity in 
vivo (231). Furthermore, 1 mM DEDC did not affect ATP levels in rat liver slices, 
but caused ATP depletion and increased lipid peroxidation at doses of 5 mM and 
10 mM (232). Based on these findings, we chose to use DEDC at concentration of 
0.5 mM which is likely sub-toxic, and an equimolar dose of 0.5 mM APAP as a 
comparator. 
Our results suggest that glutathionylation of proteins deemed biological important 
to the development of APAP toxicity was decreased as a result of exposure to a 
lower dose of APAP. Although there was only a small decrease in total number of 
glutathionylated peptides with 0.5 mM APAP, there was a far larger decrease for 
the subset of toxicologically important peptides. This seems to suggest that there 
was an apparent redistribution of the glutathionylation profile at low dose APAP, 
since the total number of glutathionylated peptides was not significantly affected. 
This was not further analyzed as the objective of this investigation was to 
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examine the effect of low dose APAP on the glutathionylation of peptides 
identified as important in mediating APAP toxicity namely energy metabolism, 
protein turnover and defense against cellular stress. This possibility is also 
supported by a similar observation in the longitudinal study, where the number of 
glutathionylated peptides in these 3 groups decreased over time while the total 
number of glutathionylated peptides remained steady from 6-24 h. The 
redistribution of protein glutathionylation as a function of time and dose would be 
an interesting aspect for further investigations. 
The importance of APAP bioactivation in the genesis of aberrant 
glutathionylation is indicated by the decrease in the total number of 
glutathionylated peptides, as well as those deemed biologically important when 
comparing 0.5 mM APAP and 0.5 mM APAP + DEDC. Although the number of 
glutathionylated peptides involved energy metabolism was not significantly 
different, decreases were observed for protein turnover and defense against 
cellular stress. The use of DEDC to inhibit CYP2E1-dependent NAPQI formation 
did not abolish APAP-induced glutathionylation for several reasons. Firstly, the 
use of DEDC itself may introduce another source of oxidative stress, although we 
attempted to limit this by using a low DEDC concentration. Secondly, NAPQI 
formation can also be mediated by other CYP450 enzymes, including CYP3A4, 
although the contributions from these enzymes are reported to be low (233, 234). 
It should be noted that while some authors have reported that CYP3A4 is the 
primary isoform responsible for NAPQI generation (235), it is generally accepted 
that CYP2E1 is the major isoform responsible for NAPQI formation. Inhibition of 
CYP2E1 by DEDC thus may reduce, but not completely eliminate 
glutathionylation. The use of a pan-CYP inhibitor may circumvent this 
possibility; nevertheless we decided to utilize DEDC as there are a number of in 
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vitro and in vivo studies demonstrating that DEDC can protect against APAP 
toxicity, while no pan-CYP inhibitor has been shown to exhibit this effect. 
Thirdly, APAP-induced glutathionylation is likely to arise as a result of both 
NAPQI and ROS formation (Figure 2-11). Oxidative stress would account for 
background glutathionylation. As such, this result serves as a positive indication 
that bioactivation of NAPQI contributes to APAP-induced glutathionylation. 
Future follow-up studies using siRNA-based CYP2E1 and CYP3A4 knockdown 
systems would further clarify this phenomenon. 
2.5.2.8 Comparative Analysis of AMAP- and APAP-induced Protein 
Glutathionylation 
AMAP has often been used as a non-toxic regioisomer of APAP in comparative 
studies of the effects of covalent binding on toxicity. Both AMAP and APAP 
cause equivalent levels of covalent binding, however AMAP is non-hepatotoxic, 
while APAP causes liver toxicity (236). This apparent difference is attributed to 
differential covalent binding at a subcellular level, where reactive metabolites of 
AMAP preferentially bind to mouse liver proteins in the cytosolic and 
microsomal compartment, while NAPQI binds more extensively to mitochondrial 
and nuclear proteins (201). Mass spectrometric analysis of covalent adducts 
formed with AMAP and APAP appear to confirm this observation (42, 43). This 
is unsurprising given that the mitochondria plays a central role in APAP toxicity. 
Importantly, this difference was not due to preferential generation of reactive 
metabolites from APAP in the mitochondria (201). There are two phenotypic 
differences between APAP and AMAP that could explain mechanistically the 
differential toxicity observed. Firstly, despite causing equivalent levels of 
covalent binding in the plasma membrane, AMAP did not exhibit inhibition of 
PMCA activity, nor did it cause elevations in cytosolic and mitochondrial calcium 
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levels (201). Secondly, AMAP did not cause a decrease in free protein thiols, as 
does APAP (80). This suggests that a possible explanation for the non-toxic 
nature of AMAP is due partly to its inertness with regards to thiol modification, 
which also corroborates the absence of PMCA inhibition. Given the differences 
observed between AMAP and APAP, particularly with regards to their 
preferential covalent binding, we sought to use AMAP as a tool to elucidate 
differentially glutathionylated proteins between APAP and AMAP. Unexpectedly, 
there was a large overlap between proteins glutathionylated by these two agents, 
even for those postulated to play key roles in the genesis of APAP toxicity. 
Furthermore, in contrast to previous reports on proteins covalently bound by 
AMAP, we found that more than 1/3 of glutathionylated proteins were localized 
in the mitochondria, while none were found in the endoplasmic reticulum. A 
potential explanation for this result was provided by Hadi et al., who found that 
contrary to expectations, AMAP was toxic in rat and human liver, while 
remaining non-toxic in mouse liver (237). This is an important finding as the 
comparative toxicology studies between APAP and AMAP described above were 
performed in mice. There was a dramatic difference in ATP levels, liver 
morphology and viability of mouse precision cut liver slices compared with those 
of rat and human origin. In fact, APAP and AMAP caused the same extent of cell 
death in human liver. While the protein targets of APAP and AMAP in mouse, rat 
and human liver were not elucidated, similar protein expression profiles were 
found between APAP-treated mice liver, and AMAP- or APAP-treated rat and 
human liver, which was markedly different from that of AMAP-treated mouse 
liver (237). The reason for the species difference is still unclear, but it would be 




The treatment duration of 6 h was initially chosen for AMAP as we observed 
substantial glutathionylation by APAP in our pilot study of the 6 h time-point. 
Samples for the longitudinal study of APAP and 6 h AMAP were prepared at the 
same time, before we observed that glutathionylation of APAP was highest at 3 h. 
Nevertheless, the large degree of overlap of glutathionylated proteins between 
APAP and AMAP corroborates the finding of similar toxicity between APAP and 
AMAP. As it was reported that AMAP does not modulate calcium levels and 
PMCA activity, we examined glutathionylation of proteins involved in calcium 
dynamics and found that AMAP glutathionylated SERCA but not PMCA. 
However, it is possible that we missed observing PMCA glutathionylation by 
AMAP, especially if the temporal glutathionylation profile of AMAP parallels 
that of APAP, as PMCA glutathionylation by APAP occurred only at the 3 h 
time-point. 
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2.6 Chapter Conclusion 
Protein glutathionylation is a regulatory PTM that is redox sensitive. 
Perturbations of this PTM can alter cellular homeostasis and cause deleterious 
effects. We present a framework to illustrate the mechanisms of covert APAP-
induced protein glutathionylation which is secondary to overt covalent binding. 
To study aberrant protein glutathionylation by APAP, the GluICAT methodology 
was developed which was carefully designed to circumvent many limitations of 
existing approaches. Global profiling of APAP-induced protein glutathionylation 
in HepaRG cells using GluICAT revealed a number of aberrantly glutathionylated 
proteins in several key biological processes that are central to APAP toxicity. 
Importantly, proteo-metabonomic mapping correlated functional impairment of 
energy metabolism networks and GSH synthesis with metabonomic perturbations 
caused by APAP, providing a mechanistic explanation for these aspects of APAP 
toxicity. Glutathionylation provides an explanation for the increase in 
mitochondrial oxidative stress, derangements in calcium dynamics and 
mitochondrial dysfunction, which are key events in the toxicity spectrum. 
Aberrant glutathionylation illuminates the mechanism of action for agents 
exhibiting prophylactic or therapeutic activity, which are suggested to counteract 
the debilitating effects of APAP-induced glutathionylation. A temporal analysis 
of glutathionylation patterns suggested that glutathionylation is likely to 
participate in the early stages of APAP toxicity, and proposed the existence of 
two groups of proteins, whereby glutathionylation of the first group precipitated 
and/or propagated toxicity, while glutathionylation of the second group is likely a 
consequence of toxicity. The former is possibly induced by covalent binding, 
while the latter driven by oxidative stress. Aberrant glutathionylation was also 
likely dose-dependent, and could be ameliorated by inhibition of APAP 
 127 
 
bioactivation. Comparative analysis of glutathionylation patterns between AMAP 
and APAP unexpectedly revealed broad overlaps between proteins 
glutathionylated by both these agents, which is in line with recent reports that 
they exhibit comparable toxicity in humans. Collectively, these findings provide 
strong mechanistic evidence that covert, aberrant APAP-induced 
glutathionylation is responsible for the initial events in APAP toxicity, which 
occurs as a result of overt covalent binding. Our work furnishes previously 
unrecognized mechanisms of drug-induced liver injury to the attention of 
mechanistic toxicology and fuels fresh perspective into the role of covalent 





 Chapter 3 Strategies to Mitigate the Deleterious Effects of 
Covalent Binding 
3.1 Chapter Summary 
Background: Covalent and coordinate binding caused by reactive metabolites 
can lead to irreversible inactivation of CYP450 enzymes, which can cause DDIs 
and ADRs. These undesirable effects are attributed to the unexpected formation 
of reactive metabolites. The extent of reactive metabolite formation is a function 
of a number of factors, including the intrinsic bioactivation potential of the 
molecule, dose burden administered and the metabolic capacity of the enzymes 
responsible for its generation. Reactive metabolite formation by lapatinib results 
in MI complex formation and MBI, resulting in permanent inactivation of 
CYP3A4/5, leading to significant DDIs with CYP3A4/5 substrates. Additionally, 
covalent binding by the reactive quinone-imine intermediate may be responsible 
for the hepatotoxicity seen with lapatinib. 
Objective: In this chapter, we explore two approaches to reduce reactive 
metabolite formation. Firstly, we attempt to reduce the bioactivation potential of 
the molecule by strategic deuteration at positions critical for bioactivation. We 
also assessed the relationship between metabolic capacity and susceptibility to 
inactivation by CYP3A5 as a function of genetic disposition. 
Methodology: Deuterated analogues at the benzylic and/or N-methylene position 
were assessed for their potential to undergo O-debenzylation, N-dealkylation and 
GSH adduct formation. The strength of inactivation of each analogue elicited 
against CYP3A4/5 was also investigated. The most promising deuterated 
analogue was then examined to determine if it retained pharmacological activity 
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similar to lapatinib. The strength of inactivation and GSH adduct formation was 
also assessed in a panel of CYP3A5 genotyped pooled human liver microsomes. 
Results and discussion: Among the three deuterated lapatinib analogues, O-d2 
lapatinib was found to exhibit to lowest rates of O-debenzylation, N-dealkylation 
and GSH adduct formation, and exhibited a similar extent of cytotoxicity as 
lapatinib. However, it retained the same magnitude of CYP3A4/5 inactivation as 
lapatinib. Separately, CYP3A5*1/*1 carriers experienced the greatest decrease in 
CYP3A4/5 activity, were most susceptible to inactivation by lapatinib, and also 
generated the highest levels of quinone-imine as measured by GSH adduct 
formation. 
Conclusion: The results of this study suggests that structural modification of 
lapatinib through deuteration does not ameliorate its potential for DDIs, while 




3.2 Chapter Introduction 
Lapatinib is a dual tyrosine kinase inhibitor of the epidermal growth factor 
receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). This 
orally active drug was first approved by the US FDA in 2007 for the targeted 
therapy of breast cancer overexpressing HER2. By reversibly competing with 
ATP for the intracellular ATP binding site on the receptors, lapatinib blocks auto-
phosphorylation of the receptors, leading to inactivation of downstream cell 
proliferation and induction of apoptosis (238, 239). Lapatinib is typically 
indicated for use with capecitabine to treat HER2-positive metastatic breast 
cancer patients who are refractory towards therapies such as anthracyclines, 
taxanes and trastuzumab-containing regimens (240). In 2010, lapatinib was also 
approved for coadministration with letrozole for the treatment of patients 
suffering from hormone-positive and HER2-postive metastatic breast cancer (241, 
242).  
3.2.1 Generation of Reactive Metabolites from Lapatinib 
Lapatinib undergoes extensive metabolism in the liver, mediated mainly by 
CYP3A4/5, forming reactive metabolites that are postulated to inactivate 
CYP3A4 (243-245) and CYP3A5 (246). This auto-catalytic inactivation proceeds 
via two main pathways as illustrated in Figure 3-1. N-dealkylation, mainly 
mediated by CYP3A4 (245), generates N-dealkylated lapatinib (ND lapatinib), 
which can be further oxidized to an alkylnitroso intermediate suggested to 
inactivate CYP3A4 by forming a quasi-irreversible metabolite-intermediate (MI) 
complex (244). Alkylnitroso groups are highly electrophilic, and can form strong 
coordinate bonds with the heme groups of CYP450 enzymes, which prevents the 
metabolism of other CYP450 substrates (247). Conversely, O-debenzylation is 
primarily mediated by CYP3A5 (245), where O-debenzylated lapatinib (OD 
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lapatinib) is further oxidised to a quinone-imine that covalently inactivates 
CYP3A5 irreversibly via mechanism-based inactivation (MBI) (246). In this 
study, the term MBI is used solely to describe the covalent binding of a reactive 
metabolite to the enzyme responsible for its formation, as opposed to being an 
umbrella term for irreversible time-dependent inactivation, which can include 
coordinate and covalent binding. In parallel, an MI complex is used in this work 
to describe the coordinate binding of a reactive metabolite to the heme group of 
CYP450 enzymes. Both ND lapatinib and OD lapatinib have also been detected in 
the plasma, urine, and faeces of human subjects (248), suggesting that further 
bioactivation to reactive lapatinib metabolites is likely in vivo. The auto-catalytic 
inhibition of CYP3A4/5 by reactive lapatinib metabolites is a clinical concern, as 
CYP3A4/5 play major roles in the metabolism of many drugs, potentially leading 
to clinically significant DDIs with other CYP3A4/5 substrates. These DDIs could 
consequently lead to sub- or supra-therapeutic drug levels, and consequently 































































Figure 3-1 Major CYP3A4/5-dependent biotransformation pathways of lapatinib 
(adapted from (245, 246)). Intermediates in square brackets are putative reactive 
metabolites believed to inactivate CYP3A4 or CYP3A5. The predominant 
biotransforming enzyme for each step is indicated in bold. 
 
Interestingly, the differential inactivation of CYP3A4 and CYP3A5 through a MI 
complex and MBI respectively appears to be mutually exclusive, although each 
enzyme is capable of forming both ND lapatinib and OD lapatinib, albeit in 
differing amounts. For example, the inactivation of CYP3A4 which is 
characterized by the presence of a Soret peak is nearly completely reversible by 
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apoprotein failed to identify mass shifts corresponding to the formation of a 
protein adduct (244), suggesting that the inactivation is exclusively due to the 
formation of an MI complex. On the other hand, the inactivation of CYP3A5 by 
lapatinib was shown not to be reversed by potassium ferricyanide (245), and 
together with the observed lack of a Soret peak (244), these findings suggest that 
the inactivation is likely exclusively due to MBI. 
3.2.2 Adverse Drug Reactions Associated with Lapatinib 
Lapatinib has been associated with frequent ADRs such as diarrhoea and skin 
rash which are clinically manageable (249, 250). However, it was reported to 
cause potentially fatal hepatotoxicity, leading to a black-box warning issued in 
2008 (251). As only less than 1% of patients experienced hepatotoxicity and it 
occurs several days to months after initiation of treatment with lapatinib (Tykerb 
package insert, 2007), such toxicity appears to be a type B idiosyncratic reaction. 
Additionally, lapatinib-induced hepatotoxicity has been postulated to have an 
immunological dimension, as a series of pharmacogenomic studies revealed 
associations with the MHC class II HLA-DQA1*02:01 and HLA-DRB1*07:01 
alleles, which are in strong linkage disequilibrium (odds ratio of 14) (252-255). 
Of these two alleles, modelling studies of the binding pocket amino-acid 
specificity suggested that HLA-DRB1*07:01 is most likely the causal allele (255). 
The negative predictive values and positive predictive values for ALT elevations 
3× the upper limit of normal were 99.1% and 11.7% respectively. In other words, 
essentially all individuals who experience serious lapatinib-induced liver injury 
carry this biomarker, but the majority of biomarker carriers do not develop serious 
liver injury, suggesting that there may be other concurrent cofactors or triggers 
that contribute to this event. While the mechanism of lapatinib-related 
hepatotoxicity remains unknown, the generation of a reactive intermediate from 
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lapatinib capable of covalent binding to CYP3A5 is suggestive of the hapten 
hypothesis and may be the additional cofactor that predisposes a HLA-
DRB1*07:01 allele carrier to lapatinib-induced hepatotoxicity. 
3.2.3 Variables Affecting Lapatinib-induced DDIs and ADRs 
While the DDIs, and possibly hepatotoxicity caused by lapatinib are precipitated 
by the formation of reactive metabolites leading to covalent and coordinate 
binding, these are not static events, but are a function of the inherent bioactivation 
potential of the drug, dose burden and metabolic capacities of the enzymes 
responsible for its bioactivation, CYP3A4 and CYP3A5. Modulation of any of 
these variables could change the extent of DDIs and ADRs caused by lapatinib. 
3.2.3.1 Reducing Generation of Reactive Metabolites from Lapatinib 
Structural modification of the pharmacophore is a well-known strategy in 
medicinal chemistry to alter binding properties of a drug to its pharmacological 
target. Similar approaches have been applied to modify the toxicophore to prevent 
or reduce bioactivation to form a reactive metabolite believed to be responsible 
for toxicity. A common example is the substitution of a labile hydrogen atom with 
a fluorine atom to prevent bioactivation that leads to the formation of a reactive 
metabolite. Care must be taken to ensure that the chemical modification does not 
compromise the pharmacological activity of the compound. This is illustrated in 
the example of amodiaquine, an antimalarial which is oxidized to form a quinone-
imine. Fluorination of the 2’,6’- and 4’- positions produced analogues more 
resistant to oxidation but still retaining activity against malarial parasites (256).  
Despite successful examples using fluorine as a bioisostere, the physicochemical 
properties of fluorine are sufficiently different from hydrogen that the 
pharmacological activity of the fluorinated analogue may be compromised. In 
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recent years, drug deuteration has gained interest as a viable strategy to 
manipulate metabolic susceptibilities. Deuteration involves the substitution of a 
hydrogen (H) atom with deuterium (D), and this increases the C-D bond strength 
relative to the C-H bond strength, resulting in a higher energy barrier for C-D 
bond cleavage and hence a slower rate of reaction. This effect on reaction rate is 
also known as the primary deuterium isotope effect (DIE). In the context of 
CYP450-mediated drug metabolism, the characteristics of the DIE present a 
unique opportunity to modulate undesirable biotransformation pathways by 
selective and judicious deuteration at metabolic soft spots. For example, O-
debenzylation of lapatinib proceeds via the mechanism as shown in Figure 3-2 
where a proton is first abstracted by the heme group of the CYP enzyme, and the 
hydroxyl group is subsequently transferred onto the benzylic carbon. This forms 
an unstable hemiacetal group, which leads to a loss of the benzylic group and the 
formation of OD lapatinib. By substituting the benzyl proton with deuterium, the 
DIE slows down the rate of C-D bond cleavage. This has a carry-over effect on 
the subsequent steps, thus reducing the overall rate of O-debenzylation. A similar 


















Figure 3-2 Mechanism of (A) O-debenzylation and (B) N-dealkylation of 
lapatinib. 
 
Unlike fluorine substitution, the DIE generally has little influence on the 
physicochemical properties of deuterated compounds, as deuterium has a similar 
size to hydrogen and imposes minimal changes in steric effects. Although small 
changes such as reduced hydrophobicity (257, 258), decreased acidity of 
carboxylic acids and phenols (259), and increased basicity of amines (260) have 
been reported, these physicochemical differences generally do not exert a 
significant influence on target engagement by the deuterated compound. Hence, 
deuteration has become a promising approach to improve the pharmacokinetic 
and/or safety profile of the drug while imposing a minimal efficacy penalty. 
However, it is important to note that mechanistically, a decrease in one metabolic 






















































































compensatory increase in an alternative/competing metabolic pathway can 
continue to sustain metabolic clearance, a phenomenon known as metabolic 
switching (261). This may also elevate the levels of minor metabolites and elicit 
unanticipated consequences. Thus the effect of the DIE can be difficult to predict 
and requires additional in vitro and in vivo experimental elucidation.  
Deuteration has been successfully applied to a number of drugs to improve their 
pharmacokinetic and/or safety performance. One example is C-20081 (Figure 
3-3), a deuterated analogue of linezolid, which is an antibiotic indicated for 
serious Gram-positive infections. Deuteration of the morpholine ring led to 
decreased metabolism of linezolid and a 43% increase in plasma half-life, with 
unchanged efficacy (262). The reason for deuteration adjacent to the acetamide 
moiety is unclear, but might be a pre-emptive attempt to suppress metabolic 
switching as a result of attenuated morpholine ring opening. Drug deuteration can 
also reduce toxic metabolite production by diverting metabolism along pathways 
that avoid the formation of toxic metabolites, hence improving the safety profile. 
This can be seen in the deuteration of efavirenz (263). Efavirenz undergoes a 
four-step reaction to produce a nephrotoxic metabolite; it undergoes oxidation, 
sulfation at the C8 position, oxidation at the propargyl group, formation of an 
adduct with GSH that is finally cleaved by γ-glutamyl transpeptidase to yield the 
metabolite responsible for nephrotoxicity (Figure 3-4). Deuteration of efavirenz at 
the propargyl group diminishes the formation of reactive metabolite precursors, 
thus decreasing reactive metabolite concentration and hence reducing renal 
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Figure 3-4 Single deuteration of efavirenz at the propargyl group reduces reactive 
metabolite formation. 
 
Despite examples of successful modulation of pharmacokinetic and toxicological 
profiles by deuteration, the desired outcomes can be unpredictable. Due to the 
complexity of biological processes and various competing pathways in multistep 
enzyme-catalyzed reactions, the expected effects are difficult to predict from a 
structural perspective alone (264, 265). In some cases, a significant effect in vitro 
may not translate to the expected outcome in vivo. A deuteration study on 
tramadol showed that one of the deuterated tramadol analogues had a 5-fold 
reduction in in vitro metabolic clearance and was thus expected to have a longer 
duration of action, yet in vivo rat studies showed that the deuterated analogue was 































































that although deuteration appears to be a viable approach to modulate reactive 
metabolite generation and, potentially DDIs and/or ADRs from lapatinib, 
comprehensive experimental investigations are still required to ascertain the true 
effect of this structural modification. 
3.2.3.2 Assessing the Capacity of Lapatinib in Generation of Reactive 
Metabolites 
The metabolic capacity of CYP450 enzymes, and accordingly, the levels of 
reactive metabolites generated are determined by extrinsic and intrinsic factors. In 
the case of lapatinib, examples of extrinsic factors include the concomitant 
administration of xenobiotics that are inducers or inhibitors of CYP3A4 and 
CYP3A5. In vitro studies by Teo et al. and Hardy et al. demonstrated that 
CYP3A4/5 inducers such as dexamethasone and rifampin potentiated the 
cytotoxicity of lapatinib, which correlated with an increase in the formation of 
OD lapatinib, and GSH adducts of the putative quinone-imine metabolite (267, 
268). Additionally, OD lapatinib was found to be more toxic that lapatinib itself 
in HepaRG cells (268). These findings were further substantiated in a 
retrospective clinical analysis which found that patients taking a combination of 
lapatinib and dexamethasone were 4.57 times more likely to develop lapatinib-
induced hepatotoxicity than those exposed to lapatinib alone (267). Conversely, 
inhibitors such as ketoconazole were found to reduce the clearance of and 
increase exposure to lapatinib (269); however the effect of CYP3A4/5 inhibition 
on the extent of reactive metabolite generation and toxicity were not examined. 
Given the ability of CYP3A4/5 inducers to potentiate the toxicity of lapatinib, 




From an intrinsic perspective, metabolic capacity is determined by a number of 
factors including age, nutritional status, concomitant diseases (e.g. liver 
dysfunction) and the genetic makeup of an individual. Pharmacogenetic 
associations have been noted to influence either the functional characteristics or 
abundance of CYP450 enzymes. For example, CYP2D6 has more than 80 
polymorphic forms, resulting in individuals characterised as poor- to ultra-
metabolizers (270). For the CYP3A4/5 family, genetic polymorphism is noted to 
affect the level of CYP3A5 expression. Unlike CYP3A4, CYP3A5 levels are 
generally lower and its endogenous expression is dependent on its allele (271). 
Carriers of CYP3A5*1/*1 alleles can possess CYP3A5 levels up to 50% of total 
CYP3A4/5 content while CYP3A5*3/*3 carriers possess almost no functional 
CYP3A5, and heterozygous CYP3A5 *1/*3 carriers express intermediate 
CYP3A5 levels. It is important to note that this polymorphism governs the 
abundance, rather than the functional activity of CYP3A5 enzymes.  
CYP3A5 polymorphism has been demonstrated to affect plasma concentrations of 
tacrolimus, an immunosuppressant with a narrow therapeutic index used in organ 
transplant patients. Carriers of at least one CYP3A5 *1 allele experience greater 
tacrolimus clearance and require higher doses to reach therapeutic concentrations 
(272). On the other hand, CYP3A4 is not known to be prominently influenced by 
genetic polymorphisms, although the CYP3A4*22 variant which is associated 
with reduced CYP3A4 mRNA levels and CYP3A4 activity, and exerts some 
influence on tacrolimus clearance, primarily in the non-CYP3A5 expressing 
*3/*3 carriers (273). Nevertheless, the CYP3A4*22 allele is expressed in only 8% 
of Caucasians and has not been detected in subjects of African or Asian descent 
(273), and thus is not thought to affect CYP3A4/5 metabolic capacity 
prominently. Although the role of CYP3A5 polymorphism in drug disposition is 
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established, its influence on xenobiotic-induced CYP450 inactivation is not 
conclusive. 
3.2.4 Mitigating Lapatinib-induced DDIs and ADRs through Deuteration and 
CYP3A5 Genotyping 
Given that covalent (and coordinate) binding are thought to precipitate DDIs and 
ADRs with lapatinib, such undesired outcomes may be attenuated by 
manipulating the variables that contribute to covalent binding. As described 
earlier, these variables include the innate bioactivation potential of the drug, dose 
burden and metabolic capacity of the bioactivating enzymes, the latter of which is 
governed by the effects of co-administered drugs and an individual’s genetic 
disposition. While the dose burden and choice of concomitant drugs may appear 
to be the easiest to manipulate, decreasing the administered dose may 
compromise efficacy, while there may not be much flexibility in choosing 
alternative drugs that do not modify the metabolic capacity particularly if the 
therapeutic regimen is strict or limited in options. The remaining options are to 
reduce the bioactivation potential and to carefully consider of the genetic status of 
a patient. This chapter explores a two-pronged approach to achieve these 
objectives. Firstly, the effect of drug deuteration on the generation of reactive 
metabolites from lapatinib is explored using a series of deuterated lapatinib 
analogues. This is followed by an assessment of the effect of CYP3A5 genetic 
polymorphism on the magnitude of CYP3A4/5 inactivation by lapatinib and the 




3.3 Materials and Methods 
3.3.1 Materials 
Lapatinib (free base) was purchased from LC Laboratories (Woburn, MA, USA). 
Deuterated lapatinib analogues (Figure 3-5 (A-C)) and their respective O-
debenzylated standards (Figure 3-5 (D-F)) were provided by Concert 
Pharmaceuticals (Lexington, MA, USA). HPLC-grade acetonitrile (ACN) was 
purchased from Tedia Company Inc. (Fairfield, OH, USA). Dimethyl sulfoxide 
(DMSO) was obtained from ACS Chemical Inc. (Point Pleasant, NJ, USA). 
Pooled human liver microsomes (HLM) (Lot No. 18888 and 70196), recombinant 
CYP3A4 (rCYP3A4), recombinant CYP3A5 (rCYP3A5), and NADPH-
regenerating system consisting of NADPH A (NADP+ and glucose-6-phosphate) 
and NADPH B (glucose-6-phosphate dehydrogenase) were obtained from BD 
Gentest (Franklin Lakes, NJ, USA). Single donor HLM genotyped for 
CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 4), and CYP3A5*3/*3 (n = 4) were 
purchased from commercial sources such as BD Gentest and XenoTech, LLC 
(Lenexa, KS, USA) (See Table S3 showing characteristics of the different 
CYP3A5-genotyped HLM donors). 6β-Hydroxytestosterone and 1’-
hydroxymidazolam were purchased from Cerilliant Corporation (Round Rock, 
TX, USA). A crude preparation of 4-hydroxymidazolam was generated using rat 
liver microsomes that were isolated in-house (274).  Water was obtained using a 
Milli-Q water purification system (Milipore, Bedford, MA, USA). 
Carbamazepine, glutathione (GSH), trypan blue, RPMI medium 1640 without 
phenol red and fluorescein diacetate (FDA), were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Midazolam was obtained from Tocris Bioscience (Bristol, 
United Kingdom). Testosterone was purchased from Tokyo Chemical Industry 
CO., Ltd. (Tokyo, Japan). Formic acid was obtained from BDH Chemicals 
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(Radnor, PA, USA). BT-474 cell line was a kind gift from Dr. Yang Yi Yan 
(Institute of Bioengineering and Nanotechnology, Singapore). Fetal bovine serum 
(FBS) was obtained from Hyclone Laboratories (Logan, Utah, USA). Trypsin was 
obtained from Life Technologies, Invitrogen (Waltham, MA, USA). Phosphate-
buffered saline (PBS) was obtained from Vivantis (Selangor, Malaysia). 1% 
penicillin/streptomycin was obtained from PAN Biotech (Aidenbach, Germany). 










N-d2 methylene lapatinib 
(N-d2 lapatinib) 
N-d2 methylene O-debenzylated lapatinib 




O-d2 benzyl N-d2 methylene α-furyl-d2 lapatinib 
(d6 lapatinib) 
N-d2 methylene α-furyl-d2 O-debenzylated 
lapatinib  
(N-d2 α-furyl-d2 OD lapatinib) 
Figure 3-5 (A-C) Deuterated lapatinib analogues and (D-F) corresponding 
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3.3.2 Kinetic Studies of Lapatinib Metabolite and GSH Adduct Formation 
from Lapatinib and Deuterated Lapatinib Analogues in Pooled HLM, 
rCYP3A4 and rCYP3A5 
Incubation experiments were performed in 96-well plates. Incubation mixtures for 
kinetics studies of lapatinib metabolites formation consisted of pooled HLM (0.5 
mg/mL), 100 mM potassium phosphate buffer (pH 7.4), NADPH B and varying 
concentrations of lapatinib or its deuterated analogues (0-100 µM). The mixtures 
were pre-warmed at 37°C for 5 min. Each reaction was initiated by adding 5 μL 
of NADPH A. The final volume in each well was 100 μL, and the final organic 
content in each incubation mixture was less than 0.5% v/v. After incubation at 
37°C for 10 min, a 50 μL aliquot was withdrawn and quenched with an equal 
volume of ice-cold ACN containing 0.5 μM of carbamazepine (internal standard 
(IS)). To assess GSH adduct formation kinetics, the reaction mixture was enriched 
with 50 mM GSH, and all other parameters were kept identical. Kinetic studies of 
lapatinib metabolite formation were repeated using 50 pmol/mL of rCYP3A4 or 
rCYP3A5, and all other parameters were kept identical.  The samples were 
centrifuged at 4,000 g for 30 min at 4°C, and the supernatants were removed for 
determination of the formation of OD, ND metabolites and GSH adducts derived 
from lapatinib and its deuterated analogues by liquid chromatography-tandem 
mass spectrometry (LC/MS/MS). For quantification, appropriate lapatinib 
standards (0-1 μM) were also prepared in the same HLM mixture mixed with an 




3.3.3 Time- and Concentration-dependent Inactivation of CYP3A4/5 by 
Lapatinib and Deuterated Lapatinib Analogues in Pooled HLM 
3.3.3.1 Assessment of the Suitability of Midazolam as a Probe Substrate 
Incubation experiments were performed in 96-well plates. A two-step incubation 
scheme was used, in which the metabolism of lapatinib or its deuterated 
analogues were allowed to occur during the pre-incubation step. Pre-incubation 
mixtures consisting of 0.5 mg/mL pooled HLM, 100 mM potassium phosphate 
buffer (pH 7.4), NADPH B and varying concentrations of lapatinib (0-20 μM) 
were pre-warmed at 37°C for 5 min. Each reaction was initiated by adding 5 μL 
of NADPH A. The final volume in each well was 100 μL, and the final organic 
content in each incubation mixture was less than 0.5% v/v. After 0, 3, 8, 15, 22 
and 30 min of pre-incubation, 8 μL of the pre-incubation mixture was transferred 
to a secondary incubation mixture containing 25 μM midazolam as probe 
substrate (at ~5× Km) and NADPH-regenerating system in 100 mM potassium 
phosphate buffer (pH 7.4). The final volume of each secondary incubation 
mixture was 80 μL, which facilitated a 10-fold dilution of the pre-incubation 
mixture. The secondary incubation mixture was incubated for another 10 min at 
37°C before a 50 μL aliquot was withdrawn and quenched with an equal volume 
of ice-cold ACN containing 0.5 μM carbamazepine (internal standard (IS)). The 
samples were centrifuged at 4,000 g for 30 min at 4°C, and the supernatants were 
removed for determination of midazolam 4-hydroxylation and 1’-hydroxylation 
activity by LC/MS/MS. The experiment was repeated using rCYP3A5 (20 
pmol/mL) in place of HLM to assess the presence of time-dependent inhibition of 
CYP3A5 by lapatinib using midazolam as probe substrate. 
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3.3.3.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM using Testosterone as 
Probe Substrate 
As midazolam was found to be unsuitable as a probe substrate to assess the 
inactivation of CYP3A4/5 by lapatinib, testosterone was used as the probe 
substrate instead. The experimental conditions were identical to those in section 
3.3.3.1, except that testosterone (500 μM) was used as the probe substrate, 0.5 μM 
prednisolone as the IS and a different set of lapatinib or deuterated lapatinib 
concentrations (0-100 μM). Residual CYP3A4/5 activity was monitored by 
determination of testosterone 6β-hydroxylation using LC/MS/MS. 
3.3.4 Cytotoxicity of Lapatinib and O-d2 Lapatinib in BT474 Breast Cancer 
Cells 
BT474 cells were cultured in phenol red-free RPMI medium 1640, supplemented 
with 10% FBS and 1% penicillin/streptomycin, maintained under a humidified 
atmosphere of 5% CO2 at 37°C. Cells were grown to confluence in T-75 flasks, 
and were seeded into 96-well plates at a density of 10 000 cells/well. The plates 
were incubated at 37°C, 5% CO2 overnight. Serial dilutions of lapatinib and O-d2 
lapatinib (0-10 μM) were added to the respective wells at 200 μL per well. The 
cells were treated for a total of 3 days. The percentage cell survival rate was 
obtained using fluorescein diacetate assay (FDA) and the half-maximal inhibitory 
concentration (IC50) was determined from cell survival curves using the sigmoidal 
dose-response (variable slope) algorithm in Prism 6 (Graphpad Software Inc., San 
Diego, CA, USA). The experiment was carried out in triplicates using cells 
cultured across 3 passages. The difference between lapatinib and O-d2 lapatinib 
IC50 values were analyzed in Prism 6 via an unpaired t-test with equal variances 
assumed, and p < 0.05 was considered statistically significant. 
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3.3.5 Time- and Concentration-dependent Inhibition of CYP3A4/5 by 
Lapatinib in CYP3A5 Genotyped HLM 
Preliminary experiments were conducted to optimize the conditions for the 
metabolism of testosterone to 6β-hydroxytestosterone in genotyped HLM, 
particularly in the low CYP3A4/5 activity, non-expressing CYP3A5 *3/*3 
genotype. In order for the incubation experiments to be conducted with 
consideration of the quantitation limit of the bioanalytical assay, a microsomal 
protein concentration of 0.6 mg/mL and secondary incubation duration of 15 
minutes were adopted in the subsequent assays involving CYP3A5-genotyped 
HLM. A two-step incubation scheme was employed as described in section 
3.3.3.1. The concentrations of lapatinib were optimized according to the 
genotyped HLM donors. The pre-incubation reaction mixture was exposed to 
lapatinib for 0, 3, 7, 12, 20, and 30 min before being transferred to the secondary 
incubation mixture. All samples were subjected to LC/MS/MS analysis for 
determination of testosterone 6β-hydroxylation activity. 
3.3.6 Phenotyping of CYP3A4/5 Activity in CYP3A5 Genotyped HLM via 
Testosterone 6β-Hydroxylation 
Incubation experiments were performed in 96-well plates. Incubation mixtures 
consisting of 0.5 mg/mL genotyped HLM, 100 mM potassium phosphate buffer 
(pH 7.4), NADPH B and 75 µ were pre-warmed at 37°C for 5 min. Each reaction 
was initiated by adding 5 μL of NADPH A and allowed to proceed at at 37°C. 
The final volume in each well was 100 μL, and the final organic content in each 
incubation mixture was less than 0.5% v/v. After 10 min, 50 µL of each 
incubation mixture was quenched with an equal volume of ice-cold ACN 
containing 0.5 µM prednisolone as an IS. The samples were centrifuged at 4,000 
g for 30 min at 4°C, and the supernatants were removed for determination of the 
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formation of 6β-hydroxytestosterone using LC/MS/MS. For quantification, 6β-
hydroxytestosterone (0-1 μM) was also prepared in the same HLM mixture mixed 
with an equal volume of ice-cold ACN supplemented with IS. 
3.3.7 Quantitation of Lapatinib, Midazolam and Testosterone Metabolites, 
and Detection of GSH Adduct Formation by LC/MS/MS 
Chromatographic optimization was performed to ensure baseline separation of 
OD lapatinib and ND lapatinib. OD lapatinib (provided by Concert 
Pharmaceuticals), and ND lapatinib (synthesized in-house) were used as 
chromatographic standards for the optimization process. OD lapatinib, ND 
lapatinib, 4-hydroxymidazolam, 1’-hydroxymidazolam, 6β-hydroxytestosterone,   
and GSH adduct derived from lapatinib were analyzed by an Agilent 1290 
Infinity LC system (Agilent Technologies, Santa Clara, CA, USA) interfaced with 
an AB Sciex QTrap 5500 hybrid linear ion-trap quadrupole mass spectrometer 
equipped with a TurboIonSpray source (Applied Biosystems, Foster City, CA, 
USA). Mili-Q water and HPLC-grade ACN, both acidified with 0.1% formic acid, 
were used as mobile phases A and B respectively. Both mobile phases were 
pumped through a Waters Acquity UPLC BEH C18 130Å column (1.7 μm, 50 mm 
× 2.1 mm i.d.; Waters, Milford, MA, USA) at a flow rate of 0.6 mL/min. Using an 
autosampler thermostatted at 4°C, 2 μL of each sample was injected into the 
UPLC column maintained at 45°C. The needle was flushed with ACN post-
injection to minimize carry-over effect. Tandem mass spectrometry was operated 
in the positive ion electrospray ionization mode. The MS source conditions were: 
curtain gas, 25 psi; collision gas, medium; ionspray voltage, 5500 V; temperature, 
550°C; ion source gas 1, 50 psi; and ion source gas 2, 55 psi. The UHPLC elution 
conditions used for analysis are summarized in Table 3-1, while compound-
dependent MS parameters were optimized and are summarized in Table 3-2. 
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Table 3-1 UHPLC elution conditions. 
Analyte Elution Conditions 
OD lapatinib 
ND lapatinib 
O-d2 ND lapatinib 
N-d2 OD lapatinib 
N-d2 α-furyl-d2 OD lapatinib 
α-furyl-d2 O-d2 ND lapatinib 
Carbamazepine (IS) 
Linear gradient 25 to 48% B (0-1.60 min), isocratic 
95% B (1.61-2.10 min), and isocratic at 25% B 
(2.11-2.50 min) 
Lapatinib-GSH adduct  
N-d2 lapatinib-GSH adduct  
N-d2 α-furyl-d2 lapatinib-GSH adduct 
Carbamazepine (IS) 
Linear gradient 5 to 60% B (0-1.50 min), isocratic 





Linear gradient 20 to 80% B (0-1.40 min), isocratic 




Linear gradient 20 to 70% B (0-1.40 min), isocratic 






Table 3-2 MRM transitions and compound-dependent MS parameters for the 
detection of OD lapatinib, ND lapatinib, lapatinib-GSH adducts, their deuterated 

















OD lapatinib 473 → 350 43 136 14 22 
ND lapatinib 475 → 366 55 136 14 22 
O-d2 ND lapatinib 477 → 366 60 136 14 22 
N-d2 OD lapatinib 475 → 350 13 40 5 12 
N-d2 α-furyl-d2 OD 
lapatinib 
477 → 352 13 40 5 12 
α-furyl-d2 O-d2 ND 
lapatinib 
479 → 368 60 136 14 22 
Lapatinib-GSH adduct 778 → 655 30 75 10 3 
N-d2 lapatinib-GSH 
adduct 
780 → 655 30 75 10 3 
N-d2 α-furyl-d2 
lapatinib-GSH adduct 
782 → 657 30 75 10 3 
Carbamazepine (IS) 237 → 194 27 151 7 12 
4-hydroxymidazolam 342 → 325 40 125 10 14 
1’-hydroxymidazolam 342 → 203 40 125 10 14 
6β-hydroxytestosterone 305 → 269 20 200 7 11 
Prednisolone (IS) 380 → 91 51 106 9 14 
 
3.3.8 Data Analysis  
Integration of all chromatographic peaks was performed using Analyst Software 
(version 1.5.2, Applied Biosystems). 
3.3.8.1 Enzyme Kinetics Analysis 
Final concentrations of OD and ND lapatinib were then normalized against 
incubation time and amount of microsomal protein used. Enzyme kinetic 
parameters (Vmax and Km) were determined through nonlinear regression analysis 
using Prism 6. Data were fitted to the Michaelis-Menten model. The intrinsic 
clearance (CLint) was then determined by taking quotient of Vmax over Km. As 
GSH adduct standards were unavailable, and the amount ND lapatinib 
synthesized in-house was insufficient for quantitation purposes, the Vmax values of 
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ND lapatinib, lapatinib-GSH and its deuterated analogues were expressed as peak 
area ratios, derived from the quotient of analyte peak area over IS peak area.  
3.3.8.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib or 
Deuterated Lapatinib Analogues 
To determine time- and concentration-dependent inactivation, the mean of 
triplicate analyses was used to calculate the natural log of percentage residual 
CYP450 activity (normalized to vehicle at each corresponding time-point). The 
data were fitted to linear regression and plotted against pre-incubation time. The 
individual gradient of each curve (kobs) was subsequently plotted against inhibitor 
concentration to obtain the kobs graph. Two kinetic parameters can be obtained 
from the kobs graph, the maximal rate constant of inactivation (kinact) and the 
inhibitor concentration at half the maximal rate constant of inactivation (KI). The 
curve is described by the equation 𝑘obs =  
𝑘inact×[𝐼]
𝐾I+[𝐼]
 . The potency of the test drug 
as an inactivator can be described by the ratio of both parameters, i.e. kinact/KI. The 
kinact/KI ratios were used to compare the potencies of inactivation between the 
different CYP3A5 genotypes. Statistical comparisons of kinact/KI ratios, and the 
extent of quinoneimine formation between genotypes were performed by using 
one-way analysis of variance followed by the Kruskal-Wallis test for multiple 
comparisons, and p < 0.05 was considered significant. Correlation analyses were 
assessed using Pearson correlation coefficients, and p < 0.05 was considered 





3.4.1 Optimization of Chromatographic Separation for OD Lapatinib and ND 
Lapatinib 
Using a generic chromatographic gradient, the chromatographic trace for ND 
lapatinib show two overlapping peaks sharing the same MRM transition within 
the retention period of 1.4 to 1.5 min (Figure 3-6A), necessitating optimization of 
the elution conditions (Table 3-1) to ensure baseline separation of the two co-
eluting peaks. The in-housed synthesized ND lapatinib standard confirmed that 
the peak at retention time of 1.12 min belonged to ND lapatinib (Figure 3-6B). 
 
Figure 3-6 (A) Non-optimized chromatogram of ND lapatinib, showing two co-
eluting peaks within the retention period of 1.4 to 1.5 min, while the peak at 0.84 
min belongs to OD lapatinib and (B) optimized chromatogram of ND lapatinib 
with baseline-separated peaks at retention time 1.12 min (ND lapatinib) and 1.22 






































3.4.2 Kinetic Studies of Lapatinib Metabolite Formation from Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM, rCYP3A4 and 
rCYP3A5 
The kinetic plots for the formation of ND lapatinib and OD lapatinib from 
lapatinib or deuterated lapatinib analogues are shown in Figure 3-7 and Figure 
3-8. The kinetic parameters CLint, Vmax and Km for the formation of each of these 
metabolites in each metabolic system are summarized in Table 3-3 and Table 3-4. 
As expected, lapatinib had the highest CLint values across all three metabolic 
systems for both N-dealkylation and O-debenzylation metabolic pathways, 
indicating that deuteration appears to exert some influence on reducing the 
formation of ND lapatinib and OD lapatinib. These observations are supported by 
the kinetic plots which show the curves for lapatinib biotransformation to be 
generally higher than that of the deuterated analogues for both pathways in all 
three systems. Of the three deuterated lapatinib analogues, interestingly, both O-
d2 lapatinib and d6 lapatinib consistently demonstrated the greatest reduction in 
CLint for N-dealkylation in all three metabolic systems (up to 4.7- and 7.4-fold 
respectively), while N-d2 lapatinib showed a moderate reduction in intrinsic 







Figure 3-7 Kinetic plots for N-dealkylation of lapatinib and its deuterated 
analogues in (A) pooled HLM, (B) rCYP3A4 and (C) rCYP3A5 (mean of 
triplicate experiments). 
A     







Figure 3-8 Kinetic plots for O-dealkylation of lapatinib and its deuterated 
analogues in (A) pooled HLM, (B) rCYP3A4 and (C) rCYP3A5 (mean of 
triplicate experiments). 
  
A                           
B                           
C                           
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Table 3-3 CLint values for N-dealkylation of lapatinib and deuterated lapatinib 












(area ratio/min/mg) × 10-3 
2.557 0.6748 2.663 0.2207 
Km (µM) 28.50 35.62 66.71 11.77 
CLint (Vmax/Km) × 10
-5 
8.97 1.89 3.99 1.88 
CLint fold-change - 4.7 2.2 4.8 
rCYP3A4 
Vmax  
(area ratio/min/pmol) × 10-3 
4.653 1.222 2.427 1.665 
Km (µM) 19.49 22.27 19.19 51.50 
CLint (Vmax/Km) × 10
-5 23.9 5.49 12.6 3.23 
CLint fold-change - 4.4 1.9 7.4 
rCYP3A5 
Vmax  
(area ratio/min/pmol) × 10-3 
12.94 2.606 9.291 3.133 
Km (µM) 24.43 17.57 32.26 38.83 
CLint (Vmax/Km) × 10
-5 53.0 14.8 28.8 8.07 
CLint fold-change - 3.6 1.8 6.6 
N.B.: CLint fold-change values are obtained by comparison with lapatinib 
 
Table 3-4 CLint values for O-dealkylation of lapatinib and deuterated lapatinib 













12240 9095 8775 15334 
Km (µM) 7.353 17.96 26.71 20.48 
CLint (Vmax/Km) 
 1665 506 329 749 




8.685 2.876 8.067 5.897 
Km (µM) 0.2927 N.D. 1.297 N.D. 
CLint (Vmax/Km)  29.7 N.D. 6.22 N.D. 




7.077 3.864 6.928 6.891 
Km (µM) 2.312 1.696 2.231 N.D. 
CLint (Vmax/Km)  3.06 2.28 3.11 N.D. 
CLint fold-change - 1.3 1.0 N.D. 
N.D., not determined due to ambiguous Km values 




For O-debenzylation, the kinetic plots suggest that O-d2 lapatinib exhibited the 
greatest reduction in the formation of OD lapatinib in all three systems. Although 
N-d2 lapatinib appears to have the lowest CLint values in pooled HLM, the kinetic 
plot (Figure 3-8A) suggests that both O-d2 lapatinib and N-d2 lapatinib have 
almost identical kinetic profiles, indicating that CLint values are sensitive to the 
denominator Km which is obtained by non-linear regression fitting. This is 
apparent in the CLint values for rCYP34A4 and rCYP3A5, where ambiguous Km 
values preclude the determination of CLint values for O-d2 lapatinib and d6 
lapatinib. Despite this apparent ambiguity, visual inspection of the kinetic plots 
and comparison of Vmax values indicate that in contrast to N-d2 lapatinib and d6 
lapatinib, the formation of OD lapatinib was the lowest for O-d2 lapatinib in 
rCYP3A4 and rCYP3A5. Overall, O-d2 lapatinib exhibited the lowest metabolic 
clearance for N-dealkylation and O-debenzylation in all three metabolic systems.  
3.4.3 Kinetic Studies of GSH Adduct Formation from Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM  
The GSH adduct formed with lapatinib is indicative of the generation of the 
putative quinone-imine reactive metabolite responsible for CYP3A5 inactivation. 
GSH adducts were detected using an MRM transition of m/z 778 → 655 based on 
our previous studies (243, 246), while the MRM transitions for GSH adducts formed 
with deuterated lapatinib analogues were derived by adding the appropriate mass 
number to the parent compound and the m/z 655 fragment, based on the remaining 
number of deuterium atoms in each molecule. Consistent with the kinetic 
measurements of O-debenzylation, which is the precursor step to the formation of the 
quinone-imine, O-d2 lapatinib demonstrated the lowest CLint values, comparable with 
that of d6-lapatinib (Table 3-5). Visual inspection of the kinetic plots for GSH adduct 
formation support this observation (Figure 3-9). Taken together, O-d2 lapatinib 
 159 
 
demonstrated the greatest attenuation of N-dealkylation, O-debenzylation and GSH 
adduct formation among the three deuterated lapatinib analogues. 
Table 3-5 CLint values for GSH adduct formation from lapatinib and deuterated 








(area ratio/min/mg) × 10-3 
0.1040 0.06320 0.1328 0.06168 
Km (µM) 23.01 20.83 21.45 17.39 
CLint (Vmax/Km) × 10
-5 
0.452 0.303 0.619 0.355 
CLint fold-change - 4.7 2.2 4.8 
 
 
Figure 3-9 Kinetic plot for GSH adduct formation from lapatinib and its 
deuterated analogues in pooled HLM (mean of triplicate experiments). 
 
3.4.4 Time- and Concentration-dependent Inactivation of CYP3A4/5 by 
Lapatinib and Deuterated Lapatinib Analogues in Pooled HLM 
3.4.4.1 Assessment of the Suitability of Midazolam as a Probe Substrate 
Testosterone and midazolam are listed by the U.S. FDA as preferred probe 
substrates for in vitro evaluation of CYP3A4/5 inhibition, where testosterone 6β-
hydroxylation, midazolam 1’-hydroxylation and midazolam 4-hydroxylation can 
be monitored to assess CYP3A4/5 activity (246, 275). Lapatinib has been 
reported to inactivate CYP3A4/5 in pooled HLM when assessed using 
testosterone 6β-hydroxylation (243) and midazolam 1’-hydroxylation (276), as 
well as to form an MI complex with rCYP3A4 (244) and cause MBI of rCYP3A5 
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(246) when assessed using testosterone 6β-hydroxylation. Midazolam 4-
hydroxylation has not been used to assess CYP3A4/5 inactivation by lapatinib in 
pooled HLM, and both midazolam metabolic pathways have not been monitored 
for the same in rCYP3A5. To identify the optimal metabolic activity to be 
monitored as an indicator of remaining CYP3A4/5 activity, inhibition assays were 
performed using midazolam as a probe substrate in pooled HLM and rCYP3A5. 
Figure 3-10A shows that midazolam 4-hydroxylation activity decreased in a time- 
and concentration-dependent manner when pooled HLM was pre-incubated with 
lapatinib in the presence of NADPH. The inset kobs plot shows that the slopes of 
the curves increased in a hyperbolic trend with increasing concentration of 
lapatinib. To further assess whether midazolam 4-hydroxylation activity can 
appropriately reveal the presence of MBI in CYP3A5, another inhibition assay 
was performed using rCYP3A5. Figure 3-10B shows that midazolam 4-
hydroxylation activity was not affected in either a time- or concentration-
dependent manner when rCYP3A5 was pre-incubated with lapatinib in the 
presence of NADPH, and the kobs values failed to show a distinct hyperbolic trend 
in its kobs plot. Collectively these suggested that midazolam is not a suitable probe 
substrate for monitoring the inactivation of CYP3A4/5 by lapatinib, as unlike 





Figure 3-10 (A) Inactivation plot of CYP3A4/5 by lapatinib using pooled HLM, 
monitoring residual CYP3A4/5 activity by means of midazolam 4-hydroxylation. 
kinact and KI values were 0.02532 min
-1 and 2.110 μM, respectively. The kinact/KI 
ratio was 12.0 min-1mM-1. (B) Inactivation plot of CYP3A5 by lapatinib using 
rCYP3A5, monitoring residual CYP3A5 activity by means of midazolam 4-
hydroxylation. Inset kobs plot lacking a distinct hyperbolic trend. kinact and KI 
values were not determined. For both plots, each point represents the mean of 
three replicates with less than 10% S.D. 
 
3.4.4.2 Determination of CYP3A4/5 Inactivation Kinetics by Lapatinib and 
Deuterated Lapatinib Analogues in Pooled HLM using Testosterone as 
a Probe Substrate 
CYP3A4/5 inactivation by lapatinib and deuterated lapatinib analogues was 
assessed in pooled HLM using testosterone as a probe substrate, as it has been 
shown to capture inactivation in both CYP3A4 and CYP3A5, while midazolam 
does not afford the same utility (section 3.4.4.1). Figure 3-11 shows the 
inactivation plots, while Figure 3-12 illustrates an overlay of kobs plots for all four 
compounds. The corresponding inactivation parameters are presented in Table 
3-6. 





Figure 3-11 Inactivation plots of CYP3A4/5 by (A) lapatinib, (B) O-d2 lapatinib, 
(C) N-d2 lapatinib and (D) d6 lapatinib in pooled HLM. For all plots, each point 
represents the mean of three replicates with less than 10% S.D. 
  
A                          B 




Figure 3-12 Overlay of kobs plots for lapatinib and deuterated lapatinib analogues. 
 
Table 3-6 Inactivation parameters kinact and KI derived from kobs plots for lapatinib 
and deuterated lapatinib analogues. 
Compound kinact (min
-1) KI (µM) kinact/KI
 (min-1·mM-1) 
Lapatinib 0.03067 8.138 3.768 
O-d2 lapatinib 0.02669 6.662 4.006 
N-d2 lapatinib
 0.06141 15.99 3.841 
d6-lapatinib 0.04573 5.504 8.309 
 
 
All four compounds tested showed varying degrees of inactivation of CYP3A4/5 
in pooled HLM. Unexpectedly, all three deuterated compounds exhibited higher 
kinact/KI values than lapatinib, which indicate that they elicit a greater magnitude 
of irreversible time-dependent inactivation caused by MI complex formation and 
MBI. Although O-d2 lapatinib demonstrated the lowest extent of OD lapatinib and 
ND lapatinib formation which are thought to be the precursors to lapatinib 
reactive metabolite generation, and also the lowest levels of GSH adduct 
formation which is a surrogate indicator of lapatinib quinone-imine formation, 
these did not translate to an improvement in inactivation characteristics, as it 
exhibited a comparable kinact/KI ratio to that of lapatinib, which is also supported 
by visual inspection of the kobs plot. Collectively, these suggest that deuteration at 
the positions examined in this study did not have an appreciable negative impact 
on the magnitude of CYP3A4/5 inactivation caused by lapatinib, and d6 lapatinib 
even augmented the extent of inactivation. 
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3.4.5 Cytotoxicity of Lapatinib and O-d2 Lapatinib in BT474 Breast Cancer 
Cells 
As O-d2 lapatinib demonstrated the overall best performance among the 
deuterated lapatinib analogues in the preceding assays, it was selected for further 
evaluation to determine if it exhibits pharmacological activity similar to that of 
lapatinib in the HER2-overexpressing BT474 cell line. There were no significant 
differences between the IC50 values obtained for lapatinib (0.276 ± 0.059 μM) and 
O-d2 lapatinib (0.391 ± 0.049 μM) (p > 0.05) (Figure 3-13), suggesting that O-d2 
lapatinib exhibits comparable in vitro efficacy as that of lapatinib. 
 
Figure 3-13 The cytotoxicity effect of lapatinib and O-d2 lapatinib in BT474 
cells. Each data point is the average of 3 independent experiments with at least 5 
replicates each. 
 
3.4.6 Time- and Concentration-dependent Inhibition of CYP3A4/5 by 
Lapatinib in CYP3A5-Genotyped HLM 
The influence of CYP3A5 polymorphism on inactivation by lapatinib was 
assessed using a panel of genotyped HLM (CYP3A5*1/*1, n = 4; CYP3A5*1/*3, 
n = 4; CYP3A5*3/*3, n = 4), and the inactivation plots are shown in Figure 3-14, 
Figure 3-15 and Figure 3-16. Inactivation kinetic parameters (kinact, KI, and kinact/KI 
ratio) of lapatinib derived from the various CYP3A5-genotyped HLM donors are 
summarized in Table 3-7. For the CYP3A5*3/*3 donor HH507, and the 
inactivation parameters could not be determined. The kinact/KI ratios as a function 
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of the CYP3A5 genotypes are shown in Figure 3-17A. The mean kinact/KI ratios 
for CYP3A5*1/*1, CYP3A5*1/*3, and CYP3A5*3/*3 exhibited a decreasing 
trend across the genotypes, where the ratio was nearly two-fold higher for *1/*1 
than *3/*3 carriers, although they were not significantly different (p > 0.05). 
When examined as a cross-section across all donors at a common lapatinib 
concentration (20 µM) and inactivation duration (30 min), CYP3A5*1/*1 carriers 
demonstrated the greatest mean loss of CYP3A4/5 activity, followed by 
CYP3A5*1/*3 and CYP3A5*3/*3 carriers (Figure 3-17B and C). There was 
considerable inter-subject variability in the kinetics and magnitude of inactivation 




   
 
  
Figure 3-14 Inactivation plots of CYP3A4/5 by lapatinib on single donor HLM 
genotyped for CYP3A5*1/*1. Plots A, B, C and D represent donors HH785, 
HH860, HH867 and H0331 respectively. For all plots, each point represents the 
mean of three replicates with less than 10% S.D. Each respective inset shows the 
kobs plot. 
 
A                          B 
C                          D 
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Figure 3-15 Inactivation plots of CYP3A4/5 by lapatinib on single donor HLM 
genotyped for CYP3A5*1/*3. Plots A, B, C and D represent donors HH757, 
HH868, H0239 and H0280 respectively. For all plots, each point represents the 
mean of three replicates with less than 10% S.D. Each respective inset shows the 
kobs plot.  
A                          B 








Figure 3-16 Inactivation plots of CYP3A4/5 by lapatinib on single donor HLM 
genotyped for CYP3A5*3/*3. Plots A, B, C and D represent donors HH507, 
H0307, H0204 and H0182 respectively. For all plots, each point represents the 
mean of three replicates with less than 10% S.D. Each respective inset shows the 
kobs plot. 
A                          B 
C                          D 
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Table 3-7 Inactivation parameters kinact and KI derived from kobs plots for lapatinib 





−1) KI (μM) 
kinact/KI 
(min-1 ∙ mM−1) 
HH785 
*1/*1 
0.0254 2.56 9.92 
HH860 0.0422 6.45 6.54 
HH867 0.0212 3.71 5.71 
H0331 0.0468 8.75 5.35 
Mean ± S.D.  0.0339 ± 0.0125 5.37 ± 2.78 6.88 ± 2.09 
HH757 
*1/*3 
0.0201 4.72 4.26 
HH868 0.0145 2.77 5.23 
H0239 0.0332 7.82 4.25 
H0280 0.0484 5.92 8.18 
Mean ± S.D.  0.0291 ± 0.0151 5.31 ± 2.12 5.48 ± 1.86 
HH507 
*3/*3 
ND ND ND 
H0307 0.0461 9.39 4.91 
H0204 0.0335 7.56 4.43 
H0182 0.0298 21.6 1.38 
Mean ± S.D.  0.0365 ± 0.0086 12.85 ± 7.63 3.57 ± 1.92 






Figure 3-17 Comparison of (A) kinact/KI ratios of lapatinib and (B) CYP3A4/5 
remaining activity in CYP3A5*1/*1 (●), *1/*3 (■), and *3/*3 (▲) genotypes. 
Each point represents a single HLM donor. (C) Bar graph illustrating CYP3A4/5 
residual activity as triplicate determinations in each HLM donor. For (B) and (C), 
lapatinib was pre-incubated for 30 min at 20 µM. 




When the kinact/KI ratios were compared with the baseline CYP3A4/5 activity of 
the CYP3A5 genotyped HLM as determined using testosterone 6β-hydroxylation, 
a significant correlation was observed (r = 0.6819; p < 0.05) (Figure 3-18A). A 
similar correlation was found between the percentage CYP3A4/5 activity 
remaining following lapatinib treatment and CYP3A4/5 baseline activity, where 
the higher the baseline activity, the greater the decrease in CYP3A4/5 activity 





Figure 3-18 Correlation analyses describing the relationship between the extent 
of inactivation measured using (A) kinact/KI ratio and (B) residual CYP3A4/5 
activity with baseline CYP3A4/5 activity as measured using testosterone 6β-
hydroxylation in genotyped HLM. Each point represents a single HLM donor. 
 
3.4.7 GSH Adduct Formation as a Function of CYP3A5 Genotype 
The area ratios for GSH adduct formation as determined from integration of MS 
response in CYP3A5-genotyped HLM donors are presented in Table 3-8 and 
Figure 3-19A. Mean area ratios were not significantly different across the 
genotypes (p > 0.05), however *1/*1 carriers exhibit the greatest extent of GSH 
adduct formation. Again there was obvious inter-individual variability in the 
extent of GSH adduct formation within each genotype. Figure 3-19B shows the 
extent of GSH adduct formation compared with baseline CYP3A4/5 activity in 
each donor, with a statistically significant correlation (r = 0.9115; p < 0.0001). 
Finally, there was poor correlation between kinact/KI ratios and the extent of GSH 
adduct formation (r = 0.4439; p > 0.05) (Figure 3-19C). For the correlation graphs 
A       B 
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using baseline CYP3A4/5 activity, donor H0331 exhibited a 2-fold higher activity 
than the next highest donor was excluded from the analysis as an outlier. Figure 
S3 illustrates the appearance of Figure 3-19B if the outlier was included. 
Table 3-8 GSH adduct formation in various CYP3A5-genotyped HLM donors. 

























Figure 3-19 Comparison of (A) GSH adduct formation in CYP3A5*1/*1 (●), 
*1/*3 (■), and *3/*3 (▲) genotypes. Correlation analyses describing the 
relationship between (B) GSH adduct formation with baseline CYP3A4/5 activity 
and (C) kinact/KI ratio with GSH adduct formation. Each point represents a single 
HLM donor. 




 3.5 Discussion 
3.5.1 Influence of Selective Deuteration on the Metabolic and Bioactivation 
Susceptibilities of Lapatinib 
The development of an analytical method to detect OD lapatinib and ND lapatinib 
permitted kinetic profiling of the formation of both metabolites from lapatinib and 
its deuterated metabolites. Based on the metabolic pathways of lapatinib that lead 
to the formation of the reactive nitroso and quinone-imine metabolite responsible 
for MI complex formation with CYP3A4 and MBI of CYP3A5, judicious 
deuteration at positions critical to O-debenzylation and N-dealkylation were 
hypothesized to reduce these processes and attenuate reactive metabolite 
formation. Deuteration at these metabolic soft spots individually and in 
Figure 3-5combination were explored in this study ( ). d6 lapatinib represents 
simultaneous deuteration of both the N-alkyl and O-benzyl positions, although it 
Figure 3-5. An also possesses an additional deuterated carbon as indicated in 
analogue with deuteration of only the N-alkyl and O-benzyl positions was 
 unavailable to us.
O-d2 lapatinib and N-d2 lapatinib were hypothesized to reduce O-debenzylation 
and N-dealkylation respectively, while d6 lapatinib which is deuterated at both 
positions was postulated to exhibit concurrent decreases in the kinetics of both 
pathways. The rate of O-debenzylation was indeed reduced by O-d2 lapatinib, 
however it also unexpectedly reduced the rate of N-dealkylation to a greater 
extent than that of N-d2 lapatinib. Interestingly, deuteration at the benzylic carbon 
appeared to exert a disproportionate influence on the formation of OD lapatinib 
and ND lapatinib. On the contrary, d6 lapatinib, with deuterations at both 
positions generally did not modulate the metabolic susceptibilities of lapatinib 
significantly, as the apparent decrease in N-dealkylation is likely due to the effect 
 173 
 
of benzylic deuteration, rather than the expected synergistic interaction of double 
deuterations. This finding was recapitulated in the investigation of GSH adduct 
levels in pooled HLM, which also established that O-d2 lapatinib and d6 lapatinib 
exhibited the greatest decrease in GSH adduct formation, suggesting that benzylic 
deuteration diminished the formation of the reactive quinone-imine metabolite. 
Another interesting observation from the deuteration studies are the kinetics of O-
debenzylation and N-dealkylation by rCYP3A4 and rCYP3A5. Using a single 
concentration of lapatinib (50 µM) and a single incubation time-point (30 min), 
Barbara et al. (245) reported that the formation of OD lapatinib was nearly 2-fold 
greater in CYP3A5 than CYP3A4, while Barbara et al. and Takakusa et al. (244, 
245) reported that the formation of ND lapatinib was over 2-fold greater in 
CYP3A4 than CYP3A5. Inconsistent with their findings, our results indicate that 
the formation of OD lapatinib was approximately equal in rCYP3A4 and 
rCYP3A5 at a concentration of 50 µM lapatinib, while the formation of ND 
lapatinib was more than 2-fold lower in CYP3A4 than CYP3A5. As the amount 
of recombinant protein and incubation duration used were identical in kinetic 
studies involving both rCYP3A4 and rCYP3A5, the rate and amount of 
metabolite formation are equal, allowing a direct comparison using the kinetic 
plots of both recombinant systems. While the reason for these contrasting results 
is uncertain, it is clear that O-d2 lapatinib is able to attenuate the metabolism of 
lapatinib to OD lapatinib and ND lapatinib. Importantly, because the formation of 
OD lapatinib and ND lapatinib were measured concurrently within the same 
experiment and analytical run for each enzyme system, it is interesting that 
deuteration at the benzylic position did not result in metabolic switching via 




Prior to investigating the CYP3A4/5 inactivation potential of the deuterated 
lapatinib analogues, we sought to establish the choice of probe substrate used to 
ascertain the remaining enzymatic activity after inactivation by these compounds. 
While testosterone has been shown to capture inactivation by lapatinib in both 
CYP3A4 and CYP3A5, the characterization for midazolam using both of its 
metabolic pathways is incomplete, particularly with CYP3A5. Barbara et al. (245) 
reported that lapatinib (50 µM) inhibited midazolam 4-hydroxylation but not 1’-
hydroxylation in rCYP3A5 after a 30 min preincubation, while Chan et al. (246) 
reported an absence of inactivation in rCYP3A5 by lapatinib using midazolam 1’-
hydroxylation. Thus we speculated that midazolam could capture inactivation in 
rCYP3A5 through the 4-hydroxylation pathway, which hitherto has not been 
evaluated. From a probe substrate perspective, midazolam is preferred to 
testosterone in this study. Using a combination of ketoconazole and the CYP3A4-
selective inactivator CYP3cide, Tseng et al. (277) estimated that CYP3A5 
contributed approximately 50% of midazolam 4-hydroxylation and 1’-
hydroxylation, while the contribution of CYP3A5 to testosterone 6β-
hydroxylation was estimated at only 16%. Our findings suggested that lapatinib 
did not inhibit midazolam 4-hydroxylation by CYP3A5 in a time-dependent 
manner, thus midazolam is unsuitable for use as a probe substrate in our study, 
and testosterone was retained for subsequent inactivation kinetics experiments. 
We also infer that the inactivation captured in pooled HLM by midazolam 4-
hydroxylation likely reflects the inactivation of CYP3A4 only. The differential 
inactivation of testosterone and midazolam in rCYP3A5 is consistent with the 
findings of Chan et al. (246 suggests that the reactive metabolite of lapatinib ), and 
blocks a pocket of the large CYP3A5 active site that impedes testosterone but not 
midazolam metabolism, affirming the need to investigate both CYP3A4 and 
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CYP3A5 separately, despite the fact that they share a high percentage of 
structural homology and exhibit broad substrate overlaps. In other words, 
potential DDIs with lapatinib are likely victim-drug specific and require further 
investigation to determine the overall strength of the interaction. 
Uttamsingh et al. recently reported the first example where deuteration 
successfully reduced CYP450 inactivation. In their study, CTP-347, a deuterated 
analogue of the antidepressant paroxetine dramatically ameliorated the formation 
of the carbene reactive metabolite responsible for MI complex formation with 
CYP2D6. Accordingly, the time- and concentration-dependent inactivation, and 
Soret peak formation observed with paroxetine was abolished, and DDI with 
tamoxifen was also attenuated, while pharmacological activity as measured by 
serotonin reuptake inhibition was retained (278). Although deuteration of 
lapatinib, particularly at the benzylic carbon successfully reduced the magnitude 
of OD lapatinib, ND lapatinib and GSH adduct formation, these findings did not 
translate into a decrease in the extent of inactivation as measured by kinact/KI 
values. One possibility is that that although the levels of OD lapatinib, ND 
lapatinib and GSH adduct formation was reduced, reactive metabolites could still 
be generated at levels adequate to cause functionally meaningful inactivation of 
CYP3A4/5. A second possibility is that while benzylic deuteration might have 
attenuated quinone-imine formation, deuteration on the N-alkyl chain was 
insufficient to block nitroso and MI complex formation. Barbara et al. (245) 
provided evidence that nitroso formation proceeds via a secondary hydroxylamine 
pathway, which involves N-hydroxylation followed by dealkylation, rather than 
the primary hydroxylamine pathway which proceeds via dealkylation followed by 
 the primary hydroxylamine was not detected, N-hydroxylation. This is because
thus it is likely that nitroso formation proceeds via the secondary hydroxylamine 
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pathway Figure 3-20 ( ). In other words, N-alkyl deuteration is ineffective in 
preventing nitroso formation, rendering CYP3A4 still susceptible to inactivation 
by lapatinib. It is not possible to generate a stable N-deuterated lapatinib analogue 
as the N-H proton is labile and solvent-exchangable. With respect to cytotoxicity, 
the reduction in GSH adduct formation by O-d2 lapatinib could potentially 
attenuate lapatinib-induced hepatotoxicity, which is hypothesized to be a result of 
hapten formation that in turn triggers an immune-mediated response. While we 
did not investigate this possibility as there is currently no suitable model to 
recapitulate immune-mediated drug-induced liver injury, Wahlin et al. reported 
that O-d2 lapatinib exhibited a reduction in acute cytotoxicity in HepaRG cells 
(279), suggesting that benzylic deuteration may be a promising approach to 









Figure 3-20 Mechanistic pathways for nitroso intermediate formation from 
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Most drug deuteration studies that investigate the reduction of reactive metabolite 
formation focus on drug safety profiles, but often neglect to assess whether 
efficacy remains unchanged after deuteration. In our study, despite the absence of 
a decrease in CYP3A4/5 inactivation, we elected to investigate if the in vitro 
efficacy of the deuterated lapatinib remains unchanged. Although uncommon, 
there are examples where deuteration unexpectedly induced changes in binding to 
a pharmacological target. In deuteration studies of sildenafil, a phosphodiesterase-
5 (PDE5) inhibitor, a deuterated analogue of sildenafil reportedly exhibits a 2-fold 
increase in PDE5 selectivity as compared to PDE6, and greater activity in vitro 
(280). The HER2-overexpressing, BT474 breast cancer cell line was chosen to 
evaluate the pharmacodynamic effect of lapatinib and O-d2 lapatinib as it was 
previously used to investigate the efficacy of HER2 antagonism by lapatinib 
(281). The absence of a significant difference between the IC50 values of lapatinib 
and O-d2 lapatinib suggests that deuteration at the benzylic position does not 
modify the cytotoxic efficacy against breast cancer cells.  This unchanged 
efficacy is also seen in other drug deuteration studies involving paroxetine (278), 
imatinib (282) and fludalanine (283).  
 3.5.2 Impact of CYP3A5 Genetic Polymorphism on CYP3A4/5 Inactivation by 
Lapatinib 
Our primary objective in this study was to examine the relationship between 
CYP3A5 genotype and the susceptibility to inactivation by lapatinib. Although 
we did not observe a statistically significant difference in the mean kinact/KI ratios, 
the *1/*1 genotype exhibited a greater potency of inactivation compared to the 
*3/*3 genotype. This was supported by a greater mean decrease in CYP3A4/5 
activity in *1/*1 versus *3/*3. Both measures of irreversible inactivation 
exhibited moderate correlations with total CYP3A4/5 activity, suggesting that the 
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inactivation may be broadly influenced by overall CYP3A4/5 capacity, which 
itself is influenced by a variety of factors including CYP3A5 genotype. GSH 
adduct formation, which is indicative of the quinone-imine reactive metabolite 
also demonstrated higher levels in the *1/*1 genotype, although this was not 
statistically significant. A strong correlation was observed with total CYP3A4/5 
activity, suggesting that GSH adduct levels, and possibly the extent of covalent 
binding is strongly influenced by CYP3A4/5 capacity. Unsurprisingly, the kinact/KI 
ratios did not correlate well with GSH adduct levels, as the inactivation is a 
composite of both MI complex formation and MBI, while GSH adduct levels 
 reflects only MBI via covalent inactivation.
CYP450 polymorphisms have been demonstrated to affect drug disposition (e.g. 
CYP2D6 and tamoxifen) as well as the extent of CYP450 inhibition, including 
reversible inhibition and irreversible inactivation. Shirasaka et al. reported that 
reversible CYP3A4/5 inhibition of ketoconazole and itraconazole as measured by 
IC50 values were most potent in CYP3A5 *3/*3 carriers, followed by *1/*1 and 
*1/*3 carriers (284). This was attributed to the lower inhibitory potency of these 
compounds against CYP3A5 compared with CYP3A4, thus the greater expression 
of CYP3A5 in carriers of at least one *1 allele serves as a reservoir of CYP3A 
drug metabolizing activity. Several small scale studies have also demonstrated 
differences in irreversible inactivation as a function of CYP450 polymorphism. 
Hall and colleagues reported that the inactivation parameters  kinact/KI for
verapamil was 30 times higher in one CYP3A5 *3/*3 donor compared to one 
*1/*3 donor (285). The much greater potency of inactivation in the *3/*3 
genotype was ascribed to absence of inhibition of CYP3A5 by verapamil, thus 
CYP3A5-expressing genotypes are less susceptible to inactivation. However, only 
1 donor each from both genotypes was studied, making it difficult to generalize 
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this finding. Hollenberg and colleagues found that the disulfiram metabolite, 
diethyldithiocarbamate exhibited a 1000-fold lower kinact/KI
 ratio in the 
inactivation of a CYP2E1*2 allele, compared with the wild-type (228). The 
effects of the *2 allele in terms of abundance or functional activity of the protein 
in humans is not well-described, however it has been reported to result in lower 
recombinant protein expression in COS-1 cells (286), while having comparable or 
greater metabolic activity than the wild-type, depending on the substrate (286, 
287). It is important to bear in mind that the results described by Hollenberg were 
studied in a recombinantly generated CYP2E1*2 variant, rather than in genotyped 
 HLM. 
Although our study is not the first to explore the gene-response relationship in the 
context of xenobiotic-mediated inactivation of CYP450, there are several 
important differences in our study which merits further discussion. Firstly, the 
perpetrator in our study is lapatinib, which differentially inactivates both CYP3A4 
and CYP3A5 via MI complex formation and MBI respectively. This is a crucial 
difference as the study of CYP3A5 polymorphism cited above investigated 
verapamil which preferentially inactivates CYP3A4 over CYP3A5. This is a 
possible reason to account for the contrasting trends regarding the potency of 
inactivation across CYP3A5 genotypes. In our study, we found that CYP3A5 
*1/*1 carriers exhibited the greatest potency of inactivation as measured by 
kinact/KI
 ratios and decrease in CYP3A4/5 activity. In contrast, the study using 
verapamil documented that *1/*1 carriers were the least susceptible to inhibition 
 We postulate that since CYP3A5*1 carriers generally have a and inactivation.
higher CYP3A capacity, they possess a higher baseline CYP3A activity as 
measured by testosterone 6β-hydroxylation. Conversely, CYP3A5*3/*3 carriers 
have an intrinsically lower baseline CYP3A activity level. Upon inactivation of 
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both CYP3A4 and CYP3A5 by lapatinib, the magnitude of decrease in CYP3A 
activity is quantitatively greater for CYP3A5*1 carriers compared to 
CYP3A5*3/*3 carriers, hence the gradient of the inactivation curves, or kobs is 
steeper in CYP3A5*1 carriers. At saturation, CYP3A5*1 carriers would have 
higher kinact values, thus resulting in higher . The greater decrease in kinact/KI
 ratios
CYP3A4/5 activity in *1/*1 donors is illustrated in Figure 3-17B. This effect 
would not manifest for a CYP3A4-selective inactivator such as verapamil. 
A second important difference in our study is that this is the first to use a panel of 
CYP3A5 genotyped HLMs to investigate xenobiotic-mediated CYP450 
inactivation. Our study clearly demonstrates that there is considerable inter-
individual variability with regards to the potency of inactivation within each 
genotype. The study by Hall et al. (285) used only a single donor each from 2 
CYP3A5 genotypes, and may not be representative of the population 
characteristics. For example, if we consider only donors HH785 (*1/*1) and 
H0182 (*3/*3), we would have concluded that *1/*1 carriers experience a 7-fold 
greater potency of inactivation compared with *3/*3 carriers. Conversely, we 
would have concluded that there is no difference in susceptibility to inactivation if 
we compared only donors H0331 (*1/*1) and H0307 (*3/*3). It is important to 
exercise caution when interpreting studies of gene-response relationships, as 
genetic disposition is not the sole determinant of CYP450 activity. Environmental 
factors such as diet or alcohol intake can give rise to exacerbated or diminished 
CYP3A activity independent of genotype, and thus contribute to intra-genotype 
variability. This emphasizes the importance of having a sufficient pool of donors 
per genotype when conducting such studies, or by using matched donors where 
possible. The small sample size of this study (4 donors per genotype) could be a 
possible reason for the absence of statistical significance. Nevertheless, this 
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investigation serves as a pilot study to elucidate the possible trend for lapatinib 
inactivation as a function of CYP3A5 genotype. Physiologically-based 
pharmacokinetic (PBPK) modeling can be used to quantify the extent of potential 
DDIs with lapatinib for each CYP3A5 genotype to better understand the clinical 




3.6 Chapter Conclusion 
The adverse drug reactions (e.g. hepatotoxicity) and DDIs perpetrated by 
lapatinib are thought to be the result of reactive metabolite formation. Judicious 
deuteration of lapatinib reduced O-debenzylation and N-dealkylation of lapatinib, 
as well as decreased quinone-imine levels as measured by GSH adduct formation. 
However, these findings did not translate to an attenuation of the magnitude of 
irreversible inactivation of CYP3A4/5, possibly because suppression of reactive 
metabolite formation was insufficient. Separately, CYP3A5*1/*1 carriers were 
found to exhibit the greatest susceptibility to CYP3A4/5 inactivation, 
accompanied by the largest decrease in CYP3A4/5 activity and highest GSH 
adduct levels. Importantly, this is the first study to characterize the effect of 
CYP3A5 polymorphism on CYP450 inactivation with a panel of genotyped 
donors, using an inactivator that simultaneously inactivates CYP3A4 and 
CYP3A5. These findings suggest that a gene-response relationship exists for 





 Chapter 4 Circumventing Covalent Binding via 
Combinatorial Lapatinib and Endoxifen Therapy 
4.1 Chapter Summary 
Background: De novo and acquired tamoxifen resistance is a major challenge in 
the treatment of breast cancer. One underlying cause is the development of 
estrogen receptor α/human epidermal growth factor receptor 2 (ERα/HER2) 
crosstalk, where HER2 provides an alternative pathway for generation of 
proliferative signals despite antagonism of ERα by tamoxifen and its active 
metabolites. To overcome the crosstalk and restore sensitivity to tamoxifen 
therapy, simultaneous inhibition of ERα and HER2 using tamoxifen and lapatinib 
respectively has been explored pre-clinically and clinically. However, the efficacy 
of this combination may be confounded by lapatinib, which is a potent covalent 
and coordinate inactivator of CYP3A4/5, a major enzyme responsible for 
bioactivation of tamoxifen to the active metabolite endoxifen.  
Objective: In this chapter, we attempt to circumvent the deleterious inhibition of 
tamoxifen bioactivation by directly administering endoxifen with lapatinib, and 
explore the pharmacodynamic and pharmacokinetic interactions between lapatinib 
and endoxifen. 
Methodology: Metabolism studies were performed to determine the extent of 
covalent and coordinate inhibition of tamoxifen bioactivation by lapatinib. 
Pharmacodynamic interactions between lapatinib and endoxifen were assessed 
using the combination index design in a panel of de novo and acquired tamoxifen-
resistant cell lines. Pharmacokinetic interactions via modulation of P-glycoprotein 
(P-gp) efflux were explored using the MDCKII-MDR1 cell line. 
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Results and discussion: Lapatinib was found to inhibit tamoxifen bioactivation 
by up to 2.2-fold, suggesting that co-administration of lapatinib with tamoxifen 
may nullify expected synergistic effects in vivo. Strong pharmacodynamic 
synergism was uncovered between lapatinib and endoxifen in cell models of both 
de novo and acquired resistance to tamoxifen. Molecular biology studies 
confirmed that simultaneous administration of lapatinib and endoxifen disrupted 
the crosstalk between ERα and HER2. Additionally, lapatinib and endoxifen were 
both found to be substrates and inhibitors of P-gp, and exhibited mutual inhibition 
of drug efflux when used in combination. Importantly, these pharmacodynamic 
and pharmacokinetic synergistic effects occurred at drug concentration levels 
achievable using available dose regimens. 
Conclusion: The apparent liability of lapatinib in tamoxifen bioactivation was 
negated by direct administration of lapatinib with endoxifen. This combination 
exhibits potent pharmacodynamic and pharmacokinetic synergism in tamoxifen-
resistant breast cancer. This study illuminates a novel and potentially efficacious 




4.2 Chapter Introduction 
Unforeseen covalent binding by a drug is often a liability due to its unpredictable, 
and often detrimental consequences which surface during clinical use. In the case 
of lapatinib, as discussed in Chapter 3, covalent binding perpetrated by its 
reactive quinone-imine metabolite is responsible for the MBI observed with 
CYP3A5, while the quasi-irreversible binding of the nitroso reactive metabolite to 
the heme group results in the formation of a MI complex and inactivation of 
CYP3A4, collectively causing permanent inhibition of CYP3A4/5 activity and 
potential DDIs with CYP3A4/5 substrates. Nevertheless, the presence of covalent 
(and coordinate) binding is not always detrimental. As illustrated in this chapter, 
what might be perceived as a liability can instead be turned into an opportunity. 
4.2.1 Tamoxifen in the Treatment of Breast Cancer 
Over 70% of breast cancer is estrogen receptor-α positive (ERα+) (288). For 
nearly three decades, tamoxifen has been the cornerstone treatment for the 
prevention and treatment of early and advanced ERα+ breast cancer (289-291) in 
both pre- and post-menopausal women. The widespread usage of tamoxifen is 
believed to have contributed significantly to the decrease in breast cancer 
mortality (292).  
As a prodrug, tamoxifen is metabolized extensively by CYP450 enzymes to 
several key metabolites as illustrated in Figure 4-1 (293). Tamoxifen is 
metabolized to the primary metabolites 4-hydroxytamoxifen (4-OHT) and N-
desmethyltamoxifen (NDMT) by CYP2D6 and CYP3A4/5 respectively, and 
undergo further metabolism to form the common secondary metabolite, 






Figure 4-1 Metabolic pathway of tamoxifen and its metabolites. Thick arrows 
indicate predominant pathways, predominant enzymes in each pathway are 
indicated in bold. 
 
Among these metabolites, 4-OHT, endoxifen, and norendoxifen are reported to be 
pharmacologically active (294, 295). Tamoxifen metabolites exert their 
pharmacological effect via two mechanisms, namely, ERα antagonism or 
aromatase inhibition. As ERα antagonists, they compete reversibly with estrogen 
for binding to the nuclear receptor ERα, preventing its translocation to the 
nucleus, binding to the estrogen response element and transcription of genes that 
promote cell proliferation, survival and invasion (296). Additionally, endoxifen 
and norendoxifen are reported to be inhibitors of aromatase, which converts 
androgens (e.g. testosterone) to estrogens (e.g. estradiol). Collectively, ER 
inhibition, and aromatase inhibition which occurs upstream of ER inhibition 
prevents estrogen-responsive gene transcription and reduces proliferation of 
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towards ER (297) and are 30- to 100-fold more potent than tamoxifen in vitro 
(293), plasma levels of endoxifen are 6- to 7-fold higher than that of 4-OHT 
(295). As a result, endoxifen is considered the main pharmacologically active 
metabolite of tamoxifen (295). Endoxifen is additionally reported to target ERα 
for its degradation, a unique mechanism of action not reported for other tamoxifen 
metabolites (298). 
4.2.2 Challenges in Tamoxifen Therapy 
4.2.2.1 Inter-individual Variability 
The dependence on CYP450-mediated bioactivation of tamoxifen exposes 
tamoxifen therapy to the influence of CYP450 genetic polymorphisms, giving rise 
to considerable inter-individual variability in tamoxifen response, which is a 
major clinical challenge. CYP2D6 has more than 80 polymorphic forms, resulting 
in individuals characterised as poor- to ultra-metabolizers (270). Separately, 
CYP3A5, a member of the CYP3A4/5 family also demonstrates genetic 
polymorphism (section 3.2.3.2). Efforts to establish the clinical significance of 
prospective genotyping for CYP2D6 and CYP3A4/5 status in tamoxifen therapy 
have proven to be inconclusive, as conflicting results are reported with regards to 
the relationship of these genotypes to plasma metabolite levels and survival rates 
(299).  
4.2.2.2 Development of Tamoxifen Resistance 
Tamoxifen therapy is also complicated by the heterogeneous nature of breast 
cancer, which is classified into different subtypes depending on the molecular 
phenotype (300). The luminal A subtype is characterised by being ERα+, human 
epidermal growth factor receptor 2 negative (HER2-), and progesterone receptor 
positive (PR+) or negative (PR-) (300), while the luminal B subtype is 
characterised by being ERα+, HER2+, and PR+ or PR-. Of the various breast 
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cancer subtypes, the luminal A and luminal B subtypes constitute almost 70% of 
all breast cancer cases in both Caucasian and Asian populations (288).  
While patients expressing the luminal A subtype typically respond well to 
tamoxifen therapy (301), as a consequence of the long duration of treatment, up to 
30% acquire tamoxifen resistance, resulting in cancer relapse over a 15-year 
period (302), leading to tumour progression and death. Additionally, the luminal 
B subtype exhibits de novo resistance to tamoxifen where it is inherently less 
responsive to ER antagonism and has poorer tumour grade and poorer survival 
rates (303-305).  
In vitro studies using tamoxifen-resistant MCF-7 cells, generated via continual 
exposure to 4-OHT, demonstrated that one possible mechanism for tamoxifen 
resistance is the crosstalk between ERα and HER2 (304-306). Leary et al. 
suggested that the up-regulation of HER2 suppresses ERα function, circumvents 
the inhibitory signals of 4-OHT on ERα and results in continued cell proliferation 
(304). Separately, Shou et al. provided evidence suggesting that 4-OHT and 
estrogen act as agonists to the up-regulated HER2 in MCF-7 cells transfected with 
HER2 (305). This activates downstream kinases such as mitogen-activated 
protein kinase (MAPK) and protein kinase B (Akt), which in turn potentiates ERα 
function by phosphorylating and activating ERα independently of estrogen 
binding, a process known as ligand-independent activation (307, 308). These 
kinases were also found to suppress ERα expression at both mRNA and protein 
levels (309, 310). Collectively, these processes diminish the responsiveness of the 
ER to endocrine antagonism. While there are numerous mechanisms supported by 
in vitro evidence suggested to contribute to tamoxifen resistance, it is noteworthy 
that HER2 overexpression is the only mechanism of anti-estrogen resistance with 






4.2.3 Overcoming Tamoxifen Resistance due to ERα/HER2 Crosstalk 
To overcome ERα/HER2 crosstalk and restore sensitivity to tamoxifen, one 
promising strategy is to inhibit both pathways concurrently. This approach has 
shown evidence of efficacy in in vitro and preclinical animal studies. For 
example, Shou et al. demonstrated that co-administration of 4-OHT and gefinitib, 
an inhibitor of the epidermal growth factor receptor (EGFR) family including 
HER2, abrogated the ERα/HER2 crosstalk in vitro and in vivo (305). As 
compared to either drug alone, co-administering tamoxifen and gefinitib inhibited 
the growth of HER2-transfected MCF-7 tumour xenografts to a much greater 
extent. Separately, Leary et al. showed that lapatinib, an EGFR and HER2 
inhibitor, restored endocrine sensitivity by increasing ERα transcriptional activity 
in long-term tamoxifen-treated MCF-7 cells, which exhibited endocrine resistance 
characterised by suppressed ERα transcription (304). Co-administration of 4-OHT 
with lapatinib completely attenuated the increased ERα activity. These results 
were substantiated with work by Chu et al. demonstrating that concurrent 
treatment of tamoxifen-resistant MCF-7 tumour xenografts with lapatinib and 4-
OHT significantly inhibited tumour growth when compared to 4-OHT treatment 
alone (306).  
Building upon the strength of these preclinical results, phase I (LAPATAM) and 
phase II (NCT00118157) clinical trials are currently being conducted on the co-
administration of lapatinib and tamoxifen. It is important to recognize that while 
reversal of tamoxifen resistance was demonstrated in vitro using 4-OHT (304, 
306), tamoxifen instead of 4-OHT is being investigated in clinical trials. As 
lapatinib is a potent inactivator of CYP3A4/5, it can potentially inhibit the 
formation of active tamoxifen metabolites, given that CYP3A4/5 is an integral 
contributor to tamoxifen bioactivation (Figure 1) (244, 246). As a result, co-
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administration of tamoxifen and lapatinib has important consequences as it may 
result in pharmacokinetic antagonism, essentially abrogating the predicted 
pharmacodynamic synergism. 
4.2.4 Lapatinib and Endoxifen: a Superior Combination? 
Given that combinatorial tamoxifen and lapatinib may exhibit pharmacokinetic 
antagonism, a possible solution would be to co-administer lapatinib with an active 
metabolite of tamoxifen to circumvent the covalent and coordinate inhibition of 
CYP3A4/5-dependent tamoxifen bioactivation and overcome ERα/HER2 
crosstalk. Lapatinib and endoxifen appear to be promising candidates for 
combinatorial therapy for reasons that are detailed below. Based on literature 
findings, these two agents may have interactions at both the pharmacodynamic 
and pharmacokinetic level, both of which could augment the clinical efficacy of 
the proposed combination through complementary mechanisms.   
Pharmacodynamic interaction. It may be argued that since lapatinib does not 
affect CYP2D6, this is unnecessary as tamoxifen can still undergo bioactivation 
by CYP2D6 to form 4-hydroxytamoxifen, and thus continue to exert 
antiproliferative effects. Therein however lies another clinical challenge, as 
relying on tamoxifen bioactivation to 4-OHT is subject to the considerable effects 
of CYP2D6 polymorphism. Of the known active tamoxifen metabolites, 
endoxifen is a promising candidate as it is the primary active metabolite 
downstream of CYP2D6 and CYP3A4/5 metabolism and bypasses the issues with 
inter-individual variability due to CYP450 polymorphism. Additionally, 
endoxifen possesses unique pharmacological activities such as aromatase 
inhibition, which is not observed for 4-OHT, and it also induces ERα degradation 
(298), which is not exhibited by norendoxifen. Given that lapatinib has already 
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been shown to exhibit synergism with 4-OHT, it is surprising that combinatorial 
lapatinib and endoxifen has not yet been explored for synergistic activity.  
Pharmacokinetic interaction. Another promising aspect of this combination lies 
in potential pharmacokinetic synergism, as at plasma concentrations, lapatinib is 
both a substrate and inhibitor of the P-glycoprotein (P-gp) efflux pump (311), 
while endoxifen is reported to be a P-gp substrate (312, 313). P-gp is an 
adenosine triphosphate (ATP)-dependent efflux transporter that enables cancer 
cells to actively pump drugs, which are P-gp substrates, out of the cell. 
Physiologically, P-gp efflux transporters are found to be highly expressed in 
various part of the human body such as epithelial cells of the gut, endothelial cells 
of blood-brain barrier (BBB) and adrenal cortical cells, where their physiological 
role is to protect these organs from xenobiotic exposure (314). Given their role in 
xenobiotic transport, P-gp expression can modulate the pharmacokinetics of 
drugs. For example, the levels of P-gp transporters found in intestine, unaltered or 
induced by rifampicin, is inversely correlated to the intestinal absorption and 
bioavailability of digoxin (315). Beyond pharmacokinetics, P-gp upregulation can 
alter therapeutic outcomes by preventing intracellular drug concentrations from 
reaching levels needed for efficacy. In oncology, increased P-gp expression has 
been documented both in tumours arising from tissues that have high basal P-gp 
expression (e.g. colon carcinoma), and from tissues that normally expresses P-gp 
at low levels (e.g. ovarian cancer) after exposure to chemotherapeutic agents 
(316). In breast cancer, there is evidence to suggest that P-gp expression in 
tumour cells may be associated with diminished intra-tumoral drug accumulation, 
drug resistance, poor drug response, aggressive metastatic breast tumour and poor 
prognosis and (317-321).  Tumours which overexpress P-gp can become resistant 
to multiple chemotherapeutic agents which are also P-gp substrates, and in some 
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cases, co-administration of a P-gp inhibitor such as verapamil or cyclosporin A 
has improved clinical efficacy (322) by increasing absorption and cellular uptake 
of the victim drug. Indeed, lapatinib has been shown in vitro to enhance 
intracellular accumulation of topotecan and doxorubicin, which are P-gp 
substrates, and increase systemic exposure of topotecan in a phase I trial (323, 
324), suggesting that a similar interaction occurring via P-gp may exist for 
lapatinib and endoxifen. Beyond interactions at the target tissue, P-gp is also 
known to limit intestinal absorption due to expression in enterocytes, promote 
excretion into bile and urine as a result of its expression in the canalicular 
membrane of hepatocytes and in the luminal membrane of renal proximal tubule 
cells, and is part of the panel of efflux transporters that reduce CNS penetration 
due to expression at the luminal membrane of the endothelial cells lining the brain 
capillaries in the blood-brain barrier (325). P-gp interactions at these 
physiological sites could augment oral absorption, reduce biliary and urinary 
excretion thus sustaining plasma concentrations, and also enhance CNS 
penetration. The latter is particularly intriguing since the brain is a common 
secondary site of breast tumour metastasis (326). 
Taken together, the combined effects of endoxifen and lapatinib on ERα and 
HER2 suggest potential pharmacodynamic synergism, while the intrinsic 
characteristics of lapatinib and endoxifen, as a P-gp substrate and inhibitor 
respectively hints at potential pharmacokinetic synergism. This chapter focuses 
on the co-administration of lapatinib and endoxifen to circumvent the potential 
deleterious effects of covalent and coordinate inhibition of tamoxifen 
bioactivation.  Firstly, the extent of inhibition of tamoxifen bioactivation by 
lapatinib is determined using pooled human liver microsomes (HLM). The 
combination of lapatinib and endoxifen is subsequently investigated from both 
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pharmacodynamic and pharmacokinetic aspects. The former is performed in a 
panel of breast cancer cells, while the latter is determined in the P-gp 
overexpressing MDCKII-MDR1 cells. By studying the interaction between these 
two agents from both perspectives, we aim to demonstrate that covalent binding is 
not necessarily a liability, but can instead be leveraged into an opportunity to 
enhance therapeutic efficacy in breast cancer.  
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4.3 Materials and Methods 
4.3.1 Materials 
Tamoxifen citrate was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
NDMT, endoxifen, norendoxifen and amprenavir were from Toronto Research 
Chemicals (Toronto, ON, Canada). Lapatinib was from LC Laboratories 
(Woburn, MA, USA). Pooled HLM were obtained from BD Gentest (Franklin 
Lakes, NJ, USA). HPLC-grade methanol and acetonitrile (ACN) were purchased 
from Tedia Company Inc. (Fairfield, OH, USA). NADPH-regenerating system 
consisting of NADPH A (NADP+ and glucose-6-phosphate) and NADPH B 
(glucose-6-phosphate dehydrogenase) was acquired from BD Gentest (Woburn, 
MA, USA). RIPA lysis buffer, Pierce BCA protein assay kit, Halt protease 
inhibitor cocktail, and SuperSignal West Pico Chemiluminescent Substrate were 
obtained from Thermo Scientific (Waltham, MA, USA), while PhosSTOP 
phosphatase inhibitor cocktail tablet was purchased from Roche Life Science 
(Indianapolis, IN, USA). Primary antibodies against HER2, pHER2 (Tyr1248), 
pHER2 (Tyr1221/1222), ERα, pERα (S104/106), pERα (S118), pERα (S167) and 
secondary horseradish peroxidase–conjugated goat anti-mouse and anti-rabbit IgG 
antibodies were from Cell Signaling Technology (Danvers, MA, USA). 4-OHT, 
RPMI medium 1640 without phenol red, fluorescein diacetate (FDA), geneticin, 
dextromethorphan hydrobromide and anti-β-actin antibody were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) and L-glutamine 
were obtained from Hyclone (Logan, UT, USA), while 1% 
penicillin/streptomycin was purchased from PAN Biotech (Aidenbach, Germany).  
Charcoal-stripped FBS was obtained from Biowest (Nuaillé, France). Dulbecco's 
modified eagle's medium (DMEM) with phenol red, DMEM without phenol red, 
Dulbecco’s phosphate buffer solution (DPBS), and HEPES buffer were from 
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Gibco Life Technologies (Waltham, MA, USA). Lucifer yellow CH dilithium salt 
was from MP Biomedicals (Santa Ana, CA, USA). Elacridar (GF120918A) were 
from GlaxoSmithKline (GSK) Laboratories (Middlesex, United Kingdom).  
Potassium phosphate monobasic (ACS grade) was purchased from Mallinckrodt 
Baker (Phillipsburg, NJ, USA). Water was obtained using a Milli-Q water 
purification system (Millipore, Bedford, MA, USA). All other chemicals and 
reagents used were of analytical grade. 
4.3.2 Effect of Lapatinib on Tamoxifen Bioactivation 
4.3.2.1 Effect of Lapatinib on Intrinsic Clearances of Tamoxifen and 4-OHT in 
Pooled HLM  
The intrinsic clearances (CLint) of tamoxifen to NDMT, and 4-OHT to endoxifen, 
both mediated by CYP3A4/5 were investigated in the presence and absence of 
lapatinib using pooled HLM. A primary incubation mixture containing 10 μM 
lapatinib, NADPH B, 0.5 mg/mL pooled HLM and 100 mM phosphate buffer (pH 
7.4) was pre-incubated for 5 min at 37°C with shaking; subsequently, the reaction 
was initiated with NADPH A. After a 30 min incubation period, 10 μL of the 
primary incubation mixture was transferred to a secondary incubation mixture in a 
96-well polypropylene plate containing NADPH A, NADPH B, tamoxifen (0−100 
μM) and 100 mM phosphate buffer (pH 7.4) to achieve a 10-fold dilution of HLM 
to a final concentration of 0.05 mg/mL. The reaction was terminated 10 min later 
with 100 μL of ice-cold ACN containing 0.5 μM donepezil as an internal standard 
(IS). The plate was centrifuged at 2900 g for 30 min at 4°C to remove precipitated 
protein. 100 μL of the supernatant was carefully withdrawn and dispensed into 
another 96-well polypropylene plate for analysis with LC/MS/MS. To establish 
baseline CLint of tamoxifen via the formation of NDMT in the absence of 
lapatinib, 100 mM phosphate buffer (pH 7.4) was used to replace lapatinib in the 
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preparation of primary incubation mixtures without lapatinib. The above 
procedures were repeated using 4-OHT (0-200 µM) as a probe substrate. The final 
organic concentration in each incubation mixture did not exceed 2% (v/v). All 
reactions were performed in triplicates. Samples were stored at -80°C and 
protected from light until analysis with liquid chromatography-tandem mass 
spectrometry (LC/MS/MS). 
4.3.2.2 Quantification of Tamoxifen Metabolites by LC/MS/MS 
Experiments were performed using an Agilent 1290 Infinity LC system interfaced 
with an AB Sciex Qtrap 5500 hybrid linear ion-trap quadrupole mass 
spectrometer equipped with a TurboIonSpray source (Applied Biosystems, Foster 
City, CA). Milli-Q water and HPLC-grade ACN, both acidified with 0.1% formic 
acid, were used as mobile phases A and B respectively. Both mobile phases were 
pumped through a Waters Acquity UPLC BEH C18 column (1.7 μm, 50 mm × 2.1 
mm i.d.; Waters, Milford, MA, USA) at a flow rate of 0.6 mL/min. Elution 
conditions were as follows: linear gradient 38 to 39% B (0−1.00 min), linear 
gradient 39 to 95% (1.01−1.04 min), isocratic 95% B (1.05−1.55 min), linear 
gradient 95 to 38% (1.56−1.59 min) and isocratic at 38% B (1.60−2.50 min). 
Using an autosampler thermostatted at 6°C, 3 μL of each sample was injected 
onto the UPLC column maintained at 45°C. The needle was flushed with 
methanol post-injection to minimize carry-over effect. Tandem mass spectrometry 
was operated in the positive ion electrospray ionization (ESI +ve) mode. MS 
source conditions were: ionspray voltage, 4000 V; temperature, 450°C; curtain 
gas 25 psi; ion source gas 1, 45 psi; and ion source gas 2, 50 psi. Compound-
dependent MS parameters were optimized using pure standards and are 
summarized in Table 4-1. Multiple reaction monitoring (MRM) experiment was 
performed for quantification of analytes. The retention times of NDMT, 
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endoxifen and donepezil were 1.5, 1.1 and 0.4 min respectively. Calibration 
samples containing NDMT and endoxifen (0, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 
μM), 100 mM phosphate buffer (pH 7.4) and ACN containing 0.5 μM donepezil 
were freshly prepared and underwent the same sample preparation for each 
analysis. The calibration data for NDMT and endoxifen were fitted to a linear 
model, with the reciprocal of the squared concentration (1/x2) used as the 
weighting factor. 
Table 4-1 MRM transitions and compound-dependent MS parameters for the 

















NDMT 358 → 58 51 101 9 12 
Endoxifen 374 → 58 57 111 8 8 
Donepezil (IS) 380 → 91 51 106 9 14 
 
4.3.2.3 Data Analysis 
Integration of chromatographic peaks was performed using Analyst Software 
(version 1.5.2, Applied Biosystems). Final concentration levels of tamoxifen 
metabolites calculated based on relative responses were normalized to incubation 
time and amount of HLM (pmol/min/mg). The data was subsequently processed 
with Prism 6 (GraphPad Software Inc., San Diego, CA, USA) by nonlinear 
regression analysis using either the Michaelis-Menten or allosteric sigmoidal 
model, where a comparison of fits test was performed using Prism 6 to obtain the 
best-fit model for determining the enzyme kinetics parameters Vmax and Km. CLint 




4.3.3 Investigation of Pharmacodynamic Interaction between Lapatinib and 
Tamoxifen or its Active Metabolites 
This in vitro investigation was divided into 2 phases. In a pilot study, potential 
synergism between lapatinib and tamoxifen or its active metabolites (4-OHT, 
endoxifen and norendoxifen) were determined in the de novo tamoxifen-resistant 
phenotype. The best combination was then advanced to the second phase, where 
potential synergism was explored in a luminal A subtype exhibiting acquired 
tamoxifen resistance. 
4.3.3.1 Cell Culture 
De novo tamoxifen resistance. The MCF-7 cell line which was previously 
obtained from the British Columbia Cancer Centre, Vancouver, Canada was a 
kind gift from Dr. Chiu Ngar Chee, Gigi (National University of Singapore, 
Singapore), while the BT474 cell line was a kind gift from Dr. Yang Yi Yan 
(Institute of Bioengineering and Nanotechnology, Singapore). Both cell lines 
were cultured in phenol red-free RPMI medium 1640, supplemented with 10% 
heat-inactivated FBS and 1% penicillin/streptomycin.  
Acquired tamoxifen resistance. Isogenic tamoxifen-sensitive MCF-7 and 
tamoxifen-resistant TAM-R cell lines were kind gifts from Dr. Julia M. W. Gee 
(Cardiff University, United Kingdom). MCF-7 cells were cultured in phenol red-
free RPMI 1640 medium supplemented with 5% heat-inactivated FBS and 1% 
penicillin/streptomycin. TAM-R cells derived from the tamoxifen-sensitive 
parental MCF-7 cell line were cultured in phenol red-free RPMI 1640 medium, 
supplemented with 5% heat-inactivated charcoal-stripped FBS, 1% 
penicillin/streptomycin and 0.1 μM 4-OH-T to maintain tamoxifen resistance. 
MCF-7 cells stably transfected with HER2 (MCF-7/HER2) cell line was a kind 
gift from Dr. Dawn Waterhouse (British Columbia Cancer Centre, Vancouver, 
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Canada)  and was cultured in phenol red-free RPMI medium 1640, supplemented 
with 10% FBS and 100 µg/mL geneticin. 
All cell cultures were incubated in a humidified environment kept at 5% CO2 and 
37°C. All cell lines used were authenticated in November 2014 using short 
tandem repeat DNA profiling of 9 loci with 100% identity match against the 
DSMZ database (Genetica DNA Laboratories, Burlington, NC, USA). 
4.3.3.2 In Vitro Monotherapy Cytotoxicity Assay 
De novo tamoxifen resistance. MCF-7 and BT474 cells were seeded into 96-well 
plates at a density of 7 000 and 10 000 cells/well respectively. Serial dilutions of 
tamoxifen (0.3 – 100 µM), 4-OHT (0.3 – 100 µM), endoxifen (0.3 – 100 µM), 
norendoxifen (0.3 – 100 µM) and lapatinib (0.001 - 100 µM) using culture media 
were added to the respective wells at 200 µL per well. For vehicle controls, up to 
1% ethanol was used for tamoxifen, up to 1% methanol was used for 4-OHT, 
endoxifen, and norendoxifen, and up to 0.5% DMSO was used for lapatinib. Cell 
viability was greater than 90% at these concentration levels of solvents. 
Acquired tamoxifen resistance. MCF-7, TAM-R and MCF-7/HER2 cells were 
seeded into 96-well plates at a density of 7 000 cells/well. TAM-R cells were 
cultured in 4-OHT-free media for 7 days before any drug exposure. MCF-7/HER2 
cells were seeded in geneticin-free media during drug treatment. Serial dilutions 
of tamoxifen (0.3-50 μM), endoxifen (0.3 – 30 µM), and lapatinib (0.1 - 50 µM) 
using culture media were added to the respective wells at 200 µL per well. For 
vehicle controls, up to 0.5% ethanol was used for tamoxifen and endoxifen, and 
up to 0.5% DMSO was used for lapatinib. These concentrations were not found to 
affect cell viability. 
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Cells were treated for a total of 5 days and the media containing drugs was 
refreshed after 3 days. Cell survival was measured using fluorescein diacetate 
(FDA) assay (327). The percentage cell survival was subsequently calculated and 
the half-maximal inhibitory concentration (IC50) was determined from cell 
survival curves using Prism 6. Each experiment was carried out in triplicates, and 
the average IC50 for each drug was obtained. Comparisons of IC50 values within 
each cell line for tamoxifen and its metabolites, as well as for lapatinib across 
both cell lines were performed using one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc test using Prism 6, and p < 0.05 was considered 
statistically significant. 
4.3.3.3 In Vitro Combination Therapy Cytotoxicity Assay 
De novo tamoxifen resistance. In MCF-7 cells, combination therapy was 
performed using equipotent doses (based on monotherapy IC50
 values) of lapatinib 
and tamoxifen (1:1.48 ratio), lapatinib and 4-OHT (1:1.1), lapatinib and 
endoxifen (1:0.954), and lapatinib and norendoxifen (1:1.22). In BT474 cells, 
combination therapy was performed using equipotent doses of lapatinib and 
tamoxifen (1:244), lapatinib and 4-OHT (1:193), lapatinib and endoxifen (1:170), 
and lapatinib and norendoxifen (1:252). Concentration levels of solvents did not 
exceed 0.7% methanol and 0.5% DMSO in vehicle controls. 
Acquired tamoxifen resistance. In isogenic MCF-7 cells, combination therapy was 
performed using equipotent doses of lapatinib and tamoxifen (1:1.37), and 
lapatinib and endoxifen (1:0.79). In TAM-R cells, combination therapy was 
performed using equipotent doses of lapatinib and tamoxifen (1:2.24), and 
lapatinib and endoxifen (1:1.57). In MCF-7/HER2 cells, combination therapy was 
performed using equipotent doses of lapatinib and tamoxifen (1:11.6), and 
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lapatinib and endoxifen (1:8.21). Concentration levels of solvents did not exceed 
0.5% ethanol and 0.5% DMSO in vehicle controls. 
The cells were treated for a total of 5 days and the media containing drugs was 
refreshed on day 3. Cell survival was measured using the FDA assay and the 
cytotoxic effect of combinatorial treatment was evaluated using the multiple drug 
effect analysis by Chou and Talalay (328, 329). Briefly, the combination index 










used, where (Dx)1 or (Dx)2 is the dose of drug 1 or 2 “alone” that demonstrates a 
particular effect (e.g. x% cytotoxicity or cell kill, which is also known as 
fractional effect or fraction affected, fa), while (D)1 and (D)2 represents the dose 
of both drugs “in combination” that demonstrates the same effect. (Dx)1 or (Dx)2 





𝑚 , where Dm 
represents IC50 and m is the sigmoidity of the curve. By solving for different 
values of fa, different CI values were obtained, where CI < 1, = 1 and > 1 
indicates synergism, additive effect and antagonism respectively. In other words, 
if the numerator (dose of drug used in combination) is lower than the denominator 
(dose of drug used singly) required to achieve the same effect, CI will be less than 
1 and would reflect synergism. The dose reduction index at 50% cytotoxicity 
(DRI50) was used to determine the fold-reduction in doses in combination therapy 
compared with IC50 of monotherapy according to the method by Chou and 
Talalay (329).  
4.3.3.4 Western Blot 
Western blot analysis of protein expression and phosphorylation was performed 
for the isogenic MCF-7 and TAM-R pair representing acquired tamoxifen 
resistance. MCF-7 and TAM-R cells were seeded into 6-well plates at a density of 
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300 000 cells/well and incubated overnight. Each well was treated with 2 mL of 
culture media containing individual drugs or in combination at half their IC50 for 
72 h, where MCF-7 cells were exposed to 2.6 μM tamoxifen, 1.5 μM endoxifen or 
1.9 μM lapatinib, while TAM-R cells were treated with 3.8 μM tamoxifen, 2.7 
μM endoxifen or 1.5 μM lapatinib. Untreated controls were cultured in media 
containing the highest concentration of ethanol and DMSO used in the drug-
treated samples. Cell monolayers were washed twice with ice-cold phosphate 
buffered saline (PBS) and collected by scraping in RIPA lysis buffer containing 
Halt protease inhibitor cocktail and PhosSTOP phosphatase inhibitor cocktail. 
Cell lysates centrifuged at 14 000 g at 4°C for 20 min. The supernatant was 
withdrawn and its protein concentration quantified using Pierce BCA protein 
assay kit. Cell lysates (30 µg) were resolved by 10% sodium dodecyl sulphate 
polyacrylamide gels (SDS-PAGE) and transblotted to nitrocellulose membranes. 
Protein transfer and equal loading of proteins were visualized by Ponceau S 
staining. Membranes were blocked at room temperature (25°C) for 30 min in 
Tris-buffered saline with 0.1% v/v Tween 20 (TBST) containing 5% w/v bovine 
serum albumin (BSA), followed by incubation at 4°C overnight with primary 
antibody (1:1000) diluted in 5% w/v BSA in TBST. The membranes are washed 
thrice in TBST, and incubated in appropriate secondary antibody (1:2000) for an 
hour at room temperature (25°C) and developed using enhanced 
chemiluminescence. Primary antibodies against HER2, pHER2 (Tyr1248), 
pHER2 (Tyr1221/1222), ERα, pERα (S104/106), pERα (S118), pERα (S167), β-
actin and secondary horseradish peroxidase–conjugated goat anti-mouse and anti-
rabbit IgG antibodies were used according to manufacturer’s instructions. β-actin 
bands were visually compared to ensure equal sample loading. Densitometric 
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analysis was conducted and band intensity was normalized to control for each cell 
line using ImageJ software version 1.48. 
4.3.4 Determination of Pharmacokinetic Interaction between Lapatinib and 
Endoxifen 
4.3.4.1 Cell Culture 
Madin-Darby canine kidney sub-clone II cells transfected with multi-drug 
resistance protein 1 (MDCKII-MDR1) were obtained from BioCat (Heidelberg, 
Germany). Cells were cultured in DMEM with phenol red supplemented with 
10% heat-inactivated FBS and 0.5% penicillin/streptomycin and seeded at 166 
667 cells/well within the insert of the 24-well Falcon HTS Multiwell insert 
system (Waltham, MA, USA). Media was refreshed at every 2 or 3 days and also 
1 h before the start of assay.  Cultures were maintained under a humidified 
atmosphere of 5% CO2 at 37°C for 1 week to allow formation of a polarized 
monolayer, whereby the cell surface membrane not attached to any surface, 
termed the apical (A) side expresses P-gp transporters, while the basolateral (B) 
side which is attached to the insert does not. Figure 4-2 illustrates the concept of 
the A and B side of the MDCKII-MDR1 monolayer.  
 
Figure 4-2 Illustration of A and B side of MDCKII-MDR1 monolayer. 
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4.3.4.2 Transport Assay 
The transport assay involves measurement of the apparent permeability of a 
substrate from the A to B direction (Papp (A→B)), and the B to A direction (Papp 
(B→A)). These two parameters are then used to determine the efflux ratio 
(section 4.3.4.4). Two solutions were defined in this assay: a donor solution 
comprising a transport vehicle, lucifer yellow, and substrate with or without 
inhibitor; and a receiver solution consisting of transport vehicle only. To measure 
Papp (A→B), the A chamber was incubated with donor solution while the B 
chamber was incubated with receiver solution; similarly, to measure Papp (B→A), 
the B chamber was incubated with donor solution while the A chamber was 
incubated with receiver solution as illustrated in Figure 4-3.  
 
Figure 4-3 Illustration of measurement of Papp (A→B) and Papp (B→A). 
 
Three types of transport assays were performed to evaluate the interaction of 
lapatinib and endoxifen with P-gp as described below.  
Substrate assay. The donor solution comprised DMEM without phenol red 
containing 10% FBS and 0.5% penicillin/streptomycin as transport vehicle, 




Inhibitor assay. The donor solution comprised HEPES buffer (pH 7.4) as 
transport vehicle, supplemented with 10 μM amprenavir as the probe substrate 
and either lapatinib (0 – 50 μM) or endoxifen (0 – 50 μM) as the inhibitor. 
Combinatorial treatment. The donor solution comprised of DMEM without 
phenol red containing 10% FBS and 0.5% penicillin/streptomycin as transport 
vehicle, supplemented with 1 μM substrate and inhibitor (0 – 50 μM), where 
lapatinib/endoxifen or endoxifen/lapatinb were used as substrate/inhibitor pairs. 
Treated cells were incubated and shaken on a PHMP Grant-bio (Cambridgeshire, 
United Kingdom) microplate shaker at 37°C at 250 rpm. All incubations were 
maintained for 1.5 h except when endoxifen was used as a substrate, where 
incubations were maintained for 3 h. At the end of the incubation, 150 μL of 
solution from each chamber was aliquoted into a 96 deep well block for drug 
analysis. 300 μL of internal standard (IS) solution was added to each well to 
precipitate the proteins present. IS solution was prepared from 100 μg/mL 
dextromethorphan stock solution diluted to 50 ng/mL in acetonitrile (ACN). The 
plates were then centrifuged at 2147 g at 10°C to pellet precipitated protein and 
other particles. The supernatant was injected for analysis using LC/MS/MS. All 
donor solutions were supplemented with 100 μM lucifer yellow to assess 
monolayer integrity. For each plate, a set of controls consisting of 10 μM 
amprenavir as probe substrate with and without 2 μM elacridar, a FDA-
recommended P-gp inhibitor was employed to ascertain maintenance of P-gp 
efflux during the course of the experiment. Concentration levels of organic 
solvents did not exceed 0.8%.  
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4.3.4.3 Quantification of Substrates using LC/MS/MS   
Samples were quantified using the instrumentation described in section 4.3.2.2. 
Mobile phase A was 10 mM ammonium acetate acidified with 0.1% formic acid 
and mobile phase B was HPLC-grade ACN delivered at flow rate of 1 mL/min. 
Analytes were separated using a Discovery Cyano HPLC Column Supelco 59355-
U (180 Å, 5 μm, 5 cm × 4.6 mm i.d) (Sigma-Aldrich, St.Louis, MO, USA) 
maintained at 40°C. Elution conditions were as follows: linear gradient 30 to 90% 
B (0-1.2 min), held at 90% B (1.2-1.6 min) and 90 to 30% B (1.6-1.61 min). 
Using an autosampler thermostatted at 4 °C, 1 μL of each sample was injected 
into the column. Tandem mass spectrometry was operated in the positive ion 
electrospray ionization (ESI +ve) mode. MS source conditions were: curtain gas 
20 psi; ionspray voltage, 5500 V; temperature, 400°C; ion source gas 1, 40 psi; 
and ion source gas 2, 40 psi. Compound-dependent MS parameters were 
optimised using pure standards and are summarized in Table 4-2. Multiple 
reactions monitoring (MRM) transition was applied for quantification. The 
retention times for amprenavir, endoxifen, lapatinib and dextromethorphan were 
1.44, 1.50, 1.60 and 1.13 min respectively. Integration of chromatographic peaks 
was performed using ABSciex Analyst Software version 1.6. 
Table 4-2 MRM transition and compound-dependent MS parameters for P-gp 

















Amprenavir 506.2 → 245.2 25 76 10 18 
Endoxifen 373.9 → 58.1 49 101 10 8 
Lapatinib 581.1 → 365.1 53 66 10 14 
Dextromethorphan 
(IS) 




4.3.4.4 Determination of Efflux Ratio and Monolayer Integrity 
Apprarent permeability. Apparent permeability (Papp) of a drug from one chamber 
to the other chamber is described by the following equation: 
Apparent permeability (Papp) of substrate (nm/s) = 
𝑑Q/𝑑𝑡
C0 × SA
   
where 
Q is the amount of substrate (nmol)  
C0 is the concentration at t = 0 s (nM) 
SA is the surface area (cm2) 
t is the incubation time (s) 
 
Efflux ratio. Efflux ratio is defined as the ratio of Papp (B→A) to Papp (A→B), as 
described by the following equation: 





Papp (B→A) is the apparent permeability from B to A (nm/s) 
Papp (A→B) is the apparent permeability from A to B (nm/s) 
 
The efflux ratio data was subsequently processed by non-linear regression 
analysis using Prism 6. 
Monolayer integrity. Monolayer integrity was assessed using lucifer yellow, a 
fluorescence dye that is impermeable through the cell membrane. By measuring 
the movement of lucifer yellow across the monolayer, the “leakiness” of the 
monolayer can be determined. An intact monolayer is a pre-requisite for a 
validated MDCKII-MDR1 efflux ratio assay. 100 μL of solution from each 
chamber was transferred into a 96-well flat bottom black plate. Lucifer yellow 
fluorescence of each chamber was measured at an excitation wavelength of 485 
nm and emission wavelength of 530 nm. Permeability of lucifer yellow was 




Permeability of lucifer = – (
VDVR
(VD+ VR)A𝑡
) ln [1 − 
(VD+ VR)CR(𝑡)
VDCD(𝑡)+ VRCR(𝑡)
] × 107    
yellow (nm/s) 
where 
 𝑉𝐷 is the volume in donor chamber (mL) 
𝑉𝑅 is the volume in receiver chamber (mL) 
A is the surface area (cm2) 
t is the incubation time (s) 
 𝐶𝐷(𝑡) is the measured concentration in the donor well at time t (nM) 
𝐶𝑅(𝑡) is the measured concentration in the receiver well at time t (nM) 
 
Acceptance criteria for an intact monolayer was defined as permeability of lucifer 
yellow less than 80 nm/s. 
4.4 Results 
4.4.1 Effect of Lapatinib on Tamoxifen Bioactivation 
In establishing CLint values of tamoxifen to NDMT, and 4-OHT to endoxifen, we 
aimed to assess the effects of mechanism-based inactivation of CYP3A4/5 by 
lapatinib on the bioactivation of tamoxifen by CYP3A4/5. Metabolism of 
tamoxifen to NDMT was best fitted using the Michaelis-Menten model, while 
metabolism of 4-OHT to endoxifen was best fitted using the allosteric sigmoidal 
model Figure 4-4. Vmax, Km and CLint values of each pathway in the absence and 
presence of lapatinib are given in Table 4-3. A 2.2- and 1.5-fold decrease in CLint 
values were observed in the presence of lapatinib for the metabolism of tamoxifen 
to NDMT and 4-OHT to endoxifen respectively, indicating that lapatinib inhibited 






Figure 4-4 Metabolism kinetics of (A) tamoxifen to NDMT and (B) 4-OHT to 
endoxifen in the absence and presence of lapatinib in pooled HLM. 
 
Table 4-3 Kinetic parameters for the metabolism of tamoxifen and 4-OHT to 






























63.39 50.42 1.25 
 
 
4.4.2 Pharmacodynamic Interaction between Lapatinib and Tamoxifen or its 
Active Metabolites in the De Novo Tamoxifen-Resistant Luminal B 
Subtype 
4.4.2.1 Monotherapy in MCF-7 and BT474 Cells 
Figure S4 and Figure S5 shows the cytotoxicity results of 5-day treatment of 
MCF-7 (ERα+/HER2-) and BT474 (ERα+/HER2+) cells with tamoxifen, its 
metabolites or lapatinib. The MCF-7 cell line was used as a comparator against 
the HER2-expressing BT474 cell line. Cell proliferation was inhibited in a dose-
dependent manner by all compounds in each cell line. As summarized in Table 
4-4 tamoxifen was less potent than its active metabolites in MCF-7 cells, but was 
A            B 
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comparable in BT474. Among the active metabolites, 4-OHT and endoxifen 
yielded comparable IC50 values against both cell lines, while norendoxifen was 
less potent in BT474. Lapatinib demonstrated nanomolar IC50 values in BT474 
cells, while in MCF-7 it was far less potent and had an IC50 value comparable to 
those of tamoxifen active metabolites. 
Table 4-4 IC50 values of tamoxifen, 4-OHT, endoxifen, norendoxifen, and 
lapatinib monotherapy in MCF-7 and BT474 cells. 
Treatment 
IC50 ± SD (µM) 
MCF-7 BT474 




4-OHT 7.24 ± 0.13 5.18 ± 0.52 
Endoxifen 6.17 ± 0.86 4.56 ± 0.43 




Lapatinib 6.49 ± 0.61
d 
0.0270 ± 0.01 
aIC50 value of tamoxifen against MCF-7 is significantly higher than 4-OHT, endoxifen or 
norendoxifen (p < 0.05). 
bIC50 value of tamoxifen against BT474 is significantly higher than endoxifen (p < 0.05). 
cIC50 value of norendoxifen against BT474 is significantly higher than 4-OHT or endoxifen (p 
< 0.05). 
dIC50 value of lapatinib is significantly higher against MCF-7 than BT474 (p < 0.0001). 
 
 
4.4.2.2 Combination Therapy in MCF-7 and BT474 Cells 
Against MCF-7 cells, an antagonistic effect (CI > 1) was observed at low levels of 
cytotoxicity, or cell kill for all the drug combinations except for the combination 
of lapatinib and norendoxifen, which showed synergism (CI < 1) at all levels of 
cell kill (Figure 4-5A). Synergism was observed at fa ≥ 0.2 for the combination of 
lapatinib and endoxifen, and at fa ≥ 0.3 for the combinations of both lapatinib and 
tamoxifen, and lapatinib and 4-OHT. Against BT474 cells (Figure 4-5B), 
synergism was observed at all levels of cell kill for the combination of lapatinib 
and endoxifen, fa ≥ 0.2 for the lapatinib and norendoxifen combination, and fa ≥ 




Concentration levels of each drug required for 50% cytotoxicity based on dose 
reduction index (DRI50) in each cell line is summarized in Table 4-5. The DRI50 
represents the order of magnitude, or fold, of dose reduction required for 50% cell 
death in a combination therapy setting compared to that in monotherapy, which is 
conventionally described as IC50. In other words, the DRI50 is used to estimate the 
concentration of a drug in a combination pair that achieves that same extent of 
cell kill (50%) as in monotherapy, and provides a means to interpret the fractional 
effect, fa in concentration terms. It is noteworthy that for the luminal B BT474 
cell line, the concentration levels of endoxifen required was much lower than 
those of tamoxifen or its active metabolites, while the concentration levels of 
lapatinib required was consistently lower when it was co-administered in 
combination with endoxifen than with tamoxifen or 4-OHT. Thus the 
combination of lapatinib and endoxifen was the most promising in killing BT474 
cells. Although endoxifen did not demonstrate a large dose reduction against 








Figure 4-5 Combination index (CI) against fractional effect (fa) plots of the 
combination of lapatinib and tamoxifen, lapatinib and 4-OHT, lapatinib and 
endoxifen, and lapatinib and norendoxifen in (A) MCF-7 and (B) BT474. CI < 1, 
CI = 1, and CI > 1 indicates synergism, additive effect, and antagonism, 
respectively. 
A            







Table 4-5 Concentration levels of tamoxifen, 4-OHT, endoxifen, norendoxifen, and lapatinib at DRI50 in combination therapy calculated based on 
fold-reduction of IC50 in monotherapy in MCF-7 and BT474 cells. 
Cell line Combination DRI50
 Concentration of lapatinib 
at DRI50 (nM) 
Concentration of tamoxifen 
or metabolite at DRI50 (nM) 
MCF-7 
Lapatinib + tamoxifen Lapatinib: 7.66; tamoxifen: 7.05 847 1360 
Lapatinib + 4-OHT Lapatinib: 9.04; 4-OHT: 7.28 718 995 
Lapatinib + endoxifen Lapatinib: 32.8; endoxifen: 2.65 198 2328 
Lapatinib + norendoxifen Lapatinib: 30.0; norendoxifen: 34.3 216 189 
BT474 
Lapatinib + tamoxifen Lapatinib: 3.74; tamoxifen: 1.45 7.22 4537 
Lapatinib + 4-OHT Lapatinib: 3.19; 4-OHT: 1.55 8.46 3342 
Lapatinib + endoxifen Lapatinib: 5.93; endoxifen: 11.6 4.55 393 
Lapatinib + norendoxifen Lapatinib: 8.72; norendoxifen: 9.49 3.10 715 
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4.4.3 Pharmacodynamic Interaction between Lapatinib and Tamoxifen or 
Endoxifen in the Luminal A Subtype with Acquired Tamoxifen 
Resistance 
The MCF-7 cells described in this section are the parental cells from which 
tamoxifen-resistant TAM-R cells were derived by continuous culture in 4-OHT, 
and were obtained from a different source compared to those utilized in section 
4.4.2. Separately, the combination of lapatinib and endoxifen showed the 
strongest synergism in BT474 cells based on DRI50 values (section 4.4.2.2). 
Hence only lapatinib, tamoxifen and endoxifen were studied in this section, with 
tamoxifen acting as a comparator. 
4.4.3.1 Monotherapy in MCF-7, TAM-R and MCF-7/HER2 Cells 
TAM-R cells exhibit acquired tamoxifen-resistance attributed to increased HER2 
expression (330). MCF-7/HER2 cells were derived from MCF-7 cells stably 
transfected with HER2. Similar to TAM-R cells, MCF-7/HER2 cells represent 
acquisition of tamoxifen resistance and have been used previously to understand 
the role of HER2 in tamoxifen resistance (331). Figure S6, Figure S7 and Figure 
S8 shows the cytotoxicity results of 5-day treatment of MCF-7, TAM-R, and 
MCF-7/HER2 cells with tamoxifen, endoxifen and lapatinib. Cell proliferation 
was inhibited in a dose-dependent manner by all compounds in each cell line. As 
summarized in Table 4-6, the mean IC50 values of endoxifen were lower than 
tamoxifen in all three cell lines, but only reached statistical significance in MCF-7 
cells (p < 0.01). Comparing between cell lines, the mean IC50 of both tamoxifen 
and endoxifen were higher in TAM-R and MCF-7/HER2 cells as compared to 
MCF-7 cells, which is in line with the acquisition of tamoxifen resistance in 
TAM-R cells; however statistical significance was observed only with endoxifen 
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(p > 0.05). Mean IC50 of lapatinib in MCF-7 cells were comparable to TAM-R cells, 
and was significantly lower in MCF-7/HER2 cells (p < 0.01). 
Table 4-6 IC50 values of tamoxifen, endoxifen and lapatinib monotherapy in 
MCF-7, TAM-R and MCF-7/HER2 cells. 
Treatment 
IC50 ± SD (µM) 
MCF-7 TAM-R MCF-7/HER2 




6.55 ± 1.21 
Endoxifen 2.95 ± 0.58 5.32 ± 0.83 4.59 ± 0.22 
Lapatinib 3.73 ± 0.79
 
3.38 ± 0.93 0.558 ± 0.12 
 
4.4.3.2 Combination Therapy in MCF-7, TAM-R and MCF-7/HER2 Cells 
Against MCF-7 cells (Figure 4-6A), both combinations show synergism at all 
levels of cell kill, where the combination of lapatinib with endoxifen showed 
greater synergism than that of lapatinib with tamoxifen. Against TAM-R cells 
(Figure 4-6B), both combinations demonstrated similar synergistic effects above 
fa ≥ 0.3. Against MCF-7/HER2 cells (Figure 4-6C), synergism was observed at fa 
≥ 0.2 for the combination of lapatinib and endoxifen, and fa ≥ 0.3 for the 
combination of lapatinib and tamoxifen.  
Concentration levels of each drug required for 50% cytotoxicity based on dose 
reduction index (DRI50) in each cell line are summarized in Table 4-7. When 
administered in combination with lapatinib, the concentration of endoxifen 
required was consistently lower in all three cell lines. On the other hand, the 
concentration of lapatinib required was highest in TAM-R, followed by MCF-7 






Figure 4-6 Combination index (CI) against fractional effect (fa) plots of the 
combination of lapatinib and tamoxifen, and lapatinib and endoxifen in (A) MCF-
7 (B) TAM-R and (C) MCF-7/HER2. CI < 1, CI = 1, and CI > 1 indicates 
synergism, additive effect, and antagonism, respectively. 
A            
B            







Table 4-7 Concentration levels of tamoxifen, endoxifen, and lapatinib at DRI50 in combination therapy calculated based on fold-reduction of IC50 in 
monotherapy in MCF-7, TAM-R and MCF-7/HER2 cells. 
Cell line Combination DRI50
 Concentration of lapatinib 
at DRI50 (nM) 
Concentration of tamoxifen 
or endoxifen at DRI50 (nM) 
MCF-7 
Lapatinib + tamoxifen Lapatinib: 7.02; tamoxifen: 3.50 531 1460 
Lapatinib + endoxifen Lapatinib: 7.24; endoxifen: 4.53 515 651 
TAM-R 
Lapatinib + tamoxifen Lapatinib: 2.54; tamoxifen: 10.5 1331 722 
Lapatinib + endoxifen Lapatinib: 2.48; endoxifen: 15.9 1363 335 
MCF-
7/HER2 
Lapatinib + tamoxifen Lapatinib: 4.2; tamoxifen: 7.25 133 903 
Lapatinib + endoxifen Lapatinib: 12.1; endoxifen: 6.36 46.1 722 
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4.4.3.3 Western Blot Analysis of Combination Therapy in MCF-7 and TAM-R 
Cells 
The basal expression and phosphorylation of ERα and HER2 in MCF-7 and 
TAM-R cells are shown in Figure 4-7 and Figure 4-8. Both cell lines express 
ERα, with MCF-7 cells expressing slightly higher levels than TAM-R cells. A 
greater extent of phosphorylation of ERα at the Ser-118 site was observed in 
untreated MCF-7 cells. On the contrary, ERα was phosphorylated to a greater 
extent at the Ser-167 site in TAM-R cells. Consistent with the HER2-negative 
phenotype of MCF-7 cells, HER2 expression and phosphorylation in MCF-7 cells 
were observed to be intrinsically low. HER2 expression and phosphorylation were 
elevated in the tamoxifen-resistant untreated TAM-R cells, which is in line with 
the association between acquired tamoxifen resistance and the development of 
ERα/HER2 crosstalk.  
 
Figure 4-7 Expression and phosphorylation levels of ERα and HER2 in untreated 
controls of MCF-7 and TAM-R cells. For comparative purposes, the 
densitometric analysis was normalized against values obtained in MCF-7 cell line. 




Figure 4-8 Effects of acquired tamoxifen resistance on the expression and 
phosphorylation of ERα and HER2 in MCF-7 and TAM-R cells after individual 
or combinatorial tamoxifen, endoxifen and lapatinib treatment. For comparative 
purposes, the densitometric analysis was normalized against values obtained in 
the untreated control of each cell line. *Not quantifiable 
 
As illustrated in Figure 4-8, ERα expression was enhanced and reduced by 
tamoxifen and endoxifen monotherapy respectively in both cell lines. This 
phenomenon was recapitulated in the phosphorylation of ERα (pERα) at Ser-118 
and Ser-167 in MCF-7 cells. Conversely, both anti-estrogenic monotherapy 
treatments led to an increase in ERα phosphorylation in TAM-R cells, where the 
increase relative to the control was greater at pERα Ser-118 as compared to pERα 
Ser-167. In this study, pERα Ser-104/106 was not observable in MCF-7 cells, and 
detected as a very faint band in TAM-R cells (results not shown). This could be 
attributed to the inherently low extent of phosphorylation at these sites (332). 
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Lapatinib had no significant impact on the expression and phosphorylation of 
ERα in MCF-7 cells, but yielded differential effects in TAM-R cells (Figure 4-8). 
Lapatinib monotherapy reduced pERα Ser-118 in TAM-R cells, but this reduction 
was masked when tamoxifen and endoxifen was introduced. In contrast, lapatinib 
appeared to reduce pERα Ser-167 significantly after monotherapy, which 
persisted even in combination with tamoxifen and endoxifen. Interestingly, when 
used in combination with lapatinib, treatment with endoxifen consistently resulted 
in lower expression and phosphorylation of ERα in both cell lines compared with 
tamoxifen. Separately, treatment with lapatinib up-regulated the expression of 
HER2, but completely attenuated its phosphorylation in both MCF-7 and TAM-R. 
4.4.4 Pharmacokinetic Interaction between Lapatinib and Endoxifen in 
MDCKII-MDR1 Cells 
4.4.4.1 Substrate Assay  
Efflux ratios for lapatinib and endoxifen increased sharply as the concentration of 
both compounds increased, and peaked at approximately 1 μM before decreasing 
gradually and reaching a plateau (Figure 4-9). As the efflux ratios were generally 
above 1, our findings suggested susceptibility of both compounds to P-gp 






Figure 4-9 Efflux ratio of (A) lapatinib (0 – 30 μM) and (B) endoxifen (0 – 30 
μM) across the MDCKII-MDR1 monolayer as a mean of duplicate 
determinations. 
 
4.4.4.2 Inhibitor Assay 
As shown in Figure 4-10, the efflux ratio of the P-gp probe substrate amprenavir 
decreased in a concentration-dependent manner as the concentration of lapatinib 
and endoxifen increased, suggesting that lapatinib and endoxifen inhibited P-gp 
mediated efflux of the probe substrate, amprenavir. The average IC50 values of 
lapatinib and endoxifen in inhibition of amprenavir efflux were 6.80 ± 4.20 μM 
and 7.16 ± 2.63 μM respectively. 
A            




Figure 4-10 Efflux ratio of 10 μM amprenavir across the MDCKII-MDR1 
monolayer, in the presence of (A) lapatinib (0 – 50 μM) and (B) endoxifen (0 – 50 
μM) as a mean of duplicate determinations. 
 
4.4.4.3 Pairwise Combinatorial Treatment 
The efflux ratio of endoxifen decreased in a concentration-dependent manner as 
the concentration of lapatinib increased (Figure 4-11A). At increasing 
concentrations of endoxifen from 0 to 50 μM, the efflux ratios of lapatinib 
decreased in a concentration-dependent manner, suggesting that lapatinib 
inhibited P-gp mediated efflux of endoxifen. The average IC50 value of lapatinib 
in inhibiting endoxifen efflux was 0.45 ± 0.110 μM. Similarly, the efflux ratio of 
lapatinib decreased in a concentration-dependent manner as the concentration of 
endoxifen increased (Figure 4-11B). At increasing concentrations of endoxifen 
from 0 to 50 μM, the efflux ratios of lapatinib decreased in a concentration-
dependent manner, suggesting that endoxifen inhibited P-gp mediated efflux of 
lapatinib. The average IC50 value of endoxifen in inhibiting lapatinib efflux was 
4.16 ± 3.54 μM.  




Figure 4-11 Efflux ratio of (A) endoxifen (1 μM) in the presence of lapatinib (0 – 
50 μM) and (B) lapatinib (1 μM) in the presence of endoxifen (0 – 50 μM) across 
the MDCK-MDR1 monolayer, as a mean of duplicate determinations. 
 
  




4.5.1 Lapatinib Impairs CYP3A4/5-Dependent Bioactivation of Tamoxifen 
While tamoxifen has been used successfully in treating ERα+ breast cancer, 
approximately 50% of ERα+ expressing tumours do not respond to tamoxifen (de 
novo resistance) (333), while for those that respond, another 30% become 
tamoxifen-resistant and the cancer relapses over a 15-year period (acquired 
resistance) (302), leading to tumour progression and death. Importantly, the 
development of resistance is not attributable to a loss in expression or mutation of 
ERα (334). One mechanism identified to promote tamoxifen resistance, whether 
de novo or acquired is the cross-talk between ER and HER2, where tamoxifen-
resistant cells either overexpress or upregulate HER2 expression as an alternative 
pathway driving proliferation. Of note, HER2 overexpression is the only 
mechanism of anti-estrogen resistance with supportive clinical data (335).  
These findings encouraged clinical explorations of combinatorial lapatinib and 
tamoxifen to circumvent the crosstalk and restore sensitivity to tamoxifen. 
However these trials were initiated before it was discovered that lapatinib is a 
potent and irreversible mechanism-based inactivator of CYP3A4/5 (244, 246), 
which is a crucial enzyme mediating the biotransformation of tamoxifen to its 
primary active metabolite, endoxifen (Figure 4-1). The two-step incubation design 
was adapted from classical assays of mechanism-based inactivators to evaluate 
the effect of lapatinib on tamoxifen metabolism. This design permits mechanism-
based covalent inactivation of CYP3A4/5 in the primary incubation, while a 10-
fold dilution step in the secondary incubation where tamoxifen or NDMT was 
introduced is necessary to minimize potential competitive enzyme inhibition, thus 
allowing evaluation of the effects of mechanism-based inactivation of CYP3A4/5 
by lapatinib. Through this approach, permanent and irreversible inactivation of 
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CYP3A4/5 is achieved while maintaining exposure to a conservative, clinically 
relevant concentration level of lapatinib of 1 µM. This concentration level of 
lapatinib falls within the plasma concentration levels of lapatinib in the recently 
published phase I trial of combinatorial lapatinib and tamoxifen (LAPATAM) 
(336). Our results demonstrate that lapatinib can indeed compromise the 
CYP3A4/5-mediated metabolism of tamoxifen in vitro, suggesting that the 
efficacy of tamoxifen when co-administered with lapatinib may be negated in vivo 
due to the inability to bioactivate tamoxifen. The LAPATAM study reported that 
the steady state concentration levels of tamoxifen were not affected by lapatinib 
(336). However, the systemic levels of tamoxifen metabolites such as NDMT, 4-
OHT and endoxifen were not monitored in the study. Therefore, it is not possible 
to conclude whether antagonistic pharmacokinetic interactions existed between 
lapatinib and tamoxifen in vivo. The unchanged steady state concentration levels 
of tamoxifen can be attributed to the plurality of pathways for tamoxifen 
metabolism, i.e. inhibition of CYP3A4/5 by lapatinib may not result in an 
increase in tamoxifen plasma levels due to shunting of tamoxifen to alternative 
phase I and phase II elimination pathways (337). It is important to note that the 
extent of inhibition quantified in this study is conservative, because the dilution 
step employed in the experimental design nullifies the effects of competitive 
inhibition. In its FDA regulatory submission (Application Number 22-059), 
lapatinib was noted to be a mixed competitive and non-competitive inhibitor of 
CYP3A4/5, with a Ki of 4 µM as measured using testosterone as a probe 
substrate. As such, when administered in vivo lapatinib is likely to cause both 
reversible and irreversible inhibition of CYP3A4/5 simultaneously, and at 
concentrations more than two-fold higher than investigated here, as demonstrated 
by the mean steady state Cmax achieved in the LAPATAM trial (336).  
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4.5.2 Lapatinib Exhibits Pharmacodynamic Synergism with Endoxifen in De 
Novo Tamoxifen Resistant Luminal B BT474 Cells 
The finding that lapatinib could indeed impair the bioactivation of tamoxifen led 
to investigations of efficacy between lapatinib and other pharmacologically active 
tamoxifen metabolites such as 4-OHT, endoxifen and norendoxifen. In this pilot 
study, two breast cancer cell lines with different molecular profiles, namely MCF-
7 and BT474 were used to investigate potential pharmacodynamic synergism in 
overcoming ERα/HER2 crosstalk, where MCF-7 represented the luminal A 
subtype, while BT474 represented the luminal B subtype. Consistent with 
literature reports, 4-OHT and endoxifen were equipotent in MCF-7 cells (338). In 
our study, these two drugs were also equipotent in BT474 cells. In agreement with 
reported data, lapatinib was significantly more cytotoxic in BT474 cells as 
expression of HER2 is up to 100-fold greater in these cells than MCF-7 cells 
(304). Norendoxifen was recently identified to be another active metabolite of 
tamoxifen which inhibits recombinant aromatase, ERα and ERβ with nanomolar 
potencies (297); however its cytotoxicity against breast cancer cells has not been 
reported thus far. In this study, the cytotoxicity of norendoxifen was generally 
comparable to 4-OHT or endoxifen in both cell lines.  
Combinatorial treatment of breast cancer using lapatinib with tamoxifen or each 
of its active metabolites resulted in synergistic killing of the low HER2-
expressing MCF-7 and, importantly, in high HER2-expressing BT474. Potent 
synergism between lapatinib and endoxifen as well as norendoxifen was 
demonstrated in both cell lines. In particular, the combination of lapatinib and 
endoxifen demonstrated the greatest dose reduction and synergism in BT474 and 
was chosen for further study in the acquired tamoxifen-resistant phenotype. The 
unexpected synergism observed for the combinatorial therapies in low HER2-
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expressing MCF-7 suggests that there may be other crosstalk pathways 
responsible for cell proliferation and survival besides the crosstalk between ERα 
and HER2.  
The luminal B subtype is reported to exhibit de novo resistance to tamoxifen 
where it is inherently less responsive to ER antagonism and has poorer tumour 
grade and poorer survival rates (303-305). However, the monotherapy IC50 values 
obtained for BT474 when treated with tamoxifen were lower than that of MCF-7. 
The reason for this observation is unclear; however similar trends have been 
reported in literature. For example, Sharma et al. reported the IC50 of tamoxifen as 
10 µM in MCF-7 (339), while Ropero et al. found that the IC50 of tamoxifen in 
BT474 was 6.95 µM (340). In contrast, in combination therapy the DRI50 values 
of tamoxifen was clearly higher in BT474 versus MCF-7 cells. Using BT474 as a 
model for the luminal B phenotype, this suggests that the combination of lapatinib 
and endoxifen exhibits strong pharmacodynamic synergism in de novo tamoxifen 
resistance.   
4.5.3 Lapatinib Exhibits Pharmacodynamic Synergism with Endoxifen in 
Luminal A Subtypes with Acquired Tamoxifen Resistance 
4.5.3.1 Monotherapy and Combination Therapy 
In agreement with literature and results presented in section 4.4.2.1, endoxifen 
consistently demonstrated greater cytotoxicity than tamoxifen in tamoxifen-
sensitive MCF-7, and for the first time, in tamoxifen-resistant TAM-R and MCF-
7/HER cells as well. Evidence of tamoxifen resistance is also apparent in the 
increased mean IC50 values of tamoxifen and endoxifen, although only endoxifen 
demonstrated statistical significance. Separately, lapatinib demonstrated 
equivalent potency in the isogenic MCF-7 and TAM-R pair, despite the 8-fold 
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higher HER2 expression in TAM-R (Figure 4-7). In contrast, sub-micromolar 
potencies were achieved in MCF-7/HER2, similar to that seen in BT474. 
Although HER2 levels were not determined in the MCF-7/HER2 and BT474 cell 
lines used in this study, it has been reported that MCF-7/HER2-18, a HER2 
cDNA-transfected MCF-7 cell line, has a 45-fold higher HER2 expression than 
MCF-7 (303, 341), while BT474 have 100-fold higher HER2-expression 
compared to MCF-7 (304). The significantly higher HER2 expression may 
account for the greater potency of lapatinib in these cells. On the other hand, 
HER2 levels, although elevated in TAM-R, appear to be insufficient for single 
therapy lapatinib to exhibit greater cytotoxicity than in MCF-7. This may be due 
in part to the ERα offering an escape pathway to maintain cellular proliferation 
when HER2 is inhibited. This is evidenced by the IC50 values of tamoxifen and its 
metabolites in all 5 cell lines investigated in this study, which fell within the same 
order of magnitude. In other words, despite the increased expression of HER2, 
cellular proliferation did not completely shift to HER2 (i.e. ERα independent), 
which would be characterized by significantly elevated IC50 values for tamoxifen 
and its metabolites in TAM-R and MCF-7/HER2 cells. This observation supports 
the existence of the crosstalk between ERα and HER2, and indicates that singular 
inhibition of either pathway alone is insufficient. 
In parallel with the observations for de novo tamoxifen resistance, combinatorial 
therapy resulted in synergistic effects in the isogenic MCF-7 and TAM-R pair, as 
well as MCF-7/HER2 cells. The antagonism observed at low concentrations of 
lapatinib and tamoxifen or endoxifen (corresponding to fa < 0.3 for TAM-R and fa 
< 0.2 for MCF-7/HER2), which is absent in the tamoxifen-sensitive MCF-7 
isogenic counterpart reflects the tamoxifen-resistant phenotype of both cell lines. 
This trend is less clear in the DRI50 values; however, the lower concentration of 
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endoxifen needed to effect 50% cytotoxicity compared with tamoxifen in TAM-R 
and MCF-7/HER2 clearly indicates that the combination of lapatinib with 
endoxifen is superior in achieving pharmacodynamic synergism in the luminal A 
subtype with acquired tamoxifen resistance. 
4.5.3.2 Acquired Tamoxifen Resistance Alters ERα and HER2 Expression 
Patterns 
As expected, TAM-R cells showed an increase expression and phosphorylation of 
HER2 as compared to MCF-7 cells, in agreement with the development of the 
ERα/HER2 crosstalk that is associated with tamoxifen resistance (Figure 4-7). 
TAM-R cells also showed a reduced expression of ERα relative to MCF-7. It has 
been reported that HER2 signaling members such as p44/42 MAPK and Akt can 
reduce ER expression at the mRNA and protein level, and may account for 
decreased ERα levels in HER2-expressing TAM-R cells (296, 310). 
ERα phosphorylation is thought to permit ligand-independent activation of ERα 
and thus stimulate transcription of estrogen-responsive genes. Increased pERα 
Ser-167 has been demonstrated in tamoxifen-resistant MCF-7 cells, and 
associated with the acquisition of tamoxifen resistance (342, 343). In agreement 
with literature, our findings suggest that TAM-R cells are less sensitive to ER 
antagonism, mediated in part by pERα Ser-167. pERα Ser-118 has been well-
studied and shown to decrease ERα affinity for tamoxifen (344), and is elevated 
with tamoxifen resistance in vitro. However we observed that basal levels of 
pERα Ser-118 was lower in TAM-R than MCF-7. Phosphorylation of ERα at Ser-
118 is estrogen-dependent (345). In our study, parental MCF-7 cells were cultured 
in normal FBS that contains small amounts of estradiol, while TAM-R cells were 
cultured in charcoal-stripped FBS where growth factors including estradiol have 
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been removed. Thus the differential basal expression of pERα Ser-118 between 
MCF-7 and TAM-R might be a result of the different culture conditions. 
4.5.3.3 Tamoxifen and Endoxifen Show Differential Effects on ERα Expression 
and Phosphorylation in MCF-7 and TAM-R Cells 
The differential effects of tamoxifen and endoxifen on total ERα expression in 
MCF-7 are in line with literature, which reported the binding of tamoxifen to ERα 
increased its stability (346), while endoxifen caused the degradation of the 
receptor (298). Similarly, endoxifen decreased the levels of both pERα Ser-118 
and pERα Ser-167 (Figure 4-8) and this may account for the greater potency of 
endoxifen in MCF-7 cells. Notably, the decrease in ERα, pERα Ser-118 and pERα 
Ser-167 by endoxifen was also sustained when combined with lapatinib. 
Interestingly, pERα Ser-118 is associated with a reduction in proteasomal 
degradation of ERα in MCF-7 cells (347). The mechanism of endoxifen-induced 
degradation of ERα is currently unknown, and this may in part explain the unique 
ability of endoxifen to reduce ERα levels (298). In contrast, when TAM-R was 
treated with tamoxifen and endoxifen, increases in pERα Ser-118 and pERα Ser-
167 were observed, suggesting that the acquisition of tamoxifen resistance results 
in insensitivity to both tamoxifen and endoxifen mediated by phosphorylation of 
ERα, a finding that is supported by the higher IC50 values of both these 
compounds in TAM-R cells. Densitometric analysis suggests that ERα levels are 
lower in TAM-R cells when treated with endoxifen; however the expected 
decrease in pERα Ser-118 was not observed. The multi-factorial regulation of 
ERα turnover is a function of transcription, translation and degradation and may 
involve other pathways in the resistant phenotype. For example, as discussed 




4.5.3.4 Lapatinib Reverses Tamoxifen Resistance by Overcoming ERα/HER2 
Crosstalk   
Lapatinib exerts its pharmacological effect by binding to the intracellular domain 
of EGFR and HER2, blocking the auto-phosphorylation and consequently 
activation of downstream kinases. As expected, lapatinib completely abolished 
the phosphorylation and activation of HER2, both in monotherapy and 
combinatorial therapies against both cell lines. The increase in HER2 levels is in 
agreement with literature where lapatinib is reported to prevent the ubiquitination 
and degradation of HER2, leading to accumulation of inactive HER2 at the cell 
membrane (348). 
In tamoxifen-sensitive MCF-7 cells, lapatinib alone had minimal effect on the 
expression and phosphorylation of ERα, due to the absence of direct 
pharmacological action on ERα and the minimal HER2 expression in these cells. 
In combination with tamoxifen and endoxifen, the total levels of ERα were 
similar as compared to either anti-estrogen alone. While decreased levels of pERα 
Ser-118 and pERα Ser-167 were observed in combination with endoxifen, this 
effect is attributed to the presence of endoxifen, and overall lapatinib did not 
affect pERα levels. Collectively these findings are in agreement with literature 
that ERα/HER2 crosstalk is not prominent in MCF-7 cells (330). Additionally, it 
suggests that lapatinib and endoxifen may interact through alternative pathways to 
account for the synergism observed in luminal A subtype. For example, lapatinib 
was recently reported to exert off-target pharmacological activity independently 
of EGFR/HER2 antagonism that promotes synergism even in non-EGFR/HER2 
expressing, triple-negative breast cancer cells (349-351). However, the relevance 
of these off-target activities to the synergism observed in MCF-7 cells remains 
unknown and requires further investigation. 
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In tamoxifen-resistant TAM-R cells, lapatinib had minimal effect on ERα 
expression, while it exerted a greater effect on the decreased phosphorylation of 
ERα Ser-118, and ERα Ser-167, both in monotherapy and combination therapy. 
Phosphorylation of ERα Ser-118 is driven by a number of kinases including 
p44/42 MAPK, GSK-3β IKKα, CDK7, and mTOR/p70S6K, while ERα Ser-167 
is phosphorylated by Akt, p90RSK and mTOR/p70S6K (352). Ligand-bound 
HER2 activates p44/42 MAPK and Akt, which in turn phosphorylates ERα, 
activating ERα in a ligand-independent manner and accounting for the crosstalk 
between ERα and HER2 (343, 353). By antagonizing HER2, lapatinib reduces 
phosphorylation of ERα Ser-118 and ERα Ser-167 and diminishes ERα/HER2 
crosstalk. This effect is more prominent for the combination of lapatinib and 
endoxifen. This in in line with the general observation made previously that the 
combination of lapatinib and endoxifen consistently resulted in lower expression 
and phosphorylation of ERα in both cell lines compared with the combination of 
lapatinib and tamoxifen. Collectively, these results suggest that a greater benefit 
will be derived from combining lapatinib with endoxifen, instead of tamoxifen.  
The overarching theme drawn from the results presented in sections 4.4.2 and 
4.4.3 is that the combination of lapatinib with endoxifen is superior to that with 
tamoxifen in eliciting pharmacodynamic synergism to overcome tamoxifen 
resistance, supported by both cytotoxicity and molecular biology studies. 
4.5.4 Lapatinib and Endoxifen Exhibit Mutual Pharmacokinetic Synergism 
via P-gp Inhibition 
To study the interactions between lapatinib and endoxifen with P-gp, the 
MDCKII-MDR1 model, a kidney cell line that overexpresses P-gp transporters 
was used. Unlike Caco-2, an intestinal cell line that expresses many other uptake 
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and efflux transporters (354), the MDCKII-MDR1 presents a clean system, with 
three times more P-gp transporters than its un-transfected parental cell line (355). 
This model therefore facilitated our study of the effect of P-gp transport without 
the confounding effects of other transporters. While there are other similar P-gp 
specific transporter cell models such as the Lilly laboratories porcine kidney cells 
transfected with multi drug resistance protein 1 (LLCPK-MDR1), the MDCKII-
MDR1 is an established cell model (356) recommended by the US Food and Drug 
Administration, and adopted by the pharmaceutical industry. The cell-free, 
‘inside-out’ vesicle system is another alternative model system, where compounds 
which are P-gp substrates accumulate within the vesicles (357). However, the 
vesicle system is relatively new and it is also found to be unsuitable for testing 
lipophilic drugs that are highly permeable (357) which include lapatinib and 
endoxifen, as they would freely diffuse out and not be retained within the 
vesicles.  
To understand the combined pharmacokinetic interaction between lapatinib and 
endoxifen, we first determined the individual P-gp interactions of both 
compounds. Although there are existing reports that lapatinib is both a P-gp 
substrate and inhibitor, while endoxifen is a P-gp substrate, these were performed 
using a single concentration of each compound as a substrate or inhibitor. We 
performed comprehensive dose-response investigations to ascertain the nature and 
magnitude of P-gp-mediated efflux for each compound, with an upper limit of 50 
μM as the experimental data suggests that the monolayer integrity is 
compromised beyond 50 μM (results not shown), presumably due to non-specific 
cytotoxicity at higher drug concentration levels. 
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In agreement with the reports by Polli et al. (311) and Teft et al. (313), both 
lapatinib and endoxifen were found to be P-gp substrates. Instead of displaying 
Michaelis–Menten kinetics as expected of a typical P-gp substrate, the efflux 
ratios of both compounds decreased at concentration levels beyond 1 μM. This 
observation was important as it suggested that apart from being P-gp substrates, 
lapatinib and endoxifen could exhibit P-gp inhibition as well where the decrease 
in efflux ratios could be a consequence of auto-inhibition of P-gp at higher 
concentration levels. Importantly, from these experiments, 1 μM of lapatinib or 
endoxifen was determined to be the optimal substrate concentration in the 
subsequent combinatorial treatment assays to ensure maximal efflux transport and 
mitigate potential auto-inhibition effects, demonstrating the value of dose-
response investigations in contrast to typical single concentration investigations 
commonly reported in literature and performed during drug discovery.  
Our observation of potential auto-inhibition of P-gp transport prompted further 
investigation of the inhibitory potential of both compounds. Amprenavir is a 
commonly used P-gp probe substrate that permits the assessment of P-gp 
inhibition (358). Consistent with the report by Polli et al., we found that lapatinib 
was a P-gp inhibitor when tested against amprenavir using MDCKII-MDR1 
(311). While endoxifen was reported by Teft et al. (313) and Iusuf et al. (312) to 
be a P-gp substrate, no reports about its possible role as a P-gp inhibitor are 
available. Our findings demonstrated for the first time that endoxifen is a P-gp 
inhibitor.  
As lapatinib and endoxifen are both substrates and inhibitors of P-gp transporters, 
combinatorial experiments were carried out to elucidate the mutual inhibitory 
effects between these two compounds with regards to P-gp efflux transport. For 
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the first time, endoxifen was found to inhibit the efflux transport of lapatinib in a 
concentration-dependent manner. Similarly, lapatinib inhibited the efflux 
transport of endoxifen in a concentration-dependent manner. Notably, the 
inhibition of endoxifen efflux by lapatinib is more than 10-fold greater than the 
converse. Collectively, these novel findings suggested that when used in 
combination, lapatinib and endoxifen may potentially exhibit mutually beneficial 
pharmacokinetic interactions mediated via P-gp transport. This effect could 
potentially result in an overall increase in intra-tumoral accumulation of both 
drugs, thus allowing a lower dose and consequently a potential decrease in dose-
dependent side effects. Since lapatinib appears to be the stronger P-gp inhibitor, 
the extent of intra-tumoral accumulation for endoxifen may be greater.  
A number of studies have reported that increased P-gp expression in breast cancer 
may be associated with drug resistance, poor drug response, aggressive metastatic 
breast tumour, poor prognosis and lowered intra-tumoral drug accumulation (317-
320). P-gp efflux also affects drug uptake and penetration in the gut and BBB 
respectively. The latter is intriguing because brain metastasis is a common clinical 
sequelae of breast cancer (326); however P-gp efflux in the BBB may not have a 
significant impact on brain penetration of lapatinib and endoxifen as the integrity 
of the BBB itself is known to be compromised in cancer. For example, increase 
lapatinib uptake into the brain was observed in patients with cranial metastasis, 
but not so in patients without cranial metastasis (359). Separately, increased 
systemic exposure may also be expected due to inhibition of intestinal efflux and 
biliary and urinary excretion. This effect could minimize dose-limiting toxicities 
such as lapatinib-induced diarrhea, which is a common reason for dose reduction 
or discontinuation of lapatinib (360). Collectively, the ability of lapatinib and 
endoxifen to mutually modulate P-gp efflux undoubtedly confers an additional 
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advantage to complement the pharmacodynamic synergism identified in breast 
cancer cells.  
4.5.5 Lapatinib and Endoxifen: the Superior Combination 
In BT474, TAM-R and MCF-7/HER cells associated with tamoxifen resistance, 
significantly lower concentration levels of endoxifen (393-722 nM) was required 
to achieve 50% cytotoxicity in combination with lapatinib than observed using 
tamoxifen (722-4537 nM). It is noteworthy that when used combinatorially with 
endoxifen, anti-proliferative activity was achieved in all three cell lines using 
concentration levels of lapatinib that are 3- to 685-fold lower than that observed 
clinically in the plasma (3.12-4.25 µM) (361, 362). Similarly, in MDCKII-MDR1 
cells, the IC50 inhibition of endoxifen efflux by lapatinib falls within these 
concentrations levels as well, while the IC50 of endoxifen inhibition of lapatinib 
efflux is approximately 4.2 µM. The plasma concentration range of endoxifen is 
reported to be 10.2-83.7 nM after 20 mg daily tamoxifen administration, with 
levels near the upper limits achieved by CYP2D6 extensive metabolizers (363). 
Separately, Ahmad et al. reported plasma concentration levels of 40.4 nM after a 
single oral dose of 4 mg endoxifen, with a predicted steady state concentration 
level of 147.5 nM (364), while Goetz et al. reported that steady state plasma 
concentration levels after 28 days of endoxifen administration were 390 nM for a 
dose of 20 mg/day, 2480 nM for a dose of 100 mg/day, and 5200 nM for a dose of 
160 mg/day which were well-tolerated (365, 366). The latter two doses provide 
sufficient endoxifen levels to reach the in vitro DRI50
 in all cell lines evaluated 
combinatorially. The Mayo Clinic is further evaluating doses of 20 mg/day and 
100 mg/day in subsequent studies (365).  It is also important to note that 
tamoxifen and its metabolites are known to exhibit extensive tissue binding (367). 
4-OHT levels in breast tumours were reported to be up to 3 times higher than 
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serum levels (368), while endoxifen levels in primary and metastatic breast 
tumours were reported to be markedly higher than serum levels when the standard 
dose of tamoxifen was administered (367). Collectively, these evidences suggest 
that the observed pharmacodynamic and pharmacokinetic synergistic 
concentration levels of endoxifen could possibly fall within target tissue 
concentration levels, particularly when endoxifen doses are adjusted to achieve 
maximally tolerated plasma concentration levels with adequate safety profiles. It 
should also be noted that in this study, breast cancer cells were only treated for 5 
days, while in vivo malignant cells are exposed to these agents on the scale of 
months to years. Thus these short term cytotoxic concentration levels may not 
adequately reflect the potency of longer term treatments. Therefore, further in 
vivo studies on lapatinib and endoxifen combinatorial treatment is warranted.  
Combinatorial lapatinib and endoxifen improves upon existing tamoxifen 
regimens on several fronts. Firstly, it circumvents the possible pharmacokinetic 
antagonism between lapatinib and tamoxifen since lapatinib inhibits the 
bioactivation of tamoxifen to its active metabolites via potent irreversible 
CYP3A4/5 inactivation (244, 246). Secondly, it bypasses the considerable 
confounding effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen 
response, whereby patients of certain CYP450 genotypes may experience 
insufficient systemic exposure of endoxifen. Thirdly, combinatorial therapy may 
mitigate the ERα/HER2 crosstalk, as suggested by the results of this study. And 
finally, it negates the effect of P-gp efflux which may result in improved oral 
absorption, intratumoral or brain penetration.  
The attractiveness of endoxifen for clinical use is due in part to the vast history of 
clinical experience with tamoxifen from both an efficacy and safety perspective. 
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The clinical development of endoxifen is underway, where endoxifen was found 
to be safe even at the highest dose of 160 mg per day (369). Furthermore, 
preliminary evidence of efficacy following administration of endoxifen was 
observed in patients who failed standard hormonal therapies including tamoxifen, 
fulvestrant and aromatase inhibitors (369). Apart from inhibiting ERα, endoxifen 
is also reported to have a unique mechanism of action by targeting ERα for 
degradation. Interestingly, endoxifen exhibits similar positive effects as tamoxifen 
in protecting against bone loss (370). Separately, although norendoxifen shows 
similar synergism as endoxifen, the administration of norendoxifen in humans is 
not being studied currently, and its contribution to the anti-proliferative effect of 
tamoxifen is not expected to be significant as in vivo levels of norendoxifen are 6-
fold lower than endoxifen (371). Additionally, while efforts have been made to 
investigate combinations of aromatase inhibitors such as letrozole with lapatinib 
(241), a drawback with such combinations is that aromatase inhibitors are not 
recommended in pre-menopausal women, and this may limit the population of 
patients who might benefit from such combinatorial therapy. Although endoxifen 
has been reported to inhibit aromatase (294), it is a weak inhibitor with an IC50 
value more than 500 times greater than letrozole (372) and thus would not be 
contraindicated in pre-menopausal women. All these underscore the importance 
of establishing the efficacy of combinatorial lapatinib and endoxifen against 
breast cancer. 
Another potential benefit of combination treatment is that the adverse drug 
reactions may be reduced since lower dosage and systemic exposure of each drug 
may be required. However, the specific adverse effects of administering 
tamoxifen metabolites in humans are currently not known and are being studied in 
clinical trials (NCT01327781, NCT01273168). For example, it has been reported 
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that endoxifen exhibits similar uterotrophic effects as tamoxifen in rats; however, 
given the superior anti-tumour activity of endoxifen, the authors suggested that 
the risk/benefit profile of endoxifen may be superior to that of tamoxifen (373). 
Given that the plasma concentration levels of endoxifen described in that study 
are much higher than the synergistic concentrations reported here, it is plausible 
that the uterotrophic effects of endoxifen may be less prominent in a 
combinatorial scenario; however care must be taken when comparing in vitro 
versus in vivo data and inter-species data. Some toxicities associated with 
tamoxifen, such as endometrial cancer are hypothesized to be associated with 
upstream metabolites of tamoxifen (374). The genotoxic α-hydroxylated 
metabolite of tamoxifen is believed to cause formation of DNA adducts which 
have been detected in the endometrial lining. Although it is not known if α-
hydroxylation occurs with endoxifen, one may anticipate endoxifen to exhibit a 




4.6 Chapter Conclusion 
In conclusion, here we observed a deleterious effect of covalent and coordinate 
binding by lapatinib, which results in inhibition of CYP3A4/5 activity. When 
used in combination with tamoxifen, the detrimental effect elicited by covalent 
and coordinate binding was found to impair the crucial bioactivation of tamoxifen 
to its active metabolite, endoxifen. This can abrogate the expected 
pharmacodynamic synergism from this drug combination by compromising the 
inhibition of ERα/HER2 crosstalk. Despite this apparent liability, we postulated 
that co-administration of lapatinib with the active tamoxifen metabolite, 
endoxifen, could circumvent the inhibition of tamoxifen bioactivation by 
lapatinib. This new combination was investigated from both pharmacodynamic 
and pharmacokinetic angles, and was found to exhibit complementary synergism 
in both aspects. Importantly, these synergistic effects occurred at drug 
concentration levels achievable with current dose regimens, with the potential for 
dose reductions in a combinatorial setting. By leveraging covalent drug binding, 
we uncovered a novel drug combination that shows potential to enhance 
therapeutic efficacy in breast cancer at the pharmacodynamic and 
pharmacokinetic levels, thereby converting a liability into an opportunity. This 
novel and exciting drug combination is ripe for further preclinical investigations 




 Chapter 5 Conclusions and Future Perspectives 
Unintended covalent drug binding is a prevalent phenomenon in 
pharmacotherapy, and has been implicated in ADRs, which is associated with a 
high economic and morbidity burden. Separately, covalent binding is also 
increasingly pursued as a pharmacological mechanism of action due to several 
advantages including a sustained duration of action and uncoupling of 
pharmacodynamic and pharmacokinetic parameters. While medicinal chemistry 
efforts attempt to tune the reactivity of the electrophile conferring the covalent 
interaction with the target protein, off-target effects are possible which could lead 
to unexpected toxicity. Despite decades of research, the mechanism by which 
covalent drug binding causes toxicity remains unclear. The consequences of 
covalent binding can be severe and unpredictable, which makes it challenging to 
anticipate and prevent or mitigate such deleterious effects.  
Covalent binding can be classified as exerting overt or covert effects in biological 
systems. While a significant amount of research has been devoted to elucidating 
the overt consequences of covalent binding, the covert effects are far less 
understood. In Chapter 2, we explored the covert effects of covalent binding 
caused by APAP, which results in drug-induced protein glutathionylation. We 
present the possible mechanisms by which APAP causes protein 
glutathionylation, which can occur secondary to covalent binding. The 
perturbation of basal protein glutathionylation, which is a PTM regulating a 
variety of cellular processes, results in derangement of key biological processes 
such as energy metabolism, protein turnover, defense against cellular stress, 
calcium dynamics and MPTP opening. These processes can be correlated to the 
toxicity manifestations known to occur with APAP. Importantly, proteo-
 243 
 
metabonomic mapping provided further confidence in the importance of APAP-
induced protein glutathionylation by associating the functional protein deficits 
caused by glutathionylation with metabolic derangements caused by APAP. 
Notably, aberrant glutathionylation also provides mechanistic insights which 
illuminate the mode of action of N-acetylcysteine, S-adenosyl methionine and 
fibrates which protect against or reverse APAP hepatotoxicity. This illustrates 
how a deep mechanistic understanding the covert effects of covalent binding may 
guide the development of therapeutic strategies to prevent or ameliorate instances 
of toxicity. Furthermore, longitudinal analysis suggested the classification of 
glutathionylated proteins into two groups: those that cause toxicity as a result of 
overt covalent binding, and those that are a consequence of toxicity as a result of 
increased oxidative stress, providing a deeper mechanistic definition of aberrant 
protein glutathionylation. The role of overt covalent binding in APAP-induced 
protein glutathionylation was strengthened by our observation that this 
phenomenon is dose- and bioactivation-dependent. We further demonstrated that 
AMAP and APAP unexpectedly exhibited broad overlaps in glutathionylated 
proteins, agreeing with recent findings that both agents were toxic in human liver. 
Collectively, in this chapter we establish drug-induced protein glutathionylation 
as a previously unrecognized covert mechanism of drug-induced liver injury, 
which is secondary to overt covalent binding.  
We next revisited overt covalent binding in Chapter 3, in the form of covalent and 
coordinate inactivation of CYP3A4/5 by lapatinib. Based on our prior 
investigations into the mechanisms of irreversible inactivation of CYP3A4/5 by 
lapatinib, we identified two potential strategies to mitigate the deleterious effects 
of covalent binding caused by lapatinib. In the first, we attempt to ameliorate the 
bioactivation of lapatinib to its reactive metabolites by judicious deuteration at 
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positions critical to its bioactivation. Secondly, we also determined the dose-
response relationship between CYP3A5 genotype and the susceptibility to 
inactivation by lapatinib. While strategic deuteration at the benzylic carbon could 
reduce the bioactivation potential of lapatinib, it did not result in a reduction in 
inactivation of CYP3A4/5. Separately, we observed that CYP3A5 *1/*1 carriers 
were most susceptible to inactivation and loss of CYP3A4/5 activity, which was 
accompanied by an increase in reactive metabolite formation. The role of 
prospective stratification of patients undergoing lapatinib pharmacotherapy using 
the CYP3A5 genotype will require further assessment using physiologically-
based pharmacokinetic (PBPK) modeling, and may prove to be a viable strategy 
to mitigate DDIs, and potentially ADRs with lapatinib. 
In Error! Reference source not found., we identified a potential DDI as a result 
of covalent and coordinate binding of lapatinib to CYP3A4/5, between lapatinib 
and tamoxifen that could have major clinical implications. We leveraged the 
potential liability of this phenomenon to propose a combinatorial drug treatment 
using lapatinib and the active tamoxifen metabolite, endoxifen for the treatment 
of tamoxifen-resistant breast cancer. We determined that as expected, lapatinib 
could indeed reduce tamoxifen bioactivation to endoxifen, which may nullify the 
expected synergism between lapatinib and tamoxifen. We further investigated the 
characteristics of the lapatinib-endoxifen combination from a pharmacodynamic 
and pharmacokinetic perspective. We uncovered strong pharmacodynamic 
synergism between these two agents in in vitro models of de novo and acquired 
tamoxifen resistance and established that simultaneous administration of lapatinib 
and endoxifen disrupted the ERα/HER2 crosstalk responsible for tamoxifen 
resistance. From a pharmacokinetic angle, this combination demonstrated mutual 
inhibition of P-gp-mediated drug efflux, an effect that could complement the 
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pharmacodynamic synergism by potentially increasing systemic exposure, 
intratumoral drug accumulation and CNS penetration of these agents. We further 
determined that these synergistic effects occurred at concentration levels 
achievable with current clinical regimens. Lapatinib-endoxifen combinatorial 
therapy is poised for further translational studies using patient-derived xenograft 
models and PBPK modeling to quantify the extent of pharmacodynamic and 
pharmacokinetic synergism in vivo. We thus demonstrate how covalent binding, 
which is often regarded as a therapeutic liability can be circumvented strategically 
to inspire advancements in therapeutic efficacy. 
In conclusion, this thesis provides a mechanistic exploration of the overt and 
covert effects of covalent binding using a variety of approaches. With a sound 
understanding of the mechanisms underlying the deleterious consequences of 
covalent binding, strategies can be developed not only to mitigate the undesirable 
outcomes of covalent binding, but to deliver advances in pharmacotherapy, thus 
improving safety and efficacy. The paradigms and approaches utilized in this 
thesis are not unique to APAP and lapatinib, hence we are convinced that this 
work provides an impetus for future mechanistic studies on other drugs that cause 
covalent protein binding to deliver innovation and improvement in clinical 
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Figure S1 Indirect monitoring of GAPDH glutathionylation and 












Figure S3 Correlation between GSH adduct formation and baseline CYP3A4/5 





Figure S4 The cytotoxicity effect of (A) tamoxifen, (B) 4-OHT, (C) endoxifen, 
(D) norendoxifen, and (E) lapatinib against MCF-7 cells. Each data point is the 





Figure S5 The cytotoxicity effect of (A) tamoxifen, (B) 4-OHT, (C) endoxifen, 
(D) norendoxifen, and (E) lapatinib against BT474 cells. Each data point is the 







Figure S6 The cytotoxicity effect of (A) tamoxifen, (B) endoxifen and (C) 
lapatinib against MCF-7 cells. Each data point is the average of at least 2 
independent experiments with at least 5 replicates each. 
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Figure S7 The cytotoxicity effect of (A) tamoxifen, (B) endoxifen and (C) 
lapatinib against TAM-R cells. Each data point is the average of at least 2 
independent experiments with at least 5 replicates each. 
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Figure S8 The cytotoxicity effect of (A) tamoxifen, (B) endoxifen and (C) 
lapatinib against MCF-7/HER2 cells. Each data point is the average of at least 2 




Table S1 List of proteins found to be glutathionylated by APAP in at least 1 time-





Q04446 1,4-alpha-glucan-branching enzyme                   GLGB CADGGLYCK 
   CIAYAESHDQALVGDK 
   HFTCNVLPR 
Q15029 116 kDa U5 small nuclear ribonucleoprotein 
component              
U5S1 VEESGEHVILGTGELYLDCVMHDL
R 
P31946 14-3-3 protein beta/alpha                  1433B IEAELQDICNDVLELLDK 
Q04917 14-3-3 protein eta                  1433F NCNDFQYESK 
P27348 14-3-3 protein theta                  1433T SICTTVLELLDK 
   YLAEVACGDDR 
P15428 15-hydroxyprostaglandin dehydrogenase [NAD(+)]                  PGDH TLFIQCDVADQQQLR 
O14756 17-beta-hydroxysteroid dehydrogenase type 6                 H17B6 VLAACLTEK 
P09543 2',3'-cyclic-nucleotide 3'-phosphodiesterase                   CN37 LDEDLAAYCR 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial                  DECR VHAIQCDVRDPDMVQNTVSELIK 
P62333 26S protease regulatory subunit 10B                PRS10 AVASQLDCNFLK 
P62191 26S protease regulatory subunit 4                PRS4 AICTEAGLMALR 
Q99460 26S proteasome non-ATPase regulatory subunit 1               PSMD1 QCVENADLPEGEK 
   MEEADALIESLCR 
O00232 26S proteasome non-ATPase regulatory subunit 12               PSD12 AIYDTPCIQAESEK 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13               PSD13 FLGCVDIK 
Q16401 26S proteasome non-ATPase regulatory subunit 5               PSMD5 FFGNLAVMDSPQQICER 
   TTLCVSILER 
Q15008 26S proteasome non-ATPase regulatory subunit 6               PSMD6 VYQGLYCVAIR 
Q9Y2R5 28S ribosomal protein S17, mitochondrial                RT17 TYFAHDALQQCTVGDIVLLR 
Q96EL2 28S ribosomal protein S24, mitochondrial                RT24 GNQLEICAVVLR 
P82933 28S ribosomal protein S9, mitochondrial                RT09 LLTSQCGAAEEEFVQR 
Q02218 2-oxoglutarate dehydrogenase, mitochondrial                  ODO1 DVVVDLVCYR 
   CSTPGNFFHVLR 
Q9ULD0 2-oxoglutarate dehydrogenase-like, mitochondrial                  OGDHL DVVVDLVCYR 
P12694 2-oxoisovalerate dehydrogenase subunit alpha, 
mitochondrial                
ODBA DYPLELFMAQCYGNISDLGK 
P21953 2-oxoisovalerate dehydrogenase subunit beta, 
mitochondrial                
ODBB GLLLSCIEDK 
  TIIPWDVDTICK 
P31937 3-hydroxyisobutyrate dehydrogenase, 
mitochondrial                  
3HIDH HGYPLIIYDVFPDACK 
P25398 40S ribosomal protein S12                 RS12 LVEALCAEHQINLIK 
   QAHLCVLASNCDEPMYVK 
P15880 40S ribosomal protein S2                 RS2 AGIDDCYTSAR 
P63220 40S ribosomal protein S21                 RS21 TYAICGAIR 
P23396 40S ribosomal protein S3                 RS3 GLCAIAQAESLR 
   GCEVVVSGK 
   ACYGVLR 
P61247 40S ribosomal protein S3a                 RS3A LFCVGFTK 
P62701 40S ribosomal protein S4, X isoform               RS4X ECLPLIIFLR 
   ECLPLIIF 
P62753 40S ribosomal protein S6                 RS6 LNISFPATGCQK 
P62241 40S ribosomal protein S8                 RS8 LDVGNFSWGSECCTR 
   NCIVLIDSTPYR 
P80404 4-aminobutyrate aminotransferase, mitochondrial                  GABT CLEEVEDLIVK 
P49189 4-trimethylaminobutyraldehyde dehydrogenase                   AL9A1 SPLIIFSDCDMNNAVK 
   TVCVEMGDVESAF 
P10809 60 kDa heat shock protein, mitochondrial               CH60 CEFQDAYVLLSEK 
   AAVEEGIVLGGGCALLR 
P10155 60 kDa SS-A/Ro ribonucleoprotein                 RO60 GMLDMCGFDTGALDVIR 
P05388 60S acidic ribosomal protein P0                RLA0 AGAIAPCEVTVPAQNTGLGPEK 
   NVASVCLQIGYPTVASVPH 
   CFIVGADNVGSK 
P27635 60S ribosomal protein L10                 RL10 MLSCAGADR 
P62906 60S ribosomal protein L10a                 RL10A VLCLAVAVGH 
   VLCLAVAVGHVK 







P50914 60S ribosomal protein L14                 RL14 ALVDGPCTQVR 
P62829 60S ribosomal protein L23                 RL23 ISLGLPVGAVINCADNTGAK 
P39023 60S ribosomal protein L3                 RL3 VACIGAWHPAR 
   TVFAEHISDECK 
   YCQVIR 
P62910 60S ribosomal protein L32                 RL32 ELEVLLMCNK 
Q969Q0 60S ribosomal protein L36a-like  RL36L LECVEPNCR 
P36578 60S ribosomal protein L4                 RL4 SGQGAFGNMCR 
   GPCIIYNEDNGIIK 
P46777 60S ribosomal protein L5                 RL5 IEGDMIVCAAYAHELPK 
   VGLTNYAAAYCTGLLLAR 
   AAAYCTGLLLAR 
   DIICQIAY 
P62424 60S ribosomal protein L7a                 RL7A TCTTVAFTQVNSEDK 
P62917 60S ribosomal protein L8                 RL8 AQLNIGNVLPVGTMPEGTIVCCLEE
KPGDR 
P52209 6-phosphogluconate dehydrogenase, 
decarboxylating                  
6PGD SAVENCQDSWR 
  MVHNGIEYGDMQLICEAYHLMK 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic                  THIC IGEMPLTDSILCDGLTDAFHNCHM
GITAENVAK 
Q9NR19 Acetyl-coenzyme A synthetase, cytoplasmic                 ACSA GATTNICYNVLDR 
Q99798 Aconitate hydratase, mitochondrial                  ACON CTTDHISAAGPWLK 
P60709 Actin, cytoplasmic 1                  ACTB DDDIAALVVDNGSGMCK 
P63261 Actin, cytoplasmic 2                  ACTG EEEIAALVIDNGSGMCK 
O96019 Actin-like protein 6A                  ACL6A SPLAGDFITMQCR 
   AGYAGEDCPK 
P59998 Actin-related protein 42065 complex subunit 4               ARPC4 ATLQAALCLENFSSQVVER 
P61158 Actin-related protein 3                  ARP3 TLTGTVIDSGDGVTHVIPVAEGYVI
GSCIK 
O95433 Activator of 90 kDa heat shock protein ATPase 
homolog 1           
AHSA1 NGETELCMEGR 
Q96CM8 Acyl-CoA synthetase family member 2, 
mitochondrial               
ACSF2 TVGQCLETTAQR 
Q08AH3 Acyl-coenzyme A synthetase ACSM2A, 
mitochondrial                
ACS2A ELSENSQQAANVLSGACGLQR 
Q53FZ2 Acyl-coenzyme A synthetase ACSM3, 
mitochondrial                
ACSM3 ANCIITNDVLAPAVDAVASK 
O95372 Acyl-protein thioesterase 2                  LYPA2 DLAILQCHGELDPMVPVR 
P07741 Adenine phosphoribosyltransferase                   APT LQAEVLECVSLVELTSLK 
P23526 Adenosylhomocysteinase                    SAHH QAQYLGMSCDGPFKPDHYR 
P54819 Adenylate kinase 2, mitochondrial                 KAD2 LAENFCVCHLATGDMLR 
Q01518 Adenylyl cyclase-associated protein 1                 CAP1 CVNTTLQIK 
   INSITVDNCK 
P12235 ADP/ATP translocase 1                  ADT1 QYKGIIDCVVR 
P05141 ADP/ATP translocase 2                  ADT2 QYKGIIDCVVR 
O43488 Aflatoxin B1 aldehyde reductase member 2               ARK72 LQCPQVDLFYLHAPDHGTPVEETL
HACQR 
P07327 Alcohol dehydrogenase 1A                  ADH1A NPESNYCLK 
P00325 Alcohol dehydrogenase 1B                  ADH1B MVAVGICR 
   NPESNYCLK 
P00326 Alcohol dehydrogenase 1C                  ADH1G NPESNYCLK 
P08319 Alcohol dehydrogenase 4                  ADH4 ALGATDCLNPR 
Q06278 Aldehyde oxidase                   AOXA IPAICDMPTELHIALLPPSQNSNTLY
SSK 
   NLIQCWR 
   TAEHLSDVNSFCFFTEAEK 
Q04828 Aldo-keto reductase family 1 member C1               AK1C1 SPVLLEDPVLCAL 
P52895 Aldo-keto reductase family 1 member C2               AK1C2 ILFDTVDLCATWEAMEK 
   KLLDFCK 
   SPVLLEDPVLCAL 
P42330 Aldo-keto reductase family 1 member C3               AK1C3 KLLDFCK 
   YKPVCNQVECHPYFNR 
P12814 Alpha-actinin-1                    ACTN1 CQLEINFNTLQTK 







   EGLLLWCQR 
O43707 Alpha-actinin-4                    ACTN4 CQLEINFNTLQTK 
   EGLLLWCQR 
Q9UDR5 Alpha-aminoadipic semialdehyde synthase, 
mitochondrial                 
AASS AGGILQEDISEACLILGVK 
   QLLCDLVGISPSSEHDVLK 
P06733 Alpha-enolase                    ENOA QIGSVTESLQACK 
P21397 Amine oxidase [flavin-containing] A                 AOFA ICELYAK 
   KICELYAK 
P27338 Amine oxidase [flavin-containing] B                 AOFB LCELYAK 
   CIVYYK 
   KLCELYAK 
Q9H4A4 Aminopeptidase B                   AMPB AFFPCFDTPAVK 
Q9P2R3 Ankyrin repeat and FYVE domain-containing 
protein 1              
ANFY1 NQLPLVVDAICTR 
P04083 Annexin A1                   ANXA1 CLTAIVK 
P07355 Annexin A2                   ANXA2 GDLENAFLNLVQCIQNK 
   GLGTDEDSLIEIICSR 
   SLIEIICSR 
   STVHEILCK 
P09525 Annexin A4                   ANXA4 FLTVLCSR 
P08133 Annexin A6                   ANXA6 ALLALCGGED 
   FMTILCTR 
P20073 Annexin A7                   ANXA7 VLIEILCTR 
Q10567 AP-1 complex subunit beta-1                 AP1B1 YESVIATLCENLDSLDEPEAR 
O95782 AP-2 complex subunit alpha-1                 AP2A1 AADLLYAMCDR 
   ACNQLGQFLQHR 
   LVECLETVLNK 
   QSAALCLLR 
Q96CW1 AP-2 complex subunit mu                 AP2M1 MCDVMAAYFGK 
O14617 AP-3 complex subunit delta-1                 AP3D1 YISQCIDEIK 
   DLILQCLDDKDESIR 
P02649 Apolipoprotein E                   APOE LGADMEDVCGR 
O95831 Apoptosis-inducing factor 1, mitochondrial                 AIFM1 SITIIGGGFLGSELACALGR 
   SNIWVAGDAACFYDIK 
P54136 Arginine--tRNA ligase, cytoplasmic                  SYRC AYQCVVLLQGK 
   IVFVPGCSIPLTIVK 
   MDVLVSECSAR 
   MLLCEAVAAVMAK 
P04424 Argininosuccinate lyase                   ARLY MAEDLILYCTK 
   CAGLLMTLK 
P00966 Argininosuccinate synthase                   ASSY SGGLDTSCILVWLK 
O43776 Asparagine--tRNA ligase, cytoplasmic                  SYNC HLAEYTHVEAECPFLTFDDLLNR 
   LEDLVCDVVDR 
P00505 Aspartate aminotransferase, mitochondrial                  AATM TCGFDFTGAVEDISK 
   VGAFTMVCK 
P14868 Aspartate--tRNA ligase, cytoplasmic                  SYDC LEYCEALAMLR 
Q9ULA0 Aspartyl aminopeptidase                   DNPEP NDTPCGTTIGPILASR 
P24539 ATP synthase F(0) complex subunit B1, 
mitochondrial              
AT5F1 CIADLK 
Q8NBU5 ATPase family AAA domain-containing protein 1               ATAD1 DAALLCVR 
Q9NP58 ATP-binding cassette sub-family B member 6, 
mitochondrial              
ABCB6 FYDISSGCIR 
Q8NE71 ATP-binding cassette sub-family F member 1               ABCF1 TLLIVSHDQGFLDDVCTDIIHLDAQ
R 
P53396 ATP-citrate synthase                   ACLY FICTTSAIQNR 
   AVQGMLDFDYVCSR 
P17858 ATP-dependent 6-phosphofructokinase, liver type                 PFKAL LPLMECVQMTK 
Q08211 ATP-dependent RNA helicase A                 DHX9 NFLYAWCGK 
   LQISHEAAACITGLR 
   SSVNCPFSSQDMK 
O00148 ATP-dependent RNA helicase DDX39A                 DX39A CMALAQLLVEQNFPAIAIHR 
   HFVLDECDK 







   VRPCVVYGGADIGQQIR 
O95816 BAG family molecular chaperone regulator 2               BAG2 FQSIVIGCALEDQK 
P35613 Basigin                    BASI SSEHINEGETAMLVCK 
Q9BXK5 Bcl-2-like protein 13                  B2L13 HTSPVFSPANPESSMEDCLAHLGE
K 
Q3LXA3 Bifunctional ATP-dependent dihydroxyacetone 
kinase/FAD-AMP lyase (cyclizing)               
DHAK VCSTLLGLEEHLNALDR 
P07814 Bifunctional glutamate/proline--tRNA ligase                  SYEP INEAVECLLSLK 
   HEELMLGDPCLK 
   EAPCVLIYIPDGHTK 
O60502 Bifunctional protein NCOAT                  NCOAT SMMACLLSSLK 
P31939 Bifunctional purine biosynthesis protein PURH                PUR9 MSSFGDFVALSDVCDVPTAK 
   VCMVYDLYK 
Q06520 Bile salt sulfotransferase                  ST2A1 ICQFLGK 
P53004 Biliverdin reductase A                  BIEA ILHCLGLAEEIQK 
O15382 Branched-chain-amino-acid aminotransferase, 
mitochondrial                  
BCAT2 LELLECIR 
  EVFGSGTACQVCPVHR 
   LCLPSFDK 
P04632 Calpain small subunit 1                 CPNS1 YSDESGNMDFDNFISCLVR 
P07384 Calpain-1 catalytic subunit                  CAN1 LEICNLTPDALK 
Q15417 Calponin-3                    CNN3 DGIILCELINK 
P13861 cAMP-dependent protein kinase type II-alpha 
regulatory subunit              
KAP2 LLGPCMDIMK 
P31327 Carbamoyl-phosphate synthase [ammonia], 
mitochondrial                 
CPSM SAYALGGLGSGICPNR 
   SVDYPCLLR 
P16152 Carbonyl reductase [NADPH] 1                 CBR1 DVCTELLPLIK 
Q96DG6 Carboxymethylenebutenolidase homolog                   CMBL ANEAYPCPCDIGHR 
P50416 Carnitine O-palmitoyltransferase 1, liver isoform                CPT1A SCTTESCDFVR 
   FCLTYEASMTR 
P29466 Caspase-1                    CASP1 CFYLFPGH 
P04040 Catalase                    CATA LCENIAGHLK 
P35221 Catenin alpha-1                   CTNA1 IVAECNAVR 
P35222 Catenin beta-1                   CTNB1 MMVCQVGGIEALVR 
O60716 Catenin delta-1                   CTND1 TPAILEASAGAIQNLCAGR 
P07858 Cathepsin B                   CATB ICEPGYSPTYK 
P07339 Cathepsin D                   CATD AIGAVPLIQGEYMIPCEK 
   EGCEAIVDTGTSLMVGPVDEVR 
   IQGEYMIPCEK 
   LLDIACWIH 
   TVVFDTGSSNLWVPSIHCK 
P07711 Cathepsin L1                   CATL1 NHCGIASAASYPTV 
A5YKK6 CCR4-NOT transcription complex subunit 1                CNOT1 CPVVLAPLLYPEK 
P48509 CD151 antigen                   CD151 TVVALCGQR 
Q13740 CD166 antigen                   CD166 QIGDALPVSCTISASR 
   SAYGDTIIIPCR 
   TCSVTYYGPSGQK 
Q8N163 Cell cycle and apoptosis regulator protein 2              CCAR2 GEASEDLCEMALDPELLLLR 
   TVDSPICDFLELQR 
Q7Z7K6 Centromere protein V                  CENPV CGVQSFYTPR 
P00450 Ceruloplasmin                    CERU DIASGLIGPLIICK 
O00299 Chloride intracellular channel protein 1                CLIC1 LHIVQVVCK 
Q9Y696 Chloride intracellular channel protein 4                CLIC4 AGSDGESIGNCPFSQR 
   IEEFLEEVLCPPK 
O75390 Citrate synthase, mitochondrial                  CISY LPCVAAK 
Q00610 Clathrin heavy chain 1                 CLH1 LECSEELGDLVK 
   LPVVIGGLLDVDCSEDVIK 
   CNEPAVWSQLAK 
   VIQCFAETGQVQK 
   AHIAQLCEK 
   EDKLECSEELGDLVK 
   GQCDLELINVCNENSLFK 
   IHEGCEEPATHNALAK 







P09497 Clathrin light chain B                 CLCB VAQLCDFNPK 
Q16630 Cleavage and polyadenylation specificity factor 
subunit 6              
CPSF6 VLISSLQDCLHGIESK 
O75153 Clustered mitochondria protein homolog                 CLU CLTQQAVALQR 
   DAAAFLLSCQIPGLVK 
P53621 Coatomer subunit alpha                  COPA FPVFNMSYNPAENAVLLCTR 
   GNNVYCLDR 
   HAIVICNR 
   QEIAEAQQLITICR 
P53618 Coatomer subunit beta                  COPB AAAQCYIDLIIK 
P35606 Coatomer subunit beta'                  COPB2 VDACLELLIR 
   TFEVCDLPVR 
O14579 Coatomer subunit epsilon                  COPE NAFYIGSYQQCINEAQR 
Q9Y678 Coatomer subunit gamma-1                  COPG1 ELAPAVSVLQLFCSSPK 
   CVMDDDNEVR 
   HEMVVYEAASAIVNLPGCSAK 
Q9UBF2 Coatomer subunit gamma-2                  COPG2 ELAPAVSVLQLFCSSPK 
P23528 Cofilin-1                    COF1 AVLFCLSEDK 
   HELQANCYEEVKDR 
O75534 Cold shock domain-containing protein E1                CSDE1 QRPGQQVATCVR 
P0C0L5 Complement C4-B         CO4B VDVQAGACEGK 
Q13098 COP9 signalosome complex subunit 1                CSN1 CAAGLAELAAR 
Q9UNS2 COP9 signalosome complex subunit 3                CSN3 CIELDER 
Q9BT78 COP9 signalosome complex subunit 4                CSN4 CQQLAAYGILEK 
Q7L5N1 COP9 signalosome complex subunit 6                CSN6 QVCEIIESPLFLK 
O75131 Copine-3                    CPNE3 ISLNSLCYGDMDK 
O75367 Core histone macro-H2A.1                  H2AY NCLALADDKK 
Q9BR76 Coronin-1B                    COR1B NDQCYEDIR 
P28845 Corticosteroid 11-beta-dehydrogenase isozyme 1                 DHI1 VVSHCLELGAASAH 
P17812 CTP synthase 1                  PYRG1 GLGLSPDLVVCR 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1                 CAND1 FCNVDDDELR 
   TVIGELPPASSGSALAANVCK 
   TYIQCIAAISR 
   CLDAVVSTR 
O43927 C-X-C motif chemokine 13                 CXL13 CVQESSVFIPR 
P35520 Cystathionine beta-synthase                   CBS CIIVMPEK 
P21291 Cysteine and glycine-rich protein 1                CSRP1 TVYFAEEVQCEGNSFHK 
P31930 Cytochrome b-c1 complex subunit 1, mitochondrial               QCR1 NALVSHLDGTTPVCEDIGR 
   SICYAETGLLGAHFVCDR 
P22695 Cytochrome b-c1 complex subunit 2, mitochondrial               QCR2 ENMAYTVECLR 
   NALANPLYCPDYR 
P08574 Cytochrome c1, heme protein, mitochondrial                CY1 HLVGVCYTEDEAK 
P10632 Cytochrome P450 2C8                  CP2C8 DFIDCFLIK 
P05181 Cytochrome P450 20                  CP2E1 DLTDCLLVEMEK 
Q9HBI6 Cytochrome P450 4F11                  CP4FB LQCFPQPPK 
Q14204 Cytoplasmic dynein 1 heavy chain 1               DYHC1 SSLQSQCLNEVLK 
   MLSAVSQQVQCIQEALR 
Q7L576 Cytoplasmic FMR1-interacting protein 1                 CYFP1 NFVGPPHFQVICR 
Q96KP4 Cytosolic non-specific dipeptidase                  CNDP2 FCLEGMEESGSEGLDELIFAR 
Q15392 Delta(24)-sterol reductase                   DHC24 GLEAICAK 
P30038 Delta-1-pyrroline-5-carboxylate dehydrogenase, 
mitochondrial                  
AL4A1 CDDSVGYFVEPCIVESK 
P13716 Delta-aminolevulinic acid dehydratase                  HEM2 CVLIFGVPSR 
P15924 Desmoplakin                    DESP YCYLQNEVFGLFQK 
P60981 Destrin                    DEST LGGSLIVAFEGCPV 
   ASGVQVADEVCR 
   HECQANGPEDLNR 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial                  DLDH ILGPGAGEMVNEAALALEYGASCE
DIAR 
P10515 Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial             
ODP2 ASALACLK 
P09417 Dihydropteridine reductase                   DHPR GAVHQLCQSLAGK 







P49326 Dimethylaniline monooxygenase [N-oxide-
forming] 5                 
FMO5 ICGQSLANK 
Q9NY33 Dipeptidyl peptidase 3                  DPP3 FSTIASSYEECR 
   ADTQYILPNDIGVSSLDCR 
P27487 Dipeptidyl peptidase 4                  DPP4 CSGPGLPLYTLH 
Q16531 DNA damage-binding protein 1                 DDB1 IGRPSETGIIGIIDPECR 
P49736 DNA replication licensing factor MCM2                MCM2 FDILCVVR 
P25205 DNA replication licensing factor MCM3                MCM3 GVVCIDEFDK 
   AILCLLLGGVER 
P33992 DNA replication licensing factor MCM5                MCM5 CPLDPYFIMPDK 
   GVVCIDEFDK 
P33993 DNA replication licensing factor MCM7                MCM7 CSILAAANPAYGR 
P11387 DNA topoisomerase 1                  TOP1 CDFTQMSQYFK 
P27695 DNA-(apurinic or apyrimidinic site) lyase                APEX1 EEAPDILCLQETK 
   ICSWNVDGLR 
P78527 DNA-dependent protein kinase catalytic subunit                PRKDC INLVEFCR 
   INQVFHGSCITEGNELTK 
   DILPCLDGYLK 
   ELLNPVVEFVSHPSTTCR 
   FNNYVDCMK 
   GLSSLLCNFTK 
   LAAVVSACK 
   CFGTGAAGNR 
   CGAALAGHQLIR 
   GYGLFAGPCK 
   LACDVDQVTR 
   LLELMTEVLCR 
   LPVLAGCLK 
   NCISTVVHQGLIR 
   SLGTIQQCCDAIDHLCR 
O60884 DnaJ homolog subfamily A member 2               DNJA2 NVLCSACSGQGGK 
P04843 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1                 
RPN1 TEGSDLCDR 
Q14203 Dynactin subunit 1                  DCTN1 DLETSCSDIR 
P50570 Dynamin-2                    DYN2 CVDLVIQELINTVR 
P49792 E3 SUMO-protein ligase RanBP2                 RBP2 IAELLCK 
Q14258 E3 ubiquitin/ISG15 ligase TRIM25                 TRI25 NTVLCNVVEQFLQADLAR 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1                 HUWE1 VLGPAACR 
Q63HN8 E3 ubiquitin-protein ligase RNF213                 RN213 STDFLPVDCPVR 
Q9HC35 Echinoderm microtubule-associated protein-like 4                 EMAL4 VIAVADDFCK 
P13804 Electron transfer flavoprotein subunit alpha, 
mitochondrial               
ETFA TIYAGNALCTVK 
  LGGEVSCLVAGTK 
P38117 Electron transfer flavoprotein subunit beta                ETFB HSMNPFCEIAVEEAVR 
Q16134 Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial                
ETFD FCPAGVYEFVPVEQGDGFR 
P68104 Elongation factor 1-alpha 1                 EF1A1 KDGNASGTTLLEALDCILPPTRPTD
KPLR 
   NMITGTSQADCAVLIVAAGVGEFE
AGISK 
   DGNASGTTLLEALDCILPPTRPTDK 
   SGDAAIVDMVPGKPMCVESFSDYP
PLGR 
   DGNASGTTLLEALDCILPPTR 
   DGNASGTTLLEALDCILPPTRPTDK
PLR 
   CLYASVLTAQPR 
P13639 Elongation factor 2                  EF2 STLTDSLVCK 
   YVEPIEDVPCGNIVGLVGVDQFLV
K 
P43897 Elongation factor Ts, mitochondrial                 EFTS ALETCGGDLK 
P49411 Elongation factor Tu, mitochondrial                 EFTU NMITGTAPLDGCILVVAANDGPMP
QTR 
Q9NZ08 Endoplasmic reticulum aminopeptidase 1                 ERAP1 MAFPCFDEPAFK 







P14625 Endoplasmin                    ENPL LTESPCALVASQYGWSGNMER 
P42126 Enoyl-CoA delta isomerase 1, mitochondrial                ECI1 SAGLDLTEMCGR 
O75521 Enoyl-CoA delta isomerase 2, mitochondrial                ECI2 EFVGCFIDFPK 
   EFVGCFIDFPKPL 
Q96DC8 Enoyl-CoA hydratase domain-containing protein 3, 
mitochondrial               
ECHD3 DYHAEVFQTCSK 
P30084 Enoyl-CoA hydratase, mitochondrial                  ECHM ALNALCDGLIDELNQALK 
P61916 Epididymal secretory protein E1                 NPC2 AVVHGILMGVPVPFPIPEPDGCK 
   DCGSVDGVIK 
   SGINCPIQK 
O94905 Erlin-2                    ERLN2 ADAECYTAMK 
Q96HE7 ERO1-like protein alpha                  ERO1A YSEEANNLIEECEQAER 
P30042 ES1 protein homolog, mitochondrial                 ES1 VVTTPAFMCETALHYIHDGIGAMV
R 
Q9H0W9 Ester hydrolase C11orf54                  CK054 APLVCLPVFVSR 
Q8NBQ5 Estradiol 17-beta-dehydrogenase 11                  DHB11 VHTFVVDCSNR 
Q53GQ0 Estradiol 17-beta-dehydrogenase 12                  DHB12 MININILSVCK 
P60842 Eukaryotic initiation factor 4A-I                 IF4A1 VVMALGDYMGASCHACIGGTNVR 
P15170 Eukaryotic peptide chain release factor GTP-
binding subunit ERF3A             
ERF3A QDQVCIAR 
P62495 Eukaryotic peptide chain release factor subunit 1              ERF1 CGTIVTEEGK 
P47813 Eukaryotic translation initiation factor 1A, X-
chromosomal               
IF1AX LEAMCFDGVK 
P41091 Eukaryotic translation initiation factor 2 subunit 3              IF2G YNIEVVCEYIVK 
P55884 Eukaryotic translation initiation factor 3 subunit B              EIF3B NLFNVVDCK 
   YWLEEAECR 
Q99613 Eukaryotic translation initiation factor 3 subunit C  EIF3C CLEEFELLGK 
O15371 Eukaryotic translation initiation factor 3 subunit D              EIF3D TQGNVFATDAILATLMSCTR 
P60228 Eukaryotic translation initiation factor 3 subunit E              EIF3E FQYECGNYSGAAEYLYFFR 
   LFIFETFCR 
   IHQCISIN 
O75822 Eukaryotic translation initiation factor 3 subunit J              EIF3J ITNSLTVLCSEK 
Q9UBQ5 Eukaryotic translation initiation factor 3 subunit K              EIF3K FICHVVGITYQHIDR 
Q15056 Eukaryotic translation initiation factor 4H                IF4H GFCYVEFDEVDSLK 
O60841 Eukaryotic translation initiation factor 5B                IF2P APIICVLGHVDTGK 
Q9Y2L1 Exosome complex exonuclease RRP44                 RRP44 LACLSEEGNEIESGK 
O14980 Exportin-1                    XPO1 DLLGLCEQK 
P55060 Exportin-2                    XPO2 NLFEDQNTLTSICEK 
P49327 Fatty acid synthase                  FAS AAPLDSIHSLAAYYIDCIR 
   TGGAYGEDLGADYNLSQVCDGK 
   AALQEELQLCK 
   ACLDTAVENMPSLK 
   DGLLENQTPEFFQDVCK 
   LTPGCEAEAETEAICFFVQQFTDME
HNR 
   MASCLEVLDLFLNQPH 
   AINCATSGVVGLVNCLR 
   CTVFHGAQVEDAFR 
   LSIPTYGLQCTR 
   SFYGSTLFLCR 
   SGVVGLVNCLR 
P51648 Fatty aldehyde dehydrogenase                  AL3A2 EKDILTAIAADLCK 
   DILTAIAADLCK 
P02792 Ferritin light chain                  FRIL TDPHLCDFLETHFLDEEVK 
P02675 Fibrinogen beta chain                  FIBB LESDVSAQMEYCR 
   TPCTVSCNIPVVSGK 
   ECEEIIR 
   NYCGLPGEYWLGNDK 
P02679 Fibrinogen gamma chain                  FIBG CHAGHLNGVYYQGGTYSK 
   VAQLEAQCQEPCKDTVQIHDITGK 
Q53EP0 Fibronectin type III domain-containing protein 3B               FND3B LECAAAGPQSLK 
P21333 Filamin-A                    FLNA VHSPSGALEECYVTEIDQDK 
O75369 Filamin-B                    FLNB SPFVVQVGEACNPNACR 







P04075 Fructose-bisphosphate aldolase A                  ALDOA ALANSLACQGK 
P07954 Fumarate hydratase, mitochondrial                  FUMH FEALAAHDALVELSGAMNTTACSL
MK 
P51570 Galactokinase                    GALK1 MTGGGFGGCTVTLLEASAAPH 
O75223 Gamma-glutamylcyclotransferase                    GGCT NPSAAFFCVAR 
P36269 Gamma-glutamyltransferase 5                   GGT5 FLNVVQAVSQEGACVYAVSDLR 
   HQAPCGPQAF 
P57764 Gasdermin-D                    GSDMD ELCQLLLEGLEGVLR 
Q9NQX3 Gephyrin                    GEPH VGVLTVSDSCFR 
P11413 Glucose-6-phosphate 1-dehydrogenase                   G6PD LILDVFCGSQMH 
   DNIACVILTFK 
   DVMQNHLLQMLCL 
   DVMQNHLLQMLCLVAMEK 
   LILDVFCGSQM 
   LILDVFCGSQMHF 
P14314 Glucosidase 2 subunit beta                 GLU2B YEQGTGCWQGPNR 
P00367 Glutamate dehydrogenase 1, mitochondrial                 DHE3 CAVVDVPFGGAK 
P48506 Glutamate--cysteine ligase catalytic subunit                 GSH1 GYVSDIDCR 
Q06210 Glutamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1                 
GFPT1 ETDCGVHINAGPEIGVASTK 
  CQNALQQVVAR 
P47897 Glutamine--tRNA ligase                   SYQ VGVTVAQTTMEPHLLEACVR 
P35754 Glutaredoxin-1                    GLRX1 AQEFVNCK 
Q9Y2Q3 Glutathione S-transferase kappa 1                 GSTK1 SWLGFEILCR 
P48637 Glutathione synthetase                   GSHB IEPEPFENCLLR 
P21695 Glycerol-3-phosphate dehydrogenase [NAD(+)], 
cytoplasmic                 
GPDA VCYEGQPVGEFIHCLQNHPEHM 
P43304 Glycerol-3-phosphate dehydrogenase, 
mitochondrial                  
GPDM NYLSCDVEVR 
P35573 Glycogen debranching enzyme                  GDE HLSLGSVQLCGVGK 
P11216 Glycogen phosphorylase, brain form                 PYGB MSVIEEGDCK 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase                  GRHPR GVAGAHGLLCLLSDHVDK 
   NCVILPH 
P49915 GMP synthase [glutamine-hydrolyzing]                  GUAA NFLYDIAGCSGTFTVQNR 
Q12849 G-rich sequence factor 1                 GRSF1 YIELFLNSCPK 
Q14353 Guanidinoacetate N-methyltransferase                   GAMT TEVMALVPPADCR 
P63244 Guanine nucleotide-binding protein subunit beta-2-
like 1               
GBLP HLYTLDGGDIINALCFSPNR 
  FSPNSSNPIIVSCGWDK 
   YTVQDESHSEWVSCVR 
O60832 H/ACA ribonucleoprotein complex subunit 4                DKC1 DSAVNAICYGAK 
P00738 Haptoglobin                    HPT SCAVAEYGVYVK 
P08107 Heat shock 70 kDa protein 1A/1B               HSP71 FEELCSDLFR 
   CQEVISWLDANTLAEKDEFEHK 
P34932 Heat shock 70 kDa protein 4               HSP74 FLEMCNDLLAR 
O95757 Heat shock 70 kDa protein 4L               HS74L AQFEQLCASLLAR 
P11142 Heat shock cognate 71 kDa protein               HSP7C CNEIINWLDK 
P07900 Heat shock protein HSP 90-alpha                HS90A CLELFTELAEDK 
   FENLCK 
P08238 Heat shock protein HSP 90-beta                HS90B VFIMDSCDELIPEYLNFIR 
   AKFENLCK 
   FENLCK 
Q15477 Helicase SKI2W                   SKIV2 GLDPTGTVILLCK 
Q13151 Heterogeneous nuclear ribonucleoprotein A0                 ROA0 MENSQLCK 
P09651 Heterogeneous nuclear ribonucleoprotein A1                 ROA1 SHFEQWGTLTDCVVMR 
   LTDCVVMR 
P51991 Heterogeneous nuclear ribonucleoprotein A3                 ROA3 LTDCVVMR 
P52597 Heterogeneous nuclear ribonucleoprotein F                 HNRPF GLPFGCTK 
P31943 Heterogeneous nuclear ribonucleoprotein H                 HNRH1 GLPWSCSADEVQR 
P61978 Heterogeneous nuclear ribonucleoprotein K                 HNRPK IIPTLEEGLQLPSPTATSQLPLESDA
VECLNYQHYK 
P14866 Heterogeneous nuclear ribonucleoprotein L                 HNRPL QPAIMPGQSYGLEDGSCSYK 
P52272 Heterogeneous nuclear ribonucleoprotein M                 HNRPM ACQIFVR 
O60506 Heterogeneous nuclear ribonucleoprotein Q                 HNRPQ HIGVCISVANNR 
   SAFLCGVMK 







   HLGVCISVANNR 
   SAFLCGVMK 
Q00839 Heterogeneous nuclear ribonucleoprotein U                 HNRPU GNFTLPEVAECFDEITYVELQK 
   TCNCETEDYGEK 
   CAVEFNFGQK 
   VLCHNCAVEFNFGQK 
Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like 
protein 1               
HNRL1 NCAVEFNFGQR 
  WDVLIQQATQCLNR 
P37235 Hippocalcin-like protein 1                  HPCL1 LLQCDPSSASQF 
P84243 Histone H3.3                   H33 FQSAAIGALQEASEAYLVGLFEDT
NLCAIHAK 
P30481 HLA class I histocompatibility antigen, B-44 alpha 
chain             
1B44 AYLEGLCVESLR 
Q9NYQ3 Hydroxyacid oxidase 2                  HAOX2 ALVITLDTPVCGNR 
P35914 Hydroxymethylglutaryl-CoA lyase, mitochondrial                  HMGCL LLEAGNFICQALNR 
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic                  HMCS1 NNLSYDCIGR 
P54868 Hydroxymethylglutaryl-CoA synthase, 
mitochondrial                  
HMCS2 CVSPEEFTEIMNQR 
Q9Y4L1 Hypoxia up-regulated protein 1                 HYOU1 VEFEELCADLFER 
O00629 Importin subunit alpha-3                  IMA3 SGILPILVHCLER 
P52294 Importin subunit alpha-5                  IMA5 IQAVIDAGVCR 
O60684 Importin subunit alpha-7                  IMA7 IQAVIDSGVCR 
Q14974 Importin subunit beta-1                  IMB1 HFIMQVVCEATQCPDTR 
Q8TEX9 Importin-4                    IPO4 APAALPALCDLLASAADPQIR 
   ACYALENFVENLGPK 
   DNICGALAR 
O00410 Importin-5                    IPO5 TIECISLIGLAVGK 
O95373 Importin-7                    IPO7 CLIDDR 
Q96P70 Importin-9                    IPO9 VSSVALCK 
Q68E01 Integrator complex subunit 3                 INT3 EHPEALSCLLLQLR 
P26006 Integrin alpha-3                   ITA3 SETVLTCATGR 
Q12906 Interleukin enhancer-binding factor 3                 ILF3 CLAALASLR 
   GDLDLELVLLCK 
   SCVIVIR 
Q27J81 Inverted formin-2                   INF2 CSNEEVAAMIR 
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial               
IDH3A CSDFTEEICR 
  TFDLYANVRPCVSIEGYK 
P51553 Isocitrate dehydrogenase [NAD] subunit gamma, 
mitochondrial               
IDH3G HACVPVDFEEVHVSSNADEEDIR 
  LGDGLFLQCCR 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic                 IDHC CATITPDEK 
P48735 Isocitrate dehydrogenase [NADP], mitochondrial                 IDHP DLAGCIHGLSNVK 
P41252 Isoleucine--tRNA ligase, cytoplasmic                  SYIC MGITEYNNQCR 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial                  SYIM CGFSELYSWQR 
P13645 Keratin, type I cytoskeletal 10                K1C10 AETECQNTEYQQLLDIK 
Q86UP2 Kinectin                    KTN1 TMMFSEDEALCVVDLLK 
P33176 Kinesin-1 heavy chain                  KINH VFQSSTSQEQVYNDCAK 
Q04760 Lactoylglutathione lyase                   LGUL GFGHIGIAVPDVYSACK 
P42167 Lamina-associated polypeptide 2, isoforms 
beta/gamma                
LAP2B EMFPYEASTPTGISASCR 
P20700 Lamin-B1                    LMNB1 CQSLTEDLEFR 
O43813 LanC-like protein 1                  LANC1 IPQSHIQQICETILTSGENLAR 
Q16850 Lanosterol 14-alpha demethylase                  CP51A CIGENFAYVQIK 
Q6PKG0 La-related protein 1                  LARP1 YGLECLFR 
P42704 Leucine-rich PPR motif-containing protein, 
mitochondrial                
LPPRC LEDVALQILLACPVSK 
  LIASYCNVGDIEGASK 
Q96AG4 Leucine-rich repeat-containing protein 59                 LRC59 VAGDCLDEK 
Q9P2J5 Leucine--tRNA ligase, cytoplasmic                  SYLC NFEATLGWLQEHACSR 
P23141 Liver carboxylesterase 1                  EST1 LSEDCLYLNIYTPADLTK 
   GDVKPLAEQIAITAGCK 
   KGDVKPLAEQIAITAGCK 
   SYPLVCIAK 
   TTTSAVMVHCLR 
   CLYLNIYTPADLTK 







P36776 Lon protease homolog, mitochondrial                 LONM VLFICTANVTDTIPEPLR 
P28330 Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial                
ACADL AFVDNCLQLHEAK 
P33121 Long-chain-fatty-acid--CoA ligase 1                  ACSL1 LIAIVVPDVETLCSWAQK 
   CGVEVTSMK 
   GFEGSFEELCR 
   GIQVSNNGPCLGSR 
   AAEGEGEVCVK 
O95573 Long-chain-fatty-acid--CoA ligase 3                  ACSL3 NTPLCDSFVFR 
O60488 Long-chain-fatty-acid--CoA ligase 4                  ACSL4 GDCTVLKPTLMAAVPEIMDR 
   TALLDISCVK 
Q9ULC5 Long-chain-fatty-acid--CoA ligase 5                  ACSL5 GLAVSDNGPCLGYR 
   IVQAVVYSCGAR 
Q7Z4W1 L-xylulose reductase                   DCXR GVPGAIVNVSSQCSQR 
Q14108 Lysosome membrane protein 2                 SCRB2 DEVLYVFPSDFCR 
Q96C86 m7GpppX diphosphatase                   DCPS WNQQQLDDLYLIAICHR 
P14174 Macrophage migration inhibitory factor                 MIF LLCGLLAER 
Q14764 Major vault protein                  MVP LFSVPDFVGDACK 
P40925 Malate dehydrogenase, cytoplasmic                  MDHC MGVLDGVLMELQDCALPLLK 
P40926 Malate dehydrogenase, mitochondrial                  MDHM GCDVVVIPAGVPR 
Q96IJ6 Mannose-1-phosphate guanyltransferase alpha                  GMPPA LLPAITILGCR 
Q9Y5P6 Mannose-1-phosphate guanyltransferase beta                  GMPPB YGVVVCEADTGR 
Q658P3 Metalloreductase STEAP3                   STEA3 ESNAEYLASLFPTCTVVK 
   QVPICGDQPEAK 
P56192 Methionine--tRNA ligase, cytoplasmic                  SYMC VPVLQLDSGNYLFSTSAICR 
Q96PE7 Methylmalonyl-CoA epimerase, mitochondrial                  MCEE DCGGVLVELEQA 
Q9BQA1 Methylosome protein 50                  MEP50 AHAAQVTCVAASPHK 
Q5TGZ0 MICOS complex subunit MIC10                 MIC10 CLADAVVK 
P10620 Microsomal glutathione S-transferase 1                 MGST1 VFANPEDCVAFGK 
P27816 Microtubule-associated protein 4                  MAP4 CSLPAEEDSVLEK 
Q15691 Microtubule-associated protein RP/EB family 
member 1               
MARE1 NIELICQENEGENDPVLQR 
O43772 Mitochondrial carnitine/acylcarnitine carrier 
protein                 
MCAT CLLQIQASSGESK 
Q9Y6C9 Mitochondrial carrier homolog 2                 MTCH2 LCSGVLGTVVHGK 
   QVCQLPGLFSY 
Q9Y276 Mitochondrial chaperone BCS1                  BCS1 GYLLYGPPGCGK 
Q9H1K4 Mitochondrial glutamate carrier 2                 GHC2 LINGGVAGLVGVTCVFPIDLAK 
O94826 Mitochondrial import receptor subunit TOM70                TOM70 ILLDQVEEAVADFDECIR 
   CAEGYALYAQALTDQQQFGK 
Q15070 Mitochondrial inner membrane protein OXA1L                OXA1L CLIFPLIVTGQR 
Q7L0Y3 Mitochondrial ribonuclease P protein 1                MRRP1 LNLATECLPLDK 
Q10713 Mitochondrial-processing peptidase subunit alpha                 MPPA MVLAGVGVEHEHLVDCAR 
P26038 Moesin                    MOES ILALCMGNHELYMR 
P08183 Multidrug resistance protein 1                 MDR1 TCIVIAHR 
P22234 Multifunctional protein ADE2                  PUR6 ITSCIFQLLQEAGIK 
   ACGNFGIPCELR 
Q9NUJ1 Mycophenolic acid acyl-glucuronide esterase, 
mitochondrial                
ABHDA ALAIEEFCK 
P35580 Myosin-10                    MYH10 VEDMAELTCLNEASVLHNLK 
   CNGVLEGIR 
   EDQSILCTGESGAGK 
Q7Z406 Myosin-14                    MYH14 CNGVLEGIR 
P35579 Myosin-9                    MYH9 VEDMAELTCLNEASVLHNLK 
   CNGVLEGIR 
   KQELEEICHDLEAR 
   EDQSILCTGESGAGK 
O95299 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial            
NDUAA CEVLQYSAR 
P49821 NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial               
NDUV1 GAGAYICGEETALIESIEGK 
P28331 NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial              
NDUS1 DCFIIYQGHHGDVGAPIADVILPGA
AYTEK 







Q16798 NADP-dependent malic enzyme, mitochondrial                 MAON FGINCLIQFEDFANANAFR 
Q9BXJ9 N-alpha-acetyltransferase 15, NatA auxiliary 
subunit                
NAA15 GELLLQLCR 
Q8TBC4 NEDD8-activating enzyme E1 catalytic subunit                UBA3 VLVIGAGGLGCELLK 
Q09666 Neuroblast differentiation-associated protein 
AHNAK                 
AHNK EVFSSCSSEVVLSGDDEEYQR 
Q9BYT8 Neurolysin, mitochondrial                   NEUL MSELCIDFNK 
Q14697 Neutral alpha-glucosidase AB                  GANAB TCEESSFCK 
Q15758 Neutral amino acid transporter B(0)                AAAT CVEENNGVAK 
P40261 Nicotinamide N-methyltransferase                   NNMT IFCLDGVK 
P43490 Nicotinamide phosphoribosyltransferase                   NAMPT DLLNCSFK 
Q86X76 Nitrilase homolog 1                  NIT1 LGACLAFLPEAFDFIAR 
P22307 Non-specific lipid-transfer protein                  NLTP KADCTITMADSDFLALMTGK 
   SAVDQACVGYVFGDSTCGQR 
   QLIQGGVAECVLALGFEK 
Q09161 Nuclear cap-binding protein subunit 1                NCBP1 LDTMNTTCVDR 
Q8N1F7 Nuclear pore complex protein Nup93                NUP93 CGDLLAASQVVNR 
Q9BZE4 Nucleolar GTP-binding protein 1                 NOG1 TLLLCGYPNVGK 
P78316 Nucleolar protein 14                  NOP14 CPILSLQDVVK 
O00567 Nucleolar protein 56                  NOP56 LVAFCPF 
P22392 Nucleoside diphosphate kinase B    NDKB GDFCIQVGR 
O00151 PDZ and LIM domain protein 1               PDLI1 CGTGIVGVFVK 
   GCTDNLTLTVAR 
Q96HC4 PDZ and LIM domain protein 5               PDLI5 FFAPECGR 
P62937 Peptidyl-prolyl cis-trans isomerase A                 PPIA ANAGPNTNGSQFFICTAK 
   GSQFFICTAK 
   TNGSQFFICTAK 
P30405 Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial                
PPIF VIPSFMCQAGDFTNHNGTGGK 
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5                 FKBP5 EEQCILYLGPR 
Q06830 Peroxiredoxin-1                    PRDX1 LNCQVIGASVDSHFCH 
P30044 Peroxiredoxin-5, mitochondrial                   PRDX5 GVLFGVPGAFTPGCSK 
Q9NUI1 Peroxisomal 2,4-dienoyl-CoA reductase                  DECR2 CLPLSMDVR 
Q08426 Peroxisomal bifunctional enzyme                  ECHP LCNKPIQSLPNMDSIFSEALLK 
   GGGLELALGCHYR 
O96011 Peroxisomal membrane protein 11B                 PX11B NACDLFIPLDK 
P51659 Peroxisomal multifunctional enzyme type 2                DHB4 CEAVVADVLDK 
Q9NSD9 Phenylalanine--tRNA ligase beta subunit                 SYFB YDLLCLEGLVR 
P30086 Phosphatidylethanolamine-binding protein 1                  PEBP1 APVAGTCYQAEWDDYVPK 
   CDEPILSNR 
Q16822 Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial                 
PCKGM YVAAAFPSACGK 
  FPGCMQGR 
P36871 Phosphoglucomutase-1                    PGM1 LSLCGEESFGTGSDHIR 
P00558 Phosphoglycerate kinase 1                  PGK1 ACANPAAGSVILLENLR 
P20020 Plasma membrane calcium-transporting ATPase 1                AT2B1 TICLAFR 
P13797 Plastin-3                    PLST IIQENLNLALNSASAIGCHVVNIGA
EDLR 
   LENCNYAVELGK 
Q15149 Plectin                    PLEC EYGSCSHHYQQLLQSLEQGAQEES
R 
   CVEDPETGLCLLPLTDK 
   CVEDPETGLR 
   LPLLAVCDYK 
Q15365 Poly(rC)-binding protein 1                  PCBP1 LVVPATQCGSLIGK 
   QICLVMLETLSQSPQGR 
O95758 Polypyrimidine tract-binding protein 3                 PTBP3 NLFIEAGCSVK 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8                  PRP8 FICISDLR 
Q9UHG3 Prenylcysteine oxidase 1                  PCYOX CPSIILHDR 
Q5JRX3 Presequence protease, mitochondrial                  PREP THFLMPFPVNYVGECIR 
   EFQITCGPDSFATDPSK 
   LGCGLLDYR 
Q96HY7 Probable 2-oxoglutarate dehydrogenase E1 
component DHKTD1, mitochondrial              
DHTK1 DVIIDLLCYR 







P17844 Probable ATP-dependent RNA helicase DDX5                DDX5 LIDFLECGK 
   STCIYGGAPK 
P26196 Probable ATP-dependent RNA helicase DDX6                DDX6 GNEFEDYCLK 
Q8NBJ5 Procollagen galactosyltransferase 1                  GT251 ALQAQEIECR 
P07737 Profilin-1                    PROF1 CYEMASHLR 
   IDNLMADGTCQDAAIVGYK 
Q8WUM4 Programmed cell death 6-interacting protein                PDC6I FIQQTYPSGGEEQAQYCR 
P35232 Prohibitin                    PHB GVQDIVVGEGTHFLIPWVQKPIIFD
CR 
   PIIFDCR 
Q9UQ80 Proliferation-associated protein 2G4                  PA2G4 AAHLCAEAALR 
   VAHSFNCTPIEGMLSHQLK 
P48147 Prolyl endopeptidase                   PPCE QNCFDDFQCAAEYLIK 
P05165 Propionyl-CoA carboxylase alpha chain, 
mitochondrial                
PCCA MADEAVCVGPAPTSK 
P05166 Propionyl-CoA carboxylase beta chain, 
mitochondrial                
PCCB AFENDVDALCNLR 
   CADFGMAADK 
Q15185 Prostaglandin E synthase 3                 TEBP LTFSCLGGSDNFK 
Q14914 Prostaglandin reductase 1                  PTGR1 IAICGAISTYNR 
   FGLLEICGVK 
   ASPDGYDCYFDNVGGEFSNTVIGQ
MK 
P60900 Proteasome subunit alpha type-6                 PSA6 YGYEIPVDMLCK 
Q5VYK3 Proteasome-associated protein ECM29 homolog                 ECM29 DIALVQQLFEALCK 
   IVAISCAADILK 
   TIAALLPCLLDK 
O14744 Protein arginine N-methyltransferase 5                 ANM5 QGFDFLCMPVFHPR 
P35659 Protein DEK                   DEK SICEVLDLER 
O60610 Protein diaphanous homolog 1                 DIAP1 AGCAVTSLLASELTK 
O60879 Protein diaphanous homolog 2                 DIAP2 HECTLSSQEYVHELR 
P30101 Protein disulfide-isomerase A3                  PDIA3 VDCTANTNTCNK 
Q99497 Protein DJ-1                   PARK7 GLIAAICAGPTALLAHEIGFGSK 
P49257 Protein ERGIC-53                   LMAN1 NDYEFCAK 
Q52LJ0 Protein FAM98B                   FA98B SLCNLEESITSAGR 
P49354 Protein 
farnesyltransferase/geranylgeranyltransferase type-
1 subunit alpha                
FNTA ALELCEILAK 
Q15435 Protein phosphatase 1 regulatory subunit 7               PP1R7 CIENLEELQSLR 
P29590 Protein PML                   PML LQDLSSCITQGK 
Q14690 Protein RRP5 homolog                  RRP5 CVVSSLGITDR 
   VVVLNCEPSK 
P31949 Protein S100-A11                   S10AB CIESLIAVFQK 
P05109 Protein S100-A8                   S10A8 LLETECPQYIR 
Q15436 Protein transport protein Sec23A                 SC23A ISGAIGPCVSLNSK 
P53992 Protein transport protein Sec24C                 SC24C NCASPSSAGQLILPECMK 
O94855 Protein transport protein Sec24D                 SC24D SCETDALINFFAK 
O94979 Protein transport protein Sec31A                 SC31A CLSSATDPQTK 
   EIVESCDLK 
   LVACWTK 
P21980 Protein-glutamine gamma-glutamyltransferase 2                  TGM2 CLGIPTR 
   DCLTESNLIK 
   SVPLCILYEK 
Q2TB90 Putative hexokinase HKDC1                  HKDC1 CDVTFMLSEDGSGK 
   ATDCEGEDVVDMLR 
   LPLGLTFSFPCR 
Q9Y383 Putative RNA-binding protein Luc7-like 2                LC7L2 VCEVCSAYLGLHDNDR 
   DQDLASCDR 
   SHLLNCCPHDVLSGTR 
P11498 Pyruvate carboxylase, mitochondrial                  PYC GLYAAFDCTATMK 
   DMAGLLKPTACTMLVSSLR 
P08559 Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial            
ODPA VDGMDILCVR 







   GIFPVLCK 
   NTGIICTIGPASR 
Q08257 Quinone oxidoreductase                   QOR AGESVLVHGASGGVGLAACQIAR 
Q53FA7 Quinone oxidoreductase PIG3                  QORX NVNCLALDGR 
   GAGVNLILDCIGGSYWEK 
P50395 Rab GDP dissociation inhibitor beta                GDIB TDDYLDQPCYETINR 
   QLICDPSYVK 
   VICILSHPIK 
P35241 Radixin                    RADI ILALCMGNHELYMR 
O60518 Ran-binding protein 6                  RNBP6 LCDIFAVLAR 
P46940 Ras GTPase-activating-like protein IQGAP1                 IQGA1 QLSSSVTGLTNIEEENCQR 
Q13576 Ras GTPase-activating-like protein IQGAP2                 IQGA2 EACNVPEPEEK 
P63000 Ras-related C3 botulinum toxin substrate 1               RAC1 AVLCPPPVK 
Q9UL25 Ras-related protein Rab-21                  RAB21 GIEELFLDLCK 
Q8WUD1 Ras-related protein Rab-2B  RAB2B SCLLLQFTDK 
P18754 Regulator of chromosome condensation                 RCC1 SGQVYSFGCNDEGALGR 
Q9NQC3 Reticulon-4                    RTN4 YSNSALGHVNCTIK 
P00352 Retinal dehydrogenase 1                  AL1A1 FPVFNPATEEELCQVEEGDKEDVD
K 
   LECGGGPWGNK 
   AYLNDLAGCIK 
   LNDLAGCIK 
   YCAGWADK 
O75452 Retinol dehydrogenase 16                  RDH16 VLAACLTEK 
P08134 Rho-related GTP-binding protein RhoC                 RHOC LVIVGDGACGK 
   HFCPNVPIILVGNK 
P13489 Ribonuclease inhibitor                   RINI LGDVGMAELCPGLLHPSSR 
P52758 Ribonuclease UK114                   UK114 AAGCDFTNVVK 
P23921 Ribonucleoside-diphosphate reductase large 
subunit                 
RIR1 SAGGIGVAVSCIR 
Q8TDN6 Ribosome biogenesis protein BRX1 homolog                BRX1 LFVINEVCEMK 
Q9Y3A5 Ribosome maturation protein SBDS                 SBDS KEDLISAFGTDDQTEICK 
Q9P2E9 Ribosome-binding protein 1                  RRBP1 LTAEFEEAQTSACR 
A0AV96 RNA-binding protein 47                  RBM47 SFGQFNPGCVER 
P22087 rRNA 2'-O-methyltransferase fibrillarin                  FBRL ANCIDSTASAEAVFASEVK 
Q5JTH9 RRP12-like protein                   RRP12 FCIQEIEK 
   VTVCQALR 
P16615 Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2                
AT2A2 ANACNSVIK 
  GTAVAICR 
Q13228 Selenium-binding protein 1                  SBP1 CELAFLHTSHCLASGEVMISSLGDV
K 
Q9UHD8 Septin-9                    Sep-09 WGTIEVENTTHCEFAYLR 
P34896 Serine hydroxymethyltransferase, cytosolic                  GLYC LIIAGTSCYSR 
P34897 Serine hydroxymethyltransferase, mitochondrial                  GLYM YYGGAEVVDEIELLCQR 
   GLELIASENFCSR 
Q92743 Serine protease HTRA1                  HTRA1 GACGQGQEDPNSLR 
Q8TDX7 Serine/threonine-protein kinase Nek7                  NEK7 AACLLDGVPVALK 
Q14738 Serine/threonine-protein phosphatase 2A 56 kDa 





Serine/threonine-protein phosphatase 2A 65 kDa 





  LNIISNLDCVNEVIGIR 
Q9BRF8 Serine/threonine-protein phosphatase CPPED1                  CPPED FFVLCGDLIH 
P62140 Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit                
PP1B IFCCHGGLSPDLQSMEQIR 
  QSLETICLLLAYK 
   HDLDLICR 
   IYGFYDECK 
P21549 Serine--pyruvate aminotransferase                   SPYA FLTHGESSTGVLQPLDGFGELCHR 
P10768 S-formylglutathione hydrolase                   ESTD VFEHDSVELNCK 
P42224 Signal transducer and activator of transcription 1-
alpha/beta              
STAT1 NLSFFLTPPCAR 
P62316 Small nuclear ribonucleoprotein Sm D2                SMD2 NNTQVLINCR 







P05023 Sodium/potassium-transporting ATPase subunit 
alpha-1                 
AT1A1 CSSILLHGK 
   LIIVEGCQR 
P05026 Sodium/potassium-transporting ATPase subunit 
beta-1                 
AT1B1 YNPNVLPVQCTGK 
Q13813 Spectrin alpha chain, non-erythrocytic 1                SPTN1 CTELNQAWSSLGK 
   EQADYCVSH 
Q01082 Spectrin beta chain, non-erythrocytic 1                SPTB2 AELFTQSCADLDK 
   NDSFTTCIELGK 
   DALLLWCQMK 
   SWHNVYCVINNQEMGFYK 
P19623 Spermidine synthase                   SPEE QFCQSLFPVVAY 
P52788 Spermine synthase                   SPSY LYCPVEFSK 
Q13838 Spliceosome RNA helicase DDX39B                 DX39B CIALAQLLVEQNFPAIAIHR 
   HFILDECDK 
O75533 Splicing factor 3B subunit 1                SF3B1 VQENCIDLVGR 
Q15393 Splicing factor 3B subunit 3                SF3B3 FGNICVVR 
Q9GZT3 SRA stem-loop-interacting RNA-binding protein, 
mitochondrial                
SLIRP CILPFDK 
Q7KZF4 Staphylococcal nuclease domain-containing protein 
1                
SND1 DIQNTQCLLNVEHLSAGCPHVTLQ
FADSK 
  ETCLITFLLAGIECPR 
   MVLSGCAIIVR 
   TCATVTIGGINIAEALVSK 
Q15738 Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating                  
NSDHL FFLGDLCSR 
Q9HCN8 Stromal cell-derived factor 2-like protein 1               SDF2L TGAELVTCGSVLK 
Q14683 Structural maintenance of chromosomes protein 1A               SMC1A ALVCDNVEDAR 
   EQSTCNFQAIVISLK 
P31040 Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial               
SDHA GLSEAGFNTACVTK 
  TYFSCTSAH 
   GVIALCIEDGSIHR 
P21912 Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial               
SDHB CGPMVLDALIK 
Q99643 Succinate dehydrogenase cytochrome b560 
subunit, mitochondrial               
C560 SLCLGPALIHTAK 
P51649 Succinate-semialdehyde dehydrogenase, 
mitochondrial                  
SSDH WLPAAATFPVQDPASGAALGMVA
DCGVR 
   AAYEAFCR 
P53597 Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial               
SUCA IICQGFTGK 
  LIGPNCPGVINPGECK 
P00441 Superoxide dismutase [Cu-Zn]                  SODC HVGDLGNVTADKDGVADVSIEDS
VISLSGDHCIIGR 
P04179 Superoxide dismutase [Mn], mitochondrial                 SODM GHLQIAACPNQDPLQGTTGLIPLLG
ID 
O15260 Surfeit locus protein 4                 SURF4 LCLISTFLEDGIR 
Q12846 Syntaxin-4                    STX4 CNSMQSEYR 
Q9Y490 Talin-1                    TLN1 NCGQMSEIEAK 
   TMQFEPSTMVYDACR 
   TVTDMLMTICAR 
   VQELGHGCAALVTK 
O15533 Tapasin                    TPSN WASGLTPAQNCPR 
Q13148 TAR DNA-binding protein 43                 TADBP AFAFVTFADDQIAQSLCGEDLIIK 
P17987 T-complex protein 1 subunit alpha                TCPA GANDFMCDEMER 
   IACLDFSLQK 
   ALNCVVGSQGMPK 
   ICDDELILIK 
P50991 T-complex protein 1 subunit delta                TCPD SIHDALCVIR 
   IGLIQFCLSAPK 
P48643 T-complex protein 1 subunit epsilon                TCPE SLHDALCVIR 
   VVYGGGAAEISCALAVSQEADKCP
TLEQYAMR 
P49368 T-complex protein 1 subunit gamma                TCPG NLQDAMQVCR 







P51580 Thiopurine S-methyltransferase                   TPMT SWGIDCLFEK 
Q8NBS9 Thioredoxin domain-containing protein 5                 TXND5 IAEVDCTAER 
   VDCTAHSDVCSAQGVR 
P30048 Thioredoxin-dependent peroxide reductase, 
mitochondrial                 
PRDX3 ANEFHDVNCEVVAVSVDSHFSHLA
WINTPR 
Q16762 Thiosulfate sulfurtransferase                   THTR VDLSQPLIATCR 
   KVDLSQPLIATCR 
P26639 Threonine--tRNA ligase, cytoplasmic                  SYTC CGPLIDLCR 
Q9BV79 Trans-2-enoyl-CoA reductase, mitochondrial                  MECR ELILTLCDLIR 
P37837 Transaldolase                    TALDO ALAGCDFLTISPK 
Q9Y4P3 Transducin beta-like protein 2                 TBL2 YLATCADDR 
P61586 Transforming protein RhoA                  RHOA LVIVGDGACGK 
   HFCPNVPIILVGNK 
P55072 Transitional endoplasmic reticulum ATPase                 TERA LADDVDLEQVANETHGHVGADLA
ALCSEAALQAIR 
   EAVCIVLSDDTCSDEK 
P29401 Transketolase                    TKT AIIVDGHSVEELCK 
   CSTFAAFFTR 
Q92616 Translational activator GCN1                  GCN1L CLQNPSSDIR 
   LVEVQCLLLLEVLGGSHK 
   VLQEALCVISGVPGLK 
   YLLDSCAPLLR 
Q99805 Transmembrane 9 superfamily member 2                TM9S2 DACVISSDFHER 
   FYLPGLAPVNFCDEEK 
   HTHIDKPDCSGPPMDISNK 
Q9BVK6 Transmembrane emp24 domain-containing protein 
9 
TMED9 CFIEEIPDETMVIGNYR 
Q6NUQ4 Transmembrane protein 214                  TM214 SSGFLPASQQACAK 
Q92973 Transportin-1                    TNPO1 CVNLVQK 
   SHAVACVNQF 
P53007 Tricarboxylate transport protein, mitochondrial                 TXTP GIGDCVR 
P55084 Trifunctional enzyme subunit beta, mitochondrial                ECHB FNNWGGSLSLGHPFGATGCR 
P22102 Trifunctional purine biosynthetic protein 
adenosine-3                
PUR2 QVLVAPGNAGTACSEK 
P60174 Triosephosphate isomerase                   TPIS IAVAAQNCYK 
   IIYGGSVTGATCK 
P23381 Tryptophan--tRNA ligase, cytoplasmic                  SYWC GIFGFTDSDCIGK 
   DIIACGFDINK 
P68363 Tubulin alpha-1B chain                  TBA1B MVDNEAIYDICR 
   YMACCLLYR 
   AYHEQLSVAEITNACFEPANQMVK 
   LADQCTGLQGF 
Q9BQE3 Tubulin alpha-1C chain                  TBA1C MVDNEAIYDICR 
   YMACCLLYR 
   AVCMLSNTTAVAEAWAR 
   LADQCTGLQGFLVFHSF 
   TTLEHSDCAFMVDNEAIYDICR 
P68366 Tubulin alpha-4A chain                  TBA4A MVDNEAIYDICR 
   YMACCLLYR 
   AYHEQLSVAEITNACFEPANQMVK 
   SIQFVDWCPTGF 
   TTLEHSDCAFMVDNEAIYDICR 
P07437 Tubulin beta chain                  TBB5 TAVCDIPPR 
   EIVHIQAGQCGN 
   EIVHIQAGQCGNQIGAK 
   NMMAACDPR 
Q9BVA1 Tubulin beta-2B chain                  TBB2B LTTPTYGDLNHLVSATMSGVTTCL
R 
P54577 Tyrosine--tRNA ligase, cytoplasmic                  SYYC ISEECIAQWK 
O75643 U5 small nuclear ribonucleoprotein 200 kDa 
helicase              
U520 AALETDENLLLCAPTGAGK 
  LTAIDILTTCAADIQR 
   CTLLASAQSEAEK 
O75208 Ubiquinone biosynthesis protein COQ9, 








Q92890 Ubiquitin fusion degradation protein 1 homolog               UFD1 CFSVSMLAGPNDR 
P61086 Ubiquitin-conjugating enzyme E2 K                 UBE2K ISSVTGAICLDILK 
O60701 UDP-glucose 6-dehydrogenase                   UGDH DVLNLVYLCEALNLPEVAR 
   DPYEACDGAH 
O60656 UDP-glucuronosyltransferase 42248                   UD19 NHIMHLEEHLLCHR 
O43795 Unconventional myosin-Ib                   MYO1B AAHIFNEALVCHQIR 
   LNQVCATHQHFESR 
Q5T6V5 UPF0553 protein C9orf64                  CI064 DCLLELIEQK 
   FGGSFLNCVR 
P06132 Uroporphyrinogen decarboxylase                   DCUP AAQDFFSTCR 
P26640 Valine--tRNA ligase                   SYVC GIEDNPMVVPLCNR 
   ICLQPPPTSR 
P50552 Vasodilator-stimulated phosphoprotein                   VASP MQPDQQVVINCAIVR 
P49748 Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial               
ACADV CLTEPSSGSDAASIR 
  GLQVPSELGGVGLCNTQYAR 
   VTDECIQIMGGMGFMK 
Q12907 Vesicular integral-membrane protein VIP36                 LMAN2 WTELAGCTADFR 
   NCIDITGVR 
Q00341 Vigilin                    VIGLN CDIIIISGR 
P18206 Vinculin                    VINC IAELCDDPK 
   TNLLQVCER 
Q9BQB6 Vitamin K epoxide reductase complex subunit 1              VKOR1 ALCDVGTAISCSR 
P04004 Vitronectin                    VTNC GQYCYELDEK 
P21796 Voltage-dependent anion-selective channel protein 
1                
VDAC1 YQIDPDACFSAK 
P45880 Voltage-dependent anion-selective channel protein 
2                
VDAC2 WCEYGLTFTEK 
Q9Y277 Voltage-dependent anion-selective channel protein 
3                
VDAC3 SCSGVEFSTSGHAYTDTGK 
  VCNYGLTFTQK 
   SCSGVEFSTSGH 
P21281 V-type proton ATPase subunit B, brain isoform              VATB2 IPIFSAAGLPHNEIAAQICR 
Q8IWB7 WD repeat and FYVE domain-containing protein 1              WDFY1 GLMVTCGTDR 
O75083 WD repeat-containing protein 1                 WDR1 MTVDESGQLISCSMDDTVR 
P13010 X-ray repair cross-complementing protein 5                XRCC5 CFSVLGFCK 
   CFSVLGF 
Q15043 Zinc transporter ZIP14                  S39AE IGSSELQEFCPTILQQLDSR 





Table S2 H:L fold-change values of MAT1 and MAT2 as observed in a pilot 
study, and in the triplicates of the 3 h time-point for the longitudinal study. Values 















synthase isoform type-1 
MAT1 39.2 3.12 0.73 0.92 
P31153 
S-adenosylmethionine 
synthase isoform type-2 





Table S3 Characteristics of the CYP3A5-genotyped HLM donors. Testosterone 
6β-hydroxylation was determined in-house, while all other data were obtained 
from the respective vendors. 
Donor Vendor Genotype 
Western Blot % CYP3A5 
Content 
Testosterone 6β-
Hydroxylation CYP3A5 CYP3A4 
   pmol/mg  nmol/min/mg 
HH785 BDGentest 
*1/*1 
13 170 7.10 1.06 
HH860 BDGentest 35 320 9.86 1.14 
HH867 BDGentest 17 110 13.39 0.58 
H0331 XenoTech NA NA NA 2.65 
Mean ± S.D.    10.12 ± 3.15 1.36 ± 0.90 
HH757 BDGentest 
*1/*3 
9 19 32.14 0.21 
HH868 BDGentest 13 23 36.11 0.10 
H0239 XenoTech NA NA NA 0.52 
H0280 XenoTech NA NA NA 1.22 
Mean ± S.D.    34.13 ± 2.81 0.51 ± 0.50 
HH507 BDGentest 
*3/*3 
ND 15 0.07 0.04 
H0307 XenoTech NA NA NA 1.18 
H0204 XenoTech NA NA NA 0.14 
H0182 XenoTech NA NA NA 0.20 
Mean ± S.D.     0.39 ± 0.53 
ND, not detected; NA, not available. 
 
 
